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The genetics science is less than 150 years old, but its accomplishments have been 
astonishing. Genetics has become an indispensable component of almost all research 
in modern biology and medicine. Human genetic variation is associated with many, if 
not all, human diseases and disabilities. Nowadays, studies investigating any biological 
process, from the molecular level to the population level, use the “genetic approach” to 
gain understanding of that process. This book contains many diverse chapters, dealing 
with human genetic diseases, methods to diagnose them, novel approaches to treat 
them and molecular approaches and concepts to understand them. Although this book 
does not give a comprehensive overview of human genetic diseases, I believe that 
the sixteen book chapters will be a valuable resource for researchers and students in 







HUMAN GENETIC DISEASES 
 




HUMAN GENETIC DISEASES 
 






Edited by Dijana Plaseska-Karanfilska
Contributors
Pilar Giraldo, Jose-Luis Capablo, Miguel Pocovi, Malgorzata Mrugacz, Nobuyuki Itoh, Sayaka Sasaki, Yoshiaki 
Nakayama, Morichika Konishi, Ayumi Miyake, Joaquima Navarro Ferrete, Albert Obradors, Mariona Rius, Gemma 
Daina, Juliana Cuzzi, Olga Martinez-Passarell, Esther Fernandez, Olga López, Ana Polo, José Luís Seculí, Sílvia Gartner, 
Maria Oliver-Bonet, Jordi Benet, Anna Teti, Andrea Del Fattore, Rejane Gus Kessler, Maria Teresa Sanseverino, Roberto 
Giugliani, Mariluce Riegel, Jose Antonio Magalhaes, Sandra Leistner-Segal, Jose De Celis, Cristina Molnar, Martin 
Resnik-Docampo, Maria F-Organista, Mercedes Martin, Covadonga F-Hevia, Semra Kahraman, Çağrı Beyazyurek, 
Rajech Sharkia, Esmael Athamny, Mohamad Khatib, Ahmad Sheikh-Muhammad, Abdussalam Azem, Muhammad 
Mahajnah, Verena Wally, Ulrich Koller, Johann W Bauer, Fakher Rahim, Najmoldin Saki, Mohammad Ali Jalalifar, Silvia 
Muro, Janet Hsu, Ghazi Alsbeih, Mohsen Ali Faris El-Hazmi, Ali El-Hazmi, Claudia C. Branco, Luisa Mota-Vieira, Dijana 
Plaseska-Karanfilska
© The Editor(s) and the Author(s) 2011
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2011 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Human Genetic Diseases
Edited by Dijana Plaseska-Karanfilska
p. cm.
ISBN 978-953-307-936-3
eBook (PDF) ISBN 978-953-51-6767-9
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr. Dijana Plaseska-Karanfilska graduated from the Fac-
ulty of Medicine, University “St. Cyril and Methodius” 
in Skopje, Republic of Macedonia in 1987. She defended 
the PhD thesis “Micromethodology for the characteri-
zation of haemoglobin variants” in 1994 at the Limburg 
University, in Maastricht, the Netherlands. Since 1988 
Dr.  Plaseska-Karanfilska has been employed at the 
Research Centre for Genetic Engineering and Biotechnology (RCGEB), 
Macedonian Academy of Sciences and Arts (MASA) where at present she 
holds a position of a senior scientist, group leader and head of laboratory. 
In 2010 she has been elected for Associate Professor of molecular biology 
and pharmacogenetics at the Faculty of Pharmacy, University “St. Cyril 
and Methodius”, Skopje, R. Macedonia. During her professional career Dr. 
Plaseska-Karanfilska made a contribution to the molecular characteriza-
tion of different monogenic diseases in Macedonia, such as hemoglobin-
opathies, cystic fibrosis, cystinuria, Fragile X syndrome, etc. She has been 
also involved in the research of different infectious diseases, such as HPV, 
HBV, HCV infections and molecular basis of several malignant diseases 
as well as forensic DNA identification. Dr. Plaseska-Karanfilska’s recent 
special research interest is in the field of reproductive genetics, such as 
male infertility, spontaneous abortion, rapid and non-invasive prenatal 











Chapter 1 Signalling Pathways in Development  
and Human Disease: A Drosophila Wing Perspective 1 
Cristina Molnar, Martín Resnik-Docampo, María F. Organista,  
Mercedes Martín, Covadonga F. Hevia and Jose F. de Celis 
Chapter 2 The FGF Family in Humans, Mice, and Zebrafish: 
Development, Physiology, and Pathophysiology 37 
Sayaka Sasaki, Hiroya Ohta, Yoshiaki Nakajima,  
Morichika Konishi, Ayumi Miyake and Nobuyuki Itoh 
Chapter 3 Osteoclast Genetic Diseases 57 
Andrea Del Fattore and Anna Teti 
Chapter 4 MRE11A Gene Mutations Responsible 
for the Rare Ataxia Telangiectasia-Like Disorder 79 
Ghazi Alsbeih 
Chapter 5 Neuronopathic Forms in 
Subjects with Mutations in GBA Gene 91 
Pilar Giraldo, Jose-Luis Capablo and Miguel Pocovi 
Chapter 6 The Role of Gene Mutations Detection 
in Defining the Spectrum  
of ß – Thalassemia in Various Ethnic Regions 109 
Fakher Rahim, Najmaldin Saki and Mohammad Ali Jalalai far 
Chapter 7 CCL Chemokines Levels in Tear Fluid of 
Patients with Cystic Fibrosis 121 
Malgorzata Mrugacz 
Chapter 8 The Genetic Makeup of Azoreans 
Versus Mainland Portugal Population 129 
Cláudia Castelo Branco and Luisa Mota-Vieira 
Contents 
Preface XI 
Chapter 1 Signalling Pathways in Development 
and Human Disease: A Drosophila Wing Perspective 1 
Cristina Molnar, Martín Resnik-Docampo, María F. Organista, 
Mercedes Martín, Covadonga F. Hevia and Jose F. de Celis 
Chapter 2 The FGF Family in Humans, Mice, and Zebrafish: 
Development, Physiology, and Pathophysiology 37 
Sayaka Sasaki, Hiroya Ohta, Yoshiaki Nakajima,  
Morichika Konishi, Ayumi Miyake and Nobuyuki Itoh 
Chapter 3 Osteoclast Genetic Diseases 57 
Andrea Del Fattore and Anna Teti 
Chapter 4 MRE11A Gene Mutations Responsible 
for the Rare Ataxia Telangiectasia-Like Disorder 79 
Ghazi Alsbeih 
Chapter 5 Neuronopathic Forms in 
Subjects with Mutations in GBA Gene 91 
Pilar Giraldo, Jose-Luis Capablo and Miguel Pocovi 
Chapter 6 The Role of Gene Mutations Detection 
in Defining the Spectrum  
of ß – Thalassemia in Various Ethnic Regions 109 
Fakher Rahim, Najmaldin Saki and Mohammad Ali Jalalai far 
Chapter 7 CCL Chemokines Levels in Tear Fluid of 
Patients with Cystic Fibrosis 121 
Malgorzata Mrugacz 
Chapter 8 The Genetic Makeup of Azoreans 
Versus Mainland Portugal Population 129 
Cláudia Castelo Branco and Luisa Mota-Vieira 
X      Contents
Chapter 9 Double-Factor Preimplantation 
Genetic Diagnosis: Preliminary Results 161 
Obradors A, Rius M,  Daina G, Cuzzi JF, Martínez-Pasarell O, 
Fernández E, López O, Polo A, Séculi JL, Gartner S, 
Oliver-Bonet M, Benet J and Navarro J  
Chapter 10 Preimplantation HLA Typing 179 
Semra Kahraman and Cagri Beyazyurek 
Chapter 11 The Contribution of Molecular 
Techniques in Prenatal Diagnosis and  
Post mortem Fetus with Multiple Malformation 191 
Rejane Gus Kessler, Sandra Leistner-Segal, 
Maria Teresa Sanseverino, Jose Antonio de Azevedo Magalhaes, 
Mariluce Riegel and Roberto Giugliani 
Chapter 12 Detection of the Most Common 
Genetic Causes of Male Infertility by 
Quantitative Fluorescent (QF)-PCR Analysis 203 
Dijana Plaseska-Karanfilska, Predrag Noveski and Toso Plaseski 
Chapter 13 High-Throughput Screening for Highly 
Functional RNA-Trans-Splicing Molecules: 
Correction of Plectin in Epidermolysis Bullosa Simplex 223 
Verena Wally, Ulrich Koller and Johann W. Bauer  
Chapter 14 Nanomedicine and Drug Delivery 
Strategies for Treatment of Genetic Diseases 241 
Janet Hsu and Silvia Muro 
Chapter 15 Consanguinity and Its Effect on Morbidity 
and Congenital Disorders Among Arabs in Israel 267 
Sharkia Rajech, Athamny Esmael, Khatib Mohamad, 
Sheikh-Muhammad Ahmad, Azem Abdussalam 
and Mahajnah Muhammad 
Chapter 16 Genethical Aspects of Research and 
Medical Services in Islamic Countries 277 









The genetics science is less than 150 years old, but its accomplishments have been 
astonishing. Genetics has become an indispensable component of almost all research 
in modern biology and medicine. Human genetic variation is associated with many, if 
not all, human diseases and disabilities. Nowadays, studies investigating any 
biological process, from the molecular level to the population level, use the “genetic 
approach” to gain understanding of that process.  
This book contains many diverse chapters, dealing with human genetic diseases, 
methods to diagnose them, novel approaches to treat them and molecular approaches 
and concepts to understand them. The chapters have been written by contributors 
from thirteen different countries from four continents. Thus, population specific 
genetic variation and genetics practices in relation to the religion are part of the book 
chapters as well. 
The book is composed of 16 chapters. The first two chapters are devoted to signaling 
pathways. Chapter 1 describes the general structure of signalling pathways, the 
relevance of signalling for normal development and for the appearance of multitude of 
human diseases, and underlines several strategies that Drosophila genetics offers in 
biomedical research. Chapter 2 provides a review of the fibroblast growth factor (FGF) 
family in humans, mice, and zebrafish and their developmental physiological and 
pathophysiological roles.  
Chapter 3 deals with osteoclast biology and provides examples of genetic osteoclast 
diseases, including osteopetrosis, pycnodysostosis and Paget’s disease of bone. 
Chapter 4 gives an overview of the rare Ataxia telangiectasia like disorder (ATLD) 
caused by MRE11A gene mutations and describes the study initiated to assess the 
frequency of the c.630G>C mutation in the population of Saudi Arabia.  
The next three chapters deal with different aspects of three common monogenic 
diseases. Chapter 5 gives an overview of Gaucher disease and describes the 
glucocerebrosidase gene mutations associated with neurological forms of this genetic 
disease. Chapter 6 gives an overview of the different forms of thalassemias, methods 
used for their diagnosis and describes the spectrum of β-thalassemia mutations found 
in Iran. Chapter 7 describes a study that investigates the role of chemokines in the 
pathogenesis of ocular changes in patients with cystic fibrosis (CF). 
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Chapter 8 presents the genetic make-up of Azoreans in comparison with mainland 
Portugal population and emphasizes how this genetic research has allowed the 
implementation of molecular diagnosis in the hospital of the Azores archipelago.  
Chapters 9 and 10 are devoted to preimplantation genetic diagnosis. Chapter 9 
evaluates the effect of Double-Factor Preimplantation Genetic Diagnosis (DF-PGD) on 
implantation in couples with monogenic diseases. Chapter 10 presents one of the 
world’s largest experiences on preimplantation HLA typing in families with genetic 
and acquired disorders.  
Chapters 11 and 12 describe molecular methods for diagnosis of the most common 
chromosomal abnormalities. Chapter 11 describes the usefulness of two rapid 
molecular techniques, Multiplex Ligation-dependent Probe Amplification (MLPA) and 
Quantitative Fluorescent-Polymerase Chain Reaction (QF-PCR) for prenatal diagnosis 
and post mortem fetuses with multiple malformations. Chapter 12 describes a 
multiplex QF-PCR method that allows simultaneous detection of the most common 
genetic causes of male infertility, i.e. sex chromosomal aneuploidies and azoospermia 
factor (AZF) deletions, and some potential risk factors such as partial AZFc 
deletions/duplications and androgen receptor CAG repeats. 
Chapters 13 and 14 deal with the treatment of genetic diseases.  Chapter 13 describes a 
Spliceosome Mediated RNA Trans-splicing (SMaRT) as a promising tool for gene 
therapy of epidermolysis bullosa simplex. Chapter 14 discusses some of the 
technological advances regarding the application of nanomedicine in the treatment of 
genetic conditions.   
Chapters 15 and 16 are related to genetics in relation to Islamic religion.  Chapter 15 
examines the effect of consanguinity on selected multi-factorial diseases and 
congenital disorders in a target population of the Arab community in Israel. Chapter 
16 presents the medical genetic practices in Islamic community of Iran in relation to 
the Islamic Teaching.  
Although this book does not give a comprehensive overview of human genetic 
diseases, I believe that the sixteen book chapters will be a valuable resource for 
researchers and students in different life and medical sciences. 
 
Dijana Plaseska-Karanfilska, MD, PhD 
Macedonian Academy of Sciences and Arts, 
Research Center for Genetic Engineering 
and Biotechnology “Georgi D. Efremov”, Skopje, 
Republic of Macedonia 
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Signalling Pathways in Development and 
Human Disease: A Drosophila Wing Perspective 
Cristina Molnar, Martín Resnik-Docampo, María F. Organista,  
Mercedes Martín, Covadonga F. Hevia and Jose F. de Celis 
Centro de Biología Molecular “Severo Ochoa”, CSIC and UAM 
C/Nicolás Cabrera 1, Universidad Autónoma de Madrid, Madrid 
Spain 
1. Introduction 
The proteins involved in signalling are organised in several signalling pathways, and both 
these proteins and their molecular interactions are conserved during evolution. In this 
chapter we describe the genetic structure of the main conserved signalling pathways 
identified in multicellular organisms, focusing in those signalling pathways in which the 
activation of cell receptors by proteins with ligand activity is linked to transcriptional 
responses. These pathways play key roles during normal development, and their de-
regulation has been implicated in a variety of human diseases. We will emphasize the 
conservation of the proteins and mechanisms involved in each of these pathways, and 
describe the Drosophila wing imaginal disc as an experimental system to dissect cell 
signalling in vivo. Finally, we will discuss some of the strategies that are been used to 
identify additional components of signalling pathways in Drosophila. Our main aim is to 
underline the general structure of signalling pathways, the relevance of signalling for 
normal development and for the appearance of multitude of human diseases, and describe 
several strategies that Drosophila genetics offers in biomedical research.  
2. General structure of signalling pathways in multi-cellular organisms: 
Ligands, receptors, transducers and transcriptional outputs of the Notch, 
EGFR, InR, Wnt, TGF, BMP, Hippo and JNK pathways 
Signalling pathways are molecular modules used to convey information among cells. Each 
pathway is formed by several components connected by molecular recognition and 
organised in a hierarchical manner, starting with a ligand and ending with a transcription 
factor. The temporal and spatial expression of the ligands determines the domain of 
activation of each signalling pathway. The expression of ligands is subject to transcriptional 
regulation defined by the combination of transcription factors present in the ligand-
producing cell (see for example Bachmann and Knust, 1998; Haenlin et al., 1990; Haenlin et 
al., 1994; Parks et al., 1995; Vargesson et al., 1998). The outcome of each pathway is the 
activation of a specific transcription factor, and consequently, in many respects a signalling 
pathway is a molecular device used to coordinate gene expression programs in cell 
populations. In these roles they are instrumental during multicellular development and 
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adult tissue homeostasis, regulating a variety of cell behaviours including cell division, 
apoptosis, migration and differentiation.  
The components of each signalling pathway can be operationally grouped into ligands, 
receptors, transducers and transcription factors (Table 1).  
Pathway/Organism Fly Human Fly Human Fly Human Fly Human
Argos Argos EGFR EGFR Sos Sos1 Yan ETV
EGF Sevenless ROS1 Grb Grb2 Pointed 1‐2 ETS (ELK1)
HB‐EGF Torso Ras K‐Ras /H‐Ras/N‐RAS AP1
TGF‐a HER 2‐4 Raf SHC SRF
NRG1‐4 dMEK MEK 1/2
Spitz MEKK 1/3





DCHS 1 Fat 1‐3 Hippo MST1,2 Yorkie YAP,TAZ








Delta Delta‐4/A‐D Notch1 Su(H) CSL
Serrate Serrate Notch2‐4 Notch‐i NICD
Jagged1‐2
Dll3‐4






Leucine Leucine Slimfast dRagA/C RRAG B/C UBF
Glutamine Glutamine pathetic dMAP4K3 hMAP4K3 Tif‐IA TIF‐1A





Eiger TNF Wengen TNFR1 dTRAF1‐2 TRAF1‐2 Jra Jun










Pelle IRAK1,3 Dif/Dorsal NFKB1













IFN I (a/b) Dome Hop JAK1/2/3 STAT1a/ b

























Pathway/Organism Fly Human Fly Human Fly Human Fly Human
WNT 1 Frizzled Frizzled Dishevelled Dishevelled
WNT 2‐16 Arrow LRP 5 Axin Axin




Dpp BMP2,4 Tkv BMPR IA,IB Mad Smad1,5,8 Mad Smad1,5,8
BMP5‐8 ALK‐1,2,6 dSmad2 Smad2,3 dSmad2 Smad2,3
Gbb Sax Medea Smad4,4b Medea Smad4,4b









Shh Ptc1 Smo SMO Gli‐1
























Table 1. Main components of the principal signalling pathways in Drosophila melanogaster 
and Homo sapiens. 
For references see: EGFR: Kataoka, 2009/Shilo, 2003; SWH:Gruscne et al., 2010/Kango-
Singh and Singh, 2009/Matallanas et al., 2008; Notcn:Bray 2006/Scnwanbeck et al., 2010; 
InR: Ma and Blenis, 2009; TOR: Hietakangas and Cohen, 2009/Rosner et al., 2008/Zoncu et 
al 2011; JNK: Igaki 2009- Toll' So and Oucni 2010/ Valanne et al., 2011; JAK/STAT: Rane and 
Reddy, 2000/Hou et al., 2002/Wright et al., 2011; Wnt: Seto and Bellen, 2004/Chien et al., 
2009; TGF-B: Raftery and Sutherland, 1999/Massague and Wotton, 2000/Waite and Eng, 
2003 and Hh: Ruiz-Gomez et al., 2007/Jacob and Lum, 2007. 
In the simplest example, that of steroid hormones, a single protein can recognise a ligand 
molecule and also acts as a transcription factor (Stanisic et al., 2010), but, in general, different 
proteins can be unequivocally assigned to each category in different pathways. Ligands are 
mostly proteins that can be secreted from the cell or directly presented in the cell membrane 
to neighbouring cells (Figure 1). In general, ligands are subject to considerable post-
transcriptional modifications, including ubiquitination (Delta/Serrate in the Notch 
pathway; Le Bras et al., 2011), lipid modifications (Hedgehog family of proteins; Steinhauer 
and Treisman, 2009), proteolytic processing from a larger precursor to form the active 
peptide (TGFß superfamily members and EGF/FGF ligands; Zhu and Burgess, 2001; Urban 
et al., 2002), palmitoylation and glycosylation (Wnt and EGFR ligands; Miura et al., 2006; 
Steinhauer and Treisman, 2009) and glycosylation (JAK/STAT ligands) (Figure 1). These 
modifications are required for the secretion of the ligand and its spreading through the 
tissue, and they also determine their ability to bind and activate their receptors. In addition,  
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Fig. 1. Schematic representation of the ligands and their post-transcriptional modifications. 
Upper panels: EGFR, Notch and Hh ligands, middle panels: Wnt, BMP/TGF and 
JAK/STAT ligands and bottom panels (SWH, Insulin and Toll ligands. 
most secreted ligands display strong interactions with several components of the 
extracellular matrix, which help to establish their diffusion range and to shape the 
concentration of active ligand at a distance from the ligand-producing cells (Jackson et al., 
1997; Baeg et al., 2001; Araujo et al., 2003; Bartscherer and Boutros, 2008). The distribution of 
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the ligands is also affected by interactions with their receptors, as ligand-receptor 
interactions remove the ligand from the extra-cellular milieu and regulate the concentration 
of the ligand through endocytosis and subsequent lysosomal degradation or recycling of 
ligand-receptor complexes (Lecuit and Cohen, 1998; Chen and Struhl, 1996; Funakoshi et al., 
2001; Pfeiffer and Vincent, 1999). 
Receptors are in general transmembrane proteins with two well-differentiated activities. 
Thus, they interact with the ligand through their extra-cellular domain, and recruit different 
components of the transduction machinery in their intra-cellular domain (Figure 2). The cell 
biology of receptors is complex and diverse, but in general includes mechanisms to ensure 
the correct trafficking of the receptor through the Endoplasmic reticulum-Golgi network, 
post-transcriptional modifications during trafficking to synthesize the active form of the 
protein, localization of the receptor to apical domains in the cell membrane, interaction of 
the receptor with different co-receptor molecules, and turn-over mechanisms that regulate 
the number of activated-receptors in the cell membrane and other intracellular 
compartments (Piddini and Vincent, 2003; Hoeller et al., 2005; Mills, 2007; Sorkin and von 
Zastrow, 2009; Bethani et al., 2010). Similarly, the activation of the receptor by binding to 
appropriate ligands uses different mechanisms that rely in the clustering of receptor 
complexes, phosphorylation of receptor molecules after complex formation (EGFR and 
TGFß), or conformational changes that allow the proteolytic processing of the receptor 
(Notch) or its interaction with specific transduction components (Wnt; Figure 2).  
The receptors act on their downstream transducers through a variety of mechanisms that 
include phosphorylation (EGFR/InR and JAK; Arbouzova and Zeidler, 2006; Pfeifer et al., 
2008; Hombria and Sotillos, 2008 Avraham and Yarden, 2011) and TGFß receptor complexes; 
Miyazono et al., 2010), the recruitment of intracellular transducers after conformation 
changes (Wnt receptors; Angers and Moon, 2009), or the indirect modification of the 
phosphorylation state and subcellular localization of its transducer (Hedgehog receptors; 
Ruiz-Gomez et al., 2007). In a particular case (Notch; Bray, 2006), the receptor itself directly 
contributes to modify the composition and activity of transcription complexes (Figure 2).  
The components of the transduction machinery downstream of the receptor are also 
heterogeneous, ranging from the simplest cases in which the receptor itself becomes part of 
a transcription complex (Notch) or directly modifies by phosphorylation a transcription 
factor, triggering a change in its subcellular localization from the cytoplasm to the nucleus 
(Smad and Stat proteins in TGF and JAK pathways, respectively; Miyazono et al., 2010; 
Hou et al., 2002).  In other cases the receptor (Wnt receptors; Angers and Moon, 2009) or a 
transducer regulated by the receptor (Smoothened in the Hh pathway; Ruiz-Gomez et al., 
2007) acts as a scaffold to recruit and sequester different components that prevent the 
accumulation of a transcription factor in the nucleus (ß-catenin and Gli, respectively). 
Finally, in the cases of Sav/Warts/Hippo (SWH; Harvey and Tapon, 2007; Halder and 
Johnson, 2011), Toll (Valanne et al., 2011), and receptors with tyrosin-kinase activity such as 
EGFR (Shilo, 2003) and InR (Brogiolo et al., 2001), the activation of the receptor is 
communicated to the responding transcription factor through a linear cascade of 
phosphorylation (EGFR, InR and SWH) or proteolytic events (Toll) that end in the 
generation of active forms of the transcription factor localised in the nucleus (ETS proteins 
for EGFR and Rel/Dorsal for Toll),  or in the exclusion from the nucleus of the 
transcriptional co-activator Yorki/YAP (SWH) (Table 2).  
By using these mechanisms, the state of the pathway changes the nuclear localization of a 
transcription factor that binds to the DNA with sequence–specificity. In the simplest cases 
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Fig. 2. Schematic representation of the receptors and their mechanisms of activation 
this is accomplished directly by the receptor itself, which re-localise to the nucleus upon 
ligand binding (Notch). In the case of Yorki/YAP (SWH; Harvey and Tapon, 2007) and Foxo 
(InR; Van Der Heide et al., 2004; Greer and Brunet, 2008), pathway activity prevents or 
promote, respectively, their entrance into the nucleus, and in the case of Dorsal/Rel 
(Gerondakis et al., 2006) the pathway triggers the proteolytic processing of a protein that 
sequesters this transcription factor in the cytoplasm (Table 2). In other pathways the 
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transcription factor resides in the nucleus, where it acts as a member of a transcriptional 
repressor complex. In these cases, the transcriptional output of signalling is determined by 
the induction of a transition, regulated by the pathway, from a transcriptional repressor to a 
transcriptional activator (Table 2). This transition is accomplished using different 
mechanisms such as the generation of an intracellular fragment of the receptor (Notch; Bray, 
2006), the phosphorylation of the transcription factors (ETS in EGFR; Baonza et al., 2002 and 
Smads in TGFß; Miyazono et al., 2005) or the inhibition of the proteolytic processing of the 
transcription factor (Gli in Hh and ß-Catenin in Wnt: Nusse, 1999). 
 
Pathway / Organism Fly Human Fly Human Fly Human Fly Human
Gro TLE
MAE ‐
Hh Ci Gli‐1, Gli‐2, Gli‐3 dCBP CBP
InR/TOR dFOXO FOXO










































TGFβ DSmad2‐Med/Mad‐Med Smad2‐Smad4/Smad3,Smad5‐Smad4 Phosphorylation
NOTCH Su(H)‐NICD CSL‐NICD
 
Table 2. Transcription factors and their mechanism of activation. Abbreviations: Transcription 
Factor (TF), Pointed (Pnt), Cubitus interruptus (Ci), Signal-transducer and activator of 
transcription protein at 92E (Stat92E), Jun-related antigen (Jra), Kayak (Kay), Suppressor 
Hairless (Su(H)), Notch intracellular domain (NICD), Yorki (Ykl), Mothers against dpp (Mad), 
Medea (Med), Dorsal-related inmmunity factor (Dif), Armadillo (Arm), Pangolin (Pan), 
Groucho (Gro), CREB-bincing protein (CBP), Erupted (Ept), Tumor Susceptibility Gene-101 
(TSG101), Mastermind (Mam), Skl-interacting Protein (SKIP), Scalloped (Sd), Homothorax 
(Hth), Schnurri (Shn), Human immunodeficiency virus type I enhancer binding protein 3 
(HIVEP3), Sno oncogene (Sno), SKI-like oncogene (SKIL), TBP-associated factor “60/110 
(TAF”60/110), Twist (Twi), Legless (Lgs), Brahma (Brm). Localization/State of TF: Citosolic 
(C) and nuclear (N) subcellular localization. Function as a transcriptional activator (A) or 
repression (R). TF that traslocate to the nucleus upon activation (C/N) or from the nucleus to 
the cytoplasm (N/C). For references see: EGFR: Vivekanand et al., 2004/Hassen and Paroush, 
2007; Hn: Akimarti et al., 1997a/Chen et al., 2000; InR/Tor: Ma and Blenis, 2009/Hietakangas 
and Cohen, 2009/Resnik-Docampo and de Celis, 2011; JAK/STAT: Gilbert et al., 2009 ; JNK: 
Igaki, 2009; NOTCH: Zhou et al., 2000/Petcherski and Kimble, 2000/Bray, 2006; SWH: Halder 
and Johnson, 2011; TGFb: Feng et al., 1998/Janknecht et al., 1998/Pouponnot et al., 
1998/Waltzer and Bienz, 1999/Luo et al., 1999/Strochein et al., 1999/Sun et al., 1999a/Sun et 
al., 1999b/Dai et al., 2000/Barrio et al., 2007; Toll: Dubnicoff et al., 1997/Aklkmaru et al., 
1997b/Pham et al., 1999 and Wnt: Waltzer and Bienz, 1998/Roose et al., 1998/Nusse, 
1999/Barker et al., 2001/Hoffmans and Basler, 2004. 
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In all cases, the presence in the nucleus of a transcriptional activator in response to 
signalling modifies the expression of a battery of target genes, leading to changes in cell 
behaviour that are conditioned by the state of the responding cell. In this manner, some 
aspects of the transcriptional landscape of the ligand expressing cells are communicated to 
the receiving cells, where a novel pattern of transcription can be established. Thus, the 
transcription factors regulated by each signalling pathway contribute to the combinatory of 
regulators present in a given cell, and this, combined with the structure of gene regulatory 
sequences, makes the transcriptional responses to a pathway cell type specific (Bonn and 
Furlong, 2008; Chopra and Levine, 2009). At this time, little is known about the number and 
identity of target genes whose expression are directly regulated by signalling and whose 
function contributes significantly to the cellular response to signalling. This is an area of 
intensive research, and the use of chromatin immunoprecipitation techniques coupled with 
microarrays or deep-sequencing, the development of reporter systems for cell culture assays 
and the functional analysis of the identified target genes promise a much better 
understanding of the transcriptional responses to signalling in the near future (Yang et al., 
2004; Miyazono et al., 2005; Friedman and Perrimon, 2006; Mummery-Widmer et al., 2009; 
Bernard et al., 2010; Kim and Marques, 2010).  
3. General aspects of the biological roles play by signalling pathways during 
development 
The development of multicellular organisms relies to a large extent in the spatial and 
temporal generation of gene expression domains (Arnone and Davidson, 1997). In this 
manner, and under the perspective that signalling pathways are mostly elaborate devices to 
regulate transcription, it is no wonder that these pathways play prominent roles during the 
development of all organisms. Their key contribution is mostly based in their ability to 
communicate transcriptional stages between cell populations and generate spatial domains 
of gene expression. Other characteristics that make signalling a powerful system to regulate 
cell behaviour are the quantitative response to signalling, the operation of elaborate feed-
back mechanisms, positive and negative, that modulate the intensity and duration of 
signalling (Perrimon and McMahon, 1999), and the existence of cross-interactions between 
pathways (McNeill and Woodgett, 2010). These cross-interactions occur both at the level of 
transcription, in which one pathway regulates the expression of others pathway ligands, or 
by interactions in which one pathway affects the activity of components belonging to a 
different pathway (Hasson and Paroush, 2007; McNeill and Woodgett, 2010). All these 
characteristics confer a great versatility to the function of signalling during development, 
and also contribute to the disastrous consequences that signalling miss-regulation has in 
different genetic disorders (Harper et al., 2003; Logan and Nusse, 2004; Inoki et al., 2005; 
Bentires-Alj et al., 2006; Jacob and Lum, 2007; Gordon and Blobe, 2008; Rosner et al., 2008; 
Gordon and Blobe, 2008; Table 3). To summarize, we have divided the biological roles 
played by signalling into the following categories: 
1. Cellular responses that directly modify the metabolic state of the cell. This is best 
exemplified by the action of the InR/TOR pathway, which activity is used as a way to 
adjust the growth of the cell to the availability of nutrients (Brogiolo et al., 2001). In 
addition, this pathway is also used to coordinate the growth of different organs during 
development and adult tissue homeostasis (Zoncu et al., 2011). 
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2. Cellular responses that make cells to progress through the cell cycle, acquire migratory 
behaviour, enter into the apoptotic pathway or in general to make a transition between 
cell states. All pathways contribute in different cellular settings to modify a pre-existing 
cellular state (Thompson, 2010). For example, inputs from the BMP and FGF pathways 
regulate the entrance in apoptosis of inter-digital epidermal cells during vertebrate limb 
development (Pajni-Underwood et al., 2007); and TGFß/BMPs also participate in 
regulating epithelial-mesenchymal transitions (Zavadil and Böttinger, 2005). BMP 
together with JNK also promote changes in the cytoskeleton that influence the 
movement of layers of cells during morphogenesis (Fernandez et al., 2007). On the other 
hand, several pathways have direct links with the cell cycle, either promoting the 
transitions between different phases of the cycle or triggering the entrance of cells in 
senescence (Campisi and d'Adda, 2007; Jones and Kazlauskas, 2001).  
3. Regulation of alternative cell fates within populations of competent cells. Many 
pathways are engaged in the allocation of cell fates during development. The Notch and 
EGFR pathways fall in this class, regulating neural fates within proneural clusters in a 
process that employs Notch signalling to prevent neural fate and EGFR to promote this 
fate (Lage et al., 1997; Bray, 2006; Axelrod, 2010). 
4. Regulation of spatial domains of gene expression within growing epithelia. The 
patterning of epithelial tissues is generally organised with respect to signalling centres. 
These centres operate as the source of ligands belonging to the EGFR, TGFß/BMP, Wnt 
and Hh signalling pathways. Because these ligands act in a concentration-dependent 
manner at a distance from the cells expressing them, they can set adjacent domains of 
gene expression that partition the epithelium into different territories with specific gene 
expression patterns. This process is used reiteratively during the development of all 
multicellular organisms, and some examples are the patterning of segments in the 
embryonic epidermis and the subdivision of the imaginal discs into different territories 
in flies (Moussian and Roth, 2005), the generation of cell diversity in the vertebrate 
neural tube (Lupo et al., 2006), the establishment of the antero-posterior patterning in 
the vertebrate limbs and many others (Kumar, 2001; Duboc and Logan, 2009; Towers 
and Tickle, 2009; Arnold and Robertson, 2009).  
5. Interactions between independent layers of cells. The development of tridimensional 
structures implies the coordination of cellular fates between cell layers of independent 
origin. This type of information transfer is at the base of the chains of inductive 
processes that pervade vertebrate development, and also contribute to set temporal and 
spatial patterns of cell migration during neurogenesis and myogenesis (Carmena et al., 
1998; Kimelman, 2006; Lupo et al., 2006; Wackerhage and Ratkevicius, 2008; Steventon 
et al., 2009; Mok and Sweetman, 2011). 
The correct regulation of cell proliferation, differentiation and survival is essential for the 
proper development and homeostasis of all organisms. The key roles that signalling plays in 
these processes are likely behind the multitude of human diseases caused by genetic 
alterations in the components of most signalling pathways. We outlined in Table 3 some 
examples illustrating human pathologies associated to defects in signalling, showing that 
changes in the activity of almost any component of different pathways, from the ligands to 
the transcription factors, lead to specific pathologies. In this manner, both loss and gain of 
function mutations in different pathways have been described as potential causes of 
developmental disorders and disease. For example, the loss of TGFß and SWH function, as 
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well as increase in JAK/STAT and EGFR, Wnt and Hh signalling are linked to tumour 
formation and progression in a variety of cell types (Massague et al., 2000; Waite and Eng, 
2003; Harvey and Tapon, 2007), the miss-regulation of Toll signalling is related with defects 
in the immune response (O'Neill, 2003), and is associated to the increase in the susceptibility 
of immune diseases such as Lupus and arthritis (Constantinescu et al., 2008; Schindler, 
2002). Mutations in Hh, TGFß and Notch pathways have also been related with blood and 
circulatory system diseases such as hypertension or CADASIL, and defects in JNK pathway 
to neurodegenerative diseases including Parkinson and Alzheimer. Similarly, the mTOR 
pathway is implicated in metabolic diseases including diabetes and obesity as well as in 
ageing (Inoki et al., 2005). Finally, many developmental disorders, including Noonan 
syndrome, Cleft palate, Pallister Hall syndrome, Polydactyli or Tetra-Amelia, have been 




Pathway   Component   Disease References 
EGFR 
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Pathway   Component   Disease References 
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 Receptor Ptc1  
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Medulloblastoma, Rhabdo 
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Colonic  
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NF1 Neurofibromatosis Zoncu et al., 2011 
 p14  
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Inmunodeficiency Zoncu et al., 2011 
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IL-2Rgc X-linked SCID O'Sullivan et al., 2007 
IL-7Ra  SCID O'Sullivan et al., 2007 
 IFNgRI  
Susceptibility to 
Mycobacterial infection O'Sullivan et al., 2007 
Transducer 
JAK2  ALL, AML, MPDs, PV, Constantinescu et al., 2008 
 JAK3  
SCID Schindler, 2002; O'Sullivan 




ALL, AML, CLL, Brain, 




Bromberg, 2002;  
O'Sullivan et al., 2007 
 STAT3  
AML, CLL, LGL, Crohn's 
disease, Brain, Breast,  
Head, Lung, Neck,  
Ovarian, Pancreas, Prostate 
and Renal tumours,  
Mycosis fungoides,  
Burkitt's, Hodgkins and 
Anaplastic large cell 
lymphomas, Myeloma, 
Melanoma 
Bromberg, 2002; O'Sullivan 
et al., 2007 
 STAT4  
Chronic obstructive 
pulmonary disease O'Sullivan et al., 2007 
 STAT5  
ALL, AML, CML,  
Crohn's disease, 
Erytroleukemia 
Bromberg, 2002; O'Sullivan 
et al., 2007 
JNK Transducer 
JNK1  Diabetes type 2 Waeber et al., 2000 
JNK2  
Atherosclerosis Ricci et al., 2004;   
Sumara et al., 2005 
JNK3  Parkinson Disease Resnick and Fennell, 2004 
p38 Alzheimer Disease Smith et al., 2006 
MKK4  
Breast, Biliary and Pancreatic 
carcinomas Su et al., 1998 
Notch 
Ligand 
Dll-3 Spondylocosta dysotosis Harper et al., 2003 




ALL Ellisen et al., 1991; Harper 
et al., 2003 
Notch-3  CADASIL Harper et al., 2003 




Dang et al., 2000;  
Wei and Hemmings, 2000;  
Ujike et al., 2001; 
Tazi-Ahnini et al., 2003 
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Mammary, Prostate and 
Renal cancers Rooke and Crosier, 2001 
TGF1 Camurati-Englemann disease Gordon and Blobe, 2008 




Brachydactyly type C, 
Symphalangism, Hereditary 
chondrodysplasia 
Massague et al., 2000; 
Gordon and Blobe, 2008 
BMP-15 Premature ovarian failure Gordon and Blobe, 2008 
 MIS  
Persistent Müllerian duct 
syndrome 
Massague et al., 2000;  
Gordon and Blobe, 2008 
NODAL Situs Ambiguus Gordon and Blobe, 2008 




Breast cancer, Loeys-dietz, 
Marfan and Furlong 
syndromes, Familial thoracic 
aortic aneurysm 
Rooke and Crosier, 2001;  
ten Dijke and Arthur, 2007; 
Gordon and Blobe, 2008 
 BMPRII  PAH, TADD 
Massague et al., 2000; 
Waite and Eng, 2003;  ten 
Dijke and Arthur, 2007; 
Gordon and Blobe, 2008 
 TGFBRII  
CML, Colorectal, Gastric, 
Head and Neck tumours, 
Small cell lung cancer and 
Hereditary non-polyposis 
colorectal cancers, Loeys-
dietz, Marfan and 
Sphrintzen-Goldberg 
syndromes, B and T-cell 
lymphoma, Retinoblastoma, 
Glioma, TADD 
Rooke and Crosier, 2001;  
Gordon and Blobe, 2008 
 BMPRI  
Brachydactyly type A2, JPS, 
Bannayan-Riley-Ruvalcaba 
and Cowden syndrome, 
TADD 
Waite and Eng, 2003 ; 
Gordon and Blobe, 2008 
 ALK1  HTT2 
Massague et al., 2000; 
Waite and Eng, 2003; ten 
Dijke and Arthur, 2007; 
Gordon and Blobe, 2008 
 AMHR2  
Persistent Müllerian duct 
syndrome 
Massague et al., 2000 ; 




Pancreatic, Colorectal and 
Ovarian cancers, JPS, HHT 
Massague et al., 2000; 
Waite and Eng, 2003; ten 
Dijke and Arthur, 2007; 
Gordon and Blobe, 2008 
Smad2  Colorectal cancer Rooke and Crosier, 2001 
Smad3 CML Rooke and Crosier, 2001 
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Pathway   Component   Disease References 
SWH 
Receptor Fat4  Breast cancer Qi et al., 2009; Pan, 2010 
 
Transducer 
MST 1/2  
Soft tissue sarcoma Seidel et al., 2007;  
Pan, 2010 
 RASSF1  
Lung and Kidney cancers Kango-Singh and Singh, 
2009 
 NF2  
NF2, Schwanomas Evans et al., 2000;  
Jiang et al., 2006;  
Pan, 2010;  
Bao et al., 2011 
 Lat 1/2  
Breast tumours Turenchalk et al., 1999; 
Zeng and Hong, 2008 
    
 
 
 TF YAP TAZ  
Breast, Colorectal, 
Hepatocellular, Lung, 
Ovarian, Pancreatic and 
Prostate carcinomas 
Overholtzer et al., 2006; 
Zender et al., 2006;  
Dong et al., 2007; 





Colon cancer Gram-positive 
sepsis So and Ouchi, 2010 
 TLR2  
Colon, Gastric and 
Hepatocellular  
carcinomas So and Ouchi, 2010 
 TLR3  




So and Ouchi, 2010 
 TLR4  
Atheroesclerosis,  
Arthritis, Breast,  
Colon, Gastric, 
Hepatocellular,  




So and Ouchi, 2010; Zhu 
and Mohan, 2010 
 TLR5  
Gastric and Cervical 
squamous cell carcinomas So and Ouchi, 2010 
TLR6 Hepatocellular carcinoma So and Ouchi, 2010 
 TLR7  
CLL, Lupus So and Ouchi, 2010;   
Zhu and Mohan, 2010 
 TLR9  
Breast, Cervical, Gastric, 
Hepatocelular and Prostate 
and Aquamus cell 
carcinomas, Glioma Diabetes 
type 1 
So and Ouchi, 2010 ; 
Meyers et al. 2010 
TF NF-KB  Diabetes type 2 Baker et al. 2011 
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Pathway   Component   Disease References 
Wnt 
Ligand WNT 3 Tetra-amelia Logan and Nusse, 2004 
 Receptor LRP 5  
Bone density defects, OPPG, 
FEVR Logan and Nusse, 2004 




Colon, Adeno and Basal cell 
carcinoma, Turcot's 
syndrome, FAP 
Peifer and Polakis, 2000; 
Wechsler-Reya and Scott, 
2001; Beachy et al., 2004; 
Logan and Nusse, 2004 
Axin Adenocarcinoma Beachy et al., 2004 
 Axin-2  
Tooth agenesis, 
Predisposition to Colon 
cancer Logan and Nusse, 2004 
b-catenin Adenocarcinoma Beachy et al., 2004 
 TF TCF  
Susceptibility to Diabetes 
type 2 Jin, 2008 
Table 3. Genetic diseases associated to signalling pathways. Abbreviations: Acute 
lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Chronic lymphocytic 
leukemia (CLL), Chronic myeloid leukemia (CML), Familial adenomatous polyposis (FAP), 
Familial exudative vitreoretinopathy (FEVR), Familial thoracic aortic aneurysm syndrome 
(TADD), Greig cephalopolysyndactyly syndrome (GCPS), Hereditary hemorrhagic 
telangiectasia (HHT) or Rendu-Osler-Weber syndrome, Juvenile myelomonocytic leukaemia 
(JMML), Juvenile polyposis syndrome (JPS), Large granular lymphocyte leukemia (LGL), 
Myeloproliferative diseases (MPDs), Osteoperosis-pseudoglioma syndrome (OPPG), 
Primary pulmonary arterial hypertension (PAH), Postaxial polydactyly type A (PAP-A), 
Pallister–Hall syndrome (PHS), Polycythemia vera (PV), Severed combined 
immunodeficiency (SCID). 
4. Drosophila as a model organism to analyse the genetic and cellular 
biology of signalling 
Because of the prominent roles that signalling plays during development, and its relevance in 
maintaining adult homeostasis and normal physiology (see Table 3), the analysis and 
experimental manipulation of signalling pathways has a central role in biomedical research. In 
this context, a key aspect in the analysis of signalling is the use of experimental systems 
allowing the identification of novel components of the different pathways, the manipulation of 
their activity by genetic and pharmacological approaches and the understanding of the 
mechanisms by which they regulate cell behaviour. Not surprisingly, the organisms that most 
have contributed to the analysis of signalling are those allowing a robust and efficient genetic 
approach to unravel gene function, in particular Caenorhabditis elegans and Drosophila 
melanogaster. In fact, many known components of all signalling pathway were identified in 
these organisms through genetic screens. The rationale of these experiments is 
straightforward: mutations affecting the same signalling pathway result in a similar phenotype 
and in general display genetic interactions. Thus, exhaustive genetic screens aimed to identify 
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genes regulating embryonic segmentation in flies were instrumental to identify many 
components of the Notch, BMP, Hh and Wnt pathways (Nusslein-Volhard and Wieschaus, 
1980), and genetic screens carried out in sensitized genetic backgrounds resulted in the 
identification of additional components of these pathways and also of the EGFR and InR 
pathways (Greaves et al., 1999; Rebay et al., 2000; Huang and Rubin, 2000; Guichard et al., 
2002; Mahoney et al., 2006). More recently, mosaic screens in adult structures of the fly 
uncovered the SWH pathway, because of its contribution to the regulation of cell proliferation, 
competition and apoptosis (Cho et al., 2006; Harvey and Tapon, 2007 Tyler et al., 2007).  
Signalling in C. elegans and D. melanogaster has been analysed in many different 
developmental settings, including the formation of the gonads (Horvitz and Sternberg, 
1991), the development of the imaginal discs (Sotillos and de Celis, 2005; de Celis, 2003) and 
the patterning of the embryonic segments (Irish and Gelbart, 1987; Wesley, 1999), among 
many others. In general these studies rely in a good cellular description of the tissue and its 
development, the possibility of directly monitoring the domains of signalling using specific 
reporter assays, and the availability of sophisticated techniques to manipulate the activity of 
any pathway component and analyse its phenotypic consequences. We will describe in what 
follows and from the perspective of signalling some relevant aspects of the development of 
the Drosophila wing imaginal disc, one experimental system that has been instrumental in 
the analysis of cell signalling during the development of epithelial tissues.  
5. The wing imaginal disc of Drosophila as a developmental model to analyse 
the structure, interactions and biological outcomes of signalling pathways 
Imaginal discs are epithelial structures that give rise to most of the adult external structures 
of the fly. The wing imaginal disc starts its development as a group of about 20 embryonic 
ectodermal cells (Cohen et al., 1993). These cells proliferate during larval development to 
form the mature third instar disc, composed by approximately 50000 cells primed to 
differentiate during metamorphosis the fly wing and part of the thorax (Figure 3) (de Celis, 
2003). Cell signalling pervades the development of the wing imaginal disc; from the initial 
step of primordium specification to the last stages of cellular differentiation. In this manner, 
the cells that constitute the wing disc primordium are determined by the combined actions 
of the BMP, EGFR and Wnt signalling pathways, which regulate the expression of the 
transcription factors specifying the group of wing disc precursor cells (Cohen et al., 1993; 
Goto and Hayashi, 1997). From this point onwards, the primordium enters a developmental 
program that involves cell division and different stages of territorial organization by which 
all cells acquire their individual genetic specification (Zecca and Struhl, 2002).   
Territorial subdivisions in the wing disc are regulated by coordinate signalling events 
involving the EGFR, BMP, Notch, Hh and Wnt pathways (Figure 3). First, the wing 
primordium is subdivided into anterior and posterior compartments, which correspond to 
independent cell lineages of polyclonal origin. The posterior compartment is the source of the 
ligand Hh, which signalling contributes to the maintenance of the anterior-posterior 
compartment boundary and sets specific domains of gene expression in anterior cells from this 
early stage onwards (Tabata and Kornberg, 1994) (Figure 3). The subdivision into anterior-
posterior compartments is followed later in development by patterning along the proximo-
distal axes of the disc, a process that relies in the establishment of complementary domains of 
signalling by the EGFR pathway in proximal cells and by the Wnt pathway in distal cells 
(Zecca and Struhl, 2002). These two complementary signalling centers determine the 
expression of transcription factors such as Apterous, the Iroquois gene complex and Spalt in 
proximal cells, defining what will become the thorax of the mature wing disc (Cavodeassi et 
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al., 2002). The establishment of the domain of apterous expression also triggers the initiation of 
the wing region, which will appear centred along the boundary between apterous expressing 
cells, the future dorsal compartment, and apterous non-expressing cells, corresponding to the 
ventral compartment. This boundary corresponds to the future dorso-ventral compartment 
boundary of the wing, and is the place where Notch signalling is activated to regulate the 
expression of the co-factor Vestigial, which labels the primordium of the wing blade (Figure 3). 
The establishment of the wing blade territory as a domain of cells expressing vestigial along 
the dorso-ventral boundary also requires wingless function, which expression in distal cells is 
also regulated by the transcription factors defining the proximo-distal axes of the wing disc 
(Wu and Cohen, 2002; Whitworth and Russell, 2003; Zirin and Mann, 2007). At this stage, 
which corresponds to the second instar larvae, the wing disc already contains the future thorax 
and wing territories, and the wing is already subdivided into anterior-posterior and dorso-
ventral compartments. The subsequent development of the wing disc epithelium involves the 
generation of the wing hinge, originated in the proximal part of the wing blade and specified 
by two novel rings of wingless expression (Perea et al., 2009), and the establishment of smaller 
domains of expression in both the thorax and wing regions (Figure 3). 
 
 
Fig. 3. Schematic representation of the wing disc during the second (upper panels), mid-
third (middle panel) and late-third (bottom panel) larval instard, showing the expression of 
ligands in coloured stripes. 
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The global subdivision of the wing disc into large territories described above is followed by 
the regional specification of the pattern elements characteristic of the wing and thorax.  
These elements, the sensory organs decorating the thorax and wing margin and the 
longitudinal veins running along the proximo-distal length of the wing blade and hinge, 
differentiate from fields of competent cells, the proneural clusters and the provein 
territories, respectively. As it happened with the earlier territorial subdivisions, the 
positioning of each proneural cluster and provein territory also relies on the function of 
different signalling pathways, mainly the Wnt, Hh and BMP pathways for the proneural 
clusters and the BMP and Hh pathways for the proveins (Tomoyasu et al., 1998; Sato et al., 
1999; de Celis et al., 1999; Cavodeassi et al., 2001; de Celis, 2003). These pathways now 
regulate the expression of several transcription factors that control the expression of the 
proneural and provein genes, constituting a landscape of transcriptional regulators that has 
been named the “pre-pattern” (Stern, 1954; Cavodeassi et al., 2001). At this stage, all 
patterned elements are genetically specified in the form of groups of cells with a competence 
to differentiate individual cell types. The last stage before cell differentiation is the 
assignation of cell fates within proneural clusters and provein territories. This process relies 
in a complex set of cell interactions mediated by the Notch and EGFR pathways and 
generally named “lateral inhibition”. During lateral inhibition, the EGFR pathway promotes 
the acquisition of the sensory organ precursor and vein fates and the Notch pathway 
prevents other competent cells from following these fates. In this manner, the end result is 
that only one cell from the proneural clusters will acquire the sensory organ precursor fate 
and enter a particular pattern of cell divisions (Pi and Chien, 2007). A similar process 
operates in the provein fields using the same two pathways, but in this case the maintenance 
of stripes of cells ready to differentiate as veins during pupal development also requires the 
activity of the BMP pathway, which ligand becomes expressed at this stage in the 
developing veins (de Celis, 2003). 
The patterning of the disc is accompanied by a continuous increase in its size (Baker, 2007). 
Wing disc growth occurs mainly by cell proliferation, with cells taking about 10 hours to go 
through the cell cycle (González Gaitán et al., 1994; Milan et al., 1996; Neufeld et al., 1998). 
Several pathways such as the EGFR, Wnt, SWH, Notch and TGF play key roles in 
promoting cell division. In this manner, a reduction (EGFR, Wnt, Notch and TGFor 
increase (SWH) in the activity of these pathways results in the formation of smaller adult 
structures, and this reduction in size is caused by the generation of a lower than normal 
number of cells (see Figure 4). Interestingly, these effects have a strong component of 
territorial specificity, because the reduction of each pathway activity affects each territory of 
the wing disc to different extents. For example, the Wnt pathway is particularly required to 
promote cell proliferation in the wing hinge (Dichtel-Danjoy et al., 2009), whereas the Notch 
pathway is mostly required in the wing blade (de Celis and Garcia-Bellido, 1994). As 
mutations affecting the activity of the EGFR, Wnt, BMP and Notch pathways also affect 
territorial specification, the defects in cell proliferation are accompanied by changes in the 
general organization of the disc and its patterning. Cell division is coupled with cell growth 
in a manner that wing disc cells maintain a similar size during their proliferative phase. 
From the perspective of cellular growth, the most relevant pathway operating in the wing 
disc is the InR/Tor signalling system (Hietakangas and Cohen, 2009). The activity of 
InR/Tor is mostly required as a sensor to translate nutritional and humoral signals into  
 
 




Fig. 4. Upper panel: Pictures of a wild type wing (wt, left) and third instar imaginal discs 
showing the domains of Notch, Hh, EGFR, Wg and Dpp signalling. Bottom panel: Pictures 
of mutant wings in which the activity of the InR/Tor, Notch, Hh and EGFR (left two 
columns), and Wg, dpp/BMP, TGF- and SWH (right two columns) is either increased 
(Pathway activation columns) or decreased (Pathway inhibition columns) 
adequate rates of protein synthesis, but also provides survival signals for the cell and 
stimulates cell division (Hietakangas and Cohen, 2009). In general, mutations reducing 
InR/Tor signalling result in the formation of adult structures smaller than normal, due to 
both a reduction in cell size and a diminution in the number of cells (see Figure 4).   
Although the wing disc is probably one of the best understood biological systems, there are 
still many caveats regarding the molecular mechanisms that drive cell division during the 
growth of the disc. Similarly, it is not entirely understood how the progress through the cell 
cycle is coordinated with cellular growth, and what makes the disc stop its proliferative 
phase when it reaches a particular size. In this manner, the molecular mechanisms ensuring 
the formation of patterned structures of the appropriate dimensions are still elusive. Despite 
of this, the current knowledge about imaginal disc development is robust enough to use this 
system as a model to unravel the intricacies and roles played by signalling pathways during 
development, and to model human diseases, using the advantages of fly genetics. There are 
two key aspects of the analysis of signalling in the wing disc that favours this system as an 
experimental model. First is the facility by which mutant phenotypes can be assigned to 
specific failures in particular signalling pathways. This simplifies the identification of 
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adequate rates of protein synthesis, but also provides survival signals for the cell and 
stimulates cell division (Hietakangas and Cohen, 2009). In general, mutations reducing 
InR/Tor signalling result in the formation of adult structures smaller than normal, due to 
both a reduction in cell size and a diminution in the number of cells (see Figure 4).   
Although the wing disc is probably one of the best understood biological systems, there are 
still many caveats regarding the molecular mechanisms that drive cell division during the 
growth of the disc. Similarly, it is not entirely understood how the progress through the cell 
cycle is coordinated with cellular growth, and what makes the disc stop its proliferative 
phase when it reaches a particular size. In this manner, the molecular mechanisms ensuring 
the formation of patterned structures of the appropriate dimensions are still elusive. Despite 
of this, the current knowledge about imaginal disc development is robust enough to use this 
system as a model to unravel the intricacies and roles played by signalling pathways during 
development, and to model human diseases, using the advantages of fly genetics. There are 
two key aspects of the analysis of signalling in the wing disc that favours this system as an 
experimental model. First is the facility by which mutant phenotypes can be assigned to 
specific failures in particular signalling pathways. This simplifies the identification of 
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additional components of each signalling pathway by the phenotype caused by mutations in 
the corresponding genes (Figure 4), and also allows the design of genetic screens aimed to 
identify novel elements of the pathway. Secondly, the spatial and temporal domains of 
signalling can be precisely described by monitoring the expression of target genes in the 
disc, and this allows the visualization of receptor activity both in normal conditions and 
under experimental manipulations (Figure 4).  
6. Genetic approaches to identify additional components of signalling 
pathways 
Some of the main reasons to choose Drosophila for the study of signalling are the 
availability of sophisticated genetic techniques to manipulate gene activity and the 
knowledge of the Drosophila genome (Adams et al., 2000; Matthews et al., 2005). First, there 
is a strong conservation between Drosophila proteins involved in signalling pathways and 
their human counterparts (Reiter et al., 2001; Chien et al., 2002 see Table 1). Second, 
Drosophila genes involved in signalling are generally represented in single copies, reducing 
the possibility of redundancy and facilitating the characterization of gene functions (Adams 
et al., 2000). Third, loss- and gain-of-function conditions in genes coding for signalling 
proteins of all pathways usually result in complementary phenotypes, allowing the 
assignation of genes to pathways based on mutant phenotypes (Molnar et al., 2006; Cruz et 
al., 2009 see Figure 4). The phenotypes observed upon hyper-activation of the pathways also 
allow the design of gain-of-function screens, which have the potential to uncover genes not 
found in loss-of-function screens due to functional redundancy (Rorth et al., 1998). Finally, 
mutations in different elements of each signalling pathway generally display gene-dose 
dependent phenotypic interactions in genetic combinations, allowing the hierarchical 
ordering of pathway components through genetic analysis. 
There are two main ways in which genetic screens have been used to identify the 
components of different signalling pathways. In a first approach, newly induced mutants 
are tested for a phenotype in a particular structure which development depends on the 
normal activity of specific signalling pathways. In these cases, the mutants can be induced 
by chemical mutagenesis or by mobilizing transposable elements, and they can be analyzed 
either in homozigosity in the entire animal, or in mosaics in adult tissues using a 
combination of the Gal4/UAS and FRT/FLP systems. A recent example of this approach is 
the search for novel components of the Notch signalling pathway, in which a large collection 
of interference RNAs is expressed in the wing disc to systematically reduce the expression of 
the endogenous genes, resulting in the identification of Notch pathway candidates based on 
the resulting mutant phenotypes (Mummery-Widmer et al., 2009). In addition, whereas 
chemical mutagenesis and the expression of interference RNA result in loss of gene 
function, the use of transposable elements with UAS sequences allows the generation of 
gain-of-function conditions, which can be restricted to the tissue of interest (Rorth et al., 
1998). Complementary to these approaches, the search for novel components of signalling 
pathways has also relied in the design of “modifier” screens, in which both loss- and gain-
of-function mutants are tested in particular mutant backgrounds. In these cases, the screen 
aims to identify genes belonging to a pre-determined set of interacting genes. Some 
examples of successful screens aiming to identify members of known signalling pathways 
are those targeting the Sevenless and EGFR (Karim et al., 1996; Huang and Rubin, 2000; 
Taguchi et al., 2000; Rebay et al., 2000), Notch (Verheyen et al., 1996; Go and Artavanis-
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Tsakonas, 1998; Muller et al., 2005a), Dpp (Raftery et al., 1995; Chen et al., 1998; Su et al., 
2001), JAK/STAT (Bach et al., 2003; Mukherjee et al., 2006), Hh (Haines and van den Heuvel, 
2000; Collins and Cohen, 2005), TNF (Geuking et al., 2005) and Wnt (Greaves et al., 1999; 
Cox et al., 2000; Desbordes et al., 2005) pathways.  
Although the use of genetic screens in vivo has many advantages, they are time-consuming 
and difficult to escalate genome-wide. For these reasons, and based on the knowledge of the 
Drosophila genome, several techniques using Drosophila cells in culture and interference 
RNA have been adopted in the search for novel signalling components. These screens allow 
the identification of genes affecting the expression of reporter constructs that reveal the 
activity of specific signalling pathways (Clemens et al., 2000; Flockhart et al., 2006). This 
approach has been used to search for novel components of the Hh (Lum et al., 2003; 
Nybakken et al., 2005), and of the Wnt (DasGupta et al., 2005), JAK/Stat (Muller et al., 
2005b), TNF (Kleino et al., 2005), Tor (Lindquist et al., 2011) and ERK (Friedman and 
Perrimon, 2006) signalling pathways. 
7. Drosophila models of genetic diseases 
It is clear that the main advantage of the Drosophila model from a biomedical perspective is 
the possibility of designing genetic screens aimed to the identification of genes involved in a 
particular phenotypic outcome. In this context, it is worth noticing that an estimated 60% of 
genes related to human diseases have orthologs in Drosophila, and this category includes all 
genes involved in cell signalling (Chien et al., 2002; Reiter et al., 2001). The possibility of 
generating transgenic flies expressing modified non-Drosophila proteins is allowing the 
design of “humanized” fly models for a variety of human genetic diseases such as Multiple 
Endocrine Neoplasia Type 2 (Read et al., 2005), cardiomyopathies (Vu Manh et al., 2005) and 
Adenomatous Polyposis Coli (APC; Bhandari and Shashidhara, 2001) and several 
neurodegenerative diseases (Fernandez-Funez et al., 2000; Crowther et al., 2004; Sang and 
Jackson, 2005; Botas, 2007; Branco et al., 2008; Cukier et al., 2008; Miller et al., 2010). The aim 
of these experiments is to recreate in a fly tissue some of the cellular aspects of the pathology 
caused by the human protein, and to use this genetic background as a platform to search for 
genes affecting the phenotype caused by the miss-expression of this protein (Botas, 2007). In 
the long term, it is expected that the identification of additional genes involved in a 
particular phenotypic outcome will allow the search for chemotherapeutic agents with 
therapeutical value. In addition to genetic searches, Drosophila also permits to recapitulate 
the biology of particular diseases in vivo systems, an approach that is been applied to the 
study of tumorigenesis using among other tissues the imaginal discs (Janic et al., 2010). In 
this manner Drosophila tissues can be used not only to track down the steps leading to 
tumour initiation, progression and metastasis in vivo, but also to manipulate in genetic 
mosaics the activity of genes leading to tumoral growth and to assay therapeutic drugs 
(Kango-Singh and Halder, 2004; Vidal and Cagan, 2006; Jang et al., 2007; Januschke and 
Gonzalez, 2008; Read et al., 2009; Caldeira et al., 2009; Das and Cagan, 2010; Bina et al., 2010; 
Wu et al., 2010). This approach is contributing to dissect the effects of tumour-promoting 
and tumour-suppressing genes in the regulation of proliferation, apoptosis, cell-adhesion, 
trafficking and cell polarity, and revealed the importance of cellular interactions in the 
outcome of tumoral progression.  Finally, the modelling of specific cancers, such as type 2 
multiple endocrine neoplasia (MEN2, caused by hyper-activation of RET; Read et al., 2005b) 
has allowed the design and use of pharmacological approaches to modify the phenotype 
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and tumour-suppressing genes in the regulation of proliferation, apoptosis, cell-adhesion, 
trafficking and cell polarity, and revealed the importance of cellular interactions in the 
outcome of tumoral progression.  Finally, the modelling of specific cancers, such as type 2 
multiple endocrine neoplasia (MEN2, caused by hyper-activation of RET; Read et al., 2005b) 
has allowed the design and use of pharmacological approaches to modify the phenotype 
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caused by oncogenic forms of dRET (Das and Cagan, 2010). In addition, a similar approach 
prove successful in interfering with the activation of the EGFR (Aritakula and Ramasamy, 
2008), suggesting that Drosophila has also the potential to be a robust model system for the 
screening of anticancer drugs in vivo. 
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1. Introduction 
In vertebrates, various signaling pathways are activated in a highly coordinated manner to 
ensure proper development and morphogenesis. Secreted signaling molecules such as FGFs 
(Fibroblast growth factors), BMPs (Bone morphogenetic factors), WNTs (Wingless/int), and 
Hedgehogs play crucial roles in development and morphogenesis by acting over variable 
distances to influence intracellular signaling events in neighboring cells. FGFs are 
polypeptide growth factors with diverse biological functions. The human FGF family 
comprises twenty-two members. The mouse and zebrafish are widely used vertebrate 
models for studying gene function in vivo. The mouse and zebrafish FGF families comprise 
twenty-two and twenty-eight members, respectively. These FGFs can be classified as 
paracrine, endocrine, and intracrine FGFs by their mechanisms of action (Itoh & Ornitz, 
2008). Paracrine FGFs (canonical FGFs) mediate biological responses by binding to and 
activating cell surface tyrosine kinase FGFRs. They act as local paracrine signaling molecules 
and function in multiple developmental processes including differentiation, cell 
proliferation, and migration (Itoh & Ornitz, 2008; Beenken & Mohammadi, 2009). Endocrine 
FGFs are thought to mediate biological responses in an FGFR-dependent manner. However, 
they function over long distances as endocrine hormones (Kharitonenkov, 2009; Itoh, 2010). 
In contrast, intracrine FGFs act as FGFR-independent intracellular molecules that regulate 
the function of voltage-gated sodium channels (Goldfarb et al., 2007; Laezza et al., 2009). 
Targeted mutagenesis of Fgf genes in mice has elucidated their functions in development 
and metabolism. Studies with zebrafish Fgf mutant and knockdown embryos also have 
revealed their functions in development. In addition, evidence for the involvement of FGF 
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1. Introduction 
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proliferation, and migration (Itoh & Ornitz, 2008; Beenken & Mohammadi, 2009). Endocrine 
FGFs are thought to mediate biological responses in an FGFR-dependent manner. However, 
they function over long distances as endocrine hormones (Kharitonenkov, 2009; Itoh, 2010). 
In contrast, intracrine FGFs act as FGFR-independent intracellular molecules that regulate 
the function of voltage-gated sodium channels (Goldfarb et al., 2007; Laezza et al., 2009). 
Targeted mutagenesis of Fgf genes in mice has elucidated their functions in development 
and metabolism. Studies with zebrafish Fgf mutant and knockdown embryos also have 
revealed their functions in development. In addition, evidence for the involvement of FGF 
signaling in hereditary, paraneoplastic, and metabolic diseases has also accumulated. FGF 
signaling disorders contribute to pathological conditions. In this article, we provide a 
succinct review of the FGF family in humans, mice, and zebrafish and their developmental 
physiological and pathophysiological roles.  
2. The human/mouse FGF family 
FGF1 and FGF2 are prototypic FGFs originally isolated from the brain and pituitary as 
mitogens for cultured fibroblasts (Gospodarowicz, 1975; Gospodarowicz, et al., 1978). New 
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FGF proteins have since been isolated as growth factors for cultured cells or been identified 
as oncogene products. In addition, new Fgf genes have been identified by homology-based 
PCR/DNA database searching and as genes responsible for hereditary diseases or cancer 
(Itoh & Ornitz, 2008; Beenken & Mohammadi, 2009; Itoh, 2007; Krejci et al., 2009; Turner & 
Grose, 2010). The human/mouse Fgf family comprises twenty-two members, Fgf1-Fgf23. No 
other Fgf genes have been identified in the human/mouse genome.  
Human/mouse FGFs are proteins of ~150-300 amino acids and have a conserved core of 
~120-amino acids with ~30-60% identity. Fgf15 has not been identified in humans. Fgf19 has 
not been identified in mice. Fgf15 and Fgf19 are likely to be orthologous genes in vertebrates. 
Except for rodents, the orthologs are named Fgf19 in vertebrates (Itoh & Ornitz, 2004; Itoh & 
Ornitz, 2008). In this review, we refer to these genes as Fgf15/19. Phylogenetic analysis 
indicates potential evolutionary relationships in the gene family. However, this alone is not 
sufficient to determine the relationships. Analyzing gene loci on chromosomes gives a more 
precise indication of the evolutionary relationships in a gene family. The gene location 
analysis of the human/mouse Fgf family has identified seven subfamilies; Fgf/1/2/5, Fgf3/4/6, 
Fgf7/10/22, Fgf8/17/18, Fgf9/16/20, Fgf11/12/13/14, and Fgf15/19/21/23 (Itoh & Ornitz, 2004; 
Itoh & Ornitz, 2008). FGFs can also be classified as paracrine, endocrine, and intracrine FGFs 
based on their mechanisms of action (Fig. 1). Paracrine FGFs comprise members of the 
FGF/1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18, and FGF9/16/20 subfamilies. They are 
secreted proteins, which mediate biological responses in a paracrine manner. Endocrine 
FGFs, FGF15/19, FGF21, and FGF23, are also secreted proteins. However, they mediate 
biological responses in an endocrine manner. Intracrine FGFs, FGF11-FGF14, are 
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Fig. 1. Action mechanisms of Fgfs. Fgfs act on target cells in a paracrine, endocrine , or 
intracrine manner.  
 
































Fig. 2. Schematic representations of structure. Schematic diagrams of intracrine, paracrine, 
and endocrine FGFs are shown. SP, SP* and HB indicate a cleavable secreted signal 
sequence, an uncleaved bipartite secreted signal sequence, and a heparin-binding site, 
respectively. 
3. Mechanisms of action 
3.1 Paracrine FGFs 
Most paracrine FGFs are secreted proteins with cleavable N-terminal secreted signal 
peptides. However, FGF9, FGF16, and FGF20 have uncleaved bipartite secreted signal 
sequences (Revest et al., 2000). By contrast, FGF1 and FGF2 without N-terminal signal 
sequences are not typical secreted proteins. They might be released from damaged cells or 
by an exocytotic mechanism that is independent of the endoplasmic reticulum-Golgi 
pathway (Mohan et al., 2010; Nickel, 2010). Paracrine FGFs mediate biological responses as 
extracellular proteins by binding to and activating cell surface tyrosine kinase FGFR 
receptors (FGFRs) with heparin/heparan sulfate as a cofactor.  
The human/mouse Fgfr gene family comprises four Fgfr genes, Fgfr1–Fgfr4 (Beenken & 
Mohammadi, 2009; Turner & Grose, 2010). All FGFR proteins are receptor tyrosine kinases 
of ~800 amino acids with an extracellular ligand-binding domain with three 
immunoglobulin-like domains (I, II, and III). Fgfr1–Fgfr3 encode two major versions of 
immunoglobin-like domain III (IIIb and IIIc) generated by alternative splicing that utilizes 
one of two unique exons. The immunoglobulin-like domain III is an essential determinant of 
ligand-binding specificity (Zhang et al., 2006). Thus, seven major FGFR proteins (FGFRs 1b, 
1c, 2b, 2c, 3b, 3c, and 4) with differing ligand-binding specificity are generated from four 
Fgfr genes.  
Paracrine FGFs have a heparin-binding site and interaction with heparin-like molecules is 
necessary for their stable interaction with FGFRs and local signaling (Goetz et al., 2007). 
Paracrine FGFs function in development by influencing the intracellular signaling events of 
neighboring cells from a distance. The range of FGF signaling is regulated in part by affinity 
for extracellular matrix heparan sulfate proteoglycans (Kalinina et al., 2009) and in part by 
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1c, 2b, 2c, 3b, 3c, and 4) with differing ligand-binding specificity are generated from four 
Fgfr genes.  
Paracrine FGFs have a heparin-binding site and interaction with heparin-like molecules is 
necessary for their stable interaction with FGFRs and local signaling (Goetz et al., 2007). 
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the dimerization of some FGFs (Kalinina et al., 2009; Harada et al., 2009). The binding of 
FGFs to FGFRs induces functional dimerization, receptor transphosphorylation, and the 
activation of four key downstream signaling pathways: RAS-RAF-MAPK, PI3K-AKT, STAT, 
and PLC  (Beenken & Mohammadi, 2009; Turner & Grose, 2010).  
3.2 Endocrine FGFs 
Endocrine FGFs are also thought to mediate biological responses in an FGFR-dependent 
manner. However, they bind to FGFRs and heparin/heparan sulfate with very low affinity. 
The reduced heparin-binding affinity enables endocrine FGFs to function in an endocrine 
manner (Zhang et al., 2006; Goetz et al., 2007). Klotho is a single-pass transmembrane 
protein of ~1,000 amino acids with a short cytoplasmic domain. The phenotypes of Klotho 
knockout mice are very similar to those of Fgf23 knockout mice (Shimada et al., 2004), 
indicating that FGF23 and Klotho may function in a common signal transduction pathway. 
Klotho most efficiently binds to and activates FGFR1c among several isoforms of FGFRs in 
cultured cells, suggesting that FGFR1c can transduce an FGF23/ Klotho signal(Urakawa et 
al., 2006). 
Klotho is a protein that shares structural similarity and characteristics with Klotho. The 
phenotypes of Klotho knockout mice overlap those of Fgfr4 knockout mice and Fgf15/19 
knockout mice (Ito et al., 2005; Inagaki et al., 2005). FGF15/19 can bind to a Klotho-FGFR4 
complex in cultured cells. FGF15/19 also activates FGF signaling in hepatocytes that 
primarily express Fgfr4 (Kurosu et al., 2007). These results indicate FGFR4 to be the primary 
receptor for transduction of an FGF15/19/ Klotho signal. Klotho is also essential for 
FGF21 signaling in cultured cells (Kharitonenkov et al., 2008). However, Fgf21 knockout 
mouse phenotypes are distinct from Klotho knockout mouse phenotypes (Ito et al., 2005; 
Hotta et al., 2009). In addition, the administration of recombinant human FGF21 to Klotho 
knockout mice demonstrated that FGF21 signals can be transduced in the absence of 
Klotho (Tomiyama et al., 2010). These results indicate the existence of a Klotho-
independent FGF21 signaling pathway in which undefined cofactors might be involved.  
3.3 Intracrine FGFs 
Intracrine FGFs interact with intracellular domains of voltage-gated sodium channels and 
with a neuronal MAPK scaffold protein, islet-brain-2 (Schoorlemmer & Goldfarb, 2002; 
Goldfarb et al., 2007). The only known role for intracrine FGFs is in regulating the electrical 
excitability of neurons and possibly other cell types (Goldfarb et al., 2007; Xiao et al., 2007; 
Shakkottai et al., 2009; Dover et al., 2010). 
4. Evolutionary history of the human/mouse Fgf gene family 
The FGF signaling system has been conserved throughout metazoan evolution. Two Fgf-like 
genes have been identified in the nematode, C. elegans (Huang & Stern, 2005). Six Fgf-like 
genes, which are potential ancestral genes of the human/mouse Fgf subfamilies, have been 
identified in the ascidian, C. intestinalis (Satou et al., 2002). Ascidians belong to the 
Subphylum Urochordata, the earliest branch in the Phylum Chordata. These results indicate 
that most ancestral genes of the human/mouse Fgf subfamilies were generated by gene 
duplication after the diversion of protostomes and deuterostomes. The evolutionary history 
of the mouse Fgf family has been proposed (Fig. 3) (Itoh & Ornitz, 2008). The ancestral gene 
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of the Fgf family is an ancestral intracrine Fgf gene, Fgf13-like, with a heparin-binding site 
but no secreted signal sequence. An ancestral gene of paracrine Fgfs, Fgf4-like, was generated 
from Fgf13-like by gene duplication during the early stages of metazoan evolution. During 
this evolution, Fgf4-like acquired a secreted signal sequence, thus allowing it to function as a 
paracrine Fgf. Ancestral genes, Fgf5-like, Fgf8-like, Fgf9-like, and Fgf10-like, of paracrine Fgf 
subfamilies were also generated from Fgf4-like by gene duplication after the separation of 
protostomes and deuterostomes. Secreted signal sequences were conserved in Fgf5-like, Fgf8-
like, and Fgf10-like. A cleavable secreted signal sequence also evolved into an uncleaved 
bipartite signal sequence in Fgf9-like. These FGFs with heparin-binding sites function in a 
paracrine manner. In contrast, no ancestral gene of endocrine Fgfs has been identified in 
Ciona intestinalis. The ancestral gene of endocrine Fgfs, Fgf15/19-like, appears to have arisen 
from Fgf4-like by local gene duplication early in vertebrate evolution. During this evolution, 
Fgf15/19-like lost its high affinity heparin-binding capacity, thus allowing it to function in an 
endocrine manner. Conserved gene orders are observed among members of each Fgf 
subfamily, indicating that each subfamily further expanded into three or four members via 
two large-scale genome duplication events (R1 and R2) during the evolution of early 
vertebrates.  
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Fig. 3. The functional evolutionary history of the human/mouse/zebrafish Fgf gene family. 
Fgf13-like is the ancestral gene of the Fgf family. Fgf4-like was generated from Fgf13-like by 
gene duplication during the early stages of metazoan evolution. Fgf5-like, Fgf8-like, Fgf9-like, 
and Fgf10-like were generated from Fgf4-like by gene duplication. Fgf15/19-like was also 
generated from Fgf4-like by local gene duplication. Each subfamily further expanded into 
three or four members via two genome duplication events (R1 &R2) during the evolution of 
early vertebrates. The zebrafish Fgf family further expanded via an additional genome 
duplication event (R3) shortly after the teleost radiation. 
5. The zebrafish FGF family 
Almost all zebrafish orthologs of human/mouse Fgf genes except for Fgf9 have been 
identified. In addition, Fgf24 has been identified in zebrafish as well as all teleosts examined 
including the stickleback, medaka, and puffer fish. However, Fgf24 has not been identified 
in all tetrapods examined. These results indicate that Fgf9 and Fgf24 were lost in the teleost 
lineage and tetrapod lineage during evolution, respectively. Zebrafish also has six 
additional Fgf genes including Fgf6b, Fgf8b, fgf10b, fgf13b, fgf18b, and fgf20b. The zebrafish Fgf 
family comprises twenty-eight members. Analysis of the location of the additional genes 
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the dimerization of some FGFs (Kalinina et al., 2009; Harada et al., 2009). The binding of 
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Almost all zebrafish orthologs of human/mouse Fgf genes except for Fgf9 have been 
identified. In addition, Fgf24 has been identified in zebrafish as well as all teleosts examined 
including the stickleback, medaka, and puffer fish. However, Fgf24 has not been identified 
in all tetrapods examined. These results indicate that Fgf9 and Fgf24 were lost in the teleost 
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family comprises twenty-eight members. Analysis of the location of the additional genes 
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indicates that they are paralogs (Fig. 3) (Itoh & Konsihi, 2007). Comparisons of mammalian 
genes with genes of teleost fish have shown that in teleosts, including zebrafish, there are 
often two homologs of the mammalian equivalent. This suggests that there has been an 
additional genome duplication event (R3) shortly after the teleost radiation. This duplication 
must have been either a partial or a whole genome duplication followed by rapid gene loss 
because gene duplications account for only ~20% of the zebrafish genes examined 
(Nusslein-Volhard et al., 2002). Zebrafish Fgf paralogs were also generated by genome 
duplication.  
6. Physiological roles of FGFs indicated by Fgf knockout mouse phenotypes 
The mouse is a widely used mammalian model for studying functions of genes. Gene 
functions can be effectively blocked in mice by targeted disruption of genes. Gene knockout 
mouse phenotypes have indicated their physiological functions. Most Fgf genes have been 
disrupted in mice. Phenotypes range from early embryonic lethality to changes in adult 
physiology (Table 1). Paracrine, endocrine, and intracrine FGFs mostly play roles in 
development, and metabolism, and neuronal functions, respectively.  
6.1 Paracrine Fgfs  
Paracrine FGFs are a major FGF group, canonical FGFs, including FGF1-FGF10, FGF16-
FGF18, FGF20, and FGF22. Knockout mouse phenotypes mostly indicate roles as 
growth/differentiation factors. Fgf1 knockout mice are viable and normal (Miller, et al., 
2000). Fgf2 knockout mice are also viable, but have decreased vascular tone and reduced 
numbers of neurons in deep cortical layers (Raballo et al., 2000; Zhou et al., 1998; Dono et al., 
1998). In addition, Fgf2 knockout mice show impaired recovery from ischemic injury to the 
heart (House et al., 2003; Virag et al., 2007). Fgf3 knockout mice are viable, but have 
phenotypes that include inner ear agenesis and dysgenesis, microtia, and microdontia 
(Mansour et al., 1993; Alvarez et al., 2003; Tekin et al., 2007)). Fgf4 and Fgf8 knockout mice 
die at early embryonic stages. Fgf4 and Fgf8 have essential roles in blastocyst formation and 
gastrulation, respectively (Feldman  et al., 1995; Sun et al., 1999). Conditional inactivation of 
Fgf8 has identified additional roles in limb bud development and organogenesis. Fgf5, Fgf6, 
and Fgf7 knockout mice are viable. Abnormal long hair is observed in Fgf5 knockout mice 
(Hébert et al., 1994). Fgf6 knockout mice have defects in muscle regeneration (Floss et al., 
1997). Fgf7 knockout mice have impaired hair and kidney development (Guo et al., 1996; 
Qiao et al., 1999). Fgf9, Fgf10, and Fgf18 knockout mice die shortly after birth. Fgf10 is critical 
for epithelial-mesenchymal interactions necessary for the development of epithelial 
components of multiple organs (Min et al., 1998; Sekine et al., 1999; Ohuchi et al., 2000; 
Sakaue et al., 2002). Fgf9 and Fgf18 have essential roles in the development of mesenchymal 
components of multiple organs (Colvin et al., 2001a,b; Colvin et al., 2001; Ohbayashi et al., 
2002; Liu et ,al. 2002; Usui et al., 2004; Hung et al., 2007). Fgf16 knockout mice on a C57BL/6 
genetic background are viable, but have impaired embryonic cardiomyocyte proliferation 
(Hotta et al., 2008). Fgf16 knockout phenotypes may be more severe on a Black Swiss genetic 
background where they die at embryonic day (E) 10.5 with severely impaired cardiac and 
facial development (Lu et al., 2008; Lu et al., 2010). Fgf17 and Fgf22 knockout mice are viable, 
but show impaired hindbrain development and impaired synaptic differentiation, 
respectively (Xu et al., 2000; Terauchi et al., 2010). In addition, Fgf22 knockout mice also 
show a clear delay in weight gain upon sexual maturity (Grose et al., unpublished data). 
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Fgf20 knockout mice are viable but have profound hearing loss (Ornitz et al., unpublished 
data). 
 
FGF    Physiological roles 
FGF1 None identified 
FGF2 Loss of vascular tone, slight loss of cortical neurons, defects in heart repair 
FGF3 Inner ear agenesis, microtia, microdontia 
FGF4 Defects in blastocyst formation  
FGF5 Abnormal long hair 
FGF6 Defective muscle regeneration 
FGF7 Impaired hair and kidney development 
FGF8 Defects in gastrulation, limb development, organogenesis 
FGF9 Impaired multiple organ development 
FGF10 Impaired multiple organ development 
FGF11 – 
FGF12 None identified, functional redundancy with Fgf14 
FGF13 – 
FGF14 Ataxia, paraoxysmal hyperkinetic movement disorder 
FGF15/19 * Impaired cardiac outflow tract morphogenesis and bile acid metabolism 
FGF16 Impaired cardiac and facial development Impaired embryonic cardiomyocte proliferation 
FGF17 Impaired hindbrain development 
FGF18 Impaired multiple organ development 
FGF20 Impaired inner ear development 
FGF21 Impaired lipid metabolism 
FGF22 Impaired synapse differentiation and delay in weight gain 
FGF23 Impaired phosphate and vitamin D metabolism 
Table 1. Physiological roles of FGFs indicated by Fgf knockout mice Phenotypes of most Fgf 
knockout mice have been published. Phenotypes of Fgf11, Fgf13, and Fgf20 knockout mice 
have not been published. *Fgf15 is referred to as Fg15/19.  
Although roles of paracrine FGFs in embryogenesis have been revealed from knockout 
mouse phenotypes, their contributions to adult physiology remain relatively unexplored. 
The widespread expression of paracrine Fgf genes in adult tissues suggests multiple roles in 
tissue homeostasis and repair (Fon Tacer et al., 2010). Emerging reports indicate homeostatic 
and regenerative roles for paracrine FGF signaling (Böhm et al., 2010; Yang et al., 2010). 
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indicates that they are paralogs (Fig. 3) (Itoh & Konsihi, 2007). Comparisons of mammalian 
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(Hébert et al., 1994). Fgf6 knockout mice have defects in muscle regeneration (Floss et al., 
1997). Fgf7 knockout mice have impaired hair and kidney development (Guo et al., 1996; 
Qiao et al., 1999). Fgf9, Fgf10, and Fgf18 knockout mice die shortly after birth. Fgf10 is critical 
for epithelial-mesenchymal interactions necessary for the development of epithelial 
components of multiple organs (Min et al., 1998; Sekine et al., 1999; Ohuchi et al., 2000; 
Sakaue et al., 2002). Fgf9 and Fgf18 have essential roles in the development of mesenchymal 
components of multiple organs (Colvin et al., 2001a,b; Colvin et al., 2001; Ohbayashi et al., 
2002; Liu et ,al. 2002; Usui et al., 2004; Hung et al., 2007). Fgf16 knockout mice on a C57BL/6 
genetic background are viable, but have impaired embryonic cardiomyocyte proliferation 
(Hotta et al., 2008). Fgf16 knockout phenotypes may be more severe on a Black Swiss genetic 
background where they die at embryonic day (E) 10.5 with severely impaired cardiac and 
facial development (Lu et al., 2008; Lu et al., 2010). Fgf17 and Fgf22 knockout mice are viable, 
but show impaired hindbrain development and impaired synaptic differentiation, 
respectively (Xu et al., 2000; Terauchi et al., 2010). In addition, Fgf22 knockout mice also 
show a clear delay in weight gain upon sexual maturity (Grose et al., unpublished data). 
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knockout mice have been published. Phenotypes of Fgf11, Fgf13, and Fgf20 knockout mice 
have not been published. *Fgf15 is referred to as Fg15/19.  
Although roles of paracrine FGFs in embryogenesis have been revealed from knockout 
mouse phenotypes, their contributions to adult physiology remain relatively unexplored. 
The widespread expression of paracrine Fgf genes in adult tissues suggests multiple roles in 
tissue homeostasis and repair (Fon Tacer et al., 2010). Emerging reports indicate homeostatic 
and regenerative roles for paracrine FGF signaling (Böhm et al., 2010; Yang et al., 2010). 
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6.2 Endocrine Fgfs  
Endocrine FGFs, FGF15/19, FGF21, and FGF23, are hormone-like FGFs. Hormones are 
usually responsible for communication between tissues in an endocrine manner. However, 
several hormones are produced in developing tissues that are unrelated to the endocrine 
gland of origin in adults. These hormones are synthesized locally, and serve as 
differentiation factors in embryos (Sanders & Harvey, 2008). Endocrine FGFs also act as 
differentiation factors in embryos and as hormones in adults (Itoh, 2010). 
Fgf15/19 knockout mice develop normally until E10.5, but then gradually die. The 
phenotype indicates that FGF15/19 is required for proper morphogenesis of the cardiac 
outflow tract at embryonic stages (Vincentz et al., 2005). Although most Fgf15/19 knockout 
mice die by postnatal day (P) 7, a few survive and appear phenotypically normal. However, 
fecal bile acid excretion was found to be increased in surviving Fgf15/19 knockout mice, 
indicating that intestinal FGF15/19 plays a crucial role in regulating hepatic bile acid 
synthesis (Inagaki et al., 2005). Fgf21 knockout mice are seemingly normal, but show 
hypertrophy and decreased lipolysis in adipocytes. In contrast, Fgf21 knockout mice fasted 
for 24 h show increased lipolysis in adipocytes and increased serum nonesterified fatty acid 
levels. Their phenotypes indicate that Fgf21 is important for the metabolic regulation of 
lipolysis in white adipose tissue (Hotta et al., 2009). Fgf21 knockout mice fed a ketogenic diet 
show partial impairments in ketogenesis (Badman et al., 2009). However, we have observed 
that ketogenesis is not impaired in Fgf21 knockout mice fed a ketogenic diet (Itoh et al., 
unpublished data). Fgf23 knockout mice survive until birth, but then gradually die, usually 
by 12 weeks of age (Shimada et al., 2004). The mice show hyperphosphatemia and increased 
active vitamin D levels. Fgf23, which is expressed in osteocytes, signals to the kidney where 
it regulates serum phosphate and active vitamin D levels. FGF23 may have other targets 
including the parathyroid gland and osteoblasts (Ben-Dov et al., 2007; Tang et al., 2010). 
6.3 Intracrine Fgfs  
Intracrine FGFs, FGF11-FGF14, are intracellular proteins. Fgf14 knockout mice are viable. 
However, they develop ataxia and a paraoxysmal hyperkinetic movement disorder 
(Goldfarb et al., 2007; Xiao et al., 2007; Shakkottai et al., 2009). In contrast, Fgf12 knockout 
mice are apparently normal. Fgf12/Fgf14 double knockout mice show severe ataxia and 
other neurological deficits (Goldfarb et al., 2007). Phenotypes of Fgf11 and Fgf13 knockout 
mice have not been reported. 
7. Roles of FGFs indicated by Fgf mutated or knockdown zebrafish 
phenotypes 
The zebrafish is also a widely used vertebrate model for studying functions of genes. 
Because zebrafish embryos are small, the fertilization and subsequent embryonic 
development occur externally, and the development is rapid (Nusslein-Volhard et al., 2002), 
phenotypes of zebrafish embryos in which the functions of genes are blocked–the knockout 
of which is lethal at early embryonic stages in mice–can be potentially analyzed. In a large-
scale screening, many zebrafish mutants, which were mutagenized with ethylnitrosourea, 
displaying distinct phenotypes in embryos were generated (Haffter et al., 1996). 
Furthermore, antisense morpholino oligonucleotides can easily block the functions of 
multiple genes in zebrafish embryos (Nasevicius & Ekker, 2000). Therefore the zebrafish is 
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expected to be a useful vertebrate model for studying physiological functions of Fgf genes in 
vivo.  
7.1 Paracrine FGFs 
Several zebrafish paracrine Fgf mutants have been generated by mutagenesis with 
ethylnitrosourea. acerebellar is a mutation of Fgf8. acerebellar embryos lack a cerebellum and 
the midbrain-hindbrain boundary organizer (Reifers et al., 1998). ikarus is a mutation of 
Fgf24. ikarus embryos lack pectoral fin buds (Fischer et al., 2003). daedalus is a mutation of 
Fgf10. Daedalus embryos have no pectoral fin buds either and a severely dysmorphic 
hepatopancreatic ductal system (Norton et al., 2005; Dong et al., 2007). devoid of blastema is a 
mutation of Fgf20a. devoid of blastema embryos have no pectoral fin buds (Whitehead et al., 
2005). These results indicate that zebrafish fgfs also play crucial roles in development. 
Several paracrine Fgf knockdown zebrafish embryos were generated using antisense 
morpholino oligonucleotides. Phenotypes of these embryos indicate roles of Fgfs in 
zebrafish. FGF1 is required for normal differentiation of erythrocytes (Songhet et al., 2007). 
FGF3 and FGF8 are required together for formation of the otic placode and vesicle (Maroon 
et al., 2002). FGF4 is required for left-right patterning of visceral organs (Yamauchi et al., 
2009). In addition, FGF16 is also required for the fin buds to form (Nomura et al., 2006).  
7.2 Endocrine FGFs 
Fgf15/19 and Fgf21 knockdown zebrafish embryos were generated using antisense 
morpholino oligonucleotides. FGF15/19 and FGF21 are required for the forebrain and eye to 
develop (Miyake et al., 2005; Nakayama et al., 2008), and hematopoiesis (Yamauchi et al., 
2006).  
8. FGF signaling disorders in human diseases  
As described above, FGF signaling is crucial to development, metabolism, and neuronal 
functions as paracrine, endocrine, and intracrine factors. In addition, FGF signaling 
disorders also result in human hereditary, paraneoplastic, and metabolic diseases. 
8.1 Paracrine FGFs  
Michel aplasia is a unique autosomal recessive syndrome characterized by type I microtia, 
microdontia, and profound congenital deafness associated with a complete absence of inner 
ear structures. Michel aplasia is caused by mutations in Fgf3 (Tekin et al., 2007). Nonsense 
mutations in Fgf8 are found in familial isolated hypogonadotropic hypogonadism with 
variable degrees of gonadotropin-releasing hormone deficiency and olfactory phenotypes. 
These findings confirm that loss-of-function mutations in Fgf8 cause human gonadotropin-
releasing hormone deficiency (Trarbach et al., 2010). Cleft lip and/or palate (CLP) appear 
when the two halves of the palatal shelves fail to fuse completely. A missense mutation in 
Fgf8 was found in a patient with CLP. This mutation is predicted to cause loss-of-function 
by destabilizing the N-terminal conformation, which is important for FGFR binding affinity 
and specificity (Riley et al., 2007). Aplasia of lacrimal and salivary glands (ALSG) is an 
autosomal dominant congenital anomaly characterized by aplasia, atresia, or hypoplasia of 
the lacrimal and salivary systems. Lacrimo-auriculo-dento-digital syndrome (LADD) is an 
autosomal-dominant multiple congenital anomaly disorder characterized by aplasia, atresia, 
or hypoplasia of the lacrimal and salivary systems, cup-shaped ears, hearing loss, and 
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fecal bile acid excretion was found to be increased in surviving Fgf15/19 knockout mice, 
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dental and digital anomalies. Both ALSG and LADD are caused by Fgf10 mutations 
(Entesarian et al., 2007; Rohmann et al., 2006). Fgf20 was originally identified as a 
neurotrophic factor preferentially expressed in dopaminergic neurons within the substantia 
nigra pars compacta of rat brain (Ohmachi et al., 2003). Parkinson disease (PD) is caused by 
a pathogenic process responsible for the loss of dopaminergic neurons within the substantia 
nigra pars compacta. A pedigree disequilibrium test and a case-control association study 
indicated that Fgf20 is potentially a risk factor for PD (Gao et al., 2008).   
8.2 Endocrine FGFs  
Serum FGF15/19 levels are markedly increased in patients with extrahepatic cholestasis 
caused by a pancreatic tumor. FGF15/19 is abundantly expressed in the liver of cholestatic 
patients, but not in the normal liver. FGF15/19 signaling may be involved in some of the 
adaptations that protect the liver against bile salt toxicity (Schaap et al., 2009). Serum 
FGF15/19 levels are also significantly increased in patients on chronic hemodialysis (Reiche 
et al., 2010). Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of 
metabolic syndrome, and ranges from simple fatty liver to nonalcoholic steatohepatitis. Its 
prevalence has increased dramatically over recent years in developed countries (Morris-Stiff 
& Feldstein, 2010). The pathophysiological hallmark of NAFLD is insulin resistance. NAFLD 
may increase the risk of type 2 diabetes and atheroclerosis (Bugianesi et al., 2010). Hepatic 
lipid metabolism is disturbed in patients with NAFLD. The hepatic response to FGF15/19 is 
impaired in NAFLD patients with insulin resistance. This impaired response may contribute 
to the disturbance of lipid homeostasis in NAFLD (Schreuder et al., 2010).  
Serum FGF21 levels are significantly increased in NAFLD (Yilmaz et al., 2010; Dushay et al., 
2010; Li et al., 2010). Serum FGF21 levels are positively correlated with intrahepatic 
triglyceride levels (Li et al., 2010). As NAFLD is now recognized as a major public health 
problem, reliable biomarkers for NEFLD are needed. Serum FGF21 levels might be useful as 
a biomarker for NEFLD (Morris-Stiff & Feldstein, 2010). Type 2 diabetes connected with 
visceral obesity and insulin resistance has become a global health concern. Serum FGF21 
levels are increased in patients with type 2 diabetes, gestational diabetes, and obesity, 
indicating FGF21 to be a potential new marker in patients with type 2 diabetes (Table 1) 
(Chen et al., 2008; Zhang et al., 2008; Chavez et al., 2009; Mraz et al., 2009; Stein et al., 2010; 
Matuszek et al., 2010). Serum FGF21 levels are independently associated with markers of 
insulin resistance and an adverse lipid profile (Chen et al., 2008; Stein et al., 2010). The up-
regulation of serum FGF21 levels might be a compensatory mechanism to improve glucose 
metabolism when insulin resistance is present. Impaired glucose tolerance (IGT) is an 
important category of prediabetes. Serum FGF21 levels were also increased in Chinese 
subjects with IGT, however, they did not correlate with insulin resistance (Li et al., 2009). 
Cushing's syndrome is a hormone disorder caused by high levels of cortisol 
(hypercortisolism) in the blood. Patients with Cushing's syndrome frequently suffer from 
visceral obesity, insulin resistance/diabetes, and other abnormalities similarly to patients 
with metabolic syndrome. Serum FGF21 levels are also increased in patients with Cushing’s 
syndrome. The increased FGF21 levels are due to excessive fat accumulation and related 
metabolic abnormalities rather than a direct effect of cortical on FGF21 production 
(Durovcová et al., 2010). Lipodystrophy is a common alteration in HIV-1-infected patients 
under anti-retroviral treatment. This syndrome is usually associated with peripheral 
lipoatrophy, central adiposity, and, in some cases, lipomatosis, as well as systemic insulin 
resistance and hyperlipidemia (Villarroya et al., 2007). Serum FGF21 levels are increased in 
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HIV-1-infected patients with lipodystrophy. This increase is closely associated with insulin 
resistance, metabolic syndrome, and markers of liver damage. FGF21 might be a biomarker 
of altered metabolism in HIV-1-infected, antiretroviral-treated patients (Domingo et al., 
2010). Serum FGF21 levels correlate with renal function and are markedly increased in 
chronic kidney disease patients receiving hemodialysis, suggesting a possible link between 
their FGF21 levels and renal function (Stein et al., 2009). Patients with end-stage renal 
disease (ESRD) show insulin resistance. Serum FGF21 levels are also markedly increased in 
patients with ESRD, suggesting FGF21 to play a role in insulin resistance in these patients 
(Han et al., 2010).  
Autosomal dominant hypophosphatemic rickets (AHDR) is caused by gain-of-function 
mutations of Fgf23 (ADHR Consortium, 2000). FGF23 is partially cleaved by intracellular 
proteolysis. The cleaved forms lose their biological activity. Fgf23 mutations in ADHR result 
in impaired proteolysis of FGF23 and increased serum levels of active FGF23 (White et al., 
2001). Reduced FGF23 signaling also causes human hereditary diseases. Familial tumoral 
calcinosis (FTC) is characterized by ectopic calcification and hyperphosphatemia. Loss-of-
function mutations of Fgf23 result in FTC. These mutations destabilize the tertiary structure 
of FGF23 and increase its susceptibility to degradation (Benet-Pagès et al., 2005). Tumors 
that over-produce FGF23 also cause tumor-induced osteomalacia, which is a paraneoplasitc 
disease characterized by hypophosphatemia caused by renal phosphate wasting (Shimada 
et al., 2001).  Serum FGF23 levels are also greatly increased in patients with renal failure, 
partly owing to decreased renal clearance. These results suggest that FGF23 has a 
compensatory role in the disease (Larsson et al., 2003). 
8.3 Intracrine FGFs  
Börjeson-Forssman-Lehmann syndrome (BFLS) is a syndromic X-linked mental retardation 
disease. Fgf13 is a candidate causative gene for BFLS (Gecz et al., 1999). Hereditary 
spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of 
neurodegenerative disorders. One SCA with early-onset tremors, dyskinesia, and slowly 
progressive cerebellar ataxia is caused by Fgf14 mutations (van Swieten et al., 2003; Brusse et 
al., 2006; Misceo et al., 2009).  
9. Conclusion 
The human/mouse FGF family comprises twenty-two members, which were generated by 
gene duplication after the diversion of protostomes and deuterostomes and two genome 
duplication events (R1 and R2) during the evolution of early vertebrates. In contrast, the 
zebrafish FGF family comprises twenty-eight members including several paralogs, which 
were generated by an additional genome duplication event (R3) in the teleost lineage during 
evolution. FGFs are now recognized as proteins with diverse biological functions and act as 
extracellular signaling molecules in a paracrine or endocrine manner or as intracellular 
signaling molecules. Experiments with Fgf knockout mice indicate that FGFs play vital roles 
in development, metabolism, and neuronal functions. Studies with Fgf mutated or 
knockdown zebrafish also indicate that FGFs are crucial to development. In addition, 
research on human diseases indicates that FGF signaling disorders contribute to 
pathological conditions. Secreted signaling molecules such as BMPs, WNTs, and Hedgehogs 
also play crucial roles in development by influencing the intracellular signaling events of 
their neighbors from a distance. FGFs, along with these signaling molecules, have roles in 
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dental and digital anomalies. Both ALSG and LADD are caused by Fgf10 mutations 
(Entesarian et al., 2007; Rohmann et al., 2006). Fgf20 was originally identified as a 
neurotrophic factor preferentially expressed in dopaminergic neurons within the substantia 
nigra pars compacta of rat brain (Ohmachi et al., 2003). Parkinson disease (PD) is caused by 
a pathogenic process responsible for the loss of dopaminergic neurons within the substantia 
nigra pars compacta. A pedigree disequilibrium test and a case-control association study 
indicated that Fgf20 is potentially a risk factor for PD (Gao et al., 2008).   
8.2 Endocrine FGFs  
Serum FGF15/19 levels are markedly increased in patients with extrahepatic cholestasis 
caused by a pancreatic tumor. FGF15/19 is abundantly expressed in the liver of cholestatic 
patients, but not in the normal liver. FGF15/19 signaling may be involved in some of the 
adaptations that protect the liver against bile salt toxicity (Schaap et al., 2009). Serum 
FGF15/19 levels are also significantly increased in patients on chronic hemodialysis (Reiche 
et al., 2010). Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of 
metabolic syndrome, and ranges from simple fatty liver to nonalcoholic steatohepatitis. Its 
prevalence has increased dramatically over recent years in developed countries (Morris-Stiff 
& Feldstein, 2010). The pathophysiological hallmark of NAFLD is insulin resistance. NAFLD 
may increase the risk of type 2 diabetes and atheroclerosis (Bugianesi et al., 2010). Hepatic 
lipid metabolism is disturbed in patients with NAFLD. The hepatic response to FGF15/19 is 
impaired in NAFLD patients with insulin resistance. This impaired response may contribute 
to the disturbance of lipid homeostasis in NAFLD (Schreuder et al., 2010).  
Serum FGF21 levels are significantly increased in NAFLD (Yilmaz et al., 2010; Dushay et al., 
2010; Li et al., 2010). Serum FGF21 levels are positively correlated with intrahepatic 
triglyceride levels (Li et al., 2010). As NAFLD is now recognized as a major public health 
problem, reliable biomarkers for NEFLD are needed. Serum FGF21 levels might be useful as 
a biomarker for NEFLD (Morris-Stiff & Feldstein, 2010). Type 2 diabetes connected with 
visceral obesity and insulin resistance has become a global health concern. Serum FGF21 
levels are increased in patients with type 2 diabetes, gestational diabetes, and obesity, 
indicating FGF21 to be a potential new marker in patients with type 2 diabetes (Table 1) 
(Chen et al., 2008; Zhang et al., 2008; Chavez et al., 2009; Mraz et al., 2009; Stein et al., 2010; 
Matuszek et al., 2010). Serum FGF21 levels are independently associated with markers of 
insulin resistance and an adverse lipid profile (Chen et al., 2008; Stein et al., 2010). The up-
regulation of serum FGF21 levels might be a compensatory mechanism to improve glucose 
metabolism when insulin resistance is present. Impaired glucose tolerance (IGT) is an 
important category of prediabetes. Serum FGF21 levels were also increased in Chinese 
subjects with IGT, however, they did not correlate with insulin resistance (Li et al., 2009). 
Cushing's syndrome is a hormone disorder caused by high levels of cortisol 
(hypercortisolism) in the blood. Patients with Cushing's syndrome frequently suffer from 
visceral obesity, insulin resistance/diabetes, and other abnormalities similarly to patients 
with metabolic syndrome. Serum FGF21 levels are also increased in patients with Cushing’s 
syndrome. The increased FGF21 levels are due to excessive fat accumulation and related 
metabolic abnormalities rather than a direct effect of cortical on FGF21 production 
(Durovcová et al., 2010). Lipodystrophy is a common alteration in HIV-1-infected patients 
under anti-retroviral treatment. This syndrome is usually associated with peripheral 
lipoatrophy, central adiposity, and, in some cases, lipomatosis, as well as systemic insulin 
resistance and hyperlipidemia (Villarroya et al., 2007). Serum FGF21 levels are increased in 
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HIV-1-infected patients with lipodystrophy. This increase is closely associated with insulin 
resistance, metabolic syndrome, and markers of liver damage. FGF21 might be a biomarker 
of altered metabolism in HIV-1-infected, antiretroviral-treated patients (Domingo et al., 
2010). Serum FGF21 levels correlate with renal function and are markedly increased in 
chronic kidney disease patients receiving hemodialysis, suggesting a possible link between 
their FGF21 levels and renal function (Stein et al., 2009). Patients with end-stage renal 
disease (ESRD) show insulin resistance. Serum FGF21 levels are also markedly increased in 
patients with ESRD, suggesting FGF21 to play a role in insulin resistance in these patients 
(Han et al., 2010).  
Autosomal dominant hypophosphatemic rickets (AHDR) is caused by gain-of-function 
mutations of Fgf23 (ADHR Consortium, 2000). FGF23 is partially cleaved by intracellular 
proteolysis. The cleaved forms lose their biological activity. Fgf23 mutations in ADHR result 
in impaired proteolysis of FGF23 and increased serum levels of active FGF23 (White et al., 
2001). Reduced FGF23 signaling also causes human hereditary diseases. Familial tumoral 
calcinosis (FTC) is characterized by ectopic calcification and hyperphosphatemia. Loss-of-
function mutations of Fgf23 result in FTC. These mutations destabilize the tertiary structure 
of FGF23 and increase its susceptibility to degradation (Benet-Pagès et al., 2005). Tumors 
that over-produce FGF23 also cause tumor-induced osteomalacia, which is a paraneoplasitc 
disease characterized by hypophosphatemia caused by renal phosphate wasting (Shimada 
et al., 2001).  Serum FGF23 levels are also greatly increased in patients with renal failure, 
partly owing to decreased renal clearance. These results suggest that FGF23 has a 
compensatory role in the disease (Larsson et al., 2003). 
8.3 Intracrine FGFs  
Börjeson-Forssman-Lehmann syndrome (BFLS) is a syndromic X-linked mental retardation 
disease. Fgf13 is a candidate causative gene for BFLS (Gecz et al., 1999). Hereditary 
spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of 
neurodegenerative disorders. One SCA with early-onset tremors, dyskinesia, and slowly 
progressive cerebellar ataxia is caused by Fgf14 mutations (van Swieten et al., 2003; Brusse et 
al., 2006; Misceo et al., 2009).  
9. Conclusion 
The human/mouse FGF family comprises twenty-two members, which were generated by 
gene duplication after the diversion of protostomes and deuterostomes and two genome 
duplication events (R1 and R2) during the evolution of early vertebrates. In contrast, the 
zebrafish FGF family comprises twenty-eight members including several paralogs, which 
were generated by an additional genome duplication event (R3) in the teleost lineage during 
evolution. FGFs are now recognized as proteins with diverse biological functions and act as 
extracellular signaling molecules in a paracrine or endocrine manner or as intracellular 
signaling molecules. Experiments with Fgf knockout mice indicate that FGFs play vital roles 
in development, metabolism, and neuronal functions. Studies with Fgf mutated or 
knockdown zebrafish also indicate that FGFs are crucial to development. In addition, 
research on human diseases indicates that FGF signaling disorders contribute to 
pathological conditions. Secreted signaling molecules such as BMPs, WNTs, and Hedgehogs 
also play crucial roles in development by influencing the intracellular signaling events of 
their neighbors from a distance. FGFs, along with these signaling molecules, have roles in 
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diverse biological processes in multicellular organisms. However, the 
interaction/cooperation of FGFs with BMPs, WNTs, and Hedgehogs mostly remain unclear. 
Further understanding of the roles of FGFs will provide clues to their mechanisms of 
interaction/cooperation. 
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1. Introduction   
Bone is a specialized connective tissue that performs many important functions: (i) 
mechanical, supporting the whole body and allowing the movements; (ii) protective, 
shielding many vital organs, such as brain, lung, heart and bone marrow; (iii) metabolic, 
regulating the homeostasis of calcium and phosphate (Baron, 1999); (iv) endocrine, 
regulating kidney function (Fukumoto & Martin, 2009; Mazzaferro et al., 2010) and 
contributing to global energy balance (Ducy et al., 1996; Ferron et al., 2010; Lee et al., 2007) 
and male fertility (Oury et al., 2011). Bone is a dynamic tissue, subjected to a continuous 
process of renewal and remodelling in which bone resorption by osteoclasts and bone 
formation by osteoblasts occur at the same site along the bone surface (Pogoda et al., 2005). 
About 10% of bone is replaced each year, with complete skeletal renewal every 10 years. An 
imbalance between osteoblast and osteoclast activities can cause serious consequences: if 
bone formation is enhanced or bone resorption is impaired, bone mass is increased, and vice 
versa (Parfitt, 1982; Pogoda et al., 2005). Often osteoclast diseases are monogenic, and in 
many of them the responsible gene and the respective function have been identified, while 
for other osteoclast diseases the causative gene has not been isolated or the exact function of 
the matching protein still remains unknown. In this review, a brief description of osteoclast 
biology will be provided and examples of genetic osteoclast diseases, including 
osteopetrosis, pycnodysostosis and Paget’s disease of bone, will be discussed. 
2. Osteoclast 
The osteoclast is the unique cell that is able to destroy the tissue to which it belongs 
(Teitelbaum, 2007). It is a giant cell with a diameter of 20-100 μm containing 4 to 50 nuclei, 
depending on the species (Roodman, 1996). The multinuclearity of osteoclast derives from 
the fusion of monocyte-macrophage mononuclear cells (Figure 1). In histological sections, 
osteoclasts appear variable in shape and size, adherent to the bone, within a small 
depression, called Howship’s lacuna, that is the result of their bone resorbing activity 
(Roodman, 1996). Osteoclasts are polarized cells (Takahashi et al., 2007). In fact, it is possible 
to identify a zone facing the bone matrix presenting a particular area of the plasma 
membrane, named ruffled border, composed by deep and irregular foldings that increase 
the size of the membrane located in front of the bone that will be resorbed (Stenbeck, 2002). 
The peripheral domain, named “sealing membrane”, represents the adhesion area by which 
the osteoclast attaches to the bone matrix around the site where it will be degraded. The 
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remaining membrane constitutes the basolateral domain containing proteins important for 
ion balance and response to regulatory stimuli. Opposite to the ruffled border domain, there 
is the apical domain, that is thought to be important for the transcytosis of bone resorption 
products from the resorbing lacuna to the extracellular fluids (Coxon & Taylor, 2008; Nesbitt 
& Horton, 1997; Peruzzi & Teti, 2011; Salo et al., 1996; Takahashi et al., 2007). Underneath 
the apical domain there are the nuclei that, under the light microscope, appear different in 
shape: some are round and euchromatic, others are irregular and more heterochromatic 
(Baron, 1989).  
 
 
Fig. 1. Osteoclast differentiation. The cartoon illustrates the different phases of osteoclast 
differentiation, from the hematopoietic precursor to the mature multinuclear osteoclast. 
Some of the genes implicated in this process are indicated.   
Moreover, ultrastructural studies showed Golgi complexes associated with each nucleus, 
many mitochondria and lysosomes (Baron et al., 1988; Stembeck, 2002). These latter 
organelles, approximately 0.5 μm in diameter, contain acid hydrolases, such as cathepsin K 
and Tartrate Resistant Acid Phosphatase (TRAcP), representing markers of the osteoclast 
phenotype (Garnero, 1998; Sakigiyama et al., 2001). Mitochondria are very abundant, 
correlating with the high energy expenditure that is required for the degradation of bone 
matrix (Miyazaki et al., 2006).  
2.1 The molecular mechanisms of bone resorption 
Bone resorption is a complex process requiring two different phases, the acidification of the 
extracellular lacuna to dissolve the inorganic bone matrix and the secretion of proteolytic 
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enzymes to digest the organic components (Blair et al., 1986; Vaananen et al., 1998) (Figure 
2). To achieve the acidification of the resorption lacunae and begin the process of bone 
demineralization, Carbonic Anhydrase II (CAII) generates carbonic acid from the hydration 
of CO2. Carbonic acid spontaneously dissociates in proton and bicarbonate (Bothwick et al., 
2003; Boyle et al., 2003). The protons so generated are actively released in the resorbing 
lacuna through an osteoclast-specific vacuolar-type (V)-H+-ATPase (Nishi & Forgac, 2002; 
Teitelbaum & Patrick, 2003). The excess of bicarbonate is removed by a bicarbonate/chloride 
exchanger, localised in the basolateral membrane (Baron, 1989; Teti et al., 1989). The chloride 
ion is then released in the bone resorption lacuna by a Cl-/H+ antiport, ClC7, that, coupling 
with the proton pump activity, balances the ion charge across the membrane (Boyle et al., 
2003; Graves et al., 2008; Teitelbaum & Patrick, 2003). The final goal of this process is to 
demineralise the bone and uncover the organic matrix ready to be digested by proteolytic 
enzymes, such as the metalloproteinase MMP9 released by endosomal vesicles, and the 
cathepsin K released by lysosomes (Blair et al., 1986; Bossard et al., 1996; Everts et al., 1992). 
 
 
Fig. 2. The bone resorption process. The cartoon illustrates the molecular patterns involved 
in bone resorption by osteoclasts. See text for detailed description.  
2.2 Osteoclastogenesis and regulation of osteoclast activity 
Osteoclasts are cells that belong to the monocyte/macrophage lineage and derive from the 
fusion of monocuclear precursors (Teitelbaum, 2007) (Figure 1). In 1981, Marks and Walker 
showed, by experiments with parabiotic animals, that circulating blood contains cells able to 
differentiate into osteoclasts, thus identifying their haematogenous origin (Marks & Walker, 
1981). Subsequently, in vitro studies with bone marrow-derived cells (Burger et al., 1989) 
suggested that osteoclasts arise from the differentiation of precursor cells of the CFU-M 
(Colony Forming Unit-Macrophage) lineage. This evidence suggested that osteoclasts 
present the same haematopoietic origin of antigen presenting cells and tissue macrophages. 
The pathway of osteoclast differentiation is now well characterized (Teitelbaum et al., 1997). 
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The PU.1 transcription factor is essential for the earliest phase of osteoclast differentiation, 
regulating the expression of the c-fms gene (Hayashi et al., 1998). c-fms encodes for the 
receptor of M-CSF (Macrophage-Colony Stimulating Factor), a cytokine crucial for the 
survival and the proliferation of early progenitors since it stimulates the cyclinD/CDK4 
(Cyclin-Dependent Kinase 4) pathway (Mundy, 1993; So et al., 2003). Moreover, c-fms is able 
to stimulate the expression of PU.1 itself, establishing an amplification loop (Mundy, 1993). 
The essential role of PU.1 during osteoclast commitment is even due to its ability to regulate 
the expression of RANK (Receptor Activator of NF-κB) that, upon interaction of its ligand 
RANKL, is able to initiate the differentiation and the fusion of osteoclast precursors (Kwon 
et al., 2005). In fact, subsequent to RANKL-RANK interaction, TRAF6 (TNF Receptor-
Associated Factor 6) is recruited and activates IĸB and MAP kinases (Takayanagi et al., 
2005), causing the nuclear translocation of NF-ĸB and of other transcription factors, 
including ATF2 (Activating Transcription Factor 2), c-fos and c-jun, required for the 
progression of osteoclast differentiation (Wada et al., 2006). Other two transcription factors 
important for osteoclast differentiation are MITF (MIcrophthalmia-associated Transcription 
Factor) (So et al., 2003) and NFATc1 (Nuclear Factor of Activated T-cells, cytoplasmic, 
calcineurin-dependent 1) (Takayanagi, 2007) that regulate the expression of osteoclast 
specific genes, like TRAcP, OSCAR (OSteoClast-Associated immunoglobulin-like Receptor), 
CTSK, CLC7 and OSTM1 (OSteopetrosis associated TransMembrane protein) (Takayanagi, 
2007; Meadows et al., 2007). The activation of RANK by RANKL is counterbalanced by the 
expression of a soluble decoy receptor, OPG (OsteoProteGerin), that is able to bind RANKL, 
preventing its interaction with RANK (Kong et al., 1999). The expression of RANKL by 
stromal cells and, during inflammation, by T cells and synovial fibroblasts, is regulated by 
hormones and local factors as it is stimulated by PTH (ParaThyroid Hormone), PGE2 
(ProstaGlandin E2) and 1,25(OH)2Vitamin D3 (Lips, 2006; Parfitt, 1976; Takeda et al., 1999). 
According to other studies, osteoclast progenitors express 1,25(OH)2Vitamin D3 receptors 
and their activation could contribute to the induction of RANK (Blair & Zaidi, 2006). Even 
sex hormones regulate osteoclast differentiation and function (Manolagas et al., 2002). 
Estrogens and androgens are believed to attenuate the rate of osteoclast formation 
downregulating genes essential for osteoclastogenesis (Cheung et al., 2003; Girasole et al., 
1992; Imai et al., 2009) and exerting a potent pro-apoptotic effect. Glucocorticoids are also 
thought to target the osteoclasts, preventing cell spreading and reducing their bone 
resorbing activity (Dempster et al., 1997; Kim et al., 2007). However, the use of 
glucocorticoids leads to a reduction of bone mass due to a direct negative effect on 
osteoblast activity and to inhibition of osteoclasts, that result in the interruption of the bone 
remodeling cycle (Dovio et al., 2004). Furthermore, osteoclasts are very sensitive to pH 
levels as it is known that systemic acidosis has detrimental effects on the skeleton and local 
acidosis is associated with bone destruction (Arnett, 2003; Krieger et al., 2004; Muzylak et al., 
2007). It has been shown that the Ovarian cancer G-protein-coupled Receptor 1 (OGR1 or 
GPR68), a proton sensing receptor, is essential for osteoclast formation inducing RANKL-
dependent osteoclastogenesis and activating NFATc1 (Iwai et al., 2007). 
3. Osteopetrosis 
Osteopetrosis is a rare (>1:100.000) genetic disorder characterized by an impaired 
osteoclast function that leads to pathological increase of bone mass and skeletal fragility. 
It was identified for the first time in 1904 by Albers-Scönberg, who described a patient 
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with  generalized sclerosis of the skeleton, suffering from several fractures (Albers-
Schönberg, 1904). Subsequently, in 1926, Karshner denominated the syndrome “marble 
bone disease” or “osteopetrosis” (Karshner, 1926). Impaired bone resorption causes 
persistence of old bone, increase of bone mass and obstruction of cavities containing vital 
organs such as the bone marrow and the nervous system. Osteopetrotic patients usually 
suffer from pathological fractures, short stature and haematological and neural failures 
(Balemans et al.; 2005; Del Fattore et., 2008; Frattini et.; 2003; Loria-Cortes et al., 1977). 
Osteopetrosis is a heterogeneous disorder which includes several forms that differ on the 
basis of inheritance, severity and secondary clinical features (Balemans et al., 2005). So far, 
there is no effective cure for osteopetrosis (Del Fattore et al., 2010). Haematopoietic Stem 
Cell Transplantation (HSCT) is indicated only for some severe forms; however a large rate 
of unsuccessful engraftment and persistence of irreversible symptoms are frequently 
observed (Driesses et al., 2003). 
3.1 Clinical features and genetic inheritance 
The various forms of osteopetrosis are classified on the basis of clinical, radiological and 
inheritance features into three major groups (Balemans et al., 2005; Whyte, 2002): the 
Autosomal Recessive Osteopetrosis (ARO), the Intermediate autosomal Recessive 
Osteopetrosis (IRO) and the Autosomal Dominant Osteopetrosis (ADO). Although these 
forms display different symptoms, they share common clinical traits such as increase of 
bone density, spontaneous fractures and haematological failures (Del Fattore et al., 2008). 
ARO is the most severe form and it is commonly diagnosed soon after birth or within the 
first years of life. Patients display a generalised osteosclerosis, especially in skull, pelvis, 
spine and long bones (Frattini et al., 2000; Kornak et al., 2000; Loria-Cortes et al., 1977), 
which display the so-called “bone in bone” appearance (Figure 3). The poor development 
and/or compression of the bone marrow and the nervous system leads to severe anaemia, 
pancytopenia, hepatosplenomegaly, visual impairment, optic atrophy and deafness. Less 
common features are hydrocephaly, macrocephaly and strabismus. In a subtype of ARO 
primary degeneration of brain and retina are observed (Askmyr et al., 2008). Unfortunately, 
a fatal outcome generally occurs in 75% of ARO patients, who die at 3-4 years of age because 
of haematological failure and recurrent infections (Balemans et al., 2005).   
 
 
Fig. 3. X-ray analysis illustrating generalized osteosclerosis in an ARO patient. The picture 
shows the extensive sclerosis of spine, ribs and skull. 
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IRO is milder than ARO and life expectancy is much longer. Typical symptoms of this form 
are generalized increase of bone density, osteomyelitis, short stature, dental malformations, 
and mild to moderate anaemia (Balemans et al., 2005; Bolt et al., 2005; Del Fattore et al., 2010;  
Sly et al., 1983). The Autosomal Dominant Osteopetrosis, also called Albers-Schönberg 
disease (Albers-Schönberg, 1904), was previously described inappropriately as the “benign 
form” but it is now accepted as an extremely heterogeneous osteopetrosis, ranging from 
asymptomatic to severe (Del Fattore et al., 2006; Frattini et al., 2003; Waguespack et al., 
2007). This phenotypic variability is even observed within the same family (Letizia et al., 
2004). ADO patients usually present with sclerosis of skull base, pelvis, and vertebral end-
plates (Figure 4) (sandwich vertebrae or rugger-jersey spine), bone pain, osteomyelitis and 
frequent pathological fractures. Life expectancy is generally normal, but in some cases 
complications due to cranial nerve compression, a rather poor quality of life and death have 
been reported (Albers-Schönberg, 1904; Balemans et al., 2005; Del Fattore et al., 2006).  
 
 
Fig. 4. X-ray analysis of an ADO patient showing sclerosis of vertebral end-plates (sandwich 
vertebrae) and pelvis. 
Besides these classical forms, five male cases have been described so far with X-Linked 
Osteopetrosis (XLO) associated with lymphedema, anhidrotic ectodermal dysplasia, and 
immunodeficiency (so-called OL-EDA-ID syndrome). They died very young for severe 
phenotype and infection complications (Smahi et al., 2002). 
3.2 Genetic features 
The extreme phenotypic variability of osteopetrosis arises from the genetic heterogeneity. 
As shown in Table 1, in osteopetrotic patients mutations in genes encoding proteins 
essential for correct bone resorption or for osteoclast differentiation have been observed. As 
discussed above, these mutations can be inherited in an autosomal recessive, autosomal 
dominant or X-linked manner (Del Fattore et al., 2010). ARO, the most severe form, is due in 
more than 50% of cases to loss-of-function mutations of the TCIRG1 gene, encoding for the 
osteoclast-specific a3 subunit of V-H+-ATPase (Del Fattore et al., 2006; Frattini et al., 2000; 
Kornak et al., 2000; Taranta el al., 2003). 
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Gene Protein Type of mutation 
Form of 
osteopetrosis 




TCIRG1/ATP6V1B1 a3/B1 subunits of vacuolar H
+-
ATPase Loss-of-function ARO 




OSTM1 Trasmembrane protein associated with ClC7 function Loss-of-function ARO 
PLEKHM1 
Protein with undefined function, 
probably associated with vesicular 
trafficking and acidification 
Loss-of-function IRO 
CAII Carbonic anhydrase type II Loss-of-function IRO 
NEMO Regulatory subunit of IKK Loss-of-function XLO 
TNFSF11 Receptor activator of NF-kB ligand (RANKL) Loss-of-function ARO 
TNFRSF11A RANK Loss-of-function ARO 
Table 1. Genetic defects in human osteopetroses 
The V-H+-ATPase is central to the mechanism of bone resorption because it is located in the 
osteoclast ruffled border membrane where it releases protons in the underneath resorbing 
lacuna (Nishi & Forgac, 2002). In rare cases, double mutations of the TCIRG1 gene and the 
ATP6V1B1 genes, this latter encoding the B1 subunit of V-H+-ATPase, were described 
(Bothwick et al., 2003). As shown in Table 1, other four genes are associated with ARO. 
About 10-15% of patients harbours mutations of the CLC7 gene (Frattini et al., 2003; Kasper 
et al., 2005; Kornak et al., 2001), encoding for the so called chloride channel type 7, recently 
reclassified as a Cl-/H+ antiport (Graves et al., 2008). This dimeric protein is located in 
lysosomes and osteoclast ruffled membrane where, as previously described, it is essential to 
restore the correct electrical potential altered by proton flux (Graves et al., 2008). So far, only 
5 patients affected by ARO were found to harbour loss-of-function mutations of the OSTM1 
gene, encoding for a protein whose role in bone resorption is still unknown (Chalhoub et al., 
2003; Pangrazio et al., 2006). Ostm1 function is probably important for Cl- conductance, 
because it was recently shown that the protein is involved in the stabilization and correct 
localization of the Cl-/H+ antiport (Lange et al., 2006). The correlated functions of ClC7 and 
Ostm1 proteins are demonstrated by the similar clinical features of patients harbouring 
mutations of the respective genes (Pangrazio et al., 2006). Primary retinal degeneration and 
lysosomal storage disease are observed in these patients, who are believed not to benefit 
from HSCT because it cannot cure the neural defects. Beside the types of AROs described 
above, so-called “osteoclast-rich” osteopetroses because in these forms osteoclasts form 
normally or are even increased in number, there is also a particularly rare form of ARO 
where the osteoclasts are absent (Helfrich, 2005). The patients affected by this “osteoclast-
poor” osteopetrosis present mutations of the TNFSF11 (Sobacchi et al., 2007) or the 
TNFRSF11A (Guerrini et al., 2008) genes (Table 1), encoding the RANKL and its receptor 
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RANK, respectively. Both proteins are required for osteoclast differentiation. So far, only 6 
patients have been described to carry mutations of the TNFSF11 gene. The importance of 
this discovery relies on the fact the these patients could not be effectively treated with 
HSCT, because the genetic defect is not osteoclast-autonomous but rather relies on the 
inability of stromal/osteoblastic cells to produce RANKL. ADO, the most frequent 
osteopetrosis, is caused in about 70% of patients by heterozygous dominant negative 
mutations of the CLC7 gene (Bollerslev et al., 1988; Del Fattore et al., 2005; Frattini et al., 
2003; Letizia et al., 2004; Waguespack et al., 2007). CLC7 gene mutations tend to affect the 
entire length of the gene, even if the most frequent mutations have been described in the 
regions encoding the C-terminal CBS (Cystathionine Beta Synthase) domains of the protein 
(Del Fattore et al., 2006; Waguespack et al., 2007). As described above, ADO is characterized 
by a phenotypic variability probably due to the incomplete penetrance of the mutant gene 
(Frattini et al., 2003; Letizia et al., 2004). No other genes are known so far to be correlated 
with ADO and about 30% of patients still lacks a genetic diagnosis (Del Fattore et al., 2010). 
As in ADO, also in IRO a considerable clinical heterogeneity is observed. Presently, the two 
genes known to be associated with IRO are CAII (Bolt et al., 2005) and PLEKHM1 (Van 
Wesenbeeck et al., 2007), encoding the carbonic anhydrase type II and the Plekhm1 protein, 
respectively. Patients harbouring loss of function mutations of the CAII gene display, 
besides osteopetrosis, tubular acidosis, cerebral calcifications and mental retardation 
(Balemans et al., 2005). The novel gene recently associated with osteopetrosis, PLEKHM1, 
has been identified as the human homolog of the gene responsible of the incisor absent (ia) 
rat phenotype (Van Wesenbeeck et al., 2007). To date, only one female patient affected by 
IRO has been identified to harbour a mutation of the PLEKHM1 gene. The clinical features 
described in this patient were increased bone density, Erlenmeyer flask’ deformity of the 
distal femora and a chondrolysis of the left hip. The exact function of the Plekhm1 protein is 
not completely elucidated, but recent findings suggest that it is a member of Rab7-regulated 
proteins involved in late endosomal trafficking (Del Fattore et., 2008; Van Wesenbeeck et al., 
2007), vesicular acidification and TRAcP release by osteoclasts (Del Fattore et al., 2008). As 
previously described, there is a XLO osteopetrosis, due to mutations of the NEMO (NF-ĸB 
Essential Modulator) gene, encoding the IκB regulatory subunit of IKK. The mutations 
described in the only 5 so far known patients cause the replacement of the NEMO stop 
codon with tryptophan, leading to the addition of 27 irrelevant residues that strongly 
destabilize the protein (Smahi et al., 2002). All other forms of osteopetrosis, about 30% of 
patients, still lack of a recognized gene involved and much effort should be made to identify 
new genes associated with this disease.  
4. Pycnodysostosis 
Pycnodysostosis is a skeletal disorder also known as Toulouse-Lautrec disease because it is 
believed that the famous French painter Henri Toulouse-Lautrec (1864-1901) suffered from 
this syndrome (Maroteaux & Lamy, 1965). It is a rare monogenic disease (approximately 150 
cases reported in the literature worldwide), first described in 1962 by Maroteaux and Lamy, 
who coined this term from the word of Greek origin puknos meaning “dense”, associated 
with the words dys meaning “defective” and ostosis meaning “condition of the bone”. 
Pycnodysostosis is characterised by a general osteosclerosis leading to short stature and 
increased bone mass. In fact, Schilling and coworkers analysed the volumetric bone density 
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in a cohort of pycnodysostosis patients and controls showing a value of 686 mg/cm in the 
group of patients versus 290 mg/cm in the control group (Shilling et al., 2007). This disease 
appears to be especially common among the Japanese, but many cases are even described in 
Europe and United States (Muto et al., 1991). 
4.1 Clinical features 
The diagnosis of pycnodysostosis is usually performed during infancy or early childhood 
because of increased bone mass, short stature and cranial dysplasia. Pycnodysostosis could 
be confused with osteopetrosis, although it has peculiar features such as gracile clavicles 
with hypoplastic ends, obtuse mandibular angle, enlarged skull with opened anterior 
fontanel and cranial sutures, and acroosteolysis of distal phalanges (Soliman et al., 2001). 
Moreover, in pycnodysostosis anaemia and hepatosplenomegaly have not been reported. 
The exfoliation of deciduous teeth is usually altered, as well as the eruption of the 
permanent dentition. Endobones and radiodense striations are absent. As in osteopetrosis, 
pycnodysostosis patients may suffer from frequent fractures since the first year of life. 
Moreover, fractures of the mandible during tooth extractions have been described. Lower 
limbs seem to be particularly involved in fractures, resulting in genu valgu deformity. About 
10% of the patients show mental retardation. Moreover, recurrent respiratory infections and 
right heart failure have been described (Muto et al., 2005). 
4.2 Genetic inheritance 
Pycnodysostosis is an autosomal recessive disease caused by mutations of the CTSK gene.  
In 1995, Gelb and coworkers first mapped the disease in a narrow region on chromosome 
1q21 with a maximal lod score of 11.72 (Gelb et al., 1996). In 1996, they identified the 
mutated gene, CTSK, encoding the cathepsin K, a cystein proteinase expressed in many 
tissues such as bone, ovary, colon, skeletal muscle, placenta and small intestine (Zhao et al., 
2009). Cathepsin K is synthesized as an inactive precursor of 329 amino acids (aa). The N-
terminal pro-peptide of 99 aa is cleaved between Arg 114 and Ala 115 to supply the mature 
cathepsin K of 215 aa (Bromme & Okamoto, 1995). In the bone, it plays an important role in 
bone resorption since it cleaves, at acidic pH, collagen type I, osteopontin and other proteins 
of the bone matrix (McQueney et al., 1997). Particularly, cathepsin K cuts triple-helical 
collagen into small peptides. Cleavage occurs in its non collagenous termini (N- and C-
telopeptide regions). These fragments can be detected in urine and serum as markers of 
bone resorption (Atley et al., 2000). Cathepsin K-deficient mice generated by inactivation of 
the ctsk gene display an increase of bone mass as well as radiological and histological 
abnormalities typical of pycnodysostosis (Gowen et al., 1999; Saftig et al., 1998). The analysis 
of the genomic DNA indicated that the CTSK gene is composed by eight exons and seven 
introns (Rood et al., 1997). Presently, 27 different types of mutations, spread throughout the 
whole gene, have been described in 34 unrelated families (Helfrich, 2003; Toral-López et al., 
2011). According to bio-informatic analyses, all mutations seem to affect the protein folding, 
destabilizing the whole structure or creating locally structural changes that could affect the 
conformation of a small part of the protein (Donnarumma et al., 2007).  
5. Paget’s disease of bone 
Paget’s disease of bone is a common disorder characterized by increased bone turnover 
within focal lesions throughout the skeleton. It was described for the first time in 1876 by Sir 
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James Paget as a disease that “begins in middle age or later . . . affects most frequently the 
long bones of the lower extremities and the skull”. Moreover, he stated that “the bones 
enlarge and soften, and those bearing weight yield and become unnaturally curved and 
misshapen” (Paget, 1876). Paget’s disease of bone affects both men and woman, with a slight 
predominance in males (van Staa et al., 2002). Although many patients are often 
asymptomatic, others have a poor quality of life, with bone pain, skeletal deformities and 
fractures (Selby et al., 2002). The estimated prevalence of Paget’s disease of bone in the 
world is about 1%, arising up to about 3% in North America, Great Britain, Australia and 
Western Europe. Conversely, this disease is very rare in Scandinavia and in the Indian 
subcontinent (Detheridge et al., 1982). These marked geographical differences in the 
prevalence strengthen the importance of genetic factors involved in the pathogenesis of 
Paget’s disease of bone, but some evidence suggests an important role also for 
environmental determinants. 
5.1 Clinical features 
Paget’s disease of bone is a disorder of bone remodelling. It is very important to underline 
the localized nature of the disease. It could affect a single bone or only a portion of it, or it 
could involve more bones (Ralston, 2008). As described above, many patients affected by 
Paget’s disease of bone are often asymptomatic and the diagnosis is usually performed 
incidentally on the basis of elevated serum alkaline phosphatase levels not correlated with 
other diseases, or of abnormal skeletal radiographs (Tiegs et al., 2000). Conversely, other 
patients suffer from mild to moderate bone ache that characteristically begins late in the 
clinical course (Ralston et al., 2008). The direct cause of pain could be difficult to explain, 
requiring a careful analysis. An increase of vascularity and consequent warmth usually 
occur in pagetic bones, leading to unpleasant sensation perceived by patients (Altman, 
1980). Micro-fractures that frequently affect the diseased bone can contribute to discomfort. 
Another typical sign of the disease is skeletal deformity, usually of the femur or tibia, that 
could aid in the cause of pain onset (Ralston et al., 2008). Moreover, severe secondary 
osteoarthritis can be observed at joints close to pagetic bones. Patients affected by Paget’s 
disease of bone suffer from fractures that could be either traumatic or pathologic, 
particularly involving the long bones. The involvement of the skull in the disease 
complaints occurs in up to one third of the patients, and is characterized by macrocephaly, 
frontal bossing and hearing loss. Palsies of cranial nerves II, VI and VII could also be 
observed. Neoplastic degeneration, particularly osteogenic sarcoma involving the pelvis 
(although both fibrosarcoma and chondrosarcoma are also observed), develop in less that 
1% of patients (Reddy et al., 2001). 
5.2 Genetic inheritance 
As aforementioned, both genetic and environmental factors can contribute to the 
pathogenesis of Paget’s disease of bone. In less than 15-40% of cases, this disease is inherited 
in an autosomal dominant manner, even if many patients do not have a family history 
(Haslam et al., 1998; Hocking et al., 2000). Seven different loci have been identified by locus 
linkage studies associated with the onset of the disease. They are located on chromosomes 
2p36, 5q31, 5q35, 10p13, 18q21 and 18q23 (Good et al., 2002; Haslam et al., 1998; Hocking et 
al., 2001; Laurin et al., 2001; Tilyard et al., 1982). Other studies confute this linkage 
association, showing that the analysis may have false positives (Ralston, 2008). 
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Subsequently, Laurin et al. and Hocking et al. identified, by positional cloning studies on 
chromosome 5q35, the SQSTM1 gene as the most important cause of the disease (Hocking et 
al., 2002; Laurin et al., 2002). The SQSTM1 gene encodes the p62/sequestosome 1, an 
ubiquitously expressed adapter protein involved in several cellular activities, including 
regulation of NF-κB signalling, autophagy, sequestration of ubiquitinated proteins and 
inhibition of ERK-MAPK signalling (Mosca & Diaz-Meco, 2002) (Figure 5). Particularly, it 
was shown that p62 is able to bind TRAF6 and K48- and K63-linked ubiquitin chains via the 
UBA (UBiquitin-Associated) domain (Figure 5) (Seibenhener et al., 2004). It was shown that 
sequestosome 1 colocalizes with ubiquitinated protein aggregates, and it has been detected 
in protein aggregates typical of Alzheimer’s and Parkinson’s diseases (Paine et al., 2005). 
Moreover, most of the mutations found in Paget’s disease of bone are located in the UBA 
domains, preventing protein aggregation or, conversely, inducing the formation of 
aggregates larger than normal (Cavey et al., 2005; Cavey et al., 2006; Yip et al., 2006). 
However, it is not yet clear what role these aggregates might play in the pathogenesis of 
Paget's disease of bone. 
 
 
Fig. 5. Sequestosome/p62 pathway in osteoclasts. The binding of RANKL to the receptor 
RANK results in recruitment of TRAF6, p62 and aPKC (atypical Protein Kinase C). 
Moreover, the RANKL-RANK interaction leads to the phosphorylation of IKK (Inhibitor of 
κb kinase), that subsequently phosphorylates IκB (Inhibitor of κB). The phosphorylated IκB 
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James Paget as a disease that “begins in middle age or later . . . affects most frequently the 
long bones of the lower extremities and the skull”. Moreover, he stated that “the bones 
enlarge and soften, and those bearing weight yield and become unnaturally curved and 
misshapen” (Paget, 1876). Paget’s disease of bone affects both men and woman, with a slight 
predominance in males (van Staa et al., 2002). Although many patients are often 
asymptomatic, others have a poor quality of life, with bone pain, skeletal deformities and 
fractures (Selby et al., 2002). The estimated prevalence of Paget’s disease of bone in the 
world is about 1%, arising up to about 3% in North America, Great Britain, Australia and 
Western Europe. Conversely, this disease is very rare in Scandinavia and in the Indian 
subcontinent (Detheridge et al., 1982). These marked geographical differences in the 
prevalence strengthen the importance of genetic factors involved in the pathogenesis of 
Paget’s disease of bone, but some evidence suggests an important role also for 
environmental determinants. 
5.1 Clinical features 
Paget’s disease of bone is a disorder of bone remodelling. It is very important to underline 
the localized nature of the disease. It could affect a single bone or only a portion of it, or it 
could involve more bones (Ralston, 2008). As described above, many patients affected by 
Paget’s disease of bone are often asymptomatic and the diagnosis is usually performed 
incidentally on the basis of elevated serum alkaline phosphatase levels not correlated with 
other diseases, or of abnormal skeletal radiographs (Tiegs et al., 2000). Conversely, other 
patients suffer from mild to moderate bone ache that characteristically begins late in the 
clinical course (Ralston et al., 2008). The direct cause of pain could be difficult to explain, 
requiring a careful analysis. An increase of vascularity and consequent warmth usually 
occur in pagetic bones, leading to unpleasant sensation perceived by patients (Altman, 
1980). Micro-fractures that frequently affect the diseased bone can contribute to discomfort. 
Another typical sign of the disease is skeletal deformity, usually of the femur or tibia, that 
could aid in the cause of pain onset (Ralston et al., 2008). Moreover, severe secondary 
osteoarthritis can be observed at joints close to pagetic bones. Patients affected by Paget’s 
disease of bone suffer from fractures that could be either traumatic or pathologic, 
particularly involving the long bones. The involvement of the skull in the disease 
complaints occurs in up to one third of the patients, and is characterized by macrocephaly, 
frontal bossing and hearing loss. Palsies of cranial nerves II, VI and VII could also be 
observed. Neoplastic degeneration, particularly osteogenic sarcoma involving the pelvis 
(although both fibrosarcoma and chondrosarcoma are also observed), develop in less that 
1% of patients (Reddy et al., 2001). 
5.2 Genetic inheritance 
As aforementioned, both genetic and environmental factors can contribute to the 
pathogenesis of Paget’s disease of bone. In less than 15-40% of cases, this disease is inherited 
in an autosomal dominant manner, even if many patients do not have a family history 
(Haslam et al., 1998; Hocking et al., 2000). Seven different loci have been identified by locus 
linkage studies associated with the onset of the disease. They are located on chromosomes 
2p36, 5q31, 5q35, 10p13, 18q21 and 18q23 (Good et al., 2002; Haslam et al., 1998; Hocking et 
al., 2001; Laurin et al., 2001; Tilyard et al., 1982). Other studies confute this linkage 
association, showing that the analysis may have false positives (Ralston, 2008). 
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Subsequently, Laurin et al. and Hocking et al. identified, by positional cloning studies on 
chromosome 5q35, the SQSTM1 gene as the most important cause of the disease (Hocking et 
al., 2002; Laurin et al., 2002). The SQSTM1 gene encodes the p62/sequestosome 1, an 
ubiquitously expressed adapter protein involved in several cellular activities, including 
regulation of NF-κB signalling, autophagy, sequestration of ubiquitinated proteins and 
inhibition of ERK-MAPK signalling (Mosca & Diaz-Meco, 2002) (Figure 5). Particularly, it 
was shown that p62 is able to bind TRAF6 and K48- and K63-linked ubiquitin chains via the 
UBA (UBiquitin-Associated) domain (Figure 5) (Seibenhener et al., 2004). It was shown that 
sequestosome 1 colocalizes with ubiquitinated protein aggregates, and it has been detected 
in protein aggregates typical of Alzheimer’s and Parkinson’s diseases (Paine et al., 2005). 
Moreover, most of the mutations found in Paget’s disease of bone are located in the UBA 
domains, preventing protein aggregation or, conversely, inducing the formation of 
aggregates larger than normal (Cavey et al., 2005; Cavey et al., 2006; Yip et al., 2006). 
However, it is not yet clear what role these aggregates might play in the pathogenesis of 
Paget's disease of bone. 
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first true model of the disease (Rojas et al., 2007). Several other genes have been associated 
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with Paget’s disease of bone, such as TNFSF11, TNFRSF11A and TNFRSF11B, this latter 
particularly in juvenile disease. However, these association studies still lack a sample size 
large enough to enable to draw definitive conclusions on the involvement of these genes in 
the disease (Ralston, 2008). 
6. Conclusions 
Osteopetrosis, pycnodysostosis and Paget’s disease of bone are examples of genetic diseases 
that underlie the essential role of osteoclasts in the regulation of bone homeostasis. They 
have been instrumental for the understanding of the mechanisms by which osteoclasts form 
and resorb bone and contributed to shed light on the pathogenesis of more frequent bone 
diseases, including osteoporosis and bone inflammatory disorders, such as osteoarthritis 
and rheumatoid arthritis (Tanaka et al., 2005). Further investigation on osteoclast genetic 
diseases is expected to help increase our knowledge about the recently identified 
relationships between the bone and other systems, including the immune system 
(Takayanagi, 2010), the nervous system (Kumar et al., 2010), the endocrine system (Ferron et 
al., 2010; Fukumoto & Martin, 2009; Karsenty & Oury, 2010), the reproductive system (Oury 
et., 2011) and the skeletal muscle system (Rufo et al., 2011), in which osteoclasts may be 
implicated. Therefore, in the next future we are likely to assist to flourishing novel insights 
into the osteoclast biology, physiology and pathology, which could represent the basis for a 
better prophylaxis and more effective treatments of bone diseases. 
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1. Introduction 
Ataxia telangiectasia like disorder (ATLD) is a rare variant of ataxia telangiectasia (A-T) that 
share a number of clinical features and similar cellular characteristics with the hallmark of 
increased sensitivity to ionizing radiation (Taylor et al., 1975; Taylor, 2001; Tauchi et al., 
2002). These conditions are typically diagnosed at young age at about the time the affected 
children start to walk. A-T and ATLD patients develop progressive cerebellar ataxia which 
is required for their clinical diagnosis. Although classified as another variant of A-T, 
Nijmegen breakage syndrome (NBS) is characterized by microcephaly and growth 
retardation without ataxia. The other major clinical characteristics are variable and include 
dilated blood vessels (telangiectasia) usually in the eyes, immunodeficiency, high level of 
spontaneously occurring chromosome abnormalities, and predisposition to cancer 
particularly lymphoreticular malignancies. Genetically, the A-T is caused by biallelic 
inactivating mutations in the ATM gene at 11q22-23, the NBS is caused by mutation in the 
NBS1 gene mapped at 8q21, and the ATLD is caused by mutation in the MRE11A gene 
located at 11q21.  
Therefore, a disorder virtually indistinguishable from A-T is caused by mutation in the 
MRE11A gene. In view of the fact that the ATM and the MRE11A loci are situated nearby 
(11q22-23 and 11q21) only a very detailed linkage analysis would have historically 
separated ATLD from A-T on the basis of genetic data. Assuming that the mutation rate is 
proportional to the length of the coding sequence of the two genes, about 6% of A-T cases 
might be expected to have MRE11A mutations (Stewart et al., 1999). Thus, ATLD patients 
were first recognized as a subset of A-T who does not have mutations in the ATM gene. 
Hence, Stewart et al. had designated this syndrome as ataxia-telagnietasia-like disorder 
(Stewart et al., 1999). The clinical features are very similar to those of A-T; with the clearest 
similarity being the progressive cerebellar ataxia. In contrast to A-T, however, ATLD 
patients show no telangiectasia (Hernandez et al., 1993;  Klein et al., 1996). In addition, the 
patients show later onset of the neurological features, and slower progression of the 
disorder giving the overall appearance of a milder A-T condition in early years.  
The function of Mre11 protein is linked to Nbs1 and both are members of the 
Mre11/Rad50/Nbs1 (MRN) complex involved in different DNA healing mechanisms due to 
innate processes or in responses to damage induced by ionizing radiation and radiomimetic 
chemicals (Carney et al., 1998;  Petrini, 2000), including complexing with chromatin and 
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with other damage response proteins, formation of radiation-induced foci, and the 
induction of cell cycle checkpoints (Figure 1). The MRN complex is among the earliest 
respondents to DNA damage and acts as sensor of DNA double-strand breaks (DSBs). Upon 
exposure to ionizing radiation the complex along with ATM becomes rapidly activated and 
associate with the DNA DSBs (Figure 2). This association holds broken DNA ends until the 
damage is repaired (Nelms et al., 1998). Loss of functional Nbs1 protein in NBS patients 
prevents the formation of the radiation-induced Mre11/Rad50 nuclear foci (Carney et al., 
1998). In comparison, the loss of function of ATM protein in A-T patients causes abnormal 
reduction in the formation of MRN foci that is less severe than in NBS cells (Maser et al., 
1997). Thus, the function of MRN proteins complex is biochemically linked to ATM, which 
is a critical component of the cellular response to DNA damage. Since Nbs1 and ATM 
deficiencies abrogate specific DNA damage-dependent cell cycle checkpoints, the 
association of MRN complex with DSBs suggests that the DNA damage recognition 
functions of the complex are linked to the signal transduction pathways required to activate 
ATM-dependent cell cycle checkpoints. These observations strengthen the molecular 
connection between DSB recognition by MRN protein complex and the ability of the cell to 
activate the DNA damage response pathway controlled by ATM.  
2. Clinical manifestations of ATLD 
ATLD is rare with, at present, only 25 published cases, four in the UK (2 of them from 
Pakistani origin), two in Italy, 15 in Saudi Arabia and four in Japan (Stewart et al., 1999;  
Pitts et al., 2001;  A.M. Taylor et al., 2004;  Fernet et al., 2005;  Uchisaka et al., 2009;  Bohlega 
et al., 2011;  Matsumoto et al., 2011).  The 4 British patients belonged to 2 unrelated families. 
Although none of the affected individuals from either family exhibited ocular telangiectasia, 
they presented with many clinical features consistent with the diagnosis of A-T, especially 
progressive cerebellar degeneration (Stewart et al., 1999). The 2 affected Italian patients were 
born to non-consanguineous parents. They had both normal psychomotor development 
until the age of 3 - 6 years when they developed progressive unsteadiness, showed diffuse 
cerebellar signs, i.e. ataxic gait, delayed speech and writing difficulties, choreoathetoid arm 
movements and oculomotor apraxia (Delia et al., 2004). The disease progressed slowly till 
the age of 14 and then stabilized. The latest neurological examination of the elder patient at 
36 years of age showed cerebellar dysarthria, oculomotor apraxia, ataxic gait with unaided 
walk for few steps, choreoathethosis of the superior limbs, jerk nystagmus on horizontal and 
vertical gaze, dysmetria, dyskinetic movements of mouth and slight dystonia of the hands, 
diffuse hypotonia, reduced tendon reflexes in the arms, and absent ankle jerks with flexor 
plantar responses.  
The 15 Saudi patients represent the largest set of ATLDs identified to date. Consanguinity is 
a major feature in all these families with affected children with parents were mostly first 
cousins. Patients were initially presented with clinical features that fall within the Ataxia 
Oculomotor Apraxia spectrum and exhibited a combination of early-onset, slowly 
progressive, ataxia plus ocular apraxia. Age at onset is almost similar to that of AT, but 
disease progression is slower with the absence of telangiectasia. Pedigrees and further 
details on these families were described previously (Fernet et al., 2005;  Bohlega et al., 2011). 
Clinical features include progressive ataxia that was noted as early as two years old in some 
patients. Oculomotor apraxia was variable among the affected individuals with very slow 
saccadic eye movement and impaired vertical and or horizontal pursuit eye movement with  
 
 




















Fig. 1. Role of the Mre11 protein in the cellular response and DNA repair machinery 
showing the major interacting molecules (Adapted from: www.lmb.uni-


















Fig. 2. Representation of the ATM and the Mre11/Rad50/Nbs1 (MRN) complex interacting 
with a DNA double strand break (DSB). The Mre11 exonuclease directly binds Nbs1, Rad50 
and DNA to bridge DSBs and facilitate DNA end processing. The C-terminal of the ataxia 
telangiectasia mutated (ATM) kinase contributing to MRN regulatory roles in DSB sensing, 
stabilization, signaling, and effector scaffolding. MRN has 3 coupled critical functions: (1) 
prompt establishment of protein--nucleic acid tethering scaffolds for the recognition and 
stabilization of DSBs; (2) initiation of DSB sensing, cell-cycle checkpoint signaling cascades 
via the ATM kinase; and (3) functional regulation of chromatin remodeling in the vicinity of 
a DSB (Williams et al., 2007). 
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head thrusts. Vibration senses were decreased distally and tendon reflexes were absent. 
Although few patients had no cognitive impairment, others presented cognitive and 
behavioral problem with forgetfulness, lack of attention, word finding difficulty, emotional 
liability, impulsivity and disinhibition with fragmented and reversed sleep patterns. 
Dysarthria in addition to dystonic and choreatic movement were frequently noted. The 
disease was relentlessly progressive and some patients became wheelchair-bound around 
age of 18 years. Intra-familial variability was noticeable with some patients were more 
severely affected. The clinical observations on this set of patients, together with those from 
previously reported cases, establish that ATLD is not associated with recurrent pulmonary 
infections due to immune deficiency. However, some patients presented with certain 
differences with the previously reported ATLD patients, namely the presence of 
microcephaly in at least four patients, the latter feature being reminiscent of the clinical 
presentation of NBS. Whether these differences are specific to the W210C mutation found in 
Saudi patients or only reflect the wide spectrum of the disease needs further investigation. 
The 4 Japanese patients were born to non-consanguineous parents. Two sibling patients 
were born after healthy pregnancies and deliveries. They had characteristic clinical features 
of short stature, pointy nose, small jaw, atrophy of the lower legs, and equinus foot 
deformities (Uchisaka et al., 2009). They had cerebellar ataxia, slurred and explosive speech, 
and ocular apraxia, but did not show any evidence of involuntary movement such as 
dystonia or dyskinesia. The patients started to speak at 2 years old where ataxic gait was 
noted. The cerebellar ataxia with atrophy of the cerebellum and mental retardation had 
progressed and was more severe in the elder patient who became wheelchair bound at 6 
years of age. There was no history of serious infection or evidence of skin or conjunctival 
telangiectasia. When they were 15 and 9 years old, both patients were diagnosed with 
nonsmall-cell lung cancer with multiple bone metastases. One Japanese patient was born at 
37 weeks of gestation after unremarkable pregnancy. However, the patient showed 
developmental retardation where he could sit alone but could not stand or walk 
(Matsumoto et al., 2011). At age 13 years, the patient had severe microcephaly, a bird-like 
face with sloping forehead, a big nose, large and simple ears, short palpebral fissures, a 
small mouth, and a small and receding chin with decreased range of motion in shoulders, 
elbows, hips, and knees. Also noted were scoliosis, subluxation of the left elbow joint, 
bilateral cryptorchidism, and bilateral talipes equinus. His tendon reflexes were slightly 
exaggerated. At age 33, the patient does not speak meaningful words, but recognizes people, 
communicates by gesture, shows fondness by touching, does not show ocular apraxia and 
had neither malignancy nor severe infections. The 4th Japanese patient had intrauterine 
growth retardation with a small femora and a disproportionately small head (Matsumoto et 
al., 2011). After caesarian section delivery the patient had severe microcephaly, a bird-
headed facial appearance with receding forehead, and a prominent nose. Anterior fontanel 
was not palpable. He stood holding onto a chair at age 30 months, sat alone and walked at 
age 3 years. He had no severe or recurrent infections. Now aged 8 years, he is toilet trained, 
speaks several meaningful words but sentence. He attends a primary school, and is affable 
and friendly. He is farsighted with astigmatism. He is able to run with a slow pitch and kick 
a soccer ball. He shows neither ocular apraxia nor cerebellar ataxia.  
3. MRE11A gene mutations 
The 25 genetically confirmed ATLD patients (4 in the UK, 2 in Italy, 4 in Japan and 15 in 
Saudi Arabia were either homozygous or compound heterozygous for 10 different 
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mutations (Figure 3).  The four British patients were related to two independent families. 
The two patients of the 1st family were homozygous for a C-to-T transition at nucleotide 
1897 (c.1897C>T). This change, CGA>TGA, resulted in an in frame 633R > stop codon, 
prematurely truncating the Mre11 protein. The two patients of the 2nd family were 
compound heterozygous for two mutations, an A>G missense mutation at nucleotide 350 
(c.350A>G), resulting in a Asn to Ser amino acid change at residue 117 (N117S) and C-to-T 
transition at nucleotide 1714 (c.1714C>T) resulting in a stop codon (572R> stop) (A.M. 
Taylor et al., 2004). This mutation is predicted to encode a prematurely truncated protein of 
65 kDa that was not detected suggesting that this mutation destabilizes the transcript by 
nonsense-mediated decay (NMD) surveillance mechanism which eliminates the errors in the 
biogensis of mRNA (Frischmeyer et al., 2002;  Nicholson et al., 2010). The two Italian sibling 
patients were compound heterozygous for two mutations, a missense mutation at position 
1422 (c.1422C>A) resulting in Thr to Lys amino acid change at residue 481 (T481K) and the 
already known single C>T base change in exon 15, corresponding to nucleotide 1714 in the 
cDNA sequence (c.1714C>T), which introduces a premature stop codon (Delia et al., 2004).  
The four Japanese patients belonged to 3 unrelated families. In two brothers with ATLD 
with lung cancer, genetic studies had looked at alteration in the 20 exons and the flanking 
intronic sequences of the MRE11A gene. This revealed a T>C substitution in exon 8 at 
position 727 (c.727T>C) and a G>C base substitution at nucleotide 24994 situated in intron 
10 (g.24994G>A; Figure 3), 5bp downstream from exon 10 (Uchisaka et al., 2009). RT-PCR 
showed the presence of two products. Sequencing of these cDNA products confirmed the 
T>C base substitution at nucleotide 727 in exon 8 in 1 of the alleles and uncovered an 81 bp 
deletion in exon 10 on another allele. The alteration of these DNA sequences predicted a Trp 
to Arg amino acid substitution at residue 243 (W243R) and the loss of 27 amino acids, 
respectively. The base substitution in intron 10 might have given rise to an alternative 
splicing of MRE11A, leading to an in frame 81 bp deletion in exon 10. Thus, the two 
Japanese sibling patients were compound heterozygous for two novel MRE11A gene 
mutations that have not been reported before, one in exon 8 (c.727 T>C) and one in intron 10 
(g.24994 G>A).  
The two other unrelated Japanese patients were presented with NBS-like severe 
microcephaly, bird-like faces, growth and mental retardation remnant of Nijmegen breakage 
syndrome (NBS). However, genetic studies revealed no mutation in the NBN gene 
responsible for NBS. Therefore, the MRE11A gene was sequenced in both patients and 
found to be compound heterozygous for three different types of mutations: an A-to-C 
transversion in nucleotide 658 (c.658A>C), a G-to-A transition in nucleotide 16513 (g.16513; 
i.e. c.659+1G>A) and an A-to-G transition in position 338 (c.338A>G). Patient-1 had 
c.658A>C substitution plus a g.16513 splicing mutation, and patient-2 had c.658A>C and 
c.338A>G substitutions. Sequencing analysis demonstrated that g.16513G>A resulted in 
exon 7 skipping leading to a premature termination codon (p.Ser183ValfsX31). The 
c.658A>C substitution located within exon 7 did not alter amino acids but affected splicing 
efficiency that contributed to exon 7 skipping. The c.338A>G situated in exon 5 lead to a 
missense mutation with an amino acid substitution of Asp to Gly at  residue 113 (D113G) 
located within the highly conserved phosphoesterase domain, which is essential for 
endonuclease activity. The c.658A>C substitution common to both patients and the 
c.338A>G substitution resulted in a reduced level of normally functioning Mre11 protein.  
The 15 Saudi Arabian patients were related to 5 independent families and represent the 
largest ATLD cohort (Fernet et al., 2005;  Khan et al., 2008;  Bohlega et al., 2011). Genetic 
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Fig. 3. Representation of the human (a) MRE11A gene, (b) cDNA and (c) protein. Location of 
the exonic (cDNA) and intronic mutations causing the 25 confirmed cases of ATLD from 
United Kingdom (UK), Italy (ITA), Japan (JPN) and the Kingdom of Saudi Arabia (KSA), are 
indicated. Only mutations detectable in a full-length Mre11 protein are indicated at the 
protein level. (Assembled from www.ensembl.org and Taylor et al., 2004 with substantial 
modifications and update). 
studies have identified in all patients the same G to C transversion at position 630 
(c.630G>C) located in exon 7, which results in the missense change of Trp to Cys (W210C). 
No other nucleotide change was identified in the coding sequences or flanking intronic 
sequences of MRE11A. Tryptophan at position 210 is a highly conserved residue in the 
Mre11 protein, being invariable from yeast to mammals and its replacement by the small 
polar residue cysteine is likely to affect the structure or function of the protein. In addition, 
this residue lies between motifs III and IV of the N-terminal nuclease domain of the Mre11 
protein, a region where another missense mutation (N117S) had been identified in ATLD 
patients (Figure 3). Thus, all patients were homozygous for a novel missense mutation (c.630 
G>C) of the MRE11A gene that seems to be specific to Saudi Arabia. The resulting amino 
acid change (W210C) does not seem to affect the level of Mre11 protein expression but 
results in an inability of the mutant Mre11 protein to interact with Nbs1 protein leading to 
destabilization of the MRN complex and the loss of its normal function.   
4. Frequency of MRE11A gene mutations 
While the frequency of the different mutations in the MRE11A gene is unknown, the high 
number of Saudi ATLD patients with the 630 G>C particular mutation would suggest 
noticeable frequency of heterozygous carriers in the Arabic peninsula. This may have 
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impact on premarital and preimplantation screening to limit genetic diseases and to provide 
informed genetic counseling. Therefore, a study was initiated to assess the allelic frequency 
of this mutation (Alsbeih et al., 2008). Currently, a cohort of 528 phenotypically normal 
individuals was included in the study. There were 146 females and 382 males. The 
methodological procedures to detect the G to C missense mutation at nucleotide 630 of the 
MRE11A gene and the PCR primers used were described previously (Alsbeih et al., 2008). 
Briefly, genomic DNA was extracted from 3-5 ml peripheral whole blood or cultured skin 
fibroblasts, using Puregene DNA Purification Kit (Gentra System, Minneapolis, MN). 
Relevant segments of DNA were amplified by thermal cycling (95 °C for 15 min, 39 rounds 
of 95 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min and final extension at 72 °C for 7 min) 
using HotStarTaq DNA polymerase (Qiagen, Venlo, Netherlands), and 50 ng template DNA 
in 25 microlitter volume with standard reaction conditions. The quality of the PCR product 
was checked by running 5 microlitter of the reaction in 1% agarose gel. The amplified 
fragment was directly sequenced using the DYEnamic ET Dye Terminator Cycle Sequencing 
Kit (Amersham Biosciences, Piscatway, NJ) according to the manufacturer’s instruction, and 
were run on the MegaBase 1000 sequencer (Applied Biosystems, Fostercity, CA). Sequencing 
results were aligned to the corresponding reference sequence and the missense mutation 
was genotyped using SeqManII sequence analysis software (DNASTAR Inc., Madison, WI).  
Out of the 528 individuals, only two were heterozygous (G630C) for the missense mutation, 
while the remaining 526 were all wild-type. The genotype and allelic distributions of the 
missence mutation in the MRE11A are listed in Table 1. This gives a frequency of 99.6 for the 
G/G wild-type and 0.4% for the heterozygous G/C. In addition, one individual was 
heterozygous for a new SNP in intron 6, position 18026 (Ensembl annotation), 131 
nucleotides upstream of the G630C mutation (Alsbeih et al., 2008). 
 
Genotype 
and allele Individuals n Frequencies (%) 
   
MRE11A g.18157 mutation G>C 
G/G 526 99.6 
G/C 2 0.4 
C/C 0 0 
G 1054 99.8 
C 2 0.2 
   
Table 1. Genotype and allele frequencies of the MRE11A 630G>C (g.18157, p.210 Trp>Cys) 
misense mutation in 528 Saudi individuals. Sequence reported on the negative strand as per 
the gene direction. 
The presence of two heterozygous individuals indicates the existence of this rare mutation 
in the population with an estimated heterozygous genotype G/C of 0.4% and estimated 
mutant C allele frequency of 0.2%. Therefore, the diagnosis of MRE11A ATLD should be in 
the mind of physicians whenever they encounter an A-T like disorder and genetic study 
should be carried out to confirm the diagnosis. This is how the 5 patients reported by 
Bohlega and colleagues were diagnosed (Bohlega et al., 2011). The fact that the 10 previously 
described Saudi ATLD patients (Fernet et al., 2005) are from the central region of Saudi 
Arabia could suggest higher frequency of this mutation in geographically isolated families 
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impact on premarital and preimplantation screening to limit genetic diseases and to provide 
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methodological procedures to detect the G to C missense mutation at nucleotide 630 of the 
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Briefly, genomic DNA was extracted from 3-5 ml peripheral whole blood or cultured skin 
fibroblasts, using Puregene DNA Purification Kit (Gentra System, Minneapolis, MN). 
Relevant segments of DNA were amplified by thermal cycling (95 °C for 15 min, 39 rounds 
of 95 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min and final extension at 72 °C for 7 min) 
using HotStarTaq DNA polymerase (Qiagen, Venlo, Netherlands), and 50 ng template DNA 
in 25 microlitter volume with standard reaction conditions. The quality of the PCR product 
was checked by running 5 microlitter of the reaction in 1% agarose gel. The amplified 
fragment was directly sequenced using the DYEnamic ET Dye Terminator Cycle Sequencing 
Kit (Amersham Biosciences, Piscatway, NJ) according to the manufacturer’s instruction, and 
were run on the MegaBase 1000 sequencer (Applied Biosystems, Fostercity, CA). Sequencing 
results were aligned to the corresponding reference sequence and the missense mutation 
was genotyped using SeqManII sequence analysis software (DNASTAR Inc., Madison, WI).  
Out of the 528 individuals, only two were heterozygous (G630C) for the missense mutation, 
while the remaining 526 were all wild-type. The genotype and allelic distributions of the 
missence mutation in the MRE11A are listed in Table 1. This gives a frequency of 99.6 for the 
G/G wild-type and 0.4% for the heterozygous G/C. In addition, one individual was 
heterozygous for a new SNP in intron 6, position 18026 (Ensembl annotation), 131 
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the gene direction. 
The presence of two heterozygous individuals indicates the existence of this rare mutation 
in the population with an estimated heterozygous genotype G/C of 0.4% and estimated 
mutant C allele frequency of 0.2%. Therefore, the diagnosis of MRE11A ATLD should be in 
the mind of physicians whenever they encounter an A-T like disorder and genetic study 
should be carried out to confirm the diagnosis. This is how the 5 patients reported by 
Bohlega and colleagues were diagnosed (Bohlega et al., 2011). The fact that the 10 previously 
described Saudi ATLD patients (Fernet et al., 2005) are from the central region of Saudi 
Arabia could suggest higher frequency of this mutation in geographically isolated families 
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with high level of consanguineous marriages. However, larger studies with members from 
different regions are required to precisely estimate the exact frequency of this mutation in 
Saudi Arabia.  
5. ATLD and other ataxia causing disorders 
Ataxia occurs when parts of the nervous system that control movement are damaged. Most 
disorders that result in ataxia cause cells in the cerebellum, and sometimes in the spine or 
even the peripheral nervous systems, to degenerate or atrophy. Cerebellar and 
spinocerebellar degeneration have many different causes. Genetic causes form a 
heterogeneous group with different pattern of inheritance and onset of the symptoms. 
Currently this group encompasses the following distinct conditions: ataxia telangiectasia (A-
T), ataxia telangiectasia-like disorder (ATLD), ataxia oculomotor apraxias (AOA), and the 
two "A-T variants", Nijmegen breakage syndrome (NBS) with microcephaly but without 
ataxia, and A-T (Fresno) that combines features of both NBS and A-T. This is in addition to 
other hereditary ataxia such as Friedreich ataxia (FA) and Machado-Joseph Disease (MJD) 
caused by triplet repeat expansion, spastic ataxia of the Charlevoix-Saguenay, Autosomal 
recessive ataxia associated with isolated vitamin E deficiency, Infantile onset spinocerebellar 
ataxia, ataxia with hearing loss and optic atrophy, spinocerebellar ataxia with axonal 
neuropathy, Cayman ataxia, cerebellar ataxia with mental retardation optic atrophy and 
skin abnormalities, Salla syndrome, Marinesco-Sjögren and the childhood spinocerebellar 
ataxia (Bouhlal et al., 2005). Table 2 summarizes some of the genetic disorders grouped 
under hereditary ataxias and its variants of relevance to ATLD. 
 

























NBS Recessive 8q21 Nbs1 
(nibrin) 





A-T Fresno Recessive 11q23 ATM (Gilad et al., 
1998) 
Friedreich ataxia FRDA Recessive 9q13-q21 Frataxin (Campuzano 
et al., 1996) 
Machado-Joseph 
Disease 
MJD Dominant 14q32 Ataxin-3 (Kawaguchi et 
al., 1994) 
* A-T Fresno combines features of A-T and NBS with mutation in ATM. 
Table 2. Genetic disorders grouped under hereditary ataxias and its variants 
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Diagnosis is usually suggested by the clinical manifestations. Non-specific complementary 
tests may be done to differentiate between them or to exclude other disorders or conditions 
that may cause ataxia. The molecular characterization of these different disorders allows 
genetic tests to confirm a clinically suggested diagnosis. In general, there are no specific 
treatments available for most of the inherited ataxia disorders. Symptoms are treated with 
physical and occupational therapy, assistive devices, and medication for muscle pain or 
spasms that may occur. Genetic counseling provides education to parents of individuals 
with an inherited ataxia disorder to be aware that they may pass the disorder on to their 
children. Some affected families may choose to test members to see if they have inherited 
the gene responsible for the disorder. 
6. Conclusions 
Hereditary ataxias are a heterogeneous group of cerebellar degeneration causing failure of 
muscle control, resulting in a lack of coordination, imbalance and ataxic gait. ATLD is a rare 
variant of A-T with only 25 confirmed cases worldwide, 4 in the UK, 2 in Italy, 4 in Japan 
and 15 in Saudi Arabia. The patients were either homozygous or compound heterozygous 
for 10 different hypomorphic mutations in exons and splice sites. The 15 Saudi Arabian 
patients were related to 5 independent families and represent the largest ATLD cohort 
which would suggest the presence of a noticeable frequency of heterozygous carriers of 
MRE11A gene mutation in the population. Therefore, the diagnosis of ATLD should be in 
the mind of physicians whenever they encounter an A-T like disorder and genetic study 
should be carried out to confirm the diagnosis. Testing for MRE11A gene mutations could 
ultimately be incorporated to premarital, pre-implementation or prenatal screening to 
reduce the risk of transmission of genetic diseases.  
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ataxia, ataxia with hearing loss and optic atrophy, spinocerebellar ataxia with axonal 
neuropathy, Cayman ataxia, cerebellar ataxia with mental retardation optic atrophy and 
skin abnormalities, Salla syndrome, Marinesco-Sjögren and the childhood spinocerebellar 
ataxia (Bouhlal et al., 2005). Table 2 summarizes some of the genetic disorders grouped 
under hereditary ataxias and its variants of relevance to ATLD. 
 

























NBS Recessive 8q21 Nbs1 
(nibrin) 





A-T Fresno Recessive 11q23 ATM (Gilad et al., 
1998) 
Friedreich ataxia FRDA Recessive 9q13-q21 Frataxin (Campuzano 
et al., 1996) 
Machado-Joseph 
Disease 
MJD Dominant 14q32 Ataxin-3 (Kawaguchi et 
al., 1994) 
* A-T Fresno combines features of A-T and NBS with mutation in ATM. 
Table 2. Genetic disorders grouped under hereditary ataxias and its variants 
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Diagnosis is usually suggested by the clinical manifestations. Non-specific complementary 
tests may be done to differentiate between them or to exclude other disorders or conditions 
that may cause ataxia. The molecular characterization of these different disorders allows 
genetic tests to confirm a clinically suggested diagnosis. In general, there are no specific 
treatments available for most of the inherited ataxia disorders. Symptoms are treated with 
physical and occupational therapy, assistive devices, and medication for muscle pain or 
spasms that may occur. Genetic counseling provides education to parents of individuals 
with an inherited ataxia disorder to be aware that they may pass the disorder on to their 
children. Some affected families may choose to test members to see if they have inherited 
the gene responsible for the disorder. 
6. Conclusions 
Hereditary ataxias are a heterogeneous group of cerebellar degeneration causing failure of 
muscle control, resulting in a lack of coordination, imbalance and ataxic gait. ATLD is a rare 
variant of A-T with only 25 confirmed cases worldwide, 4 in the UK, 2 in Italy, 4 in Japan 
and 15 in Saudi Arabia. The patients were either homozygous or compound heterozygous 
for 10 different hypomorphic mutations in exons and splice sites. The 15 Saudi Arabian 
patients were related to 5 independent families and represent the largest ATLD cohort 
which would suggest the presence of a noticeable frequency of heterozygous carriers of 
MRE11A gene mutation in the population. Therefore, the diagnosis of ATLD should be in 
the mind of physicians whenever they encounter an A-T like disorder and genetic study 
should be carried out to confirm the diagnosis. Testing for MRE11A gene mutations could 
ultimately be incorporated to premarital, pre-implementation or prenatal screening to 
reduce the risk of transmission of genetic diseases.  
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1. Introduction 
Gaucher disease (GD) (GD, OMIM 230800), is the most common glycosphingolipid storage 
disorder, with an estimated global prevalence of 1:200,000 of the population (Cox & Schofield, 
1997). Impaired activity of the lysosomal enzyme, -glucocerebrosidase, leads to build-up of 
glucosylceramide in macrophages, forming dysfunctional, lipid-engorged ‘Gaucher cells’ that 
accumulate primarily in the liver, spleen, bone, lungs and nervous system (Grabowski & 
Horowitz, 1997; Beutler, 1997). Figure 1 Sometimes, bone disease or cellular infiltration in bone 
marrow, could be lead to fractures or hematomas that cause neurological complications from 
compression of the spinal cord or peripheral nervous system. In addition, severe deficiency of 
-glucocerebrosidase increases the accumulation in the central nervous system of 
glucosylceramide and other toxic metabolites in the neuronopathic involvement. However the 
precise mechanisms by which glucosylceramide storage originate them is still unclear. The 
frequency of neurological GD cases is ranging between 7% and 17%, according to different 
series (Biegstraaten et al., 2008; Chérin et al., 2010). 
 
 
Fig. 1. Biosynthesis and degradation of sphingolipid 
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2. Clinical characteristics of neurological forms 
The neuronopathic forms of GD can be either acute type 2 (GD2) (MIM 230900), or chronic 
type 3 (GD3) (MIM 231000), the presence of neurological symptoms is the main 
characteristics for a diagnosis, nevertheless in a low percentage of type 1 GD (GD1) some 
neurological manifestations could be considered part of the GD1 phenotype.  
These forms are considered as ultrarare and estimated at about 5% for GD3 and 1% for GD2 
(Charrow et al., 2000).  
2.1 Type 2 Gaucher disease 
There are many descriptions of type 2 Gaucher disease presenting with hydrops fetalis and 
joint contractures. In the majority of cases with this severe phenotype, glucocerebrosidase 
activity is absent or severely de cient. In general, most patients with Gaucher disease do 
have some residual glucocerebrosidase activity, with no correlation between severity and 
the level of residual enzyme activity. 
The patients with the acute form, usually die within two years. The initial neurological 
symptoms as paralysis of horizontal gaze supranuclear are followed later, with strabismus, 
impaired vertical gaze, dysarthria, difficulty in swallowing, chewing, laryngeal stridor and a 
pyramidal syndrome with opisthotonos. Some of these patients develop a progressive 
encephalopathy that is neocortical in origin. The molecular and cellular bases for the 
phenotypic variation and the progression of the neuronopathic features in Gaucher disease 
are poorly understood. Few studies are available from human tissues that correlate 
neuronopathic progression, pathologic involvement, and the clinical manifestations. To fill 
this void, several mouse models with GCase null or point mutations or chemical inhibition 
were developed. The GCase-null mutations exhibited a defective skin permeability barrier, 
similar to that in collodion babies. Skin permeability barrier defects lead to death shortly 
after birth and have limited their utility in understanding the pathogenesis in CNS of type 2 
and 3 Gaucher disease (Xu et al, 2008) 
2.2 Type 3 Gaucher disease 
The patients with chronic form, GD3, the first neurological symptoms usually appear at a 
mean age of 8 years, and the patients with myoclonic epilepsy variant by age 15 (Park et al., 
2003) in these cases the life expectancy can reaches the third decade. Nevertheless, there 
have been reported some cases of apraxia of gaze without progression to other neurological 
symptoms (Kraoua et al., 2011).  There are other GD3 subtypes, GD3b, the neurological 
involvement is limited to apraxia of the eyes, but is associated with visceral enlargement 
and bone disease. (Patterson et al., 1993). Other less common GD3 subtype, have been 
classified as 3c characterized by heart valves calcification and eye movement disorders 
(Chabas et al., 1995).  
The GD3 has heterogeneous clinical manifestations, and therefore different subtypes have 
been referred. GD3 subtype a, is characterized by apraxia of gaze and dementia associated 
with myoclonic epilepsy, ataxia and extrapyramidal signs or spasticity. In addition in this 
subtype there are several specific forms including the myoclonus epilepsy as the main 
manifestation (Park et al., 2003). These neurological forms have slight or moderate visceral 
involvement and bone changes are characterized by chest deformities and kyphoscoliosis, 
which may have a neurological basis, however bone crises normally are absent (Tylki-
Szyma ska et al., 2010). 
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2.2.1 Myoclonic epilepsy 
Different lysosomal storage diseases: late-onset GM2 gangliosidosis, type 2 GM1 
gangliosidosis, Niemann-Pick disease, sialidosis, galactosialidosis, pseudodeficiencia of 
arylsulfatase A, Gaucher disease and some forms of ceroid lipofuscinosis have been 
associated with myoclonic epilepsy (Tinuper et al., 1994; Kowarz et al., 2005). 
The main form is an association between Gaucher disease and myoclonic epilepsy in a rare 
subgroup of patients with GD type 3 who developed a progressive myoclonus epilepsy. All 
had horizontal saccadic eye movements. The lack of a shared genotype for patients and the 
variability in clinical presentations suggesting the existence of other modifying factors 
contributing to this rare phenotype (Park et al., 2003). Have also been documented cases in 
Spanish population with symptoms of myoclonic epilepsy (Giraldo et al., 2011). In a study 
of a Spanish patient with neuronopathic type 3 GD and myoclonic epilepsy symptomatic 
improvement was observed using a combination of substrate reduction therapy with 
enzyme replacement therapy (Capablo et al., 2007). 
Although the mutation N188S in the GBA gene in Gaucher disease was initially considered 
a mild mutation or a variant modifier has been reported the association of this mutation 
with the development of myoclonic epilepsy, suggesting that the enzyme could lead to 
abnormal death of neuronal cells or modify the role of other proteins involved in epilepsy 
(Kowarz et al., 2005). In recent years, understanding the genetic basis of myoclonic epilepsy 
has progressed rapidly and several defects have been identified, specific genes and 
mutations (Scheffer & Berkovic, 2000, Stafstrom et al., 2000, Delgado-Escueta et al. 2001). 
Recently genes have been identified for other forms of progressive myoclonus epilepsy: 
a. The CLN3 gene has been associated with a type of neuronal ceroid lipofuscinosis, 
Batten disease, contains 15 exons and spans over 15 Kb. The International Batten 
Disease Consortium isolated the gene CLN3 between microsatellite markers D16S288 
and D16S383 on chromosome 16p12.2.1-16p11 (International Batten Disease 
Consortium, 1995). It is speculated that the gene product functions as a chaperone 
involved in folding / unfolding or assembly / disassembly of other proteins, 
specifically the subunit c of ATP synthase complex (Janes et al., 1996). Biochemically 
mutation causes multiple deficiencies in the enzyme complexes of the respiratory chain 
involving NADH-CoQ reductase (complex I) in the cytochrome C oxidase (COX). 
b. A mutation at nucleotide 8344 of human mitochondrial DNA causes MERRF 
(Myoclonus Epilepsy Associated with Ragged-Red Fibers) (Shoffner et al., 1990). 
c. The gene for cystatin B (CSTB) is located on chromosome 21 in a segment of about 
175KB, between D21S2040 and D21S1259. Expands into three exons over 2500bp, 
encoding a small protein of 98 amino acids. Mutations in the gene encoding cystatin B 
are responsible for primary defect in patients with progressive myoclonus epilepsy type 
Unverricht-Lundborg (EPM1) autosomal recessive (Pennacchio et al., 1996). The 
encoded protein is a member of the superfamily of cysteine protease inhibitors 
(Jarvinen & Rinne, 1982, Turk & Bode, 1991). 
d. EPM2A gene is located on chromosome 6q24 and contains 5 exons that encode two 
laforin isoforms, isoform A is located in the rough endoplasmic reticulum and isoform 
B in the nucleus. Laforin is a dual specificity phosphatase and functions are involved in 
protein degradation by the proteasome (Lohi et al., 2005) and glycogen metabolism 
(Worby et al., 2006). Mutations in the gene EPM2A cause deleterious effects on protein 
encoding the laforin, causing Lafora disease, which is an autosomal recessive 
progressive myoclonic epilepsy (Minassian et al., 1998). 
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3. Histological changes in neurological forms 
The neuropathological studies (Wong et al., 2004) in patients with different types of GD 
have found clear pathologic changes in several areas of the brain, mainly in the form of 
perivascular Gaucher cells, astrogliosis and neuronal loss. Immunohistochemical findings in 
the same study suggest that, in certain areas, elevated intracellular levels of 
glucocerebroside would further reduce glucocerebrosidase levels and contribute to citoxicity 
as well as to abnormalities in calcium homeostasis and increased sensitivity of neurons, thus 
facilitating spontaneous neuronal discharges. More recent data reinforces the role of 
citotoxic molecules, but possibly related to the intraneuronal accumulation of the defective 
enzyme (Futerman; 2006). It has also been proposed that the accumulation of 
glucosylsphingosine, is responsible for the neurological symptoms (Pelled et al., 2005). On 
the other hand, the finding that mutation N188S may be associated with the development of 
myoclonic epilepsy, suggests that the abnormal enzyme might lead to neuronal cell death, 
or modify the role on other proteins involved in epilepsy (Kowarz et al., 2005). 
Neuropathological exam in a GD3 patient suggests that cerebellum-dentate degeneration 
would play a major role in these patients’ myoclonus (Verghese et al., 2000). How this 
relates to in vivo cortical dysfunction is unclear. Probably, other factors in addition to point 
mutations, environmental, epigenetic and genetic, will ultimately be involved in the 
development of myoclonic epilepsy in GD patients.  
In some cases of myoclonic epilepsy an improvement in neurological symptoms have been 
observed with substrate reduction therapy (SRT), the biochemical basis of this improvement 
could be related with small molecules that have been shown to enter the CNS both in animal 
models and in patients and this was an important argument maybe related to the reduction 
of glucocerebroside accumulation by the substrate reduction activity. It could also be related 
to the described chaperoning effect on the defective glucocerebrosidase or a functional 
improvement, through a yet unknown mechanism, in the defective calcium homeostasis 
described above (Pelled et al., 2005).  
4. Clinical characteristics of type 1 Gaucher Disease 
Classically, GD1 is characterized by organomegaly, cytopenias, bone disease and absence of 
neurological manifestations. However, there are several reports of the co-occurrence of 
neurological problems, as a consequence of spinal cord or nerve compression following 
vertebral body collapse or bleeding within confined compartments (Grewel et al., 1991). 
There is accumulating evidence that in a few GD patients, prominent neurological 
abnormalities may become evident during adult life (McKeran et al., 1985). Several new 
lines of evidence have implicated an association between GD and the development of 
parkinsonism. The first hints of a relationship between the two disorders were suggested by 
scattered case reports of patients with Gaucher disease who developed early-onset, 
treatment-refractory parkinsonism (Neudorfer et al., 1996; Machaczka et al., 1999; Tayebi et 
al., 2001). In a clinic-based series of Parkinson disease patients from Israel, (Aharon-Peretz et 
al., 2004) screened for the most frequent mutations in glucocerebrosidase gene, they 
identified 31% with glucocerebrosidase mutations including three N370S homozygotes. This 
frequency was at least fivefold higher than the observed in their two control groups used. 
In an international collaborative study conducted in sixteen countries with 5961 patients 
with Parkinson disease in all ethnic groups, compared with 4898 controls, the odds ratio 
estimated for any type of GBA mutation has been of 5.43 (Sidransky et al., 2009).  
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We have studied the characteristics of Gaucher disease in Iberian Peninsula. The Iberian 
Peninsula (IP) is located in the extreme Southwest of Europe and includes the states of 
Portugal and Spain. It is the second-largest peninsula in Europe, with an area of 580,000 
square kilometers and with a total 55 million of inhabitants. The actual IP genetic pool has 
been influenced by many major populations and immigrations, including the Paleolithic 
Iberian population, which already existed by 50,000 B.C. Later, by North Africans who 
entered the Iberian region between 20,000 and 8,000 B.C. and by the Saharans, who arrived 
between 8,000 and 4,000 B.C. In addition, there were also people coming from central 
Europe (also generically called Celt invasions), during the first millennium B.C. At the 
beginning of the 8th century Islamic peoples (generically called Arabs) entered Spain 
(Arnaiz Villena et al 1999, Côrte-Real HB et al 1996). Taking into account all these data, 
nowadays it is believed that, the timing of divergence of populations within Iberia points to 
a shared ancestry of all populations in the Upper Palaeolithic. Further genetic subdivision is 
apparent in Catalonia and Andalusia, with increased genetic diversity in the latter. Lineage 
diversity comparisons of IP populations with European (Tuscan) and North African 
(Algerian) populations shows the Iberian Peninsula to be more similar to other European 
populations, although a small number of Iberian lineages can be traced to North Africa. 
Since the early 70s, the group of Dr. Chabas in Barcelona (Spain) and the Dr. Sa Miranda in 
Porto (Portugal) has been dedicated to the identification and study of lysosomal storage 
diseases including GD (Cormand et al. 1995, 1998; Amaral et al 1993). Moreover since 1993, 
the Spanish Foundation for the Study and Treatment of Gaucher Disease (FEETEG) keeps 
the Spanish Registry of GD (SRGD) and also coordinates the screening, diagnosis, 
characterization, treatment, and follow-up of GD patients in Spain (Giraldo et al. 2000, 
Alfonso et al 2007). 
Of the 436 subjects included in this series, the 96.1% were born in Iberian Peninsula, Balearic 
and Canary Islands,  92 patient were from Portugal (21.1%) and 327 (75.0%) Spanish origin 
and 17 were immigrants (3.9%),   Patients born at IP were classified at diagnosis: 370 as GD 
type 1 (88.3%) (age mean: 40.6 ± 20.30 years, range 0.3–87); 28 as GD type 2 (6.7%) (Age: 
mean 0.4 years, range 0–1) and 21 as GD type 3 (5.0%) (Age: mean 5.9 years, range 2–17). 
Mean age at diagnosis in the total GD patients was 26.3±19.88 years (range 0-87) and 28.7 
years in patients type 1.  To date, 63 patients from IP in this series are death (15%) and 373 
are alive (85%). According the type distribution 7.6% of type 1; 52.4% of type 3 and 100% of 
type 2 are death. 
4.1 Association of Parkinsonism with Gaucher disease 
Parkinson disease (PD), the second most common neurodegenerative disorder after 
Alzheimer's disease, has a complex and multifactorial etiology, with different contributions: 
genetic, epigenetic and environmental. It can be classified by age of onset as early PD or late 
PD and in the form of presentation as family or sporadic PD. 
The main clinical phenotype of Parkinson's disease is characterized by motor dysfunction 
such as bradykinesia, tremor at rest, rigidity and postural instability, but can also affect 
autonomic functions and knowledge (Poewe, 2008). 
The prevalence of the disease is associated with age, and is approximately 1 in 100 
individuals at 65 years and increasing to 4-5% at the age of 85 years (Van den Eeden et al., 
2003). 
Parkinson's disease is mainly due to a progressive degeneration of dopaminergic neurons in 
the substantia nigra and other monoaminergic cell groups of the brain (Braak et al., 2003), 
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resulting in increased microglial activation and accumulation of proteins in the surviving 
dopaminergic neurons, known as Lewy bodies and Lewy neurites (Forno, 1996). Symptoms 
appear when between 50-70% of nigrostriatal dopaminergic neurons are lost. 
Although Parkinson's disease has been considered a genetic disorder of not sporadic origin, 
only 5 to 10% of patients show monogenic forms of the disease. Some genes are associated 
with Parkinson's disease, and several of them are presented in an autosomal dominant or 
autosomal recessive.  
Autosomal dominant: PARK1/ -sinucleín, PARK4/ -sinucleín, PARK8/Leucine-rich 
repeat kinase 2 (LRRK2) and microtubule associated protein tau (MAPT). 
Autosomal recessive: The PARK2 gene is located on chromosome 6q25.2-q27 and comprises 
12 exons with intron structure superexpanded of 1.3 Mb of genomic DNA, which encodes a 
protein of 465 amino acid N-terminal domain similar to ubiquitin. Mutations in the parkin 
gene (PARK2) were identified for the first time in several Japanese families with autosomal 
recessive juvenile parkinsonism (Kitada et al., 1998). 
PTEN-induced PARK6/Quinasa 1 (PINK1). Homozygous mutations in this gene were 
found originally in patients with early-onset Parkinson's, and account for between 1 to 2% of 
cases of early onset of Parkinson's disease (Hatano et al., 2004). 
The PINK1 gene, located on 1p35-36, contains 8 exons spread over 1.8 kb and encodes a 
protein of 581 amino acids. The transcript is expressed ubiquitously and encodes a protein 
kinase domain of a highly conserved, which is also in the family of Ca2 + / calmodulin 
serine-threonine kinases (Valente et al., 2004). 
DJ1 PARK7/Oncogen, DJ1 gene, located on chromosome region 1p36, contains 8 exons that 
span 24 Kb and is located 25 cM from the telomere of the PINK1 gene (Bonifati et al., 2003). 
Deletions have been identified and mutations that cause amino acid change <1% of early-
onset parkinsonism (Lockhart et al., 2004). 
Monogenic forms represent less than 10% of Parkinson disease in most populations and are 
the result of complex interactions between genes and environmental factors. Genetic 
variations could be susceptibility factors or disease modifiers, affecting the penetrance, age 
of onset, severity and progression. 
The results of different studies show an association between Gaucher and Parkinson's 
disease by the occurrence of Gaucher disease and atypical parkinsonism in patients, 
appearing between the fourth and sixth decades of life, and the identification of mutations 
in the gene the GBA in probands with sporadic Parkinson's disease. 
There are different hypotheses about how to explain the association of Parkinson disease 
and Gaucher Disease. One of them claims that glucocerebrosidase gene (GBA) mutations can 
produce an aberrant protein with function gain either hetero or homozygous and facilitate 
the alpha-synuclein aggregation this effect could induces neuronal toxicity.  Wild-type 
alpha-synuclein could be selectively translocated into lysosomes for degradation by the 
chaperone-mediated autophagy pathway (Cuervo et al., 2004).  
Under these conditions the receptor LAMP2 would saturate their transport capacity, 
resulting in a jam intracellular alpha-synuclein. Another scenario would involve directly the 
accumulation of misfolded mutated glucocerebrosidase protein in the endoplasmic 
reticulum leading to a situation of stress, and decreased activity of parkin, an ubiquitin 
ligase associated with the occurrence of early onset of Parkinson disease. This stress could 
trigger the start of the mechanisms of neuronal apoptosis in the substantia nigra, and 
therefore the onset of disease (Ron et al., 2010).  
Moreover, only in patients with the two GBA mutant alleles the functional deficit of 
glucocerebrosidase, may cause accumulation of glucocerebroside and glucoesphyngosine 
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that interfere with the determination of alpha-synuclein to lipid membranes, facilitating the 
aggregation of alpha-synuclein and the formation of Lewy bodies (Schlossmacher et al., 
2005). 
4.2 Other neurological manifestations in type 1 Gaucher Disease 
Pastores et al conducted an epidemiological survey in order to ascertain the incidence of 
neurological symptoms in patients with GD1 (Pastores et al., 2003). This survey revealed 
that a significant proportion of patients with GD I experience neurological symptoms. In 
addition, we found that GD1 patients have a greater risk of suffering other common 
unrelated diseases than carriers or their healthy relatives (Giraldo et al., 2011). 
The wide spectrum phenotypic variation and neurological involvement within all types, and 
the recognition of an increasing number of subgroups of patients, support the view that GD 
is a disorder with a phenotypic continuum ranging from prenatal lethality to asymptomatic 
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A recent systematic review of published literature identified 86 studies in which patients 
with GD1, or carriers of a glucocerebrosidase gene mutation, had some form of neurological 
manifestation (Biegstraaten et al., 2008; Cherin et al., 2010) contrary to the classical 
neuronopathic phenotypical description. Peripheral nervous system manifestations appear 
to be of particular relevance in GD1. An epidemiological survey of GD1 patients undergoing 
long-term enzyme replacement therapy (ERT) revealed that 73% of patients had at least one 
neurological symptom, including paraesthesia, tremor, muscular weakness, muscle cramps 
and sciatica, most of which were thought to be due to peripheral nervous system disease 
(Pastores et al., 2003). A case–control survey in 107 GD1 patients (untreated or receiving 
ERT) corroborated these findings, reporting a significantly higher frequency of symptoms 
related to peripheral neuropathy (Halperin et al., 2007). However, the above studies were 
limited by the absence of a neurological examination and standardised nerve conduction 
studies, and as yet there are no reliable estimates of the prevalence of peripheral neuropathy 
in GD1 (Biegstraaten et al., 2010), the vast majority of these cases have subclinical peripheral 
neuropathy only detected by electroneurophysiological exams. Figure 3 
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Fig. 3. Sensorial nerve conduction in type 1 Gaucher Disease patient. Abnormal wave forms 
in radial nerve. 
The aetiology of polyneuropathy related to GD1 has not yet been elucidated, although 
certain associated conditions may predispose patients to develop neurological disease. 
Relevant conditions might include monoclonal gammopathies, vitamin B12 deficiency and 
diabetes mellitus (Gielchinsky et al., 2001; de Frost et al., 2008; Silverman et al., 2008). The 
pathophysiology of nerve injury in GD remains speculative, but may be related to an 
imbalance in calcium homeostasis. Elevated intraneuronal glucocerebroside concentrations 
have been shown to induce a 300% increase in calcium-induced calcium release by 
influencing the RyaR channel, which has been proposed as one of the mechanisms 
responsible for neuronal injury in the central nervous system of neuronopathic GD (Lloyd-
Evans et al., 2003). Whether this mechanism plays a role in peripheral nerve injury is 
unknown, but increased intracellular calcium has been implicated in the pathophysiology of 
diabetic neuropathy and neuropathic pain (Hall et al., 2001; Yaksh,2006; Finnerup et al., 
2007). 
In conclusion, polyneuropathy and other peripheral nerve involvement appear to be part of 
the natural course of disease in patients with GD1, highlighting the need for increased 
vigilance for peripheral neurological abnormalities 
5. Mutations in GBA and neuronopatic forms of Gaucher Disease   
The gene for human GCase, GBA, consists of 11 exon, have 7.2–7.4 kb in size, and maps to 
chromosome 1q21 (Barneveld et al., 1983). A pseudogene that shares 96% exonic sequence 
homology with GBA is located at 16 kb downstream from the functional gene (Horowitz et 
al., 1989). Figure 4. The pseudogene is transcribed, but does not produce a functional protein 
(Sorge et al., 1990). A significant number of mutations are present in the GBA pseudogene, 
and there are mutant alleles caused by gene conversion events with the pseudogene named 
recombinant alleles, Rec or pseudogene like mutations. Over 300 mutations have been 
identified worldwide in GBA and over 50 different mutations have been described in 
patients with neuronopatic involvement (Hruska et al., 2008) and also see 
 
Neuronopathic Forms in Subjects with Mutations in GBA Gene 
 
99 
http://www.hgmd.org. They represent a spectrum of non-sense, missense and splice mutations 
as well as gene rearrangements. Most of these mutations are rare or private mutations, but 
two missense mutations, N370S and L444P, have significant frequencies in the majority of 
populations. It has been suggested that the genotype plays an important role in determining 
the degree of neurological involvement; however genotype-phenotype correlations are not 
straightforward in GD (Beutler & Grabowski., 2001; Koprivica et al., 2000). The most 
consistent finding is that the presence of the N370S mutation, either in homozygosity or in 
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Fig. 4. Structure of glucocerebrosidase gene GBA and Seudogene -GBA 
However,  L444 P homozygosity has been shown to be associated with a neuronopathic 
phenotype in various populations, including   Spanish, Swedish, Pole, Ashkenazi Jewish, 
and other Caucasian populations, while it was clearly associated with non-neuronopathic 
Gaucher disease in Taiwanese–Chinese (Wan et al., 2006; Goker-Alpan et al., 2005; Koprivica 
et al., 2000; Stone, 2000). These observations strongly suggest that other factors, such as 
modifier loci, promoter mutations, environmental factors, and other non-genetic causes, 
must play roles in the observed genotype-phenotype variability and also that modifying 
genes could be associated with the ethnic-related genetic diversity (Montfort et al., 2004; 
Alfonso et al., 2010).  
To try to identify relationships genotype-phenotype, two approaches may be useful. First, 
the use of homogenous populations would tend to diminish genetic variation, as a 
consequence, the observed phenotype can be attributed to the identified mutants with 
greater assurance.  However, this approach is limited by the need of large sample size to 
identify sufficient numbers of homozygotes for study, and to guarantee the homogeneity.  
The second approach is to study patients with most severe disease, and the least amount of 
residual activity. It is assumed that both mutant alleles have to be highly disruptive in these 
cases. 
An additional problem arises from the analysis method used; most laboratories relied solely 
on Polymerase Chain Reaction (PCR) based mutation-detection techniques to screen for the 
presence or absence of speci c mutations. PCR amplification of a specific fragment has 
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inherent problems, because a complex allele with more than one mutation, a mutation 
located at a primer site or a deleted allele could not be detected and therefore the published 
studies on genotype-phenotype relationship may be biased. Moreover, recombinant alleles 
would not be identi ed because using this approach alleles carrying a portion of the 
pseudogene sequence will not be ampli ed by primers designed to be speci c for the 
glucocerebrosidase gene, and the patient may mistakenly be designated as a homozygote for 
the second allele (Torralba et al., 2002; Tayebi et al.,1999) 
Given these limitations, we note that some generalizations were observed that suggested 
genotype–phenotype correlations: 1) homozygosis for the L444P mutation is usually, if not 
always, associated with neuronopatic forms 2). L444P is the most common mutation 
identified in patients with the intermediate phenotype. 3) the combination of one allele with 
L444P mutation and another mutation with a null or very severe allele seemed to be 
associated with the most severe neurological form, type 2. 4) perinatal lethality due to 
hydrops fetalis often resulted from homozygosis for a null or a recombinant allele. 5) None 
of the patients with type 2 are carriers of  the N370S mutation, commonly found  in GD1. 
It is important to point out that there is an overlap between the GD2 and GD3 phenotypes 
making it difficult to categorize, on the other hand, the differentiation between GD1 and 
GD3 is sometimes difficult during early adulthood and the patients may have to be re-
classified if neurological deficits, appear later in life. Therefore it is possible that Gaucher 
disease, classically divided into three types have a continuum of phenotypes.  
There are a large number of genotypes associated with neuronopatic forms of GD. In 
Western countries, an association can be drawn between the presence of the N370S allele in 
combination with other mutation and GD1. Conversely, the L444P allele is most frequently 
associated to the neuronopathic variants.  Data from 47 neurological cases included in the 
Spanish Gaucher Disease Registry, SGDR, (Alfonso et al., 2007; Giraldo et al., 2000) indicate 
that the most frequent allele is L444P accounting for 38.3% of the total alleles, followed by 
D409H 18.1% and the double mutant allele [E326K; L444P] 12.8%. Table 1.  
Seventeen per cent of the total neurological GD cases included in the SGDR were 
homozygous for L444P mutation. It is interesting to note that this genotype was found in 
two patients classified as GD2 and in 6 GD3 and the homozygous for [E326K; L444P] as 
GD2. Surprisingly one patient with myoclonic epilepsy was carrier of N370S mutation, 
genotype N370S/G195W, no other mutations were identified in this patient in spite that the 
entire GBA was sequenced and analysed large rearrangements. It is important to point out 
that we do not know if in this case the cause of neurological impairment was due to the GBA 
gene or to other gene, gene-gene interaction or gene-environment interaction and  therefore 
we dared not classify them as GD2 or GD3.  
As we mentioned before the N370S mutation has been traditionally associated with the 
absence of neurological disease; however, several studies reported a high proportion of 
patients with the N370S mutation were diagnosed with GD 1 and showed  mild 
neurological symptoms  such  tremor, peripheral neuropathy, uncoordinated movements, 
and hearing loss (as well as Parkinson disease. (Capablo et al., 2008; Giraldo et al., 2011; 
Pastores et al., 2003). These findings are consistent with the recently established contention 
that the mutation could not fully protect the patient from the appearance of neurological 
symptoms (Halperin et al., 2007). These observations reinforce the hypothesis that 
phenotypes reflect the continuum of the GD (Sidransky  et al., 2004).  
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 Genotype   Type2 Type3        Percent         
L444P/L444P 2 6 17.0      
D409H/D409H  6 12.8        
[E326K;L444P]/R463H 3  6.3        
G195E/L444P 3  6.3        
c.1263_1317del55/L444P 3  6.3        
D409H/R120W 2  4.2        
D409H/L444P  2 4.2 
[E326K;L444P]/[E326K;L444P] 2  4.2 
[N188S;E326K]/L444P  2 4.2 
R120W/L444P 2  4.2            
[E326K;L444P]/D409H  1 2.1    
[E326K;L444P]/P182L  1 2.1 
[E326K;L444P]/G202R 1  2.1        
[E326K;L444P]/W312R 1  2.1 
[E326K;L444P]/L444P 1  2.1      
G202R/L444P 1  2.1 
I270P/L444P 1  2.1        
RecNciI/L444P 1  2.1        
S364R/L444P 1  2.1        
c.203_204insC/L444P 1  2.1 
G377S/G195W  1 2.1        
R463C/G377S  1 2.1 
N392I/L444P 1  2.1        
V15M/G195W 1  2.1           
Total 27 20 100 
Table 1. GBA genotype distribution in 47 neuronopatic forms of GD from Spanish Gaucher 
Disease Registry 
In a recent study, aimed to determine the presence of neurological symptoms and 
Parkinson’s disease in Spanish GD patients and their relatives, we have found that relatives 
with PD exhibited a wide spectrum of GBA mutations L444P, N370S, V398I, R257Q, G202R, 
c.1439- 1445del7, [E326K; N188S], and c.953delT in the other hand PD was more frequent in 
carriers of L444P mutation and other rare GBA mutations than carriers of N370S (Giraldo et 
al., 2011). 
6. Treatment of neurological forms of Gaucher Disease 
The standard care for GD patients is the enzymatic replacement therapy (ERT), 
unfortunately neurological manifestations of GD are not corrected by ERT. This failure 
should be attributed to the blood–brain barrier which is largely impermeable to proteins.  It 
is noteworthy that children without neurological symptoms at diagnosis that receive early 
infusions of ERT, are bound to develop neurological symptoms in type 3 of disease. 
The other therapy approach used in glycosphingolipid disease, is the inhibition of the 
enzyme glusylceramide synthase and is called substrate reduction therapy (SRT), these 
inhibitors decrease the biosynthesis of the substrate (glucosylceramide). The only licensed 
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Table 1. GBA genotype distribution in 47 neuronopatic forms of GD from Spanish Gaucher 
Disease Registry 
In a recent study, aimed to determine the presence of neurological symptoms and 
Parkinson’s disease in Spanish GD patients and their relatives, we have found that relatives 
with PD exhibited a wide spectrum of GBA mutations L444P, N370S, V398I, R257Q, G202R, 
c.1439- 1445del7, [E326K; N188S], and c.953delT in the other hand PD was more frequent in 
carriers of L444P mutation and other rare GBA mutations than carriers of N370S (Giraldo et 
al., 2011). 
6. Treatment of neurological forms of Gaucher Disease 
The standard care for GD patients is the enzymatic replacement therapy (ERT), 
unfortunately neurological manifestations of GD are not corrected by ERT. This failure 
should be attributed to the blood–brain barrier which is largely impermeable to proteins.  It 
is noteworthy that children without neurological symptoms at diagnosis that receive early 
infusions of ERT, are bound to develop neurological symptoms in type 3 of disease. 
The other therapy approach used in glycosphingolipid disease, is the inhibition of the 
enzyme glusylceramide synthase and is called substrate reduction therapy (SRT), these 
inhibitors decrease the biosynthesis of the substrate (glucosylceramide). The only licensed 
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SRT is a small iminosugar molecule (Miglustat) that penetrates the blood–brain barrier. In 
spite of the trial conducted in children with chronic neuronopathic GD form, Miglustat do 
not meet its clinical end points and the drug currently is not recommended for neurological 
manifestations in GD. Nevertheless, there are some reports with specific neurological cases 
treated with miglustat that showed improvement in neurological manifestations (Capablo et 
al. 2007). It is interesting that miglustat used by compassionate therapy, in some type3 
Gaucher disease gets to slow the progression of neurological manifestations, in similar 
manner that occurs in the licensed therapy with Miglustat in Niemann–Pick disease type C, 
another lysosomal disease that affects the brain in which there is disturbed cholesterol 
trafficking to lysosomes and causes secondary accumulation of glycosphingolipids in 
neurons (Wraith et al. 2010). 
Bone marrow hematopoietic stem-cell transplantation, is not in current general use for GD, 
partly because of the difficulty to found ideal donors and procedural risks. The introduction 
of successful ERT has superseded this treatment in many countries. Only neurological forms 
in early stages could be rescued by this procedure.  
The gene therapy is an interesting future option. The use of lentivirus-transduced 
autologous hematopoietic stem cells has been applied in other neurodegenerative disease as 
adrenoleukodystrophy (Cartier et al 2009) and currently in clinical trials for metachromatic 
leukodystrophy. Gene therapy has the advantage of being one procedure that requires less 
powerful myeloablative conditioning and thus is applicable for patients predicted to be at 
risk of severe neurological disease (Cox 2010).  
7. Conclusions 
Gaucher Disease is divided classically in three types based on the presence and rate of 
progression of the neurologic manifestations: type 1 non-neuronopathic, type 2 acute 
neuronopathic , and type 3 subacute neuronopathic. However there is an overlap between 
the different types suggesting that the disease have a continuum of phenotypes. There is 
accumulating evidence that in some Gaucher Disease patients classified as type 1, will 
develop neurological abnormalities during adult life such as peripheral neuropathy or early 
onset Parkinson Disease. 
In spite of that, there are some glucocerebrosidase gene mutations associated more 
frequently to neurological forms, nevertheless genotype-phenotype correlations are not 
straightforward in Gaucher Disease. 
The origin of neurological changes has not been clearly established, the neuropathological 
studies have demonstrated damage in several areas of the brain with perivascular Gaucher 
cells, astrogliosis and neuronal loss that could be attributed to intracellular deposits of 
glucocerebroside, and to abnormalities in calcium homeostasis. 
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1. Introduction 
The thalassemia is a widespread with about 5% of the world population affected by it and is 
found in some 60 countries, with the highest prevalence in the Mediterranean region, parts 
of North and West Africa, the Middle East, the Indian subcontinent, southern Far East and 
south-eastern Asia, together comprising the so-called thalassemia belt. In western countries, 
thalassemia affects mostly individuals whose ancestry is traceable to high prevalence areas. 
As an example, there are around 1,000 cases of β-thalassemia major in the United States, 
most of whom are descendants of Mediterranean, Asian Indian, South Asian or Chinese 
ancestors. This figure is even less than half of the number of β-thalassemic patients in Fars 
Province, a region only 120,000 km 2 large in southern Iran (Haghshenas and Zamani, 1997; 
Rahim et al., 2007). The gene frequency of ß-thalassemia, however, is varies from area to 
area, having its highest rate of more than 10% around the Caspian Sea and Persian Gulf. The 
prevalence of the disorder in other areas is between 4-8% (Rahim and Abromand, 2008). 
There are many genes coding for the globins. They are found on chromosome 11 (β-globin 
cluster) or chromosome 16 (α-globin cluster) figure1. 
1.1 Beta-Thalassemia 
Beta-Thalassemia, one of the most widespread genetic diseases in the world, is a common 
autosomal recessive disorder caused by point mutations in the ß- globin gene that is located 
as a cluster on the short arm of chromosome 11 (Weatherall et al., 1989; Sack, 1999; Oliveri, 
1999). More than 200 different mutations affecting diverse levels of beta-globin genes 
expression have so far been identified (Trent, 1997; Ho and Thein, 2000). South-western 
region of Iran also represented various ß-thalassemia mutations (Figure 2).   Different 
strategies of classification individuals genotypes by ß-globin gene cluster and cloning 
nucleotides sequencing lead to identification of several mutations in Mediterranean (Orkin 
et al., 1982), Asian Indians (Kazazian et al., 1984, Ohba et al., 1997), American Blacks 
 
Human Genetic Diseases 
 
108 
Wong, K.; Sidransky, E.; Verma, A.; Mixon, T.; Sandberg, GD. et al (2004). Neuropathology 
provides clues to the pathophysiology of Gaucher disease. Molecular genetics and 
metabolism ; 82: 192-207 
Wraith, JE.; Vecchio, D.; Jacklin, E. ; Abel, L.; Chadha-Boreham, H. et al. (2010) Miglustat in 
adult and juvenile patients with Niemann-Pick disease type C: long-term data from 
a clinical trial. Mol Genet Metab.;99:351–357. 
Xu, YH.; Reboulet, R.; Quinn, B.; Huelsken, J.; Witte, D. et al (2008) Dependence of 
reversibility and progression of mouse neuronopathic Gaucher disease on acid 
beta-glucosidase residual activity levels. Mol Genet Metab;94:190-203.  
Yaksh, TL. (2006). Calcium channels as therapeutic targets in neuropathic pain. J Pain;7:S13-
S30. 
6 
The Role of Gene Mutations Detection 
in Defining the Spectrum of  
ß – Thalassemia in Various Ethnic Regions  
Fakher Rahim1, Najmaldin Saki2,3 and Mohammad Ali Jalalai far2,3 
1Endocrinology and Metabolism Research Center (EMRC), 
Tehran University of Medical Sciences, Tehran 
2Department of Medical Laboratory Science, 
Ahvaz Jundishapur University of Medical Sciences, Ahvaz 
3Thalassemia and Hemoglobinopathies Research Center, 
Ahvaz Jundishapur University of Medical Sciences, Ahvaz 
Iran 
1. Introduction 
The thalassemia is a widespread with about 5% of the world population affected by it and is 
found in some 60 countries, with the highest prevalence in the Mediterranean region, parts 
of North and West Africa, the Middle East, the Indian subcontinent, southern Far East and 
south-eastern Asia, together comprising the so-called thalassemia belt. In western countries, 
thalassemia affects mostly individuals whose ancestry is traceable to high prevalence areas. 
As an example, there are around 1,000 cases of β-thalassemia major in the United States, 
most of whom are descendants of Mediterranean, Asian Indian, South Asian or Chinese 
ancestors. This figure is even less than half of the number of β-thalassemic patients in Fars 
Province, a region only 120,000 km 2 large in southern Iran (Haghshenas and Zamani, 1997; 
Rahim et al., 2007). The gene frequency of ß-thalassemia, however, is varies from area to 
area, having its highest rate of more than 10% around the Caspian Sea and Persian Gulf. The 
prevalence of the disorder in other areas is between 4-8% (Rahim and Abromand, 2008). 
There are many genes coding for the globins. They are found on chromosome 11 (β-globin 
cluster) or chromosome 16 (α-globin cluster) figure1. 
1.1 Beta-Thalassemia 
Beta-Thalassemia, one of the most widespread genetic diseases in the world, is a common 
autosomal recessive disorder caused by point mutations in the ß- globin gene that is located 
as a cluster on the short arm of chromosome 11 (Weatherall et al., 1989; Sack, 1999; Oliveri, 
1999). More than 200 different mutations affecting diverse levels of beta-globin genes 
expression have so far been identified (Trent, 1997; Ho and Thein, 2000). South-western 
region of Iran also represented various ß-thalassemia mutations (Figure 2).   Different 
strategies of classification individuals genotypes by ß-globin gene cluster and cloning 
nucleotides sequencing lead to identification of several mutations in Mediterranean (Orkin 
et al., 1982), Asian Indians (Kazazian et al., 1984, Ohba et al., 1997), American Blacks 
 
Human Genetic Diseases 110 
(Antonarakis et al., 1984) and Chinese (Cheng et al., 1984). The global distribution indicates 
a high prevalence in a belt around the earth, which is around the 40th parallel in the 
Mediterranean area but eastwards moves further south, reaching the equator in Indonesia. 
More than two million carriers of ß-thalassemia live in Iran. The Iranian populations are 



















Fig. 1. Two globin gene clusters including α- and β- represented here. 
The Role of Gene Mutations Detection in 
Defining the Spectrum of ß – Thalassemia in Various Ethnic Regions 111 
1.2 Alpha thalassemia 
Alpha thalassemia disorders are a group of hereditary anemias caused by absent or 
decreased production of the alpha chain of hemoglobin (Hb) (Vichinsky, 2009). freeAll 
affected individuals have a variable degree of anaemia (low Hb), reduced mean corpuscular 
hemoglobin (MCH/pg), reduced mean corpuscular volume (MCV/fl) and a 
normal/slightly reduced level of HbA2. Molecular analysis is usually required to confirm 
the hematological observations (especially in silent alpha thalassemia and α-thalassemia 
trait). A single gene, two-gene, three-gene or four-gene deletions result in alpha thalassemia 
silent carrier status, thalassemia trait (minor), HbH, and hemoglobin Bart’s (Hb Bart’s), 










Fig. 2. Different ß-thalassemia mutations detected in our region of study (South-western 
region of Iran), different explained groups are carrier, which represents the heterozygous 
type; Major, which represents the homozygous type; Variants, which represents the 
hemoglobin variants 
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Fig. 3. Different α -thalassemia mutations detected in our region of study (South-western-
region of Iran), different explained groups are carrier, which represents the heterozygous 
type; Major, which represents the homozygous type; HbH, Hemoglobin H disease 
1.3 Thalassemia intermedia 
Thalassemia intermedia are a clinical phenotype which displays marked genotypic 
variability in different populations or ethnic groups (Panigrahi et al., 2009). This disorder is 
a clinical designation often used to characterize individuals who are homozygous for b-
thalassemia genes but maintain hemoglobins of 6–9 g/dL without regular transfusions 
(Galanello et al., 2001). They have more severe RBC morphological abnormalities than the 
trait, as well as varying degrees of splenomegaly, thrombosis and skeletal changes (Taher et 
al., 2008). 
1.4 Hemoglobin H (Hb H) 
Hemoglobin H (Hb H) disease is the most common form of thalassemia intermedia. Hb H 
(beta4) disease results from double heterozygosity for alpha(0)-thalassemia due to deletions 
that remove both linked alpha-globin genes on chromosome 16, and deletional alpha(+)-
thalassemia from single alpha-globin gene deletions (--/-alpha). However, Hb H disease 
may occur from interactions between alpha (0)-thalassemia with nondeletional mutations or 
with abnormal hemoglobins such as Hb Constant Spring, Hb Paksé, Hb Quong Sze, and Hb 
Pak Num Po (Fucharoen and Viprakasit, 2009).  
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1.5 Hemoglobin (Hb) Bart's 
Hemoglobin (Hb) Bart's hydrops fetalis is a generally fatal intrauterine condition associated 
with homozygous alpha (0)-thalassemia. It is moderately insoluble, and therefore 
accumulates in the red blood cells (Karnpean et al., 2009; Singer, 2009). 
1.6 Simultaneous α-and β-thalassemia 
Some case of complex beta- and alpha-thalassemia coinheritance is described. The chance of 
finding an individual with co-inheritance of α0- and β-thalassemia is theoretically 1: 1000. In 
other words, one in every 25 b-thalassemia carriers co-inherits a0- thalassemia (Rahim, 2010; 
Rahim et al., 2008). Routine screening testing, such as mean cell volume (MCV) and Hb A2 
level, cannot distinguish double heterozygotes for α and β-thalassemia from the pure β-
thalassemia heterozygotes. The α0-thalassemia can be distinguished simply from double α0- 
and β-thalassemia by a normal Hb A2 level (Table 1).  
 
Case Sex Age (Y) 
Hb 





1 M 24 13.9 72.1 23.4 1.1 5.3 - α3.7/ αα A - 
2 M 32 11.7 70.7 22.6 0.4 5.1 - α3.7/ αα B - 
3 M 29 11.4 73.0 22 0.5 5.1 - α
3.7/ - 
α3.7 C - 
4 F 27 11.9 71.5 22.6 1.5 4.2 αα / - α4.2 D - 
5 F 30 10.4 65.0 21 1.4 4.5 - α3.7/ αα E - 
6 F 25 11.7 61.4 19.8 0.9 4.3 - α3.7/ αα F - 
7 F 23 13.2 69.7 23.2 1.3 5.3 αα / - - MED G - 
8 M 29 11.5 75.5 23.2 1.9 4.9 αα / - α4.2 H - 
9 M 27 13.3 67.3 22.6 1.4 5.5 αα / - - MED I + 
10 M 29 11.1 69.5 23.8 0.9 5.4 αα / - - MED J + 
A, βIVS 1-5 /βN; B, βIVS 1-25 /βN; C, βIVS 2-1 /βN; D, βCD8(-AA)/βN; E, βCD121(G-C)/βN; F, βCD6(CTC-GAG)/βN;G, βIVS 2-1 /βN; 
H, βCD121(G-C)/βN;I, βCD41/42)/βN ; J, βCD8(-AA)/βN 
Table 1. Hematologic and genotypic findings in the 10 double heterozygotes for α- and β-
thalassemia 
1.7 Co-inheritance of α-and hemoglobin variants 
The chance of finding an individual with co-inheritance of α0- thalassemia with different 
hemoglobin variants is also presented. In other words, this chance and presentation is rare 
(Rahim, 2009). 
2. Diagnosis 
The key to successful detection and characterization of the hemoglobinopathies, particularly 
the thalassemias, is the initial hematological data. The clue for a thalassemia comes with a 
low mean corpuscular volume (MCV) or mean corpuscular hemoglobin (MCH). Although 
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iron deficiency is the other explanation for a low MCV or MCH, it is likely that this finding 




*Includes hemoglobin S (HbS), hemoglobin C (HbC) and hemoglobin DPunjab (HbDPunjab) 
Table 2. Hematological parameters in different groups with microcytic hypochromic anemia 
2.1 Differential diagnosis of beta-thalassemia  
We can differentiate β -thalassemia from other disorders such as iron deficiency anemia 
with the help of discriminate indices including Mentzer Index, England and Fraser Index, 
Srivastava Index, Green and King Index, Shine and Lal Index, red blood cell (RBC) count, 
red blood cell distribution width index (RDWI), Mean Density of Hemoglobin per Liter of 
blood (MDHL) and mean cell hemoglobin density (MCHD) (Rahim and Keikhaei, 2009). If 
iron deficiency is present, it is essential to correct this and then repeat the full-blood count 
and all other investigations. The first step after the initial abnormal blood count is to exclude 
iron deficiency and if present, to treat it. The blood count is then repeated and if the 
MCV/MCH remains low, a thalassemia is most likely. Therefore, ferritin levels (and if 
necessary serum iron, iron binding capacity and percentage saturation) are sought. This is 
recommended because at times, particularly during pregnancy, it is possible that iron stores 
will be low or, in the presence of iron deficiency, it is possible that the MCV or MCH are 
influenced by the iron deficiency. It is also occasionally seen that the HbA 2 level can be 
falsely lowered by iron deficiency. In this context there are special hemoglobin tests which 
may help in the primary detection scenarios (Table 3).    
2.2 Molecular diagnostic methods 
Almost all the methods for DNA analysis of the hemoglobinopathies used today are based 
on the polymerase chain reaction (PCR). Different well-known and applied methods have 
been described in table 4. Therefore whether a mutation is a deletion, a rearrangement or a 
point mutation, a similar test will be performed with the variability and specificity coming 
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Table 3. Special hematologic tests requested once a hemoglobinopathy is suspected based on 
family history and/or full-blood count. 
from the primers used. The sensitivity and specificity of PCR has revolutionized the 
molecular diagnostic field. It has almost eliminated the use of radioactive isotopes for 
detecting sequences and has enabled diagnosis to be made on much smaller quantities of 
DNA. The PCR-based techniques used in hemoglobin diagnostics include allele-specific 
oligonucleotide (ASO) hybridization or dot-blot analysis, reverse dot-blot analysis, allele-
specific priming or amplification refractory mutation system (ARMS), restriction enzyme 
analysis, amplification created restriction analysis, mutagenically separated PCR and gap-
PCR. These PCR-based techniques are useful for identifying a known mutation; PCR-based 
approaches for scanning or screening for unknown mutations take advantage of altered 
conformation of single-stranded DNA and include denaturing gradient gel electrophoresis 
(DGGE), single-strand conformation polymorphism (SSCP) and heteroduplex analysis. The 
characteristic altered patterns of migration and their position in the scanning methods act as 
a guide for the location of the mutation, targeting the region for identification by other 
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means. The ultimate method of mutation identification is by direct sequence analysis of 
specifically amplified DNA. In the last decade, the use of automated sequencers has led to 
nonradioactive, more robust and more rapid sequencing, making it suitable as a routine 
diagnostic tool. Direct sequencing analysis is particularly applicable to the globin genes 
which are compact and relatively small (1.2-1.6kb) with most of the point mutations within 
the gene or its flanking sequences (Fakher et al., 2006). 
Southern blotting is one of the few non-PCR based molecular techniques that still have a 
significant role to play in the molecular diagnosis of the hemoglobinopathies. It is very 
useful in the screening for large deletions or rearrangements and is essential in 
characterizing novel deletions. The more common deletions can be detected by gap-PCR 
once the deletion break points have been defined and specific primers flanking the deletion 
designed. Each of these techniques has its own limitations; the particular repertoire chosen 
by a laboratory for molecular diagnosis of the hemoglobinopathies depends on the spectrum 
of mutations encountered in their catchment area and the technical expertise available in the 
diagnostic laboratory. It is good practice for any DNA diagnostic laboratory to have at least 
two alternative methods for detecting each mutation (Vrettou et al., 2003). 
2.3 Prenatal Diagnosis (PND) & Foetal DNA analysis 
Although historically, the prevention program, abortion, was considered unacceptable in 
Iran, intensive consultation led to the clerical approval of induced abortion in cases with β- 
thalassemia major in 1997, and a nationwide prevention program with screening, counseling 
and prenatal diagnosis (PND) network has been developed (Najmabadi et al., 2006 ;Rahim 
et al., 2007) (Table 4). Many laboratories offering DNA diagnostics of the Hb disorders are 
also involved in analysis of fetal DNA for the prenatal diagnosis of these disorders. Fetal 
DNA is usually and preferably, obtained through chorionic villus sampling in the first 
trimester of pregnancy (10-12 weeks). Chorionic villus sampling provides a good yield of 
DNA which is isolated using conventional methods of phenol chloroform extraction after 
careful microscopic dissection to remove any contaminating maternal deciduas. 
Occasionally, if the sample is too small, it may need to be cultured increasing the risk of 
maternal contamination. Amniocytes obtained in the second trimester can also be used as a 
source of fetal DNA but the fetal cells are often contaminated with maternal cells and the 
results have to be interpreted with caution after analysis for maternal contamination. 
Every prenatal diagnosis should be accompanied by copies of haematology results of the 
parents and prior confirmation of the parental phenotypes and genotypes. The PCR-based 
techniques that best suit the expertise of the laboratory are then used to screen for the 
presence of the parental mutations in the fetal DNA. Parental, appropriate positive and 
negative controls must always be included in the investigations. A limited number of PCR 
cycles (25-28) should be performed to avoid amplification of any minor DNA species and to 
minimize amplification of any contaminating maternal DNA. As an added precaution, 
maternal DNA contamination should be checked for by using polymorphic DNA markers 
including the variable tandem repeats (VNTRs) such as ApoB and the short tandem repeats 
or micro satellites. This is particularly important when the fetal genotype is the same as the 
maternal genotype. Fetal DNA analysis should also be performed in duplicate and 
confirmed by an independent PCR-based technique. To confirm maternal DNA 
contamination we used polymorphic DNA markers including the variable tandem repeats 
(VNTRs) in all cases. 
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Table 4. Globin mutations identified by reverse- hybridization and DNA sequencing in 254 
thalassemia patient and prenatal DNA sample were initially tested for 22 common 
mutations by reverse – hybridization (Fakher et al., 2006). 
3. Discussion 
Iran is a country which has a population with a different ethnic identity and different 
languages. As we saw mutation in ß-globin gene will lead to thalassemia. Although, all this 
mutations were found in coastline areas but their geographic distribution has special 
characteristic properties. In most parts of the world, a small number of thalassemia 
mutations predominant and the most common ones tend to be those that are geographically 
the most widespread and presumably also the oldest. For instance, in China and Southeast 
Asia, four alleles account for 91% of the genes (Kazazian et al., 1986), and in the 
Mediterranean Basin, six mutation account for 92% of the genes (Najmabadi et al., 2002). 
However, mutation 619 bp deletion is predominant in India or mutations IVS I-110 and IVS 
II-1 are most predominant in Arab populations (El-Hazmi et al., 1995). Because of Wars and 
trade off between different countries in the past years there was exchange of genetic 
materials between different populations. In one study it show that IVS II-1, IVS I-110, IVS I-
1, and CD 8/9. These mutations are the most frequent in Iran and IVS II-1(24%) is most 
predominant in Khuzestan (Rahim and Abromand, 2008). In a similar work on 1217 patients 
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with ß- thalassemia the most predominant mutation in North part of Iran was IVS II-1(34%) 
and in South part was IVS I-5(%) (Najmabadi et al., 2002).  
Najmabadi et al (2002), have studied ß -globin mutations and claimed the most common ß -
globin mutations is IVS I-130 (G-C), which was identified in six subjects from the North of 
Iran, three subjects from the Southwest, as well as in one DNA of unknown geographical 
origin.  We have found that most predominant in South was IVSII-I (34%) follows by IVS I-
110(15.7%) and CD 8/9(13.3%) (Rahim and Abromand, 2008). Previous research work 
showed most predominant mutation in Pakistan is IVS I-5(37%) therefore this mutation is 
most predominant in Sistan-Baloochestan (44.8%)(Southeast of Iran) because it is a 
neighborhood area to Pakistan (Kazazian et al., 1984). In a work done on thalassemia 
patients in Hormozgan (Southern part of Iran) claimed that most predominant mutation 
there is IVS I-5(69%) followed by IVS II- 1(9.6%) (Yavarian et al., 2001).  
Research work done in 8 Gulf (Arab) Countries showed that most predominant mutations 
are IVS I-110 and IVS II-1 followed by IVS I-5, CD39, CD6, IVS I(3' end)-25 bp del (Adekile et 
al., 2005). Our finding was similar to the work done in Kuwait which showed 6 mutations 
are most predominant involve IVS II-1, IVS I-6, CD39, IVS I-110, CD8, IVS I-1(all give 64%) 
and followed by another 2 involve CD44, CD 36/37 (Kurd, Iranian types) that give 10% of 
the population. We detected different ß-thalassemia mutations in the studied chromosomes 
and 5 different areas from Iran which showed IVS-II-I (G → A) was the predominant 
mutation found in all ethnic regions. . The presence of such a high frequency of various local 
mutants alleles confirms support for a role of non-isolating genetically areas. In likelihood, 
both founder effect and natural selection caused by migration from neighboring areas have 
complemented each other to produce the high frequency of unique alleles within each 
region (Figure 4).  
 
 
Fig. 5. The origin of mutant alleles with high frequency within different parts of Iran. The 
most frequent beta-gene mutations in each ethnic region indicated individually. 
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Fig. 5. The origin of mutant alleles with high frequency within different parts of Iran. The 
most frequent beta-gene mutations in each ethnic region indicated individually. 
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1. Introduction 
Cystic fibrosis (CF) is inherited as an autosomal recessive disorder in white populations, 
caused by a mutation in a gene that encodes cystic fibrosis transmembrane conductance 
regulator (CFTR) protein, which is expressed in many epithelial cells and blood cells. 
Although CFTR functions mainly as a chloride channel, it has many other regulatory roles, 
including inhibition of sodium transport through the epithelial sodium channel, regulation 
of the outwardly rectifying chloride channel, regulation of ATP channels, regulation of 
intracellular vesicle transport, acidification of intracellular organelles, and inhibition of 
endogenous calcium-activated chloride channels (O’Sullivan & Freedman, 2009; Reisin et al., 
1994; Schwiebert et al., 1995; Stutts et al., 1995; Vankeerberghen et al., 2002; Mehta, 2005). 
CFTR is also involved in bicarbonate–chloride exchange. A deficiency in bicarbonate 
secretion leads to poor solubility and aggregation of luminal mucins (Quinton, 2008). More 
than 1500 CFTR mutations have been identified, but only the functional importance of a 
small number is known. The absence of phenylalanine at position 508 accounts for about 
two-thirds of mutated alleles in northern European and North American populations 
(Walters & Mehta, 2007).  
The clinical manifestations of the disease vary greatly between affected individuals, which 
has led  to interest in the relation between genotype and phenotype. It is presumed that 
disease affects all secretory epithelia including the eye (Castagna, 2001; Turner et al., 2002; 
Mrugacz et al., 2006; Mrugacz et al., 2007; Mrugacz et al., 2007). The pathogenesis of ocular 
changes in CF is still unknown. CF belongs to the group of ocular surface diseases termed 
keratoconjunctivitis sicca or dry eye syndrome. The causes of dry eye are multi-factorial and 
can be connected with deficiencies in any one of the components of the ocular surface and 
tear fluid. It is known that inflammation plays a key role in the pathogenesis of dry eye 
(Baudouin, 2001; Brignole et al., 2000; Pflugfelder, 2004; Pisella et al., 2000), especially with 
the participation of chemokines.  
Chemokines are a family of small protein molecules that play an important role in normal 
leukocyte trafficking as well as in leukocyte recruitment during inflammation. These 
chemokines are grouped into CXC, CC, C, and CX3C subfamilies on the basis of the 
arrangement of the conserved cysteine residues. This molecular subvivision generally 
correlates with their function. Most recently, chemokines have been classified according to 
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their physiological features: inflammatory or inducible chemokines and homeostatic or 
constitutive chemokines. Chemokines act through both specific and shared receptors that 
belong tho the superfamily of G-protein-coupled receptors. The chemokine receptors also 
comprise four groups, including the CC receptors (CCR), which bind CC chemokines; and 
CXC receptors (CXCR), which bind CXC chemokines. Chemokine and chemokine receptor 
expression can increase in acute and chronic inflammatory conditions due to inflammatory 
mediators, such as cytokines. The CC chemokines are involved in the pathogenesis of 
immune-mediated inflammation through monocytes/macrophages activation and 
recruitment. CC chemokines, such as CCL3/macrophage inflammatory protein-1α 
(CCL3/MIP-1α) and CCL4/macrophage inflammatory protein-1ß (CCL4/MIP-1ß) are 
efficient chemoattractant for Th1 cells and contribute to the inflammatory processes in the 
eye (Locati & Murphy, 1999;  Manczak & Yiang, 2002). 
The aim of this study was to assess the potential role of chemokines in the pathogenesis of 
ocular changes in patients with CF. We assayed CCL3/MIP-1α and CCL4/MIP-1ß levels in 
tear fluid of CF patients. We also investigated the correlation between the tear levels of these 
chemokines and clinical severity of CF and ocular surface disease. 
2. Materials and methods 
2.1 Patients 
We studied 28 patients with CF  with a mean age 14.75±3.95 years (range 6-23) (14 women, 
14 men) who attended 3th Department of Pediatric Diseases, Medical University of 
Bialystok, Poland. Twenty-seven normal subjects with a mean age of 15.21±4.35 years (range 
8-23) (13 women, 14 men) were also included. All the CF patients had a comprehensive 
assessment every 6-12 months and were receiving vitamin A supplementation. They did not 
receive any systemic steroid therapy. 
The clinical status was scored according to Schwachmann and Kulczycki (Schwachman 
Score, scale 100-0: 100=excellent, 100-55=without pulmonary insufficiency, below 55=severe 
of CF) (Schwachmann & Kulczycki, 1958). 
2.2 Tear sample collection  
Tear samples were collected in graduated 30-μl disposable microcapillaries (ACCU-FILL 90 
MICROPET, Becton Dickinson and Company, Franklin Lakes, NJ) unilaterally or bilaterally 
from the conjunctival cul-de-sac without anesthesia. Care was taken to avoid touching the 
lid margin or corneal surface. We collected 50 to 100 μl of basal tears from each eye. The 
CCL3/MIP-1α and CCL4/MIP-1ß levels in tears were determined by ELISA using highly 
sensitive immunoassay kit (Endogen system, MA, USA). The collected tears were 
immediately frozen to -80C; they were thawed just before assaying. All the samples were 
coded and read blind in the assay. The procedure recommended by the manufacturer was 
followed without any modification.  
2.3 Ophthalmic examination including dry eye tests 
The ophthalmologic examination included subjective assessment, visual acuity and 
biomicroscopy. Subject complaints, such as redness, foreign body sensation, irritation, 
intense burning, and blurred vision were noted. Both patients and controls were performed 
tests for keratoconjunctivitis sicca. Tear break-up time (TBUT) was measured to assess tear 
 
 



















Fig. 1. Dry eye tests. 1- Schirmer test, 2- Tear break-up time (TBUT), 3- Lissamine green 
staining 
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film stability. A value of 10 seconds was abnormal. Schirmer test was used to estimate tear 
film quantity; a value of 5 mm after 5 minutes was abnormal. The lissamine green instilled 
into the inferior fornix was used to assess the amount of dead epithelial cells at the ocular 
surface. If two of these variables were abnormal then dry eye syndrome was the diagnosis 
according to the Copenhagen criteria (Manthorpe 1986). All clinical examinations were 
performed before any topical or systemic treatment was administered to the eye. 
2.4 Statistical analysis 
Non- parametric analysis was conducted in this study. Wilcoxon’s sum rank test was used 
to identify differences between tear chemokine levels in patients group and controls. 
Spearman’s rank correlation test was used to establish the significance of correlation 
between tear chemokine levels and severity of CF and the eye disease. A level of p 0.05 was 
accepted as statistically significant. 
3. Results 
3.1 Chemokines levels 
The tear fluid levels of CCL3/MIP-1α were 144.50±18.51 pg/mL (mean±SD) in CF patients, 
whereas in normal controls, they were 41.85±11.25 pg/mL (mean±SD). There is significant 
difference between serum levels of MIP-1α in CF patients and healthy controls  (p=0.001) 
The tear fluid levels of CCL4/MIP-1ß were 4.25±1.15 pg/mL (mean±SD) in CF patients and 
0.52±0.36 pg/mL (mean±SD) in healthy controls. The tear fluid levels of MIP-1beta were 
significantly raised in CF group compared to controls (p<0.001). 
3.2 Assessment of dry eye syndrome 
Dry eye syndrome were observed in 10 (36%) CF patients (five girls and five boys). 
However, the tear fluid levels of CCL3/MIP-1α and CCL4/MIP-1ß were significantly higher 
in CF patients with dry eye syndrome than in CF patients without dry eye symptoms:  
165.50±20.32 pg/mL (mean±SD) and 132.22±17.35 pg/mL  (mean±SD) of CCL3/MIP-1α, 
respectively; and 5.25±1.26 pg/mL (mean±SD) and 3.18±0.80 pg/mL (mean±SD) of 
CCL4/MIP-1ß, respectively (p<0.05). 
3.3 Assessment of pulmonary insufficiency 
Symptoms of pulmonary insufficiency (below 55 according to the Schwachman- Kulczycki 
Score) were found in 45% (13 out of 28) of the CF patients. Spearman correlation coefficient 
indicated a positive correlation between the tear levels of CCL3/MIP-1α and CCL4/MIP-1ß 
and severe clinical status of CF patients (R=0.869, p 0.001). However, negative correlation 
was found between the tear levels of these chemokines and mild CF (R=0.817, p 0.001). 
Fifteen of our CF patients (55%) with high levels of CCL3/MIP-1α and CCL4/MIP-1ß had 
clinical evidence of dry eye. Spearman correlation coefficient indicated a positive correlation 
between the tear levels of these chemokines and dry eye findings in CF patients.  
4. Discussion 
One of the major problems in understanding the mechanisms of dry eye symptoms in CF 
patients, is to determine the factors involved in this disease. It is known that inflammation 
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plays a key role in the pathogenesis of dry eye syndrome, especially with the participation 
of chemokines. Chemokines are expressed at sites of inflammation to attract and amplify 
the leukocyte response. It is important to identify chemokines that play a role in 
mediating response. The recruitment of leukocytes to tissue is essential for inflammation. 
This process may be controlled by MIP-1α and CCL4/MIP-1beta that contribute to the 
recruitment of inflammatory cells into the eye and plays an important role in 
pathogenicity. 
In this study, we have documented, for the first time, raised levels of  CCL3/MIP-1α  and 
CCL4/MIP-1beta in tear fluid in CF patients. The highest levels of these chemokines were 
detected in patients with dry eye syndrome and severe CF. The high levels of suggest of 
CCL3/MIP-1α  and CCL4/MIP-1beta suggest that these chemokines may be produced 
locally and may be a factor for evaluation of the clinical status of this disease.  It may 
confirm the involvement of CCL4/MIP-1beta in the local inflammatory process. Functional 
consequence of elevated levels of these chemokines has yet to be determined exactly. 
Moreover, there is evidence that dry eye stimulates the production of inflammatory 
cytokines from the ocular surface epithelium (Luo et al., 2004). The increased levels of MIP-
1α  and MIP-1beta observed in this study may be a consequence of increased secretion from 
the corneal epithelium or from the another noncorneal cell type. The tear film containing 
numerous specific and nonspecific immune components (Solomon et al., 2001) may act as a 
vehicle of chemokines produced by the lacrimal gland or other epithelia of the ocular 
surface.  
There is a little information about the role of  CCL3/MIP-1α   and CCL4/ MIP-1beta in 
eye inflammation. Despite advances in tissue typing, surgery and immunosuppressive 
treatment allogenic rejection is the most common cause of corneal graft failure. Allograft 
rejection is characterized by infiltration of leucocytes into the donor tissue, a response that 
has been associated with chemokine expression, with CCL2/MCP-1, CCL3/ MIP-1α    and 
CCL4/ MIP-1beta showing ans increased expression in rejected grafts in mice (Yamagami 
et al., 1999). In recent studies of  CCL3/MIP-1α and CCL4/ MIP-1ß,  Verma and others 
have shown that these chemokines were significantly increased in the aqueous humor 
during the active stages of human autoimmune anterior uveitis (AAU) and correlated 
with the clinical severity of the disesase (Verma et al., 1997). Anti-MIP-1α  and anti-MIP-
1ß  treatment suppressed clinical signs of recurrent anterior uveitis (RAU) in the Lewis 
rats, suggesting that these chemokines may also influence the migration of memory T cells 
across the blood ocular barrier in recurring episode of AAU. In addition, during acute 
AAU associated with experimental autoimmune encephalomyelitis (EAE), CC 
chemokines, such as CCL2/MCP-1, CCL5/RANTES, CCL3/MIP-1α and CCL4/MIP-1ß, 
contributed to the inflammatory processes in the eye and central nervous system (CNS) 
(Manczak et al., 2002). Treatment with anti-CCL4/ MIP-1ß delayed onset and reduced 
duration of AAU (Adamus et al., 2001). The retinal ischemia- reperfusion model showed 
an upregulation of CCL4/MIP-1beta in the retinal vessels and these  results confirm that 
this chemokine may be involved in the inflammatory element of pathogenesis of retinal 
neovascularization (Jo et al., 2003). 
5. Conclusion 
In conclusion, the results of this study demonstrate that increased levels of chemokines in 
the tear fluid may play an important role in the pathogenesis of dry eye in patients with 
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In conclusion, the results of this study demonstrate that increased levels of chemokines in 
the tear fluid may play an important role in the pathogenesis of dry eye in patients with 
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cystic fibrosis. The tear levels of CCL3/MIP-1α and CCL4/MIP-1ß may be a candidate 
marker to evaluate the clinical status of cystic fibrosis and eye disease. Our findings may 
contribute to further understanding of local and systemic immune responses and might lead 
to the development of new clinical approaches to inflammatory disorders. Clarification of 
the role of chemokines in the pathogenesis of ocular findings in CF patients will be useful in 
establishing immunotherapeutic strategies for this disease. 
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1. Introduction 
Since the first draft of the human genome we observed a boost in biomedical research. As 
consequence, nowadays, it is possible to know a person’s predisposition to a genetic disease 
or even how its organism will metabolize a given drug. Although, there is some delay in 
translating this knowledge to the development and implementation of personalized 
medicine, there are currently available some successful pharmacogenetic based treatment 
decisions. One of such example is abacavir, a nucleoside analog reverse transcriptase 
inhibitor used in treatment of HIV-1 infection. Abacavir hypersensitivity is strongly 
associated with HLA-B*57:01 allele. Genetic testing before abacavir’s prescription is now 
recommended in clinical guidelines and is practiced in most western countries (Chaponda & 
Pirmohamed 2011). In a near future, personalized medicine will, most certainly, bring 
considerable health gains to society. 
The new approaches to analyze the human genome, – genome-wide association studies 
(GWAS; Orange et al., 2011), deep resequencing (1000 Genomes Project Consortium, 2010) 
and gene expression variability (Li et al., 2010) –, are producing massive data, which are 
already historic marks in the understanding of the genetic makeup of traits. A good example 
is the 9p21 genomic region association with coronary artery disease (McPherson et al., 2007; 
Helgadottir et al., 2007). However, only a small fraction of the heritable variation of complex 
diseases has been identified. One possible explanation may be that many rare variants, 
which are not included in the common genotyping platforms, may contribute substantially 
to the genetic variation of complex diseases. Therefore, researchers are becoming aware that 
common disease – common variant and common disease – rare variant models (Gorlov et 
al., 2011; Carvajal-Carmona, 2010; Zhu et al., 2011) will largely contribute to understand the 
genetic architecture of the populations with a diverse ancestry, such as the Azoreans. Hence, 
regional and local studies are good approaches to comprehend the genetic specificities of 
each population.  
1.1 Mainland Portugal and Azores populations: historic and demographic data 
Portugal, with a population of 10,637,713 inhabitants, is the most western country of the 
European continent and is bordered by the Atlantic Ocean to the west and south and by 
Spain to the north and east. The present Portuguese genetic landscape is the outcome of an 
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old and slow process of gene flow, admixture with many different populations and local 
differentiation. These include the expansion from isolated population nuclei in refuges 
following the Last Glacial Maximum, the movement of peoples related to the introduction of 
agriculture, and subsequent Roman and Germanic invaders, which may have influenced the 
distribution of genetic diversity in the territory (Amaral & Amaral, 1997). Roman settlers 
strongly influenced Portuguese culture, particularly the Portuguese language, which is 
derived from Latin. During the 8th century Muslim Moors occupied most of the Iberian 
Peninsula, contributing also to admixture events observed by the presence of north African 
paternal lineages in the Portuguese genetic background (Adams et al., 2008; Pereira et al., 
2000a). With the establishment of the country in the year 1139, after several wars, Portugal is 
the oldest European nation-state. In the 15th and 16th centuries, as the result of maritime 
expeditions, the country established a global empire that included possessions in Africa, 
Asia, Oceania and South America, becoming the world's major economic, political and 
military power. Portugal's empire was the first and most long-lived global empire in the 
world, spanning almost six centuries (Russel-Wood, 1998; Jenkins & Sofos, 1996). During the 
Portuguese age of discovery, two archipelagos – Madeira and Azores (Figure 1) –, which are  
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currently part of the country’s territory, were discovered. The Azores is composed of nine 
volcanic islands unevenly distributed by three geographic groups: the Eastern group with 
two islands – São Miguel and Santa Maria –, the Central includes five islands – Terceira, 
Pico, Faial, São Jorge and Graciosa –, and the Western group with Flores and Corvo. This 
archipelago has a total area of 2332.74 km2, unevenly distributed by the nine islands, 
varying from São Miguel, the largest, with 746.82 km2 to Corvo, the smallest, with 17.13 km2. 
The present-day population is composed of 241,763 inhabitants (National Institute of 
Statistics – Portugal, 2001 Census), derived from about 27 generations. The majority of the 
population lives on São Miguel (54.4%). The remainder is unevenly dispersed throughout 
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the other eight islands; for example, Corvo has only 425 individuals. From the total Azorean 
population, 41.4% are living in the Central group, where Terceira is the most populated of 
this group (24.9%; 55,833 inhabitants). The first settlers arrived in the mid 15th century and 
were mainly Portuguese, but the peopling was a slow and difficult process (Mendonça, 
1996; Guill, 1993). Someone wrote “…The Azorean settlement was done with people from 
the interior of mainland Portugal, those who could not swim nor build boats, making 
impossible the abandonment of the islands…”. Historical data report that the Portuguese 
crown was compelled to give out land and privileges in order to attract people to the islands 
(Guill, 1993). The first islands to be settled were Santa Maria and São Miguel in 1439 and the 
last were Flores and Corvo in the beginning of the 16th century. Some early settlers were of 
foreign origin, including Flemish, Jews, Moorish prisoners and black slaves from Guinea, 
Cape Verde and São Tomé. In the following centuries, contributions from Spanish, French, 
Italians, Germans and Scottish also occurred. 
2. DNA banking of the healthy Azorean population 
Biobanks have become an absolute requirement for biomedical research (Simon et al., 2007; 
Deplanque et al., 2009) and are defined as collections of samples of human bodily 
substances that are or can be associated with personal and clinical data. Depending on the 
purpose of a given biobank, both genetic and health information may be linked with the 
samples. The location of the Azorean population in the middle of the Atlantic, its 
geography, socio-cultural characteristics and, finally, the same environmental conditions, 
make a priori this population a good model to perform population genetic studies. Bering 
this in mind, the Molecular Genetics and Pathology Unit (UGPM, located at the main 
Azorean Hospital, Hospital of Divino Espírito Santo of Ponta Delgada, EPE - HDESPD) 
researchers adopted a strategy that began with the establishment of a DNA bank of the 
Azorean healthy population. Currently, it comprises a collection of 1558 representative 
genetic samples obtained from healthy non-family-related adult volunteers. The blood 
collection counted with the collaboration of the Department of Haematology of HDESPD for 
São Miguel samples, and municipalities Health Centres (Centro de Saúde de Vila do Porto, 
Centro de Saúde de Angra do Heroísmo, Centro de Saúde da Praia da Vitória, Centro de 
Saúde da Calheta, Centro de Saúde de Velas, Centro de Saúde de Santa Cruz da Graciosa, 
Centro de Saúde da Horta, Centro de Saúde das Lajes, Centro de Saúde da Madalena, 
Centro de Saúde de São Roque, Centro de Saúde de Santa Cruz das Flores) of volunteers 
resident in the other eight islands. As part of the research project entitled “Study of the 
genetic diversity in the Azorean population”, the biobank was approved by the local Ethics 
Committee, and follows the international ethical guidelines, which include informed 
consent, confidentiality, anonymity of personal data and abandonment option in case of 
expressed will. To each volunteer was hand-out a leaflet (Figure 2) explaining thoroughly: 
(1) the purpose of the study; (2) the involvement in the blood donation process and of 
personal information sharing; (3) the risks and benefits of participation; and (4) the privacy 
protection measures.  
A code number was assigned to each blood sample, identifying it during the whole project’s 
protocol. Only authorized staff at the previously mentioned blood collection facilities had 
access to the participant’s name. After individual’s acceptance, written informed consent 
was signed and, with the help of the team involved, an anonymous blood sample record 
was filled, providing information regarding the participant’s age, sex, birthplace and 
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old and slow process of gene flow, admixture with many different populations and local 
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distribution of genetic diversity in the territory (Amaral & Amaral, 1997). Roman settlers 
strongly influenced Portuguese culture, particularly the Portuguese language, which is 
derived from Latin. During the 8th century Muslim Moors occupied most of the Iberian 
Peninsula, contributing also to admixture events observed by the presence of north African 
paternal lineages in the Portuguese genetic background (Adams et al., 2008; Pereira et al., 
2000a). With the establishment of the country in the year 1139, after several wars, Portugal is 
the oldest European nation-state. In the 15th and 16th centuries, as the result of maritime 
expeditions, the country established a global empire that included possessions in Africa, 
Asia, Oceania and South America, becoming the world's major economic, political and 
military power. Portugal's empire was the first and most long-lived global empire in the 
world, spanning almost six centuries (Russel-Wood, 1998; Jenkins & Sofos, 1996). During the 
Portuguese age of discovery, two archipelagos – Madeira and Azores (Figure 1) –, which are  
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volcanic islands unevenly distributed by three geographic groups: the Eastern group with 
two islands – São Miguel and Santa Maria –, the Central includes five islands – Terceira, 
Pico, Faial, São Jorge and Graciosa –, and the Western group with Flores and Corvo. This 
archipelago has a total area of 2332.74 km2, unevenly distributed by the nine islands, 
varying from São Miguel, the largest, with 746.82 km2 to Corvo, the smallest, with 17.13 km2. 
The present-day population is composed of 241,763 inhabitants (National Institute of 
Statistics – Portugal, 2001 Census), derived from about 27 generations. The majority of the 
population lives on São Miguel (54.4%). The remainder is unevenly dispersed throughout 
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the other eight islands; for example, Corvo has only 425 individuals. From the total Azorean 
population, 41.4% are living in the Central group, where Terceira is the most populated of 
this group (24.9%; 55,833 inhabitants). The first settlers arrived in the mid 15th century and 
were mainly Portuguese, but the peopling was a slow and difficult process (Mendonça, 
1996; Guill, 1993). Someone wrote “…The Azorean settlement was done with people from 
the interior of mainland Portugal, those who could not swim nor build boats, making 
impossible the abandonment of the islands…”. Historical data report that the Portuguese 
crown was compelled to give out land and privileges in order to attract people to the islands 
(Guill, 1993). The first islands to be settled were Santa Maria and São Miguel in 1439 and the 
last were Flores and Corvo in the beginning of the 16th century. Some early settlers were of 
foreign origin, including Flemish, Jews, Moorish prisoners and black slaves from Guinea, 
Cape Verde and São Tomé. In the following centuries, contributions from Spanish, French, 
Italians, Germans and Scottish also occurred. 
2. DNA banking of the healthy Azorean population 
Biobanks have become an absolute requirement for biomedical research (Simon et al., 2007; 
Deplanque et al., 2009) and are defined as collections of samples of human bodily 
substances that are or can be associated with personal and clinical data. Depending on the 
purpose of a given biobank, both genetic and health information may be linked with the 
samples. The location of the Azorean population in the middle of the Atlantic, its 
geography, socio-cultural characteristics and, finally, the same environmental conditions, 
make a priori this population a good model to perform population genetic studies. Bering 
this in mind, the Molecular Genetics and Pathology Unit (UGPM, located at the main 
Azorean Hospital, Hospital of Divino Espírito Santo of Ponta Delgada, EPE - HDESPD) 
researchers adopted a strategy that began with the establishment of a DNA bank of the 
Azorean healthy population. Currently, it comprises a collection of 1558 representative 
genetic samples obtained from healthy non-family-related adult volunteers. The blood 
collection counted with the collaboration of the Department of Haematology of HDESPD for 
São Miguel samples, and municipalities Health Centres (Centro de Saúde de Vila do Porto, 
Centro de Saúde de Angra do Heroísmo, Centro de Saúde da Praia da Vitória, Centro de 
Saúde da Calheta, Centro de Saúde de Velas, Centro de Saúde de Santa Cruz da Graciosa, 
Centro de Saúde da Horta, Centro de Saúde das Lajes, Centro de Saúde da Madalena, 
Centro de Saúde de São Roque, Centro de Saúde de Santa Cruz das Flores) of volunteers 
resident in the other eight islands. As part of the research project entitled “Study of the 
genetic diversity in the Azorean population”, the biobank was approved by the local Ethics 
Committee, and follows the international ethical guidelines, which include informed 
consent, confidentiality, anonymity of personal data and abandonment option in case of 
expressed will. To each volunteer was hand-out a leaflet (Figure 2) explaining thoroughly: 
(1) the purpose of the study; (2) the involvement in the blood donation process and of 
personal information sharing; (3) the risks and benefits of participation; and (4) the privacy 
protection measures.  
A code number was assigned to each blood sample, identifying it during the whole project’s 
protocol. Only authorized staff at the previously mentioned blood collection facilities had 
access to the participant’s name. After individual’s acceptance, written informed consent 
was signed and, with the help of the team involved, an anonymous blood sample record 
was filled, providing information regarding the participant’s age, sex, birthplace and 
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parental birthplace. As far as São Miguel is concerned, the sample consisted of 7.5mL of 
blood, while in the other islands only 2.7mL were collected. In order to assure individual 
ancestral origin, the blood collection was preferably taken from individuals whose parents 
were born in the same island. A thorough analysis of the parental birthplace revealed a 
distribution of individuals by four different groups (Table 1).  
 
 





Both parents were born in the same island 1373 88,13 
Both parents were born in different Azores islands 70  4,49 
Only one parent was born in the Azores islands 59 3,79 
No parents born in the Azores islands 56 3,56 
Individuals that inhabit the Azores islands 1558 100,00 
Table 1. Parental birthplace analysis of the individuals that compose the Azorean DNA 
bank. 
A total of 1443 individuals (92.6%) presented Azorean parents. Age and sex distribution 
show an average age of 42 years old, ranging from 18 to 88 years, and the majority of 
individuals are men (71%, Figure 3). Considering the individuals who both parents were 
born in the same island (N=1373), the population representativeness varies from 0.2% 
(Terceira) to 7% (Corvo). The largest sample representation is observed in São Miguel with 
64% (Figure 3). The relation between the number of inhabitants and samples in each island 
STUDY OF THE GENETIC DIVERSITY IN THE AZOREAN POPULATION
This leaflet is intended to inform you about the objectives and goal of the study entitled “Study of the genetic diversity in the Azorean 
population”. We aim that after this inf ormation you decide free and clearly whether or not you want to participate. In the affirmative case your 
participation consists in donating 2.7 mL of blood to the Hospital of Divino Espírito Santo of Ponta Delgada, EPE (HDES) collected in the Health
Centre of your residence . Your sample will be used to extract genetic material which will be stored at the Molecular Genetics and Pathology 
Unit (UGPM)of the HDES.
Why is this study being done?
The purpose of this study is to identify 
and quantify the genetic variation that is 
present in the population of the different 
Azorean islands , analysing t he diversity 
present in the genetic material (DNA).
Is my participation important? 
Yes, your particip ation is very important 
because this study is only possible if a 
large number of Azorean blood samples 
are analyzed. You will contribute to a 
better understanding of the origin , nature
and distribution of genetic disorders in 
the Azorean. 
What should I do to participate?
To participate you have to donate 2,7 ml 
of blo od for DNA extraction . With the 
help of a specialized team in the Heath 
Centre, you will fill an anonymous record
of the blood sample , providing
information concerning your age, sex, 
birth place and your parent’s birth place.
How will my personal informa tion be kept 
private? 
After your blood sample is collected a code 
number will be assigned which will identify 
sample during this project protocol. Only 
the Heath Centre will have access to your 
name, thus guaranteeing the anonymous 
nature of the genetic material and 
corresponding personal information.
Are there any risks associated with this 
study?
No, there are no risks associated with this
study.
Are there any financial benefits in taking 
part in this study?
No, there is no financial gratification in 
taking part in this study.
Do I have to pay to participate in the 
project?
No, your participation is volunteer and free
of any charge.
What will happen to my sample after the 
study is over?
After this study is over, your sample will 
be stored at MGPU and used in future 
studies, following all national and 
international ethic regulations . 
What are my rights as a participant?
You are free to choose if you want to 
participate or not; no restrictions will be 
imposed on you.
Who do I call if I have questions or 
problems?
If you have any concerns or questions 
relating this project , please contact the 
MGPU.
Can I leave this project even after I have 
signed the informed consent? 
Yes, you are free to leave the project at 
any time and we will destroy your samp le 
and personal data. All you need to do is 
inform your Heath Centre of your 
intention.
* This study was approved by the Hospital of Divino Espirito Santo of Ponta Delgada, EPE, Ethics Committee.
*
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indicates a very high correlation coefficient (r=0.92; p<0.01), demonstrating the sample 
representativeness of the population distribution by all nine Azores islands. 
Overall, Azoreans were willing to participate and understood its importance for long-term 
health gains. Until now, no requests to remove samples have been made. This biobank 




Fig. 3. DNA bank samples distribution by sex, age and general Azores population 
representativeness. Calculations were based only in the individuals whose parents were 
born in the same Azorean island (N=1443). 
3. Population studies: knowing the past to predict the future 
The plethora of genomic research, produced since the first draft of the human genome 
(Venter et al., 2001; International Human Genome Sequencing Consortium, 2001), led to the 
acknowledgment that disease related rare variants with small effects are very difficult to 
identify (Figure 4) and that common variants implicated in complex diseases are frequently 
determined by GWAS. Additionally, the Human Genome Project 
(http://www.genome.gov/ 10001772) also contributed to the understanding of the 
structure and organization of the genome. Variability is observed through single nucleotide 
polymorphisms (SNPs), variable number of tandem repeats (VNTRs; e.g. mini and 
microsatellites), presence or absence of transposable elements (e.g. Alu elements) and 
structural alterations, which include insertions, deletions, duplications, inversions, 
translocations and copy number variants (CNVs).  
The global analysis of population neutral variation is an essential part in the comprehension 
of the disease related variation, since it has also been subject to evolutionary forces, such as, 
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Sex distribution Age groups
Azores demographic data
Islands Area (km2) Inhabitants 
São Miguel 746.82 131,609 
Santa Maria 97.10 5578 
Terceira 402.20 55,833 
Pico 447.00 14,806 
Faial 172.43 15,063 
São Jorge 237.59 9674 
Graciosa 62.00 4780 
Flores 142.00 3995 
Corvo 17.13 425 
Azores 2332.74 241,763 
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parental birthplace. As far as São Miguel is concerned, the sample consisted of 7.5mL of 
blood, while in the other islands only 2.7mL were collected. In order to assure individual 
ancestral origin, the blood collection was preferably taken from individuals whose parents 
were born in the same island. A thorough analysis of the parental birthplace revealed a 
distribution of individuals by four different groups (Table 1).  
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representativeness of the population distribution by all nine Azores islands. 
Overall, Azoreans were willing to participate and understood its importance for long-term 
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The plethora of genomic research, produced since the first draft of the human genome 
(Venter et al., 2001; International Human Genome Sequencing Consortium, 2001), led to the 
acknowledgment that disease related rare variants with small effects are very difficult to 
identify (Figure 4) and that common variants implicated in complex diseases are frequently 
determined by GWAS. Additionally, the Human Genome Project 
(http://www.genome.gov/ 10001772) also contributed to the understanding of the 
structure and organization of the genome. Variability is observed through single nucleotide 
polymorphisms (SNPs), variable number of tandem repeats (VNTRs; e.g. mini and 
microsatellites), presence or absence of transposable elements (e.g. Alu elements) and 
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genetic drift, mutation, selection and migration. Altogether, the perception of our “roots” 
and genetic signature has several implications in society’s own knowledge, in the design of 
future genetic studies, as well as, in the healthcare system.  
 
 
Fig. 4. The frequency spectrum of human disease risk alleles includes alleles at all 
frequencies from rare to common, with effect sizes from high to low (from Manolio et al., 
2009).  
3.1 Diversity, ancestry and linkage disequilibrium 
The comprehension of how genetic diversity is structured in the human being is not only of 
anthropological importance, but also of medical relevance with significant implications for 
human evolution, forensics, genetic diseases and pharmacogenetics (1000 Genomes Project 
Consortium, 2010; The International HapMap Consortium, 2010; Heard et al., 2010). As 
more geographic populations are studied with high density genotype arrays it is also 
becoming apparent that allele frequencies for the relevant disease markers can vary widely. 
For instance, what is true for Europeans may not be for Africans, such is example the Type 2 
Diabetes protective allele with increased frequency in non-Africans compared to Africans 
(Silander et al., 2009; Kral et al., 2011). These emerging data must be incorporated into a 
strategy that positions genomic medicine for a clinical role.  
To grasp the genetic origins of mainland Portugal and Azorean populations studies on Y-
chromosome lineages (Pacheco et al., 2005; Montiel et al., 2005; Beleza et al., 2006; Gonçalves 
et al., 2005; Fernando et al., 2005), mitochondrial DNA (Pereira et al., 2000b; Santos et al., 
2003; Santos et al., 2005; Santos et al., 2008; Santos et al., 2010) and autosomal Alu insertion 
polymorphisms (Branco et al., 2006) were performed. The nonrecombining portion of the Y-
chromosome retains a record of the mutational events that occurred along male lineages 
throughout evolution (Karafet et al., 2008). Presently, new binary polymorphisms reshaped 
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and increased resolution of the Y-haplogroup tree; however, for comparison purposes old 
nomenclature was maintained. According to Pacheco et al. (2005), the Azorean population 
presented nine different haplogroups, most of which are frequent in Europe (Figure 5). 
Hapogroup J* is the second most frequent in Azores (13.4%), but it is modestly represented 
in mainland Portugal (6.8%). The other non European haplogroups – N3 and E3a –, which 
are prevalent in Asia and subSahara, respectively, have been found in Azores (0.6% and 
1.2%, respectively) but not in mainland Portugal (Neto et al., 2007). The absence of 
haplogroup E3a in western Iberia suggests that, despite the massive introductions of African 
slaves in historical times, there was little admixture between the African males and western 
Iberian populations (Pereira et al., 2000a). In general, four major haplogroups –
P*(xR1b8,R1a,Q3), J*, BR*(xB2b,CE,F1,H,JK) and E*(xE3) – account for the majority of the 




Fig. 5. Phylogenetic tree of the Y-chromosome haplogroups and their percent frequencies in 
the Azores and mainland Portugal. Numbers of % individuals with HG for mainland 
Portugal represent average values based on literature reports by Beleza et al. (2006) and 
Gonçalves et al. (2005).  
All studies (Pacheco et al., 2005; Montiel et al., 2005; Beleza et al., 2006; Fernando et al., 2005) 
report that the main contributors to the genetic origin of the Azores are, as expected, the 
mainland Portuguese. Moreover, an important contribution of Middle eastern (HG J*) and 
north African (HG E*(xE3)) populations is observed in both populations. This observation is 
corroborated by mitochondrial DNA HVRI (hypervariable region I) analysis, where the 
majority of mtDNA lineages originated from the Iberian peninsula, mainly from mainland 
Portugal. The presence of Jews in the Azorean Central group is also supported by the 
mtDNA data (Santos et al., 2003).  
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genetic drift, mutation, selection and migration. Altogether, the perception of our “roots” 
and genetic signature has several implications in society’s own knowledge, in the design of 
future genetic studies, as well as, in the healthcare system.  
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and increased resolution of the Y-haplogroup tree; however, for comparison purposes old 
nomenclature was maintained. According to Pacheco et al. (2005), the Azorean population 
presented nine different haplogroups, most of which are frequent in Europe (Figure 5). 
Hapogroup J* is the second most frequent in Azores (13.4%), but it is modestly represented 
in mainland Portugal (6.8%). The other non European haplogroups – N3 and E3a –, which 
are prevalent in Asia and subSahara, respectively, have been found in Azores (0.6% and 
1.2%, respectively) but not in mainland Portugal (Neto et al., 2007). The absence of 
haplogroup E3a in western Iberia suggests that, despite the massive introductions of African 
slaves in historical times, there was little admixture between the African males and western 
Iberian populations (Pereira et al., 2000a). In general, four major haplogroups –
P*(xR1b8,R1a,Q3), J*, BR*(xB2b,CE,F1,H,JK) and E*(xE3) – account for the majority of the 
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report that the main contributors to the genetic origin of the Azores are, as expected, the 
mainland Portuguese. Moreover, an important contribution of Middle eastern (HG J*) and 
north African (HG E*(xE3)) populations is observed in both populations. This observation is 
corroborated by mitochondrial DNA HVRI (hypervariable region I) analysis, where the 
majority of mtDNA lineages originated from the Iberian peninsula, mainly from mainland 
Portugal. The presence of Jews in the Azorean Central group is also supported by the 
mtDNA data (Santos et al., 2003).  
 
Human Genetic Diseases 136 
Without any doubt, Y-chromosome and mtDNA studies are crucial to address the origin of 
the population; however, a population loses mtDNA when a woman has only sons and Y-
chromosome DNA when a man has only daughters. As a result, these genetic markers may 
give less correct information on broad ancestry of most genes in a population. A full picture 
of the histories of populations requires studies of markers in the recombining parts of the 
nuclear DNA, namely the autosomes. Albeith several types of markers can be used to 
achieve this purpose, Alu insertion polymorphisms present some interesting advantages. 
These markers arose within the human population as a unique event in evolutionary 
history, making Alu repeats identical by descent from a common ancestor (Batzer & 
Deininger, 2002). Moreover, the ancestral state, which is absence of the Alu insertion, is 
always known. The allele frequencies for each Alu polymorphism in Azoreans and 




Autosomal Alu insertion polymorphisms 
TPA-25 ACE APO PV92 D1 B65 
Azores 65       
 Frequency  0.592 0.385 0.946 0.208 0.254 0.585 
 Heterozygosity  0.424 0.485 0.106 0.257 0.348 0.409 
 HW (p value)  0.323 1.000 1.000 0.033 0.524 0.211 
 Locus diversity   0.493 0.481 0.117 0.343 0.392 0.493 
 Av. gene 
diversity 
 0.383 +/- 0.233 
 FIS  0.117 
        
Portugal 30       
 Frequency  0.600 0.367 0.917 0.283 0.233 0.500 
 Heterozygosity  0.517 0.483 0.034 0.345 0.275 0.483 
 HW (p value)  0.665 1.000 0.073 1.000 0.453 1.000 
 Locus diversity  0.496 0.480 0.128 0.404 0.370 0.517 
 Av. gene 
diversity 
 0.392 +/- 0.240 
 FIS  0.094 
Table 2. Alu insertion frequencies, heterozygosity and gene diversity for Azores and 
mainland Portugal. FIS represents inbreeding coefficient (from Branco et al., 2006). 
The evolution of populations is dependent on several mechanisms, such as migration, 
genetic drift, selection and mutation, all affecting the patterns of diversity of neutral and 
disease variants. Consequently, the measure of diversity of neutral markers allows the 
inference of how these processes are shaping the overall signature of a population and has 
further implications in the general diseases apportionment. Genetic diversity values, based 
on autosomal STR markers, for Azores (0.788; Branco et al., 2008a; Santos et al., 2009) and 
mainland Portugal (0.782; Perez-Lezaun et al., 2000) indicate that both populations are very 
diverse. Studies of HLA markers in mainland (Spinola et al., 2005a; 3 loci) and in Azores 
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(Spinola et al., 2005b; 6 loci) demonstrate values of average diversity of 0.92. The results 
obtained for Azores (Pacheco et al., 2010), based in 7 loci, presented a smaller value (0.83). 
HLA haplotype analysis showed that A*01-B*08-DRB1*03 haplotype, known to be of Indo-
European Celtic origin, is present in Centre and North Portugal regions at relatively low 
frequencies of 3% and 2.2%, respectively. However, this haplotype is the most frequent in 
São Miguel Island (8%). According to Spínola et al. (2005b), it’s presence results from a 
colonizing event from people originating from the Centre of Portugal.  
The patterns of genetic diversity of a population have a direct influence in the linkage 
disequilibrium (LD) extent, which has been found to improve the knowledge of human 
evolution and origin, and to identify genes causing disease. Table 3 describes the number of 
haplotypes, gene diversity and standardized multiallelic disequilibrium coefficient (D’), 
based on X-linked markers for Azores and mainland Portugal populations (Branco et al., 
2008b; Branco et al., 2009).  
 
Populations HN GD D' 
Azores   
 Western group 93 0.718 0.328 
 Central group 150 0.690 0.189 
 Eastern group 207 0.686 0.176 
 Total 450 0.695 0.142 
mainland Portugal 97 0.683 0.226 
Table 3. Haplotype number (HN), gene diversity (GD) and standardized multiallelic 
disequilibrium coefficient (D’) for Azorean and mainland Portugal populations (from 
Branco et al., 2008b). 
The Azorean Western group shows a higher genetic diversity (0.718) when compared with 
the other two groups. Overall, Azoreans and mainland Portuguese do not show extensive 
LD, as direct consequence of the large genetic diversity of these populations. These data 
were also corroborated by Silva et al. (2010), based on pairwise linkage of 10 X-chromosome 
STRs, and Service et al. (2006), who compared levels of LD between several European 
populations. Finally, both mainland Portuguese and Azoreans constitute admixed and 
outbred populations.  
4. Studies of rare and common genetic diseases 
Population genetic architecture can also be revealed by distribution patterns of mutations 
causing Mendelian disorders. Bering this in mind, the UGPM developed three main 
research areas, based on the Azorean healthy population. The first encompassed the analysis 
of mutations causing Gilbert’s syndrome (GS) and hereditary haemochromatosis (HH), the 
second constituted the evaluation of some genetic variants predisposing to complex 
diseases, namely, congenital heart diseases (CHD) and thrombosis, and, finally, the third 
included the characterization of variants involved on drug metabolism, particularly, 
irinotecan and warfarin. The results from these research projects are presented and 
discussed in this section. 
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discussed in this section. 
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4.1 Gilbert’s syndrome 
Gilbert syndrome is a mild hereditary unconjugated hyperbilirubinemia without liver 
dysfunction or hemolytic anemia (Matsui et al., 2010; Zhang et al., 2007). No treatment or 
long-term medical attention is necessary and it is usually one of the differential diagnoses of 
liver or hemolytic disease. The primary cause of this syndrome is the accumulation of 
bilirubin – hyperbilirubinemia –, due to decreased hepatic activity levels of glucoronosyl 




Fig. 6. Bilirubin uptake and processing in the liver cell. The heme initially breaks apart into 
biliverdin, which is rapidly reduced to bilirubin (1). Bound to albumin, bilirubin is 
transported from sites of production to hepatic sinusoids (2). At the sinusoidal surface of 
hepatocytes, bilirubin dissociates from albumin and enters hepatocytes by facilitated 
diffusion (3). Binding to cytosolic glutathione-S-transferases (GSTs) increases net uptake of 
bilirubin by inhibiting its efflux (4). Bilirubin is converted to mono- and diglucuronide by 
the action of UGT1A1, which catalyses the transfer of the glucuronic acid moiety from UDP-
glucuronic acid (UDPGA) to bilirubin (5). Bilirubin glucuronides are actively transported 
into bile against a concentration gradient by the ATP-utilizing pump MRP2 (6; Figure from 
http://www.natap.org/2011/EASL/EASL_83.htm).  
Bilirubin has been shown to inhibit DNA synthesis, uncouple oxidative phosphorylation, 
and inhibit ATPase activity in brain mitochondria (Strassburg, 2010). It also inhibits a 
variety of different classes of enzymes including dehydrogenases, electron transport 
proteins, hydrolases, enzymes of RNA synthesis, protein synthesis and carbohydrate 
metabolism. All toxic effects of bilirubin are reversed by binding to albumin. In fact, 
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albumin plays a vital role in the distribution of bilirubin in the body by keeping the 
compound in solution and transporting it from sites of production (primarily bone marrow 
and spleen) to the liver (Strassburg, 2010). 
GS is associated with a dinucleotide polymorphism in the TATA box promoter of the UDP 
glucuronosyltransferase 1 (UGT1A1) gene, more precisely the UGT1A1*28 allele (Costa, 
2006). In São Miguel Island a group of 67 suspected GS patients and 469 unrelated healthy 
blood donors were studied (Pacheco et al., 2006; Table 4). The results demonstrated that 
65.9% of patients (45 out of 67) and 9.2% controls (43 out of 469) were homozygous for allele 
*28/*28. The genotype frequency in the control group showed a similar value to the 
reported to mainland Portugal (9.9%; Gonçalves et al., 2001). Additionally, Oliveira et al. 
(2007) reported, in a group of healthy individuals, an UGT1A1*28 allele frequency of 28.0%, 




 Genotype frequency 
Suspected GS patients 
(N=67) 
 Control group 
(N=469) 
Alleles Genotypes  N %  N % 
*1 A[TA]6TAA *1*1  4 6.0  237 50.5 
*28 A[TA]7TAA *1*28  18 29.9  186 39.7 
*36 A[TA]5TAA *1*36  - -  2 0.4 
*37 A[TA]8TAA *1*37  - -  1 0.2 
  *28*28  45 65.9  43 9.2 
Table 4. Genotype frequencies of UGT1A1 variants in suspected GS patients and control 
group in São Miguel islanders (adapted from Pacheco et al., 2006). 
A molecular study based in a cohort of 120 Portuguese patients with the clinical diagnosis of 
Gilbert syndrome demonstrated that 110 individuals were homozygous for the UGT1A1*28 
allele (*28/*28), and one patient was a compound heterozygote for two different insertions 
*28/*37. The remaining 9 patients were heterozygous, *1/*28 (Costa et al., 2006). The 
analysis of the control group allowed the identification of alleles characteristic of African 
populations, *36 (0.2%) and *37 (0.1%), which corroborates previous data on the Azorean 
and mainland Portuguese genetic background. 
4.2 Hereditary hemachromatosis 
Hereditary haemochromatosis (HH) is an inherited disorder characterized by accumulation 
of iron. The phenotypic condition was uncommon and typically diagnosed only when 
significant complications had ensued. The transmission mode is autosomal recessive and the 
disease manifests more commonly in males than in females, where natural iron losses are 
greater (Pietrangelo, 2004; Griffiths, 2007). In HH, gradual deposition of iron occurs in the 
liver and in a number of other tissues including the pancreas, joints, skin and heart. Disease 
manifestations include hepatic fibrosis, diabetes mellitus, arthropathy, pigmentation, 
cardiomyopathy and hypogonadotrophic hypogonadism. Fatigue and arthralgia are 
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common early symptoms and painful arthropathy is a considerable cause of morbidity. 
However, it is iron toxicity within the liver which increases mortality in patients with HH. 
Cirrhosis of the liver is associated with significantly reduced survival and there is a 200-fold 




Fig. 8. HFE -related Hereditary Hemochromatosis (adapted from Pietrangelo, 2004). 
The HFE gene encodes an HLA-A class 1-like protein and is located on 6p21.3, 4 megabases 
(Mb) telomeric to the human leukocyte antigen region (HLA). Two HFE mutations – C282Y 
(845 G>A) and H63D (187 C>G) – are significantly correlated with HH (Feder et al., 1996). 
The majority (60% to 90%) of clinically diagnosed probands are homozygous for C282Y, and 
5% are compound heterozygous for C282Y and H63D.  
The C282Y allele frequency in São Miguel population is 5.01%, a similar frequency (5.8%; de 
Fez et al., 2005; Gomes et al., 2007) to the obtained in the north of mainland Portugal, but 
statistically different from that observed in the south populations (0.9%; Cardoso et al., 
2001). Contrary to this C282Y decreasing gradient, the H63D presents an even country 
distribution (Figure 10), with values of 17.88% and 20.36% for mainland and São Miguel 
Island, respectively.  
Because C282Y mutation seems to have originated by chance on a HLA-A*03-B*07 
haplotype in an individual from northwestern Europe and early spread, by Celts or Vikings 
(Milman & Pedersen, 2003; Distante et al., 2004), in many countries including Portugal, the 
background of this mutation was assessed in São Miguel islanders (Gomes et al., 2007). Four 
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non-ancestral HLA haplotypes were associated with C282Y: A*01-B*35, A*02-B*44, A*02-
B*55 and A*24-B*15, contrary to mainland, where the C282Y occurred mainly on the 
ancestral haplotype HLA-A*03-B*07 (Cruz et al., 2006). In addition, the C282Y mutation was 
also identified in two HLA A*03 bearing: A*03-B*27 and A*03-B*50. These results evidence 
that C282Y mutation was introduced in the Azorean population by individuals with genetic 
background other than Celts or Vikings.  
 
 
Fig. 9. Geographic distribution of HFE mutations in São Miguel Island. Frequency values are 
expressed in percentage. 
 
 
Fig. 10. Geographical distribution of the allelic frequencies of the C282Y and H63D HFE 
mutations in five Portuguese regions. (adapted from Cardoso et al., 2001). 
HFE – C282Y HFE – H63D 
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4.3 Congenital heart disease 
The evaluation of genetic variants predisposing to complex diseases in Azores began with 
the characterization congenital heart diseases (CHD). Congenital malformations of the heart 
and great vessels are among the most frequent of all clinically significant birth defects, with 
a major contribution to paediatric morbidity, mortality and healthcare costs. 
  
 
Fig. 11. Three major classes of developmental defects are indicated: defects in atrial 
septation, in ventricular or atrioventricular septation, and in the great vessels. The types of 
congenital heart disease that occur within each class are indicated, with the associated 
mutated genes listed. AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal defect; 
AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; DORV, double outlet right 
ventricle; Ebstein’s, Ebstein’s anomaly of the tricuspid valve; HLHS, hypoplastic left heart 
syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, mitral atresia; 
MS, mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery stenosis; PTA, 
persistent truncus arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary 
venous return; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, 
ventricular septal defect (From Bruneau, 2008). 
Population based epidemiologic studies indicate a prevalence of CHD ranging from 3.23 to 
12.23 per 1000 live births (Dolk et al., 2011; Bruneau, 2008; Engelfriet et al., 2005). This wide 
variation in the reported values is mainly due to the difference in the methodologies used, 
but a number of other factors, such as consanguinity, ethnic background, environmental 
pollutants and access to healthcare also contribute to this variation (Becker et al., 2001; 
Nabulsi et al. 2003; Botto et al., 2001). In 2006, the first study on the prevalence of CHD in 
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children born alive in São Miguel Island from January 1992 to December 2001 was carried 
out by Cymbron et al. (2006). Based on the Azorean Registry of CHD, which includes 
complete clinical and personal information, 189 patients were diagnosed. During this 10-
year period, the average prevalence of CHD is 9.16 per 1000 live births placing Azores in the 
10 European regions with higher prevalence of CHD (Table 5).  
 
Countries Total births N Prevalence (per 1000 births) 
Austria 62,667 960 15.32 
Malta 23,668 348 14.70 
Switzerland 42,874 576 13.43 
Germany 124,952 1457 11.66 
Poland 206,170 2304 11.18 
Norway 346,838 3538 10.20 
São Miguel Island 20,634 189 9.16 
Denmark 32,003 291 9.09 
France 343,715 2853 8.30 
Ukraine 25,835 201 7.78 
UK 951,001 6497 6.83 
Italy 431,727 2944 6.82 
Belgium 182,467 1212 6.64 
Ireland 215,021 1423 6.62 
Netherlands 119,104 732 6.15 
Spain 194,234 1080 5.56 
Croatia 33,933 182 5.36 
Total 3,356,843 26,787 7.97 
Table 5. Prevalence of CHG in European countries and São Miguel Island (adapted from 
Dolk et al., 2011). The period of time analysed was from 2000 to 2005, with the exception of 
São Miguel Island (1992 to 2001). No data for mainland Portugal is available. 
Considering that half of the São Miguel population lives in small rural localities (range from 
309 – 7407 inhabitants for Lomba de São Pedro and Rabo de Peixe, respectively) and the 
internal migration is reduced, aspects that increase endogamy and inbreeding, a structured 
family questionnaire to the parents with CHD children was performed. The questionnaire 
included i) questions for CHD risk factors – maternal diabetes mellitus, alcohol and drug 
abuse by the mother during pregnancy, viral infections of the fetus and genetic conditions –, 
ii) queries concerning the number of family members affected with CHD and parental 
consanguinity, and iii) a detailed family history to construct the ascending genealogy until 
the 3th generation. Results revealed a relatively high number of multiplex families (44; 
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Fig. 11. Three major classes of developmental defects are indicated: defects in atrial 
septation, in ventricular or atrioventricular septation, and in the great vessels. The types of 
congenital heart disease that occur within each class are indicated, with the associated 
mutated genes listed. AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal defect; 
AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; DORV, double outlet right 
ventricle; Ebstein’s, Ebstein’s anomaly of the tricuspid valve; HLHS, hypoplastic left heart 
syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, mitral atresia; 
MS, mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery stenosis; PTA, 
persistent truncus arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary 
venous return; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, 
ventricular septal defect (From Bruneau, 2008). 
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12.23 per 1000 live births (Dolk et al., 2011; Bruneau, 2008; Engelfriet et al., 2005). This wide 
variation in the reported values is mainly due to the difference in the methodologies used, 
but a number of other factors, such as consanguinity, ethnic background, environmental 
pollutants and access to healthcare also contribute to this variation (Becker et al., 2001; 
Nabulsi et al. 2003; Botto et al., 2001). In 2006, the first study on the prevalence of CHD in 
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children born alive in São Miguel Island from January 1992 to December 2001 was carried 
out by Cymbron et al. (2006). Based on the Azorean Registry of CHD, which includes 
complete clinical and personal information, 189 patients were diagnosed. During this 10-
year period, the average prevalence of CHD is 9.16 per 1000 live births placing Azores in the 
10 European regions with higher prevalence of CHD (Table 5).  
 
Countries Total births N Prevalence (per 1000 births) 
Austria 62,667 960 15.32 
Malta 23,668 348 14.70 
Switzerland 42,874 576 13.43 
Germany 124,952 1457 11.66 
Poland 206,170 2304 11.18 
Norway 346,838 3538 10.20 
São Miguel Island 20,634 189 9.16 
Denmark 32,003 291 9.09 
France 343,715 2853 8.30 
Ukraine 25,835 201 7.78 
UK 951,001 6497 6.83 
Italy 431,727 2944 6.82 
Belgium 182,467 1212 6.64 
Ireland 215,021 1423 6.62 
Netherlands 119,104 732 6.15 
Spain 194,234 1080 5.56 
Croatia 33,933 182 5.36 
Total 3,356,843 26,787 7.97 
Table 5. Prevalence of CHG in European countries and São Miguel Island (adapted from 
Dolk et al., 2011). The period of time analysed was from 2000 to 2005, with the exception of 
São Miguel Island (1992 to 2001). No data for mainland Portugal is available. 
Considering that half of the São Miguel population lives in small rural localities (range from 
309 – 7407 inhabitants for Lomba de São Pedro and Rabo de Peixe, respectively) and the 
internal migration is reduced, aspects that increase endogamy and inbreeding, a structured 
family questionnaire to the parents with CHD children was performed. The questionnaire 
included i) questions for CHD risk factors – maternal diabetes mellitus, alcohol and drug 
abuse by the mother during pregnancy, viral infections of the fetus and genetic conditions –, 
ii) queries concerning the number of family members affected with CHD and parental 
consanguinity, and iii) a detailed family history to construct the ascending genealogy until 
the 3th generation. Results revealed a relatively high number of multiplex families (44; 
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40.37%, Table 6) and a significantly high value of consanguinity (9.17%). Half of the 
consanguineous families (5 out of 109 total families) are multiplex. In addition, 36 out of 44 
multiplex families are endogamous (81.8%; Table 7).  
The data suggest that genetic factors may be responsible for the development of CHD in São 
Miguel Island. Familial aggregation, which is of great interest for understanding the genes 





Type of family:   
 Simplex 65 59.63 
 Multiplex 44 40.37 
Parental consanguinity:   
 With 10 9.17 
 Without 99 90.83 















localities Do not 
know With Without Four GP Three GPTwo GP All GP 
2 26  3 23 5 5 10 3 3 
3 16 1 15 4 3 7 1 1 
4 1 0 1 - - 1 - - 
5 1 1 0 1 - - - - 
Total 44 5 39 10 8 18 4 4 
Table 7. Analysis of consanguinity and grandparental endogamy in multiplex families 
from São Miguel Island. 
Research has implicated both folate deficiency and genetic variation in folate pathway genes 
with birth defects, including CHD (Lee et al., 2005). Some studies suggest that 
polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene may be 
implicated in cardiac defects development. In mainland Portugal, Marinho et al. (2009) 
reported a higher prevalence of the 677T allele in tetralogy of Fallot (TF) compared to the 
control group (OR=1.675; 95% CI [1.022- 2.743]; p=0.05). The 677TT genotype increased by 
4.856 the risk for this congenital disease (95% CI [1.308-12.448]; p=0.028), suggesting that 
MTHFR can be considered a susceptibility gene for TF. Cabral et al. (2008) genotyped two 
polymorphisms, C677T and A1298C, in MTHFR in CHD children (N=95) and respective 
mothers (N=89), as well as in the control group (N=469; Table 8). No significant differences 
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were obtained between all studied groups, indicating that in São Miguel Island MTHFR 
C677T and A1298C polymorphisms are not the main cause of CHD development. Currently, 
further genetic studies, based on functional candidate genes, in the Azorean population are 
on-going. 
 
Variants  Allele frequency (%)  Genotype frequency (%) 
        
MTHFR - C677T  C T  CC  CT  TT  
Control group (N=469)  58.32 41.68  34.54 47.55 17.91 
CHD children (N=95)  57.89 42.11  29.47 56.84 13.68 
Mothers of CHD children 
(N=89) 
 62.92 37.08  39.33 47.19 13.48 
        
MTHFR - A1298C  A C  AA  AC  CC  
Control group (N=469)  75.16 24.84  56.29 37.74 5.97 
CHD children (N=95)  57.89 42.11  58.95 40.00 1.05 
Mothers of CHD children 
(N=89) 
 62.92 37.08  49.44 44.94 5.62 
Table 8. Allele and genotype frequencies for MTHFR C677T and A1298C polymorphisms 
in the São Miguel CHD study. 
4.4 Thrombosis 
In February 2007, the National Geographic Portugal magazine published a special issue 
dedicated to cardiovascular diseases. Based on the Euro Heart Survey 2006, the number of 
deaths per 100,000 inhabitants in 2004, due to CVD, places Portugal with higher values (390) 
compared with south-western European countries like Spain (290), France (262) and 
Belgium (364). In a similar analysis, performed within Portugal regions, the Azores 
archipelago clearly stands out with the highest value (116.9), followed by Lisbon (84.8). 
Family based investigation tends to have biased relative risk estimation, because 
oversampling of affected individuals is normally present. Therefore, the genetic 
characterization of disease variants in the general population is important to correct this 
potential bias. Since thrombosis is a common cause of CVD, Branco et al. (2009) analysed 
four polymorphisms in three thrombotic risk genes – F5 (G1691A), F2 (G20210A) and 
MTHFR (C677T, A1298C), in 469 healthy blood donors from São Miguel Island. Figure 12 
shows allele frequencies in Caucasian populations, including São Miguel, for the above 
mentioned polymorphisms.  
Comparison of allele frequencies for thrombotic risk factors between São Miguel and 
mainland Portugal (Mansilha et al., 2006) revealed statistically significant differences (2, 
p<0.001; Table 9) for F5 - 1691A, justifying the need to perform regional biomedical research 
to ultimately benefit the patient.  
 
Human Genetic Diseases 144 
40.37%, Table 6) and a significantly high value of consanguinity (9.17%). Half of the 
consanguineous families (5 out of 109 total families) are multiplex. In addition, 36 out of 44 
multiplex families are endogamous (81.8%; Table 7).  
The data suggest that genetic factors may be responsible for the development of CHD in São 
Miguel Island. Familial aggregation, which is of great interest for understanding the genes 





Type of family:   
 Simplex 65 59.63 
 Multiplex 44 40.37 
Parental consanguinity:   
 With 10 9.17 
 Without 99 90.83 















localities Do not 
know With Without Four GP Three GPTwo GP All GP 
2 26  3 23 5 5 10 3 3 
3 16 1 15 4 3 7 1 1 
4 1 0 1 - - 1 - - 
5 1 1 0 1 - - - - 
Total 44 5 39 10 8 18 4 4 
Table 7. Analysis of consanguinity and grandparental endogamy in multiplex families 
from São Miguel Island. 
Research has implicated both folate deficiency and genetic variation in folate pathway genes 
with birth defects, including CHD (Lee et al., 2005). Some studies suggest that 
polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene may be 
implicated in cardiac defects development. In mainland Portugal, Marinho et al. (2009) 
reported a higher prevalence of the 677T allele in tetralogy of Fallot (TF) compared to the 
control group (OR=1.675; 95% CI [1.022- 2.743]; p=0.05). The 677TT genotype increased by 
4.856 the risk for this congenital disease (95% CI [1.308-12.448]; p=0.028), suggesting that 
MTHFR can be considered a susceptibility gene for TF. Cabral et al. (2008) genotyped two 
polymorphisms, C677T and A1298C, in MTHFR in CHD children (N=95) and respective 
mothers (N=89), as well as in the control group (N=469; Table 8). No significant differences 
 
The Genetic Makeup of Azoreans Versus Mainland Portugal Population 145 
were obtained between all studied groups, indicating that in São Miguel Island MTHFR 
C677T and A1298C polymorphisms are not the main cause of CHD development. Currently, 
further genetic studies, based on functional candidate genes, in the Azorean population are 
on-going. 
 
Variants  Allele frequency (%)  Genotype frequency (%) 
        
MTHFR - C677T  C T  CC  CT  TT  
Control group (N=469)  58.32 41.68  34.54 47.55 17.91 
CHD children (N=95)  57.89 42.11  29.47 56.84 13.68 
Mothers of CHD children 
(N=89) 
 62.92 37.08  39.33 47.19 13.48 
        
MTHFR - A1298C  A C  AA  AC  CC  
Control group (N=469)  75.16 24.84  56.29 37.74 5.97 
CHD children (N=95)  57.89 42.11  58.95 40.00 1.05 
Mothers of CHD children 
(N=89) 
 62.92 37.08  49.44 44.94 5.62 
Table 8. Allele and genotype frequencies for MTHFR C677T and A1298C polymorphisms 
in the São Miguel CHD study. 
4.4 Thrombosis 
In February 2007, the National Geographic Portugal magazine published a special issue 
dedicated to cardiovascular diseases. Based on the Euro Heart Survey 2006, the number of 
deaths per 100,000 inhabitants in 2004, due to CVD, places Portugal with higher values (390) 
compared with south-western European countries like Spain (290), France (262) and 
Belgium (364). In a similar analysis, performed within Portugal regions, the Azores 
archipelago clearly stands out with the highest value (116.9), followed by Lisbon (84.8). 
Family based investigation tends to have biased relative risk estimation, because 
oversampling of affected individuals is normally present. Therefore, the genetic 
characterization of disease variants in the general population is important to correct this 
potential bias. Since thrombosis is a common cause of CVD, Branco et al. (2009) analysed 
four polymorphisms in three thrombotic risk genes – F5 (G1691A), F2 (G20210A) and 
MTHFR (C677T, A1298C), in 469 healthy blood donors from São Miguel Island. Figure 12 
shows allele frequencies in Caucasian populations, including São Miguel, for the above 
mentioned polymorphisms.  
Comparison of allele frequencies for thrombotic risk factors between São Miguel and 
mainland Portugal (Mansilha et al., 2006) revealed statistically significant differences (2, 
p<0.001; Table 9) for F5 - 1691A, justifying the need to perform regional biomedical research 
to ultimately benefit the patient.  
 
Human Genetic Diseases 146 
 
 
Fig. 12. Allele frequencies of the thrombotic risk factors – F5 (1691A), F2 (20210A) and 
MTHFR (677T, 1298C) – in different populations, including São Miguel (adapted from 
Branco et al., 2009). 
 
Allele frequency (%) 
Populations F5 (1691A) F2 (20210A) MTHFR (677T) MTHFR (1298C) 
São Miguel Island 4.9 1.8 41.7 24.8 
mainland Portugal 1.0 2.5 33.3 28.2 
Table 9. Comparison between thrombotic genetic risk variants frequency between Azoreans 
and mainland Portugal. 
Twenty-two different genetic profiles for F5, F2 and MTHFR (order in genotype profile) 
were observed in São Miguel's population (Figure 13). The frequency of individuals who 
present a wild-type genotype for all polymorphisms (GG GG CC AA; 11.7%) was almost 
half of the major profile (GG GG CT AA; 22.4%), differing in heterozygosity for MTHFR 
677CT. No heterozygous or homozygous profiles for all four variants were observed. 
Almawi et al. (2004) reported an OR of 10.5 (95% CI [4.3–25.3]) or 6.3 (95% CI [1.5–26.0]) for 
joint occurrence of the F5-G1691A or F2-G20210A with MTHFR-677TT genotype, 
respectively, enhancing the risk for deep vein thrombosis (DVT). Based on this criterion, 
fifteen (3.2%, F5/MTHFR) and two individuals (0.4%, F2/MTHFR) would have higher risk 
for DVT development (Figure 13 – asterisk character).  
 








Fig. 13. Combined genotypes for thrombotic risk factors – F5, F2 and MTHFR – in São 
Miguel population. Twenty-two different genetic profiles were obtained. Bold characters 
(blue and black) indicate nucleotide changes compared to the wild-type allele. Blue bars 
represent profiles with increase genetic predisposition to thrombosis. The asterisk (*) 
represents the combination of the F5-G1691A or F2-G20210A with MTHFR-677TT genotype 
(adapted from Branco et al., 2009). 
Taken together, 12.4% (58 out of 469) of São Miguel islanders have increased genetic 
predisposition to thrombosis. No general population profile analysis for mainland Portugal 
is reported in the literature, and, consequently, no comparison was performed. These results 
are corroborated by further CVD studies, where 2 genomic regions associated with CVD 
risk, USF1 and 9p21 were evaluated (Correia et al., 2010). Preliminary results, based on 
haplotype inference, showed that USF1 “CCGCC” (0.288) and “CTGCT” (0.346) are the two 
most frequent haplotypes in Azoreans, which, according to Komulainen et al. (2006), 
correspond to the protective and high risk haplotype in females, respectively. In 9p21 
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region, the risk haplotype “TGGGCGCGC”, associated with CHD in Europeans (Silander et 
al., 2009), is the most frequent (0.414). Analysis of homozygosity patterns for risk genotypes 
showed similar frequencies for USF1 (12.4%) and 9p21 region (14.7%), indicating that, 
despite recombination, homozygosity must be taken in consideration when performing risk 
profile studies. Collectively, the data suggest that there is a considerable genetic risk for 
CVD in Azoreans, evidencing the need to carry out regional genetic studies with the aim to 
improve and complement health strategies adopted by the decision makers of each country. 
Further genetic studies on CVD are on-going. 
4.5 Pharmacogenetics of irinotecan and warfarin 
In the last 50 years, fundamental developments in pharmacology and genetics led to 
important improvements in personalized medicine based on pharmacogenetics and 
pharmacogenomics. Pharmacogenomics uses a whole genome approach to investigate or 
predict drug responses, or to relate the application of these technologies to drug discovery, 
while pharmacogenetics is the study of the clinically relevant inherited differences in drug 
response that can be in part explained by genetic variations. Pharmacogenetic analysis 
contributes to reduce adverse drug reactions (ADRs) or to maximize drug efficiency. 
Variants involved in drug metabolism of two commonly prescribed drugs, irinotecan and 
warfarin, were studied in Azoreans and mainland Portugal.  
4.5.1 Pharmacogenetics of irinotecan  
Irinotecan, an antineoplastic-prodrug, is widely used for the treatment of colorectal, lung 
and other cancers. The most clinically significant adverse events for patients receiving 
irinotecan-based therapy are diarrhea, neutropenia, nausea, vomiting and alopecia (Kehrer 
et al., 2001; Marques & Ikediobi, 2010; Lankisch et al., 2008; Fujiwara & Minami, 2010). 
Irinotecan can induce both early and late forms of diarrhea and requires dose adjustment 
based on severity of diarrhea. Also, sepsis related death following severe neutropenia has 
been reported in irinotecan treated patients. The active metabolite SN-38 is responsible for 
the pharmacological and toxic effect of irinotecan. SN-38, is a topoisomerase I inhibitor 
generated by hydrolysis of irinotecan by carboxylesterases (Figure 14). SN-38 is 
subsequently glucuronidated by uridine diphosphate glucuronosyltransferase 1As 
(UGT1As) to form an inactive metabolite, SN-38G (Marques & Ikediobi, 2010; Fujiwara & 
Minami, 2010).  
The human UDP-glucuronosyltransferase 1A gene locus is organized to generate enzymes, 
which share a carboxyterminal portion and are unique at their aminoterminal variable 
region. Expression is tissue-specific and overlapping substrate specificities include a broad 
spectrum of endogenous and xenobiotic compounds, as well as many therapeutic drugs 
targeted for detoxification and elimination by glucuronidation. The absence of 
glucuronidation leads to fatal hyperbilirubinemia (Marsh & Hoskins, 2010; Zhang et al., 
2007). Genetic variants and haplotypes have been identified as risk factors for unwanted 
drug effects of cancer treatment with irinotecan. Since variants in UGT1A1, UGT1A6 and 
UGT1A7 are related to irinotecan toxicity, these were studied in 469 individuals from São 
Miguel Island by Pacheco et al. (2009). Haplotype analysis revealed that H3 (Table 10), 
which includes all low activity allelic variants of the three UGT isoforms, accounts for 23.5% 
of the population, suggesting that those individuals have reduced glucuronidation activity 
due to the combination of UGT1A1*28, UGT1A6*2 and UGT1A7*3 alleles.  
 









Fig. 14. Irinotecan pathway indicating tissue specific involvement of genes in the irinotecan 
metabolism. PharmGKB copyright. Available at 
http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp. 
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UGT1A1 UGT1A6 UGT1A7 
A[TA]nTAA 541 552 541/552 387 391/392 622 387/391/392/622 N (2N=938) 
01 TA6 (*1) A A *1 T C-G T *1 296 0.316 
02 TA6 (*1) A A *1 G A-A T *2 225 0.240 
03 TA7 (*28) G C *2 G A-A C *3 220 0.235 
04 TA6 (*1) A A *1 G A-A C *3  65 0.069 
05 TA6 (*1) G C *2 G A-A C *3  31 0.033 
06 TA6 (*1) A C *3 G A-A T *2  26 0.028 
07 TA7 (*28) A A *1 T C-G T *1  23 0.024 
08 TA6 (*1) A A *1 T C-G C *4  17 0.018 
09 TA7 (*28) G C *2 G A-A T *2  7 0.007 
10 TA7 (*28) A C *3 G A-A T *2  6 0.006 
11 TA7 (*28) A A *1 G A-A T *2  5 0.005 
12 TA7 (*28) A A *1 G A-A C *3  5 0.005 
13 TA7 (*28) A C *3 G A-A C *3  3 0.003 
14 TA7 (*28) A C *3 T C-G C *4  3 0.003 
15 TA5 (*36) A A *1 G A-A T *2  2 0.002 
16 TA6 (*1) A C *3 T C-G C *4  2 0.002 
17 TA7 (*28) A A *1 T C-G C *4  2 0.002 
18 TA6 (*1) A C *3 T C-G T *1  1 0.001 
19 TA8 (*37) G C *2 G A-A C *3  1 0.001 
Table 10. Haplotype frequencies of UGT1A1, UGT1A6 and UGT1A7 variants in São Miguel 
Island population. UGT1A6 alleles are defined by permutations of two SNPs (nucleotide 
positions 541A>G and 552A>C) and UGT1A7 by permutations of four SNPs (387T>G, 
391C>A and 392G>A, and 622T>C; adapted from Pacheco et al., 2009). 
4.5.2 Pharmacogenetics of warfarin  
Warfarin is one of the most widely used anticoagulant drug, which requires a thorough risk-
benefit analysis since the dose prescribed should avoid hemorrhagic complications and 
achieves suppression of thrombosis (Wadelius & Pirmohamed, 2007; You 2011; Limdi & 
Veenstra, 2008). The administrated drug is a racemic mixture of S- and R-enantiomers, 
having S- the majority of the therapeutic effect (Figure 15). Warfarin pharmacogenetic 
studies demonstrated that variants in the CYP2C9 (Cytochrome P450 2C9) and VKORC1 
(Vitamin K epoxide reductase complex subunit 1) genes account for approximately 50–60% 
of drug dosing variability (Finkelman et al., 2011). The remaining variability can be 
explained by clinical and environmental factors (age, sex, diet, concomitant drugs, body 
mass index), which in conjunction with genetics are used, in warfarin dosing algorithms, as 
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an advice for the best dose prescription. Cytochrome P450 2C9 is the major enzyme 
responsible for metabolising the active S-enantiomer. Although there are many 
polymorphisms in CYP2C9, the most clinically relevant variants are: CYP2C9*1 
(Arg144/Ile359, wild-type), CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu). These last 
two are associated with decreased metabolic efficiency of the CYP2C9 enzyme and 
increased risk of bleeding when administrated initial dosages of warfarin (Yasar et al., 1999). 
Considering VKCORC1, a G>A variation at position 1639 in the gene’s promoter region 
results in decreased mRNA transcription and increased sensitivity to warfarin inhibition of 
hepatic synthesis of functional vitamin K-dependent coagulation factors. Rieder et al. (2005) 
studied VKORC1 polymorphisms and classified individuals according to warfarin dose 
requirements into distinct groups: high (GG), intermediate (GA) and low (AA). Recently, the 
U.S. Food and Drug Administration (FDA) added to the warfarin product label dosing 







Fig. 15. Warfarin pharmacokinetic and pharmacodynamic pathway. Warfarin is 
administered as a racemic admixture of R- and S-enantiomers. The more potent S-
enantiomer is metabolized principally by CYP2C9. The pharmacological effect of warfarin is 
mediated by the inhibition of vitamin K epoxide reductase complex 1 (VKORC1). This 
results in decreased concentrations of activated clotting factors (II, VII, IX and X) producing 
therapeutic anticoagulation (adapted from Božina 2010). 
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UGT1A1 UGT1A6 UGT1A7 
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Comparison of separate genotypes for CYP2C9 and VKORC1 between mainland Portugal 
(Jorge et al., 2010) and the Azores (Pereirinha et al., 2009, personal communication) 
populations revealed no significant differences (Table 11). In the Azores population no 
individuals with CYP2C9-*3*3 genotype were identified, however a higher frequency of 
CYP2C9-*2*3 was observed when compared to mainland. The joint analysis of CYP2C9 and 
VKORC1, in Azoreans, showed that around 12% of individuals need low doses of warfarin, 
if treatment is started (Table 11; blue characters).  
 
CYP2C9 VKORC1 CYP2C9 /VKORC1 
Genotype Frequency (%) Genotype Frequency (%) Genotype Frequency (%) 
 Azores m. 
Portugal  
 Azores  m. 
Portugal  
 Azores  m. 
Portugal  
*1/*1 57.6 64.0 GG 30.0 33.0 *1*1-GG 17.1 NA 
*1/*2 25.3 22.0 GA 56.5 50.5 *1*1-GA 34.1 NA 
*1/*3 8.2 9.0 AA 13.5 16.5 *1*2-GG 7.0 NA 
*2/*2 5.3 3.3    *1*3-GG 2.4 NA 
*2/*3 3.5 1.1    *1*1-AA 6.4 NA 
*3/*3 0 1.1    *1*2-GA 13.5 NA 
      *1*3-GA 4.1 NA 
      *2*2-GG 1.8 NA 
      *2*3-GG 1.8 NA 
      *1*2-AA 4.7 NA 
      *1*3-AA 1.8 NA 
      *2*2-AA 0.6 NA 
      *2*2-GA 2.9 NA 
      *2*3-GA 1.8 NA 
Table 11. Genotype frequencies of CYP2C9 and VKORC1 variants in Azores (N=170) and 
mainland Portugal (N=91) populations. NA- not applicable; no joint analysis of both genes 
has been described for mainland Portugal populations. Blue characters represent 
individuals who would require low doses of warfarin.  
Overall, irinotecan and warfarin studies demonstrated that the Azores population shows 
significant differences on allele frequencies of pharmacogenetic variants, which must be 
taken in consideration when treating patients. These results have a high impact on the 
physicians’ decisions in managing patient’s treatment.  
5. Conclusion 
Genomic medicine, which uses the individual information to provide better healthcare, has 
been considerably developed since the Human Genome Project. One of its current 
challenges is the identification of risk alleles for multifactorial diseases and the study of their 
frequency in different populations. In summary, both the Azores and mainland Portugal 
populations are outbred with high genetic diversity, relative gene flow among its 
individuals, and without extensive LD. Nevertheless, the islanders have a particular genetic 
makeup evidenced by the African and Asian traits, and by the differences in terms of 
common diseases apportionment compared to mainland. Biomedical investigation has been 
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the driving force in improving practices in patient care, based on new drugs, diagnostic 
methods, medical instruments and services. The genetic research performed in the Azorean 
population allowed the implementation of molecular diagnosis in the main Hospital of the 
archipelago, as well as a faster and most costly effective response to clinicians, benefiting the 
patient and, ultimately, the Azorean Health System. 
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1. Introduction 
Preimplantation Genetic Diagnosis (PGD) was first employed successfully for a monogenic 
disease detection almost 20 years ago (Handyside et al., 1990). PGD was also applied to 
screen for chromosomal abnormalities in couples at risk of aneuploidy (i.e., Preimplantation 
Genetic Screening: PGS) six years later (Munne and Weier, 1996, Verlinsky et al., 1996, 
Verlinsky et al., 1996). Currently, both approaches have been extensively used worldwide 
with more than 2,000 scientific publications.  
Briefly, PGS aims for the selection of euploid embryos to transfer, aiming to increase their 
implantation rate. FISH for 9 chromosomes is mostly the technique applied in PGS. It 
seems, however, that according to recent publications PGS may not be useful (Staessen et 
al., 2004, Staessen et al., 2008, Hardarson et al., 2008, Mastenbroek et al., 2007). In fact, 
analyzing the latest data presented by the European Society of Human Reproduction and 
Embryology (E.S.R.H.E.), on average just 27.4% of the transferred PGS-selected embryos 
implant (3,926 positive heartbeats / 14,325 transferred embryos)( Harper et al., 2010). On 
the other hand, after 167,192 ART cycles in Europe using ICSI, the pregnancy rate is 29.8% 
(Andersen et al., 2008). Obviously, PGS patients differ from ICSI patients since the first 
ones suffer from repetitive implantation failure (RIF) or have an advanced maternal age 
(AMA), but the low implantation rate obtained in these patients still remains as a 
problematic issue.  
But, also referring to the E.S.H.R.E. data, the implantation rate in patients undergoing PGD 
for a monogenic disease, in which the maternal age is not at risk of producing aneuploid 
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gametes, is 15.2% (1067 positive heartbeats /7,035 transferred embryos) (Harper et al., 2010). 
It appears clear, then, that an increase of the implantation rate would not only be 
advantageous for the PGS patients but also for the PGD ones.  
In PGS patients, in order to increase the implantation rate, comprehensive chromosomal 
analysis techniques have been proposed to completely karyotype the embryo to be 
transferred. One of these techniques is Comparative Genomic Hybridization (CGH), which 
has been applied widely in PGS (Keskintepe et al., 2007, Sher et al., 2007, Voullaire et al., 
2002, Wells et al., 2002, Wilton, 2005), achieving up to a 74%-80% rate of implantation. Two 
different cells can be analyzed by CGH-PGS, the first polar body (1PB) and the blastomere 
(BL). Both options have their advantages and disadvantages; the use of 1PB-CGH permits 
the diagnosis of the cell within the same IVF cycle, as the CGH procedure requires up to 4 
working days, but the result obtained only reflects indirect information about the oocyte, 
despite it being known that it is during the first meiotic division when most embryonic 
aneuploidies occur (Hassold and Hunt, 2001, Nicolaidis and Petersen, 1998). On the other 
hand, BL-CGH gives information about the embryo directly, but it cannot be analyzed 
during the same IVF cycle and, therefore, involves a cryopreservation step followed by a 
defrost step of euploid embryos prior to transfer.  
Other techniques that allow for a full karyotype analysis and that are potentially useful to 
increase implantation in PGS patients are array-CGH or SNP-array, which permits a 
diagnosis within the IVF cycle and investigates the embryo directly, as it is applied to 
blastomeres. So far, several publications have tested the efficiency of array-CGH on single 
cells with promising results (Fiegler et al., 2007, Hu et al., 2004, Le Caignec et al., 2006, Wells 
et al., 2004, Handyside et al., 2009). Recently, it has been applied clinically after blastomere or 
polar body biopsy, obtaining six pregnancies (Hellani et al., 2008, Fishel et al., 2009). 
Although array-CGH is a capable technique, more research must be done to validate it and 
monitor any increase in the implantation rate. Toward this aim, the ESHRE PGS Task Force 
have proposed a multicenter randomized control trial to assess the possible positive effect 
on implantation of the PGS on polar body using a 24-chromosome detecting technique as 
array-CGH (Geraedts et al., 2009).  
Now considering the enhancement of the implantation rate on patients undergoing PGD for 
a monogenic disease (PGD-patients), several approaches have been published with this aim. 
A methodology called Cell Recycling, i.e., FISH analysis of a blastomere and posterior PCR 
amplification of the very same cell, was described as a possible option for selected the 
embryos both genetically and cytogenetically (Thornhill et al., 1994), but it was 
demonstrated that the protocol increased the allele drop-out (ADO) rate, thus reducing its 
diagnostic robustness (Rechitsky et al., 1996).  
Another approach is the Double-Factor PGD (DF-PGD) where the 1PB is analyzed using 
CGH and a single blastomere of the produced embryo is biopsied in order to diagnose the 
monogenic disease. This method permits the double selection of the embryos for being free 
of the family disease plus having originated from a potentially euploid oocyte. In addition, 
as 1PB-CGH is used, the diagnosis is performed within the same IVF cycle, avoiding the 
need of cryopreservation. The DF-PGD has been previously applied on two couples, carriers 
of cystic fibrosis and von Hippel-Lindau syndrome, respectively, achieving the birth of three 
healthy children (Obradors et al., 2008, Obradors et al., 2009).   
The aims of this work are to assess the feasibility and application of the DF-PGD after two 
year of experience and ten clinical applications and, moreover, to determine if it is a 
valuable tool to increase the implantation rate in PGD for monogenic-disease patients.  
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2. Materials and methods 
Patients 
Over two years, a total of eight couples affected by a monogenic disease participated in this 
study after fully understanding the protocol and the signing of an approved-consent form. 
The results of two of them were previously published (Obradors et al.,  2008 and 2009) 
(Table 1). Two of the couples repeated the DF-PGD clinical protocol after no pregnancy on 
the first attempt. 
The mean age of the patients was 35.1 years old. For comparison proposes, the patients were 
classified into two groups depending on the maternal age: four patients were classified with 
advanced maternal age (AMA) (mean age of 39.2 y.o.) and the other 6 patients were � 35 y.o. 
(mean age of 32.3 y.o.). 
Most of the couples (6 out of 8) were unaffected carriers of Cystic Fibrosis (CF, OMIM 
#219700) with an affected child. Considering the other two couples, one was affected by von 
Hippel-Lindau syndrome (VHL, OMIM #193300), a dominantly-inherited family cancer 
syndrome, and the other couple was an unaffected carrier of Angelman Syndrome (AS; 
OMIM #105830). 
A summary of the mutations affecting each couple can be also found in Table 1. 
Monogenic disease detection protocol 
In order to minimize misdiagnosis and increase protocol robustness, two independent 
diagnoses were performed. A direct diagnosis of the causative mutation and an indirect 
diagnosis using informative Small Tandem Repeats (STRs) were optimized for each couple. 
The causative mutation detection, mostly point-mutations, was achieved after two rounds of 
nested-PCR amplification of a region surrounding the mutation using specific primers 
designer using the Primer3 website (http://frodo.wi.mit.edu) (Table 2). After PCR 
amplification, the mutant site was interrogated using the MiniSequencing Reaction 
(Snapshot Multiplex Kit, Applied Biosystems; CA, USA). During the reaction, a mutation-
specific primer anneals a base before the point-mutation site; then, a polymerase 
incorporates a single ddNTP fluorescently labeled (Fiorentino et al., 2003).  The product of 
the reaction (1μL) is analyzed in a DNA sequencer in order to detect the presence or absence 
of the causative mutation.   
In order to detect mutations involving short deletions, such as F508 mutation in the CFTR 
gene which is causative of Cystic Fibrosis (CF), where three nucleotides are deleted in the 
mutant allele, a pair of fluorescent primers was designed to anneal on both sides of the 
deletion in order to detect the fragment analysis variation, between the alleles. After PCR 
amplification of genomic DNA of a CF carrier and analysis on a DNA sequencer, two 
different peaks appear, a wild-type peak at 94 bp followed by the mutant peak at 91 bp. 
As commented upon before, an indirect diagnosis using STRs was also applied. A minimum 
of four STRs were found surrounding each of the genes causatives of the diseases. The STRs 
were chosen using the NCBI database (http://www.ncbi.nlm.nih.gov/mapview) according 
to the following criteria: to contain a tetranucleotide repetition core, to be located as close as 
possible to the gene (upstream or downstream) and to have the highest heterozygosity 
value. Once they were chosen, the fluorescent dyes of the forward primers of each STR were 
selected in order to avoid overlapping of the expected allele size for all STRs of the same 
disease, so they could be amplified and simultaneously analyzed if required.  
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2. Materials and methods 
Patients 
Over two years, a total of eight couples affected by a monogenic disease participated in this 
study after fully understanding the protocol and the signing of an approved-consent form. 
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the first attempt. 
The mean age of the patients was 35.1 years old. For comparison proposes, the patients were 
classified into two groups depending on the maternal age: four patients were classified with 
advanced maternal age (AMA) (mean age of 39.2 y.o.) and the other 6 patients were � 35 y.o. 
(mean age of 32.3 y.o.). 
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(Snapshot Multiplex Kit, Applied Biosystems; CA, USA). During the reaction, a mutation-
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incorporates a single ddNTP fluorescently labeled (Fiorentino et al., 2003).  The product of 
the reaction (1μL) is analyzed in a DNA sequencer in order to detect the presence or absence 
of the causative mutation.   
In order to detect mutations involving short deletions, such as F508 mutation in the CFTR 
gene which is causative of Cystic Fibrosis (CF), where three nucleotides are deleted in the 
mutant allele, a pair of fluorescent primers was designed to anneal on both sides of the 
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amplification of genomic DNA of a CF carrier and analysis on a DNA sequencer, two 
different peaks appear, a wild-type peak at 94 bp followed by the mutant peak at 91 bp. 
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of four STRs were found surrounding each of the genes causatives of the diseases. The STRs 
were chosen using the NCBI database (http://www.ncbi.nlm.nih.gov/mapview) according 
to the following criteria: to contain a tetranucleotide repetition core, to be located as close as 
possible to the gene (upstream or downstream) and to have the highest heterozygosity 
value. Once they were chosen, the fluorescent dyes of the forward primers of each STR were 
selected in order to avoid overlapping of the expected allele size for all STRs of the same 
disease, so they could be amplified and simultaneously analyzed if required.  
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Table 1. Diseases and causative mutations of the eight couples included in the present DF-
PGP program. The mutation detection methods and the informative STRs to perform direct 
and indirect analysis, respectively, are also included. The dF508 mutation is detected by the 
3-bp difference between the mutant and the wild-type alleles 
To assess the diagnostic utility of the STRs, genomic DNA extracted from peripheral blood 
or from buccal cells was obtained from each member of the couple. The STRs were classified 
as being 100% informative if the both in the couple were both heterozygote, or to be 
partially informative if one of the couple was homozygote and the other one heterozygote 
for the same STR or, finally, not informative if both were homozygote. In order to detect 
which of the couple’s alleles were linked to their mutated copy of the gene, DNA from an 
affected child or first-degree relatives was also analyzed.  
With the aim of avoiding misdiagnosis due to the recombination process between the 
selected STRs and the gene of interest, a minimum of two 100% or partially informative 
 





Primer Forward (5’-3’) Reverse (5’-3’) 
K109X-outer GCCTAGAATGTTTGGCTGTTT CTCTTCCAATAACACGGATTAAA 
K109X-inner GAACTTTTTGCAACAGAGTAAACA ATCCTCTCTTTCTCTACATAATTCAAG 
K109X-
miniseq AGATGTGACTTACTTAACAGAAGAG - 
dF508 6FAM-TGGAGCCTTCAGAGGGTAAA TGGGTAGTGTGAAGGGTTCAT 
712-1 G to T-
outer TGTTAGTTTCTAGGGGTGGAAGA AAAGGAGCGATCCACACG 
712-1 G to T-
inner GACACCTGTTTTTGCTGTGC AAATGTGCCAATGCAAGTCC 
1811+1.6Kb-
outer AAAGTTTTGCCATTGGTTTTT AAAGATGAAGACACAGTTCCCATA 
1811+1.6Kb-
inner TTGTGTGCTGAATACAATTTTCTTT AAAGATGAAGACACAGTTCCCATA 
1811+1.6Kb-
miniseq AGAGAATCCTATGTACTTGAGAT - 
2711delT-
outer GGAGAGCATACCAGCAGTGA AAGCACCAAATTAGCACAAAA 
2711delT-
inner TTCGATATATTACTGTCCACAAGAGC AAGCACCAAATTAGCACAAAA 
D15S1513 6FAM-GAACTGGGGAAAATCAGGAT ACACATTTTAAGCCAGCAGC 
D15S817 6FAM-GCACCAATAGGCTAGACACG AGCTTTACATGGCATGTGGT 
D7S2847 HEX-TCACCTTCAGAAAGTATTGCC TGAGGTGTTTCTCCAAGCTC 
D7S3052 6FAM-AGTGAGACTAGCAGATGTACTTGG GCCTCCCCATTTCATCTATT 
INTRA HEX-CAAGTCTTTCACTGATCTTC TGAGCAGTTCTTAATAGATAA 
Table 2. Sequences of the primers used in this study. The underlined primers were also used 
as MiniSequencing primers, as their 3’ end hybridizes a base before the point-mutation. The 
other primers’ sequences are cited in the previous applications of DF-PGD. 
STRs located on each side of the gene (upstream and downstream) were selected for the 
PGD protocol, or in the case of intragenic STRs, a single STR was considered.  
Once both the STRs and the mutation-specific primers were chosen, the PGD protocols were 
optimized using genomic DNA from one of the patients. Briefly, a multiplex PCR containing 
the fluorescent primers for the STRs amplification, plus the first-round unlabeled primers 
for mutation detection was applied in most of the cases. When optimizing the dF508 CF 
mutation, its primers were fluorescently labeled in order to detect the deletion, as described 
before. Between 0.5-1 μL of product of this PCR multiplex was used as a template for the 
second round of amplification of the mutation-specific primers. One microliter of the PCR 
amplification product was used in a DNA sequencer to assess STRs efficiency on the 
multiplex, whereas agarose gel analysis was enough to detect to correct amplification of the 
mutation-specific loci. 
When the multiplex was efficient in genomic DNA, it was tested in whole genome-amplified 
(WGA) single cells, usually cultured fibroblast. The Multiple Displacement Amplification 
(MDA) (Genomiphi, HE Healthcare; Buckinghamshire, UK) was used following the 
manufacturer’s protocol, but with a previous step of alkaline lysis of the single cell, as 
described before (Obradors et al.,  2008 and 2009, Spits et al., 2006). Finally, and in order to 
describe the allele drop-out (ADO) rate, 30 patients’ lymphocytes were amplified with the 
optimized protocol.  
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for mutation detection was applied in most of the cases. When optimizing the dF508 CF 
mutation, its primers were fluorescently labeled in order to detect the deletion, as described 
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describe the allele drop-out (ADO) rate, 30 patients’ lymphocytes were amplified with the 
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In order to minimize the presence of contamination due to exogenous DNA, all PCR mixes 
which included primers, Taq polymerase and buffers were performed on a sterile hood. 
While the target DNA, i.e., MDA products, PCR amplicons after a first-round amplification 
and DNA extracted from peripheral blood or from buccal cells were introduced into a 
separate sterile hood in another room.  
A report, the informative study report, including the STRs analyzed, the mutation detection 
procedure and ADO rate described for each couple, was sent to the IVF centers, which 
scheduled a date for the PGD case according to the patient’s stimulation cycle.  
3. First polar body comparative genomic hybrydization  
The 1PB-CGH procedure has been extensively described previously by our group (Obradors 
et al.,  2008 and 2009). Briefly, the 1PB was washed four times with sterile PBS/0.1%PVP, in 
order to avoid potential contamination from cumulus cells, and it was then placed in a 
0.2mL PCR tube. Cell lysis (1 μl of sodium dodecyl sulfate (17 μM) and 2 μl of proteinase K 
(125 μg/ml)) was required to facilitate the cell genomic-DNA liberation. Afterwards, the 
cellular DNA was amplified by means of DOP-PCR, a WGA technique described to produce 
a sufficient amount of DNA to perform a CGH (Telenius et al., 1992, Voullaire et al., 1999, 
Wells et al., 1999). Briefly, the DOP-PCR reaction tubes contained 1X Buffer, 2 μmol/l DOP 
primer (CCGACTCGAGNNNNNNATGTGG), 0.2 mmol/l dNTP and 2.5U of SuperTaq 
Plus polymerase (Ambion, USA) in a final volume of 50 μl. The tubes were placed in a 
thermocycler and underwent the following program: 94ºC for 4.5 min; eight cycles of 95ºC 
for 30s, 30ºC for 1.5 min and 72ºC for 3 min; 40 cycles of 95ºC for 30s, 56ºC for 1 min and 
72ºC for 3 min with a final extension step of 72ºC for 8 min. After DOP-PCR amplification, 
fluorescent labeling with Spectrum-Red of the DOP-PCR product was performed by the 
Nick Translation Kit, following the manufacturer’s indications (Vysis; Downers Grove, 
USA). With the purpose of obtaining reference DNA to compare with the 1PB (test DNA), 
between twelve to fifteen tubes containing three euploid female fibroblasts each were 
lysated and amplified like the 1PBs, but labeled with Spectrum-Green instead. The reference 
DNA produced from these twelve to fifteen cells was mixed in a single tube, kept at -20ºC 
and used as reference DNA when required. The resulting reference-DNA mix avoids 
intrinsic cell-dependent amplification differences that could bias the CGH results and 
provides an intense homogeneous fluorescent signal. 
Both test and reference DNA co-precipitated with Cot-1-DNA, which blocks repetitive DNA 
sequences such as telomeres and centromeres. The resulting cytogenetic probe hybridized 
during 44 hours into a slide of euploid lymphocyte metaphases. After that, the slide was 
washed to remove unspecific hybridization and analyzed using an epifluorescence 
microscope. Ten lymphocyte metaphases were captured and karyotyped using the 
Metasystem’s software to obtain a CGH profile. When the fluorescence ratio (test/reference) 
of a CGH profile for a specific chromosome, reported by the software, was < 0.8, the 
chromosome was lost in the DNA test, whereas when the ratio is > 1.2, a chromosome gain 
was present (Wells et al., 1999). 
Potentially artifactually gained or lost chromosomes (i.e., Chromosomes 17, 19 and 22) were 
discarded from analysis when all three chromosomes were simultaneously gained or lost in 
the same cell; if not, they were considered as being real aneuploidies. 
In the present work, no distinction between chromosome or chromatid gain or loss has been 
considered because, in our experience, after analyzing 1PBs and their corresponding MII 
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using CGH and FISH, respectively, the CGH-loss or CGH-gain profiles on the 1PBs were 
indistinguishably equivalent to losses or gains of either chromosome or chromatid in the 
MIIs (Gutiérrez-Mateo, et al., 2004). 
4. Double-factor pgd clinical schedule 
Exhaustive information about the methodology and schedule, based on the following 
timetable (Figure 1), of the Double-Factor PGD (DF-PGD) clinical application performed in 
the families included in this work has been previously published (Obradors et al.,  2008 and 
2009). On Day 0, retrieved oocytes were cleaned of cumulus cells to avoid cellular 
contamination during the PGD case. Following the IVF center’s protocol, ICSI was 
performed on all MII oocytes, and immediately afterwards, the 1PB was biopsied using the 
partial zone dissection (PZD) procedure and washed four times with sterile PBS/0.1PVS as 
described above. In the cases, when the IVF center was located close to the lab (i.e., 
Barcelona), the cell lysis and DOP-PCR were done on Day 0; on the other hand, for cases 
located far from our lab (i.e., Madrid), the 1PB arrived in our lab in Bellaterra on Day +1, 
when the CGH protocol started. On the afternoon of Day +1, the CGH was placed to 
hybridize for 44 hours, thus, until the morning of Day +3. On Day +3, the CGH started to be 
analyzed; in general, a skilled technician took 1 hour to obtain a result for each CGH, so 
depending on the number of 1PBs it may last until Day +4. Also on Day +3, developing 
embryos reached the 6-8-cell stage and a single blastomere is biopsied using the same hole 
produced during the 1PB biopsy, but in order to increase the size of the hole, PZD or acid 
Tyrodes was used. Again, if the IVF center was located close to the lab (i.e., Barcelona), the 
PCR protocol started on Day +3, thus achieving the monogenic diagnosis results on Day +4. 
For IVF centers located in Madrid, the blastomere arrived on Day +4.  
Late on Day +4, after the results from the DF-PGD were obtained, a written report was sent 
to the IVF center indicating not only the embryos free of each particular monogenic family 
disease, but also the results obtained after the complete cytogenetic analyses of the whole 
female chromosome complement. At that point, embryos free from the monogenic family 
pathology that were derived from oocytes that were predicted to be euploid and with a 
good morphological appearance can be selected and transferred. As is habitual in PGD, the 
family has been informed that performing a prenatal diagnosis in case of pregnancy would 
be recommended. 
5. Results 
First polar body and blastomere obtainment 
After ovary stimulation and follicular puncture, 146 oocytes were obtained from the 10 DF-
PGD clinical cases presented (mean of 14.6 per couple). One-hundred-thirty-two of them 
(90.4%) were at the MII stage, thus containing the 1PB, and were inseminated using the 
couple’s spermatozoids by ICSI. Immediately there after, the 1PBs were biopsied, obtaining 
112 1PBs; therefore, the 1PBs biopsy efficiency was 84.8% (112/132). The oocytes were 
incubated at 37ºC and checked for fecundation on Day +1. A total of 92 showed 
morphological signs of fecundation, obtaining a fecundation rate prior to the 1PB biopsy of 
69.7%. As established in the IVF centers, embryos were checked for satisfactory division and 
quality on Day +2. On Day +3, 81 of the 92 (88%) fertilized oocytes did develop to 6-8-cell-
stage embryos (mean of 8.1 embryos per cycle) and a single blastomere was biopsied. 
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Blastomere biopsy was achieved in all embryos (100%), hence 81 blastomeres were acquired. 






Fig. 1. Illustration showing the DF-PGD timing combined with the IVF procedure.  
First polar body cgh results 
Analyzable CGH profiles were obtained in 83 of the 112 1PB-CGHs performed, resulting in 
a CGH success of 74.1%. The remaining 29 1PB-CGHs, in which poor WGA amplification 
field were observed on the agarose gel, were not analyzable due to a faint hybridization was 
obtained. Probably it was due to the corresponding 1PB was fragmented or with bad 
morphology. 
Thirty-five of the 1PBs were diagnosed as euploid, whereas the remaining 54.2% (45 out of 
83) were aneuploid (Tables 3 and 4). No differences in the incidence of aneuploidy were 
observed between the two maternal age groups (56% in  35 years vs. 51.5% in > 35 years).  
Aneuploidies involving from one to nine chromosomes were observed. All the 23 
chromosomes were involved in aneuploidy. The chromosomes that most frequently were 
found to be aneuploid were Chromosomes 19 (eleven times), 18 and 16 (nine times), 1 (eight 
times) (Figure 2). No differences were observed concerning chromosome size, as from the 
109 chromosomes involved in aneuploidy, 57 (52.3%) and 52 (47.7%) were classified into the 
A-C groups or into the D-G groups, respectively.  
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Only eight out the 45 aneuploid (17.8%) 1PBs would have been fully diagnosed using a FISH 
analysis for 9 chromosomes (13, 15, 16, 17, 18, 21, 22, X and Y), and a total of 20 (44.4%) of 
the aneuploid 1PBs would have been diagnosed incorrectly as being euploid (Figure 3). The 
remaining 17 1PBs (37.8%) would have been diagnosed as being aneuploid, but not all the 






































30 12 12 10 100 12 100 8 1 11.1 
A 32 16 16 13 81.25 13 92.3 3 9 75 
A’ 32 23 17 15 88.2 8 53.3 3 5 62.5 
B 32 13 11 9 81.8 5 55.6 1 8 88.8 
C 33 11 11 9 81.8 7 77.8 4 3 42.8 
Obradors 
et al. 2008 35 6 5 5 100 5 100 3 2 60 
D 37 7 5 5 100 3 100 1 2 66.7 
E 38 33 32 23 71.9 13 56.5 4 9 69.2 
F 41 11 11 11 100 11 100 7 4 80 
F’ 41 14 12 12 100 6 50 4 2 33.3 
TOTAL 34.75 146 132 112 86.4 83 72.8% 38 45 54.2 
 
Table 3. Summary of the oocytes retrieved from the eight couples included in the present 
DF-PGP program and cytogenetic results obtained after the 1PB-CGH analysis. 
Monogenic disease detection results 
All 81 blastomeres (a mean of 8.1 blastomeres per cycle) were amplified using MDA 
followed by a patient-specific mutation and STR detection multiplex-PCR as described.  Six 
out of the 81 blastomeres (7.4%) did not provide a diagnostic result and thus were classified 
as non-diagnosed. Hence, as informative diagnostic result was notified in 92.6% of the 
blastomeres. Allele drop-out (ADO) affected 15.4% of the analyzed loci, and the PCR 
amplification efficiency was 93.3%. 
Globally, of the 75 diagnosed blastomeres, 20 (26.1%) were homozygote wild-type, 21 (28%) 
homozygote mutant and the remanding 34 (45.3%) were diagnosed as heterozygote (Table 
5). These ratios were not statistically different from the expected Mendelian inheritance 
rates.  
Considering the studied monogenic diseases, 45 out of the 75 embryos were diagnosed as 
being non-affected (i.e., wild-type homozygotes in VHL and AS diseases, and both wild-
type homozygotes and heterozygotes in CF). 
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Blastomere biopsy was achieved in all embryos (100%), hence 81 blastomeres were acquired. 
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Fig. 2. Incidence of aneuploid chromosomes found in the 1PB-CGH results of the couples 
included in the present DF-PGP program. 
Double-factor dgp outcome and implantation rate versus pgd 
Of the 45 embryos free of the disease, in 35 the 1PB-CGH result was available, with the result 
that 20 of them (57.1%) originated from an aneuploid oocyte and the rest, 15 (42.9%), were 
potentially euploid. These 15 embryos, free of the monogenic disease and potentially euploid, 
were tagged as DF-PGD-transferable embryos. No informative 1PB-CGH profiles were 
obtained from the remaining 10 embryos free of the disease, so only the monogenic-disease 
diagnosis was performed; they were classified as conventional PGD-transferable embryos. 
Consequently, 56 embryos were DF-PGD non-transferable, due to being undiagnosed or 
affected by the corresponding monogenic disease (6 embryos and 30 embryos, respectively), 
or due to having originated from aneuploid 1PBs (20 embryos) (Table 6).  
On Day +5, according to embryo-quality criteria, nine out of the 15 and eight out of the nine 
DF-PGD-transferable and conventional PGD-transferable embryos were transferred to nine 
patients, respectively. Four of them received only DF-PGD-transferable embryos, two 
received only conventional PGD-transferable embryos and the remaining three patients 
received both types (Table 6). 
Four pregnancies were confirmed with both the hCG test and positive fetal heartbeat. None 
of the pregnancies involved patients receiving simultaneously both types of embryos (DF-
PGD-transferable embryos and conventional PGD-transferable embryos). A pregnancy 
which turned into the birth of a healthy girl was achieved in one of the patients with just 
PGD-transferable embryos transferred, and two pregnancies were achieved from the 
patients receiving only DF-PGD-transferable embryos, which resulted in the birth of three 
healthy children (one singleton and twins). 
 





Fig. 3. Comparative Genomic Hybridization profile of 1PB#1 from Patient D, indicating a 
gain of Chromosome 1 and a loss of Chromosomes 9, 10 and 11. The 1PB would have been 
misdiagnoses as euploid if instead of CGH; a nine-chromosome FISH would have been 
used. 
Due to most of the embryos were either at the morula stage or degenerated on Day +6, it 
was totally impossible to isolate blastomeres from the rejected embryos in order to perform 
a confirmation of both diagnoses.  
Prenatal diagnosis has been performed on two out of three pregnancies, according to the 
parents’ decision. In Couple C, an embryo diagnosed as a healthy homozygote turned out to 
be carrier of one of the copies of the mutation due to ADO of the mutant allele; 
consequently, the girl delivered was a healthy heterozygote, but a carrier of CF (Figure 4). 
Taking into consideration the implantation rate for the two types of embryos, one out of 
eight embryos healthy for the monogenic disease but undiagnosed for aneuploidies (i.e., 
PGD-transferable embryos) did implant, achieving an implantation rate of 12.5%, whereas 
three out of nine healthy embryos diagnosed as potentially euploid (DF-PGD transferable 
embryos) did implant, meaning an implantation rate of 33.3%. The differences between the 
groups are not significant for Fisher’s test (p= 0.576). 
Considering maternal age, none of the six embryos transferred into patients with AMA 
(mean age of 39.2 y.o.) did implant, whereas four out of the eleven embryos transferred into 
the patient without AMA (mean age of 32.3 y.o.) implanted. These differences are found to 
be significantly different (p= 0.03).  
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Fig. 4. Monogenic diagnosis results of embryos #4 and #5 of Patient C, carrier of CF. Embryo 
#4 was affected of both mutation, dF508 (A) and 712GtoC (B), and confirmed with the STR 
D7S3025 (C), whereas Embryo #5 (D, E, F) was free of both mutations. Embryo #5 was 
transferred to the patient, achieving a pregnancy. Prenatal diagnosis showed that the foetus 
carried the dF508 mutation. Therefore, two ADO events occurred in that blastomere, one in 
the dF508 locus and another in the STR D7S3025 (D and F). 
6. Discussion 
The embryo implantation rate is one of the most important values in IVF as long as the take-
home-baby rate as the major aim of the clinicians is to achieve pregnancy in their IVF 
patients. Preimplantation Genetic Screening (PGS) appeared to satisfy this demand. It is well 
documented that aneuploidy affects between 50%-65% of first-trimester abortions (Hassold 
and Jacobs, 1984, Menasha et al., 2005). Therefore, a positive selection of euploid embryos to 
transfer should be a useful tool towards an increase of their implantation rate. However, it 
has been proved that, apart of embryonic mosaicism, the screening of embryos for a limited 
number of chromosomes is insufficient Steassen et al., 2004 and 2008;  Hardarson et al., 2008; 
Mastenbroek et al., 2007) and that a complete karyotype analysis may be needed to obtain 
satisfactory results (Sher et al., 2007).  
Comparative Genomic Hybridization (CGH) and array-CGH are the main techniques used 
for comprehensive aneuploidy screening of embryos. The array-CGH has been tested lately 
for single cells and even applied clinically on blastomeres and on polar bodies, obtaining six 
pregnancies in nine couples with a clinical history of up to thirteen previous IVF failures 
(Hellani et al., 2009). One of the main advantages of array-CGH versus conventional CGH is 
that it is less labour-intensive, more informative and plus it allows embryo diagnosis on Day 
4. On the other hand, its main drawback is the cost of the array-CGHs and the consequent 
processing and analysis equipment required. Thus, in anticipation of more studies of both 
economic and technical viability of the array-CGH, conventional CGH has been 
continuously applied with the objective of enhancing the implantation rate with 
implantation rate up to 68.9% Keskintepe, et al., 2002).   
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Aiming to contribute on the increase of the implantation rate, even in patients without a 
previous clinical history of IVF failure or AMA, our group introduced the Double-Factor 
PGD (DF-PGD), which allows for the selection of potentially euploid embryos with 1PB-
CGH and moreover free of the corresponding family monogenic Obradors et al.,  2008 and 
2009). In the present manuscript we are including results obtained after two years of the 
application of DF-PGD. 
Considering the DF-PGD protocol referred to here, one single blastomere was biopsied from 
all 81 6-8-cell embryos on Day 3, as recommended by the ESHRE PGD consortium in order not 
to compromise embryo viability (Thornhill et al., 2005). All 81 blastomeres (a mean of 8.1 
blastomeres per cycle) were amplified using MDA prior to PCR amplification with an 
efficiency rate of 92.59%, similar to the large series of MDA applications previously published, 
which analyzed 88 and 49 single cells, respectively (Burlet et al., 2006, Renwick et al., 2006). One 
of the main concerns about MDA is its high ADO rate, which, according to the same cited 
studies, affects between 25%-27% of the heterozygote cells. In this work, and also analyzing a 
comparable number of cells, the ADO rate obtained was appreciably low (15.4%). Despite that, 
on one of the patients (Couple E), the ADO rate found after analyzing their embryos was 
considerably higher (50%), most probably due to intrinsical problems with this case in 
particular, as blastomeres quality or transportation issues. If the data from this couple is not 
included for the ADO rate calculation, its value becomes 11.5%, similar to the obtained from 
unamplified single cells, and also close to the recommended for the ESHRE PGD consortium 
Thornhill et al., 2005). The differences in the ADO rates showed in this results compared with 
the previously published using MDA could be explained by the differences in the size of the 
PCR amplicons and the type or quality of the amplified cells (Wells, 2004). Unfortunately, and 
despite the low ADO rate, a misdiagnosis occurred affecting a healthy cystic fibrosis (CF) 
carrier who was wrongly diagnosed as being a wild-type homozygote.  
In that particular case, the family carried two different CF mutations ( F508 and 712-1G to 
T); moreover, they were fully informative for one STR and semi-informative for two more 
STRs (only informative for one of the progenitors). After MDA and PCR amplification, the 
analysis showed wild-type alleles for both mutations, failure of amplification on the full 
informative STR and consistent results on the other two STRs, thus the embryo was 
diagnosed as being free of both CF mutations. Pregnancy was achieved in this couple, and 
following the group’s recommendation, prenatal diagnosis was performed showing a foetus 
carrier of the F508 mutation. Hence, two ADO events did occur in that cell, one affecting 
the F508 mutation site and the other on the semi-informative STR linked to the F508 
mutation. This result may indicate that the blastomere analyzed probably was insufficiently 
lysed. Nevertheless, prenatal diagnosis is mandatory in all PGD cases in order to avoid 
improbable, but possible misdiagnosis.  
In a recent publication, the ESHRE PGS Task Force has aimed for a proof of principle study 
by a multicentre RCT of the positive effect of implantation of the 1PB and 2PB analysis in the 
same IVF cycle using a whole chromosome analysis technique as CGH-array (Geraedts et 
al., 2009) in order to overpass the mosaicism issue and detected all the possible aneuploidies 
without the requirement of embryo cryopreservation.  
In the present study, we have applied a similar approach to the PGS Task Force, also using 
polar body analysis with a fully comprehensive technique (1PB-CGH). In this case we have 
decided not the analyze the 2PB in order to avoid an additional second manipulation of the 
oocytes, after the 1PB biopsy has been performed and due to the first polar body’s 
chromosomal material losing its quality progressively through time (Durban et al., 1998). We 
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also considered inappropriate to wait, at least two hours, for the 2PB extrusion and to 
perform the biopsy of both polar bodies at the same time. It is obvious that exclusively 
analyzing the 1PB, meiotic errors produced during second meiotic division remain 
undetected (Kuliev et al., 2005). Considering that the incidence of the female origin of 
aneuploidies has been widely described mainly due to errors in the first meiotic division 
(Hassold and Hunt, 2001, Nicolaidis and Petersen, 1998), we decided that our DF-PGD 
approach was more than appropriate neither the oocyte nor the embryo was compromised.  
A total of 115 1PBs were biopsied from their corresponding oocytes on Day 0, but only 77 
of them were analyzed by CGH since the producing embryo was diagnosed as being 
affected by the monogenic disease. Surprisingly, 54.2% of the 1PBs were aneuploid. This 
high rate is similar to that previously described in CGH studies of 1PBs-oocytes doublets 
of IVF patients Gutiérrez-Mateo et al., 2004 a and b). It is noteworthy that the patients that 
underwent this study were selected for monogenic disease detection, not for sterility 
problems, so the fact that their aneuploidy rate is similar to that of IVF patients 
emphasizes the importance of aneuploidy screening even in patients without fertility 
problems. Moreover, after dividing the patients into two age groups, 35 or >35 years old, 
a similar rate of aneuploidy was found between them (56% vs. 51.5%, respectively). These 
results, although higher, are comparable to the ones obtained on a previous study of our 
group after analysis, with CGH, 1PB-MII doublets from 53 IVF donors with a mean age of 
26.1 years old (Obradors et al., 2010). The study shows that, despite being produced by 
young women, 32.1% of the analyzed oocytes were aneuploid. Moreover, it demonstrates 
that almost 40% of the donors had at least one aneuploid oocyte.  
This high aneuploidy rate found in young fertile women, concordant with that described in 
this manuscript, may be explained due to the ovarian stimulation process (Weghofer et al., 
2008, Weghofer et al., 2008). This suggests that not only aged patients may benefit from 
aneuploidy screening with CGH, but also younger women without sterility problems.  
Almost half of the detected aneuploid 1PBs (44.4%), some of them containing up to 4 
chromosome abnormalities (such as 1PB#1 from Patient D), would have been diagnosed as 
being completely euploid if a nine-chromosome (13, 15, 16, 17, 18, 21, 22, X and Y) FISH had 
been used instead of CGH. This means that even performing an exhaustive FISH aneuploidy 
screening, almost half of the aneuploid embryos could still have been transferred into the 
patient’s uterus, despite their intrinsic impossibilities to develop a pregnancy.  
Consequently, in order to increase the implantation rate, not only a partial chromosome 
screening must be performed but also it must be done using a full-chromosome analysis 
technique such as CGH.  
Referring to the data presented here, from the 45 developing embryos healthy for their 
specific monogenic disease, 20 of them originated from a potentially aneuploid oocyte 
diagnosed with 1PB-CGH, whereas 15 of them were diagnosed as being potentially euploid 
(tagged as DF-PGD transferable embryos). In the remaining ten embryos, no CGH results 
had been obtained, and they were classified as PGD transferable embryos.  
Nine out of fifteen and eight out of ten embryos were transferred to the patients from the 
DF-PGD-transferable and PGD-transferable groups, respectively. Three patients (A’, B, 
and E) received both types of embryos. Three from the nine and one out of the eight 
transferred embryos from each group implanted and developed into the birth of four 
healthy children. In none of the patients receiving both types of embryos did implantation 
occur. Also, none of the patients with AMA (mean age of 39.2 y.o.) became pregnant 
although six embryos were transferred; on the other hand, the four pregnancies achieved 
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did occur in younger patients after transferring 11 embryos. These differences are found 
to be significantly different (p= 0.03), and may be explained by other factors, rather than 
aneuploidy, that might affect the implantation rate in aged women like gynecological or 
immunological aspects, although more studies are required to reach clear conclusions. 
Therefore, the implantation rate was 33.3% in the embryos doubly selected (DF-PGD 
transferable embryos) and 12.5% in the embryos selected as being of the monogenic disease 
but not screened for aneuploidy, a value that is very similar to the average value (15.2%) 
obtained in the last ESHRE Consortium Steering Committee recompilation (Harper et al., 
2010). Despite the differences between the implantation rates of the DF-DGP transferred 
embryos being two times higher that the DGP transferred embryos are promising, these 
differences were not significant. Most probably, the reduced number of clinical applications 
presented in this work is not enough to have major differences. 
In conclusion, although the DF-PGD-selected embryos did not obtain a significant increase 
of implantation compared with embryos undiagnosed for aneuploidy, it seems clear that 
comprehensive aneuploidy screening of oocytes using a PGD protocol might benefit the 
clinical outcome of their corresponding embryo. Therefore, in order to increase the 
implantation of embryos selected that are free of a monogenic disease, and until the routine 
assessment of CGH-array methodology, 1PB-CGH is the preferred technique to positively 
doubly select potentially euploid embryos. 
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occur. Also, none of the patients with AMA (mean age of 39.2 y.o.) became pregnant 
although six embryos were transferred; on the other hand, the four pregnancies achieved 
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did occur in younger patients after transferring 11 embryos. These differences are found 
to be significantly different (p= 0.03), and may be explained by other factors, rather than 
aneuploidy, that might affect the implantation rate in aged women like gynecological or 
immunological aspects, although more studies are required to reach clear conclusions. 
Therefore, the implantation rate was 33.3% in the embryos doubly selected (DF-PGD 
transferable embryos) and 12.5% in the embryos selected as being of the monogenic disease 
but not screened for aneuploidy, a value that is very similar to the average value (15.2%) 
obtained in the last ESHRE Consortium Steering Committee recompilation (Harper et al., 
2010). Despite the differences between the implantation rates of the DF-DGP transferred 
embryos being two times higher that the DGP transferred embryos are promising, these 
differences were not significant. Most probably, the reduced number of clinical applications 
presented in this work is not enough to have major differences. 
In conclusion, although the DF-PGD-selected embryos did not obtain a significant increase 
of implantation compared with embryos undiagnosed for aneuploidy, it seems clear that 
comprehensive aneuploidy screening of oocytes using a PGD protocol might benefit the 
clinical outcome of their corresponding embryo. Therefore, in order to increase the 
implantation of embryos selected that are free of a monogenic disease, and until the routine 
assessment of CGH-array methodology, 1PB-CGH is the preferred technique to positively 
doubly select potentially euploid embryos. 
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combination with HLA matching is being used to detect a particular gene mutation in an 
unaffected child who can be an HLA donor for its’ sibling. HLA typing without mutation 
analysis has also been used for acquired diseases (Verlinsky et al., 2004), such as acute 
myeloid leukemia (AML) and acute lymphoid leukemia (ALL), which require allogenic 
haemopoietic stem cell transplantation (HSCT) from an HLA identical donor for the cure of 
the disease. Stem cells in the cord blood from an HLA identical sibling can be used with a 
much higher success rate than a transplant from alternative donors (Gaziev et al., 2000; 
Orofino et al., 2003) and are therefore of great therapeutic value for hematopoietic and other 
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siblings provide the highest success rate and current results indicate that about 90% of the 
cases can be cured successfully after HSC transplantation (Gaziev et al., 2005). Use of cord 
blood as a stem cell source also results in reduced incidence of graft rejection and other 
serious complications associated with bone marrow transplantation. However, in most cases 
a suitable donor cannot be found in the family, and due to a small number of children per 
family, only one third of patients are able to find an HLA-identical sibling (Costeas, 2004). 
The probability of having an unaffected child who may also be an HLA match for an 
affected sibling is only one in five; these families often went through multiple cycles of 
pregnancy before conceiving an unaffected HLA match. In the remaining patients the only 
resort is the identification of a matched unrelated donor. However, the probability of 
finding an HLA matched unrelated donor cord blood from the cord blood units is extremely 
low. Therefore PGD is a much more attractive option, with this technique, sufficient number 
of embryos may be tested at one time, increasing the chances of identifying an appropriate 
match.  
More than 2000 healthy children have already been born after PGD and the expanding 
indications include chromosomal abnormalities, single gene disorders, HLA tissue typing of 
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for any disorder in which molecular testing can be performed. A partial list of disorders in 
which Preimplantation Genetic Diagnosis/HLA typing can be applied is shown in Table 1.  
Although the majority of these disorders are due to rare genetic defects, the incidence of 
some, such as β thalassemia, sickle cell anemia and cystic fibrosis are very common in 
certain parts of the world, such as Mediterranean region which include Turkey, Italy, Greece 
and Cyprus. Turkey is one of the Mediterranean countries in which thalassemia mutations 
are commonly seen, with a carrier rate of 2.1% in the population (Aksoy, et al., 1985).  
 
Achondroplasia (FGFR3) Hyper IgM  
Acute Lymphocytic Leukemia (ALL) Krabbe (GALC) 
Acute Myelogenous Leukemia (AML) Li-Fraumeni Syndrome (TP53) 
Alpha-Thalassemia (HBA) Marfan Syndrome (MFN1) 
Alzheimer Early Onset (PSEN1) Metachromatic Leukodystrophy (ARSA) 
Beta-Thalassemia (HBB) Mucolipidosis 2 (I-Cell) 
Charcot-Marie-Tooth  Myotonic Dystrophy  
Chronic Granulamatous Disease (CYBB) Neurofibromatosis (NF1 &NF2) 
Chronic Myelogenous Leukemia (CML) Neiman Pick Type C 
Crigler Najjar (UGTIA1) Phenylketanuria (PKU) 
Cystic Fibrosis (CFTR) Polycystic Kidney Disease (AR-PKD1) 
Diamond Blackfan Anemia( DBA-RSP19) Retinoblastoma  
Duchenne Muscular Distrophy (DMD) Sanflippo A (MPSIIIA) 
Fanconi Anemia A,C,F,G Severe combined immunodeficiency (SCID-XI) 
Fragile X (FMR1) Sickle Cell (HBB) 
Gaucher Disease (GBA) Spinal Muscular Atrophy (SMN1) 
Glycogen Storage Disease,type IA Spinocerebellar Ataxia (SCA-2,SCA-3) 
Hemophilia A,B Tay Sacs (HEXA) 
Huntington Disease (HD) Tuberosclerosis (TSC1) 
Hurler Syndrome (MPSI-IDUA) Wiscott-Aldrich Syndome  
Table 1. Some of the current indications of PGD/HLA Typing 
According to data collected by the Turkish Association of Thalassemia, the heterozygosity 
rate may be higher than 10%, particularly in the southern regions of Turkey (Basak et al., 
2007). A higher rate of consanguineous marriages in those regions is a factor which further 
increases the incidence of thalassemia. In addition, thalassemia has a great heterogeneity in 
Turkey, the total frequency of the 6 most commonly seen mutations is only 69% of the whole 
mutations. The selection of embryos for HLA typing necessitates the application of ART 
even though the vast majority of the couples are fertile. The successful outcome of ART 
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cycles is highly dependent on female age and ovarian reserve. This technique is made 
crucially important by the fact that, the theoretical probability of finding an HLA identical 
embryo in cases of acquired diseases is 25% (1/4) and the probability of finding both HLA 
identical and mutation free embryo in cases of single gene disorders no more than 18% 
(3/16). Using a standard IVF procedure, oocytes or embryos are tested for causative gene 
mutations simultaneously with HLA alleles, selecting and transferring only those unaffected 
embryos, which are HLA matched to the affected sibling. 
The HLA Complex (Human Leukocyte Antigen) is located on chromosome 6 and represents 
one of the most polymorphic regions of human genome. Comparative DNA sequence 
analysis of HLA complex has shown the presence of a high number of alleles in this region. 
Linked short tandem repeat (STR) markers scattered through the HLA complex were 
studied to increase the accuracy of the analysis and to detect potential contaminations and 
crossing over occurrence between HLA genes.  
Single cell PCR technique has several pitfalls, such as contamination by extraneous DNA, 
amplification failure, preferential amplification, and allele drop out (ADO) which is the 
failure of PCR to amplify one of the two alleles. If ADO occurs, only a single allele is 
amplified and detected after PCR, giving a heterozygous cell the appearance of 
homozygosity. This may lead to harmful consequences such as in the case for a dominant 
disease; failure to amplify the mutant allele may lead to the transfer of affected embryos. 
The ADO rate and the efficiency of amplification of targeted regions depend on efficient 
lysis methods (Shirazi et al., 2009) and also the type of cell analyzed. With simultaneous 
usage of linked STR markers the accuracy of single cell PCR is approximately 98% 
(Rechitsky et al., 2001). ADO rates in single cells can be decreased by analyzing more than 
one cell which is possible with blastocyst-stage biopsy. Trophectoderm biopsy is a good 
alternative to cleavage stage biopsy as it enables the evaluation of approximately 2-5 cells, 
thus decreasing both the rate of amplification failures and ADO associated with single cell 
PCR (McArthur et al., 2008; Pangalos et al., 2008). There are many advantages of blastocyst 
stage biopsy such that; since trophectoderm cells are extra-embryonic tissue, the removal of 
these cells avoids the risk of affecting the development of the fetus. Also the proportion of 
the cells that are removed is much lower compared to cleavage stage biopsy. Furthermore, 
blastocyst stage embryos have a higher implantation potential compared to day-3 or day-4 
embryos, so a higher rate of implantation could be achieved by trophectoderm analysis 
(Kokkali et al., 2007; McArthur et al., 2008). 
2. Materials and methods 
2.1 Study group  
The study group consisted of a total of 188 couples with a total of 362 cycles. Between 2003 
and the mid of 2011 at Istanbul Memorial Hospital, ART and Reproductive Genetics Center, 
149 couples were referred for both mutation analysis for a specific genetic disorder and HLA 
typing, while 39 couples were referred for the sole purpose of HLA typing for acquired 
disorders. The detailed list of diseases can be found in Table 2. 
2.2 Pre-clinical work up 
First, a haplotype analysis of mother, father and child, and when available of other family 
members, was performed for each family prior to preimplantation HLA typing. For this, 
genomic DNA is isolated from peripheral blood samples of father, mother and the affected 
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cycles is highly dependent on female age and ovarian reserve. This technique is made 
crucially important by the fact that, the theoretical probability of finding an HLA identical 
embryo in cases of acquired diseases is 25% (1/4) and the probability of finding both HLA 
identical and mutation free embryo in cases of single gene disorders no more than 18% 
(3/16). Using a standard IVF procedure, oocytes or embryos are tested for causative gene 
mutations simultaneously with HLA alleles, selecting and transferring only those unaffected 
embryos, which are HLA matched to the affected sibling. 
The HLA Complex (Human Leukocyte Antigen) is located on chromosome 6 and represents 
one of the most polymorphic regions of human genome. Comparative DNA sequence 
analysis of HLA complex has shown the presence of a high number of alleles in this region. 
Linked short tandem repeat (STR) markers scattered through the HLA complex were 
studied to increase the accuracy of the analysis and to detect potential contaminations and 
crossing over occurrence between HLA genes.  
Single cell PCR technique has several pitfalls, such as contamination by extraneous DNA, 
amplification failure, preferential amplification, and allele drop out (ADO) which is the 
failure of PCR to amplify one of the two alleles. If ADO occurs, only a single allele is 
amplified and detected after PCR, giving a heterozygous cell the appearance of 
homozygosity. This may lead to harmful consequences such as in the case for a dominant 
disease; failure to amplify the mutant allele may lead to the transfer of affected embryos. 
The ADO rate and the efficiency of amplification of targeted regions depend on efficient 
lysis methods (Shirazi et al., 2009) and also the type of cell analyzed. With simultaneous 
usage of linked STR markers the accuracy of single cell PCR is approximately 98% 
(Rechitsky et al., 2001). ADO rates in single cells can be decreased by analyzing more than 
one cell which is possible with blastocyst-stage biopsy. Trophectoderm biopsy is a good 
alternative to cleavage stage biopsy as it enables the evaluation of approximately 2-5 cells, 
thus decreasing both the rate of amplification failures and ADO associated with single cell 
PCR (McArthur et al., 2008; Pangalos et al., 2008). There are many advantages of blastocyst 
stage biopsy such that; since trophectoderm cells are extra-embryonic tissue, the removal of 
these cells avoids the risk of affecting the development of the fetus. Also the proportion of 
the cells that are removed is much lower compared to cleavage stage biopsy. Furthermore, 
blastocyst stage embryos have a higher implantation potential compared to day-3 or day-4 
embryos, so a higher rate of implantation could be achieved by trophectoderm analysis 
(Kokkali et al., 2007; McArthur et al., 2008). 
2. Materials and methods 
2.1 Study group  
The study group consisted of a total of 188 couples with a total of 362 cycles. Between 2003 
and the mid of 2011 at Istanbul Memorial Hospital, ART and Reproductive Genetics Center, 
149 couples were referred for both mutation analysis for a specific genetic disorder and HLA 
typing, while 39 couples were referred for the sole purpose of HLA typing for acquired 
disorders. The detailed list of diseases can be found in Table 2. 
2.2 Pre-clinical work up 
First, a haplotype analysis of mother, father and child, and when available of other family 
members, was performed for each family prior to preimplantation HLA typing. For this, 
genomic DNA is isolated from peripheral blood samples of father, mother and the affected 
 
Human Genetic Diseases 182 
child. To rule out a possible recombination in the affected child, other family members such 
as unaffected child, or grandparents’ DNA have been added to set up procedure. Figure 1 
shows the polymorphic STR markers scattered through HLA region which were used to 





         TOTAL 188 couples  362 cycles  
HLA + 
Mutation testing
β-thalassemia  131 258 
Wiscott Aldrich  3 4 
X-Adrenoleukodystrophy  3 3 
Fanconi Anemia  3 4 
Alpha-Mannosidosis  1 4 
Gaucher Syndrome  1 4 
Hurler Syndrome  2 3 
Hyper IgD  1 1 
Glanzmann Trombasthenia  1 2 
Sickle Cell Anemia  1 1 
Diamond Blackfan Anemia  1 1 
Cd3 Deficiency  1 1 
HLA only 
Acute Lymphoblastic Leukemia 17 30 
Acute Myeloid Leukemia  11 20 
Diamond Blackfan Anemia 3 11 
Histiocytosis  1 3 
Chronic Myeloid Leukemia  1 2 
Burkitt’s Lymfoma  1 2 
Aplastic Anemia  2 2 
Anaplastic Anemia  1 3 
Myelodysplastic Syndrome  1 2 
Non-hodgin Lymfoma  1 1 
 
 
Table 2. Cycle participations of patients and indications for HLA Typing. 
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Fig. 1. Polymorphic STR markers used in HLA typing of the embryos. 
A panel of 50 different short tandem repeat (STR) markers (figure 1) were tested on genomic 
DNAs to ensure the presence of enough informative markers (figure 2) to aid the 
identification of monosomy, trisomy, recombination, allele-drop out (ADO) and uniparental 
disomy (UPD) of the analyzed chromosomes and regions. For each family at least 12 
heterozygous markers spanning the HLA-A, HLA-B, HLA-C, HLA-DR,HLA-DQ regions 
(HLA Classes I, II, and III) were selected for PGD Study. 
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Fig. 2. Identification of informative markers during HLA set up study 
The study period was divided into two according to the methods used which included lysis 
of single cells, mutation testing, polymerase chain reaction (PCR) conditions and primers 
used in the PGD study. Oocyte collections, inseminations, culture, biopsy and transfer of 
embryos were performed in Istanbul Memorial Hospital ART unit and all PGD studies and 
evaluations were performed in Istanbul Memorial Hospital Reproductive Genetics Unit. 
2.3 PGD study 
The methods can be found elsewhere (Kahraman et al., 2011). In the first period, the alkaline 
lysis method was used as described previously (Fiorentino et al., 2005). Cells were lysed by 
incubation at 65Cº for 10 minutes in a sterile PCR tube containing 5 µl of lysis buffer 
(200nmol/1 KOH, 50nmol/1 DDT). The lysis buffer was then neutralized prior to adding 
the first-round PCR mix which contained all external primers for co-amplification of all 
selected HLA markers and mutation linked markers. Second-round PCR reaction for each 
locus was then performed using 2 µl of the first round product.  
In the second period, the Proteinase K method was used for lysis of the cells as described 
previously (Verlinsky et al., 2001). The biopsied single cells were placed into a lysis solution 
containing 0,5 µl of 10xPCR buffer, 0,5 µl of 1% tween-20, 0,5 µl of 1% triton X-100, 3,5 µl of 
water, and 0,05 µl of proteinase K. The lysis reaction was as follows: 45 Cº for 15 minutes for 
the lysis of the cells and 96 Cº for 20 minutes for inactivation of proteinase K. Although the 
reaction conditions were different in the two periods, both can be briefly summarized as 
follows; DNA testing was performed by two rounds of PCR reactions: in the first round, 
using multiplex PCR which allows simultaneous amplification of HLA regions and 
mutation-linked markers and in the second round, using singleplex PCR which is a 
fluorescent PCR with semi or heminested primers. Primer sequences and polymerase chain 
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reaction conditions used in this study have been reported previously (Verlinsky et al., 2001; 
Fiorentino et al., 2004; 2005; Rechitsky et al., 2004; Verlinsky et al., 2004). 
Between 2003 and 2008, mutation analysis was performed using the minisequencing 
technique, as described elsewhere (Fiorentino et al., 2003). After middle of 2008 restriction 
enzyme digestion reactions and subsequently polyacrylamide gel electrophoresis analysis 
were used (Rechitsky et al., 2004). Since the middle of 2009s, both methods are being used 
according to preference.  
2.4 IVF and embryo biopsy procedure  
The stimulation protocols were as outlined previously (Kahraman et al., 2004). Oocyte 
retrievals were performed 36 h after the injection of rhCG (ovitrel) by transvaginal-
ultrasound-guidance. Approximately 2-3 h after oocyte retrieval, cumulus cells were 
enzymatically removed. Intracytoplasmic sperm injection (ICSI) was applied to metaphase II 
oocytes. One blastomere was removed from cleavage stage embryos (figure 3a) from an 
opening made using laser (IodoLaser, Research Instruments). Subsequently, embryo transfer  
 
 
a) Clevage Stage Biopsy 
 
 
b) Blastocyst Stage Biopsy 
Fig. 3. Biopsy Techniques 
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was performed usually on day-4 but rarely on day-5. Recently, since 2009, trophectoderm 
tissue biopsies have also been performed. Blastocyst-stage biopsy was performed by making 
a hole in the zona pellucida on day-3 of embryonic development which allowed the 
developing trophectoderm cells to protrude after blastulation, facilitating the biopsy. On 
day-5 post-fertilization, approximately 4-5 cells were excised using laser energy, without 
loss of inner cell mass (figure 3b). After diagnosis, the embryos was replaced during the 
same cycle, on day-5 or 6. Pregnancy was first evaluated by serum hCG concentrations 
assay, 12 days after embryo transfer and clinical pregnancy was diagnosed by 
ultrasonographic visualization of one or more gestational sacs. 
3. Results  
In HLA+mutation testing group (Group I), and HLA-only group (Group II), 62.2% and 
72.4% of the initiated cycles reached the stage of embryo transfer, respectively. The detailed 
distribution of indications and overall results for each group was shown in Table 2 and 3. 
A full diagnosis was achieved in 91.0% of the biopsied samples. In Group I, 17.8 % of the 
analyzed embryos were found to be HLA compatible. HLA compatible and disease free 
embryos were 12.9 % of all diagnosed embryos. In group II, 17.2% of embryos were found to 







(Group II) TOTAL 
No of patients/cycles  149/286  39/76  188/362 
Maternal age, mean 32.0±4.83  33.9±5.65 
Cycles with transfer, %  62.2  72.4  
No of embryos transfered, mean  1.55±0.71  1.56±0.72  
Clinical pregnancy rate per transfer, %  37.6  32.7  
Implantation rate,%  28.9  24.4  
Clinical miscarriages,  n  14  3  
No of babies born, n  57  13  
No of succsessful transplantations, n  23  2  25*  
* 21 children are awaiting an appropriate time for HSC transplantation. 
Table 3. Overall clinical results of HLA typing. 
The majority of our HLA typing combined with PGD cases were β-Thalassemia carriers 
(87.9%). The mutations analyzed have high heterogeneity, the most frequent mutation was 
IVS-I-110 G-A and comprised 46.2% of all mutations. The total frequency of the most 
frequent 6 mutations were 74.0% (Table 4). 
A total of 85 clinical pregnancies (36.5%) were achieved from 233 ET cycles. 5 pregnancies 
are ongoing. To date, 70 healthy and HLA compatible children have been born. 25 sick 
children have already been cured with cord blood cell and/or bone marrow transplantation. 
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21 children are waiting for their newborn siblings to gain sufficient weight and maturity for 
the donation of stem cells (Table 3). The successful transplantations have been performed for 
the following indications: β-Thalassemia (n=19), Wiskott Aldrich syndrome (n=2), 
Glanzmann Disease (n=1), X-Adrenoleukodystrophy (n=1) and acute myeloid leukemia 
(n=1) and Diamond Blackfan anemia (n=1) (Table 5).  
 
Mutation Frequency , % 
IVS-I-110 G-A 46.2 
Cod8 delAA 7.3 
Cod39 C-T 6.5 
IVS-II-745 5.7 
IVS-II-1 4.6 
IVS-I-1 G-A 3.8 
TOTAL 74.0 
Table 4. The most frequent Beta-Thalassemia mutations in our sample population 
4. Conclusion  
This data presents one of the world’s largest experiences on preimplantation HLA typing, 
and the outcome of stem cell transplantation is the largest number available from one center. 
To date 25 children have been cured with this approach and 21 children are awaiting 
appropriate time for transplantation. Our results indicate HLA typing with or without 
mutation analysis is a promising and effective therapeutic tool for curation of an affected 
sibling. 
 
Indication Patients, n 
Beta-Thalassemia 19 
Wiscott-Aldrich 2 
Glanzmann disease 1 
X-Adrenoleukodystrophy 1 
Acute Myeloid Leukemia 1 
Diamond Blackfan Anemia 1 
TOTAL 25 
 
Table 5. The list of diseases and the number of patients who have complete cure after HSCT. 
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1. Introduction 
The development of conventional cytogenetic techniques in the 50’s leaded to a rapid 
increase of the knowledge on the etiology of malformation syndromes, being chromosomal 
anomalies reported as the most common genetic condition in humans (Pena, 1998). Around 
2-3% of newborns may have congenital malformations, and from those, just 20% have an 
established etiology (genetic or environmental), being 80% of these multifactorial or 
unknown (Stevenson & Hall, 2006). But this is only the tip of the iceberg, as probably half of 
the human concepts may have some kind of chromosomal defect (A. Boué & J. Boué, 1973), 
indicating that cytogenetic analysis is fundamental for the investigation of these cases. Since 
the 70’s, prenatal diagnosis for detecting cytogenetic abnormalities has become a routine 
procedure in many countries, and an important tool for the prevention of birth of 
handicapped children (A. Milunsky &  J. Milunsky, 1998). 
Cytogenetic analysis is an important component of invasive prenatal diagnosis as 
chromosomal abnormalities are detected in about 1 in 200 newborns and constitute a major 
cause of mental retardation and congenital malformations (Shaffer & Lupski, 2000). 
Microscopic chromosome analysis of cultured cells has been regarded as the gold standard 
method for prenatal diagnosis, since its first application to prenatal testing in 1966 by Steele 
and Breg (Steele & Breg, 1966) and the routine use of chromosome banding analysis in 1970s. 
Karyotyping has proved to be highly reliable for diagnosis of numerical chromosome 
abnormalities and structural rearrangements in fetal cells obtained invasively by either 
amniocentesis in the second trimester of pregnancy, or chorionic villus sampling (CVS) in the 
first trimester, since the early 1980s. The diagnostic accuracy of karyotyping fetal cells from 
cultured amniotic fluid (AF) has been found to be 99.4%-99.8%, and that of CVS 97.5-99.6%. 
However, the main limitation of karyotyping is the requirement of a cell culture, resulting in a 
period of 10-14 days for obtaining the final results (Bui, 2007). Furthermore, the success of cell 
culture depends on many factors: very good laboratory conditions for tissue culture, 
technician’s experience, and satisfactory cell growth with good quality of metaphases. 
Unfortunately, due to failure in one of these steps the whole process becomes jeopardized.  
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The development of conventional cytogenetic techniques in the 50’s leaded to a rapid 
increase of the knowledge on the etiology of malformation syndromes, being chromosomal 
anomalies reported as the most common genetic condition in humans (Pena, 1998). Around 
2-3% of newborns may have congenital malformations, and from those, just 20% have an 
established etiology (genetic or environmental), being 80% of these multifactorial or 
unknown (Stevenson & Hall, 2006). But this is only the tip of the iceberg, as probably half of 
the human concepts may have some kind of chromosomal defect (A. Boué & J. Boué, 1973), 
indicating that cytogenetic analysis is fundamental for the investigation of these cases. Since 
the 70’s, prenatal diagnosis for detecting cytogenetic abnormalities has become a routine 
procedure in many countries, and an important tool for the prevention of birth of 
handicapped children (A. Milunsky &  J. Milunsky, 1998). 
Cytogenetic analysis is an important component of invasive prenatal diagnosis as 
chromosomal abnormalities are detected in about 1 in 200 newborns and constitute a major 
cause of mental retardation and congenital malformations (Shaffer & Lupski, 2000). 
Microscopic chromosome analysis of cultured cells has been regarded as the gold standard 
method for prenatal diagnosis, since its first application to prenatal testing in 1966 by Steele 
and Breg (Steele & Breg, 1966) and the routine use of chromosome banding analysis in 1970s. 
Karyotyping has proved to be highly reliable for diagnosis of numerical chromosome 
abnormalities and structural rearrangements in fetal cells obtained invasively by either 
amniocentesis in the second trimester of pregnancy, or chorionic villus sampling (CVS) in the 
first trimester, since the early 1980s. The diagnostic accuracy of karyotyping fetal cells from 
cultured amniotic fluid (AF) has been found to be 99.4%-99.8%, and that of CVS 97.5-99.6%. 
However, the main limitation of karyotyping is the requirement of a cell culture, resulting in a 
period of 10-14 days for obtaining the final results (Bui, 2007). Furthermore, the success of cell 
culture depends on many factors: very good laboratory conditions for tissue culture, 
technician’s experience, and satisfactory cell growth with good quality of metaphases. 
Unfortunately, due to failure in one of these steps the whole process becomes jeopardized.  
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In the early 1980s, as better ultrasonographic imaging became available, the access to fetal 
blood was improved, and it could be obtained at about 18-20 weeks’ gestation from 
umbilical cord (cordocentesis) (Daffos,et al., 1983). Although blood sample allows rapid 
karyotyping within 72 hours, the gestational age at collection is already advanced, and in 
positive cases it would be too late for interruption. Besides, this procedure is associated with 
higher risk of complications than other prenatal diagnostic and, hence, has been performed 
only in selected cases (Daffos & Hobbins, 2002). 
When a fetus with multiple malformations is detected by ultrasound, the list of possible 
etiologies is very broad, and the possibility of a chromosomal anomaly is high. However, 
the result of a karyotype, so important for the clinical evaluation, is not always achieved. 
In some cases this is caused by the factors explained above, in others, due to death of the 
fetus before the initiation of any diagnostic investigation. In any case, it is very difficult to 
provide an appropriate genetic counseling without a karyotype result, and the family 
remains without information on the fetus condition and the risk for future pregnancies. 
This is a very unpleasant situation, and trying to find an alternative to decrease the 
anxiety of those families is the main goal of the strategy described below which involves 
the application of molecular techniques in different fetal materials to overcome this 
situation. 
2. Methodology 
We obtained different tissues from 50 multiple malformation fetuses distributed as: 
umbilical cord (15), lung (7), amniocytes (14) and paraffin embedded tissues (14). For 
traditional karyotypes, we used AF, UC and alternative materials from 115 fetuses, also with 
multiple malformations. The criteria for including the fetus as multiple malformations with 
indication for chromosomal aberrations were based on the “Catalogue of Unbalanced 
Chromosome Aberration in Man” (Schinzel, 2001). They are summarized in Table 1. 
 
 
Cleft palate, cleft lip, or both 
Esophageal atresia, TE fistula; anal atresia with fistula 
Malrotation of the gut, common mesentery; omphalocele 
Malformation of the heart and the great vessels 
Malformation of the kidney and urinary tract 
Certain brain malformation, particularly holoprosencephaly and agenesis of  
corpus callosum 
Absence or hypoplasia of radius and thumb 
Postaxial hexadactyly 
Microphtalmia, ocular coloboma 
Spina bifida (occipital or lumbar) 
  
Table 1. Common malformations in autosomal chromosomal aberrations 
2.1 DNA extraction 
The DNA from fresh tissues was extracted as described by Miller (Miller et al., 1988) with 
slight modifications. Tissue specimens were grinded before addition of the nuclei lysis buffer 
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and 1/10 of the reagent’s volume used for blood extraction was used. In a few cases (n=8) a 
commercial kit was used for DNA extraction. (NucleoSpin®Tissue from Macherey-Nagel). 
2.2 DNA extraction from paraffin embedded tissue  
This technique was adapted from Andreassen (Andreassen et al., 2004) and Coura (Coura et 
al., 2005) as follows: Paraffin block was sliced in small pieces between 5-10μ and 5 slices 
were placed into an ependorff. Xylol (1,5ml) was added and incubated for 30 minutes at 
37°C. Tubes were centrifuged at 14.000 rpm for 3 minutes. The supernatant was removed 
and all steps were repeated once. After the supernatant removal, samples were washed with 
70% Ethanol and centrifuged for 3 minutes at 7.200 rpm. This step was repeated twice and 
samples were left at room temperature for at least 30 minutes. After completely removal of 
the paraffin, 300 μl of Nuclei Lysis buffer, 20μl of SDS and 20μl of proteinase K were added. 
Samples were incubated for 3 days at 60°C and on the third day an extra volume of 5μl of 
proteinase K was added. The remaining steps for DNA precipitation were the same ones as 
described above for tissue DNA extraction. 
2.3 Multiplex ligation-dependent probe amplification (MLPA) 
Multiplex ligation-dependent probe amplification (MLPA) is a semiquantitatitive analysis 
based on polymerase chain reaction (PCR). It possesses many advantages such as high 
efficiency, simple operation, low cost and has been wildly applied in researches of diseases 
associated with copy number variation, point mutation and methylation (Zhou & Ren, 
2009). 
This new multiplex method is able to detect abnormal copy numbers of genomic DNA 
sequences requiring a minimum of 20ng of human DNA (Schouten et al., 2002). In this 
technique, it is not the nucleic acid, but the probes added to the samples that are 
amplified. MLPA allows discrimination of sequences that differ only in a single 
nucleotide, therefore MLPA can be used for detection of known mutation. It is basically a 
method to make a nuclei acid sample suitable for multiplex polymerase chain reaction 
(PCR) with the use of only one pair of primers. In the currently available kits, the 
products generated by PCR are separated by sequence-type electrophoresis. The 
thermocycler and sequencing-type electrophoresis equipment that are required, are 
present in most DNA diagnostic laboratories. Up to 96 samples can be handled 
simultaneously, 45 DNA sequences, and results can be obtained within 24 hours. One of 
the currently MLPA kits (P095, MRC-Holland, Amsterdam) is commercially available and 
contains eight independent probes for each of the chromosomes involved in almost 
frequent aneupolidies: 13, 18, 21, and X, and four Y-specific probes; and it is used as a 
rapid prenatal test by several medical centers on a large scale (Schouten et el., 2002). 
MLPA profiles must be compared with a similar profile obtained from a control DNA 
sample. Compared with a control reaction, the relative peak area of each amplification 
product reflects the relative copy number of the target sequence of that probe in the 
analyzed sample. An aberrant copy number of one or more of the sequences detected by 
MLPA probes can therefore be detected by a decrease or increase in relative peak area of 
the amplification products of the probes detecting those sequences.  
The length of the amplification product of each probe is different, and ranges in size 
between 130 and 480 nucleotides. This provides an optimal separation and low background 
on sequencing type electrophoresis gels. Although performing an MLPA reaction is easy, 
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the development of new MLPA assays is complex and time-consuming, and the success of 
the results depends basically on the quality of the DNA extraction. 
Briefly the protocol consists of: denaturing 20-500 ng of DNA by heating to 98°C in a 
thermocycler; adding the MLPA probes and leaving overnight at 60°C for hybridization. For 
the next step add the ligase and ligase buffer at 54°C for 15 min.(ligation of the two probe 
parts); inactivate the ligase by heating to 98°C; add PCR primers, dNTPs, and polymerase 
and start the PCR (amplification of probes).  The amplification products are separated by 
capillary electrophoresis. 
2.4 Quantitative Fluorescent-Polymerase Chain Reaction (QF-PCR) 
This method uses PCR amplification and fluorescent dye labeled primers targeting highly 
polymorphic regions of DNA sequence called short tandem repeats (STRs) that are located on 
the chromosomes of interest (Mansfield, 1993). Each target marker is specific to the 
chromosome on which it is located, thus the copy number of the STR marker reflects the copy 
number of the chromosome. Informative STR markers which exhibit a high heterogeneity have 
been selected so that copy number can be easily determined. A normal diploid sample has the 
normal complement of two of each of the somatic chromosomes, thus two alleles of a 
chromosome specific STR are determine by the QF-PCR technique as two peaks in a 1:1 ratio. 
The observation of an extra STR allele as either a three peak pattern in a 1:1:1 ratio or two peak 
pattern in a 2:1 ratio is diagnostic of a presence of an additional sequence which in turn may 
represent an additional chromosome, as in the case of a trisomy. 
Amplified products of the QF-PCR technique are analyzed quantitatively on a capillary 
Genetic Analyzer (ABI 3100) to determine the copy number of the analyzed STRs markers. 
The kit used in the study was from ELUCIGENE. The ELUCIGENE QSTR™ range of 
products are DNA based multiplexed assays for the rapid prenatal determination of 
aneuploidy status for the three most common autosomal trisomies and the sex 
chromosomes X and Y. PCR products are observed as a 5 dye labelled system using filter set 
G5. Filter set G5 detects the 6-FAM (blue), VIC (green), NED (yellow) and PET (red) labelled 
fragments plus the Size Standard marker labelled with LIZ (orange) on an 
electrophoretogram in the Genotyper program. 
The markers used are described in Tables 2 and 3. 
 




Marker Dye  
  Colour 
DXS981 Xq13.1 0.86 225-260 blue 
DXS1187 Xq26.2 0.72 122-170 green 
HPRT Xq26.2 0.78 265-300 green 
DXS7423 Xq28 0.74 372-388 green 
DXYS267 Xq21.3/Yp11.2 0.87 240-280 red 
AMEL Xp22.22/Yp11.2 - 104-110 yellow 
DXS6807 Xp22.32 0.70 331-351 blue 
DXS1283E Xp22.31 0.89 292-340 yellow 
SRY Yp11.31 - 244-251 yellow 
DYS448 Yq11.223 - 323-381 red 
 
Table 2. X and Y markers in ELUCIGENE QSTRs  
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Marker Location Observed  
Heterozygosity 
Allele Size 
 Range (bp) 
Marker Dye  
    Colour 
D13S252 13q12.2 0.85 260-330 red 
D13S305 13q13.3 0.75 418-470 green 
D13S628 13q31.1 0.69 425-472 yellow 
D13S634 13q21.33 0.81 355-440 blue 
D13S325 13q14.11 0.86 235-320 green 
D18S386 18q22.1 0.88 320-407 green 
D18S390 18q22.3 0.75 345-400 yellow 
D18S391 18q11.31 0.75 196-230 green 
D18S535 18q12.3 0.92 450-500 blue 
D18S819 18q11.2 0.70 370-450 red 
D18S978 18q12.3 0.67 180-230 yellow 
D21S11 21q21.1 0.90 220-283 blue 
D21S1437 21q21.1 0.84 283-350 blue 
D21S1409 21q21.2 0.81 160-220 red 
D21S1411 21q22.3 0.93 256-345 yellow 
D21S1435 21q21.3 0.75 152-210 blue 
Table 3. 13, 18 and 21 markers in ELUCIGENE QSTRs 
2.5 PCR Set Up 
PCR was performed according to the manufacturer’s instruction as described briefly: the 
thermal cycler is programmed for a single step cycle to activate the DNA polymerase at 
95°C, for 15 minutes, linked to an amplification cycling program of 30 seconds at 95°C 
(denaturation), 1 minute and 30 seconds at 59°C (annealing) and 1 minute and 30 seconds at 
72°C (extension) for 26 cycles. This should be linked to a 30 minutes time-delay at 72°C 
(extension) on the final cycle; sufficient vials should be separated to pre-aliquoted QSTR 
reaction mix for a number of samples and controls to be run. The vials are centrifuged at 
12,000g for 10 seconds; 2.5µl of test DNA is added to a sample vial containing QSTR reaction 
mix; the 95°C activation program is initiated (step 1). On completion of the amplification 
program the samples may be stored at room temperature overnight or at 2-8°C up to 7 days 
before analysis by capillary electrophoresis. 
Optimal results can be obtained using an ABI 3100 Genetic Analyzer  
We also obtained 115 samples from pregnant women with multiple malformations fetus, for 
traditional karyotype analysis. The biological samples obtained were: AF, UC and 
alternative materials, such as urine, cystic hygroma fluid, intraperitoneal or cerebrospinal 
fluids. AF and alternative materials were cultivated as long term culture, with Amniomax 
medium, at 37°C, in CO2 incubator. The blood culture (UC) was processed as short term 
culture (72hs) following standard cytogenetic procedures. 
3. Results 
We obtained 50 samples from different fetal materials for molecular techniques analysis, 
and 115 for traditional karyotyping (AF, UC, or alternative materials). All samples were 
from multiple malformations fetus without diagnosis. 
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For the molecular techniques, we first tested all the samples with the MLPA kit P095 and we 
observed that obtaining genetic profiles from samples containing minimal amounts of DNA 
can be difficult. Unfortunately, the quantity and quality of DNA was not adequate for this 
analysis and it was quite difficult to interpret the data obtained (the peak areas tend to be 
too variable when the DNA quality is not good enough). We then ran all samples again 
using QF-PCR. The XY test is very sensitive so that even when the quality of DNA was poor 
we could still determine the presence or absence of a Y chromosome. Thus, for some 
probands (09 cases), we could only give results for XY and not for autosomes. At times it 
was not possible to say whether the proband was 45,X or 46,XX since insufficient probes 










X / Y Interpretation/comments Traditional 
Karyotype 
01 2 2 2 XX No T13, 18, 21 detected  
02 2 2 3 XY Trisomy 13, meiotic error - 
03 2 2 2 XY No T13, 18, 21 detected  
04 2 2 2 XY No T13, 18, 21 detected  
05 - - - - Not enough DNA  
06 - - - XY Very weak peaks  
07 - - - XX No DNA left  
08 2 2 2 XX No T13, 18, 21 detected  
09 2 2 2 XY No T13, 18, 21 detected  
10 2 2 2 XX No T13, 18, 21 detected  
11 2 2 2 XY No T13, 18, 21 detected  
12 2 2 2 XY No T13, 18, 21 detected  
13 - - - XY Very weak peaks  
14 2 2 2 XX No T13, 18, 21 detected  
15 2 2 2 XY No T13, 18, 21 detected  
16 - - - XX Very weak peaks  
17 - - - XX Very weak peaks 46,XX 
18 2 2 2 XY No T13, 18, 21 detected  
19 2 2 2 XX No T13, 18, 21 detected  
20 - - - X/XX? Very weak peaks  
21 - - - XX Very weak peaks  
22 - - - XX Very weak peaks  
23 - - - - No peaks  
24 - - - XY? Very weak peaks  
25 - - - X/XX? Very weak peaks  
26 - - - - No peaks  
28 - - - - No peaks  
29 - - - - No peaks 46,XX 
30 - - - - No peaks 46,XY 
31 - - - - No peaks 47,XX+21 
32 - - - - No peaks  
33 - - - - No peaks  
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X / Y Interpretation/comments Traditional 
Karyotype 
37 - - - - No peaks  
38 - - - - No peaks 46,XX 
39 - - - - No peaks 45,X 
40 - - - - No peaks 46,XY 
41 - - - - No peaks  
42 - - - - No peaks  
43 - - - - No peaks  
44 - - - - No peaks  
45 - - - - No peaks  
46 - - - - No peaks  
47 2 3 2 XY Trisomy 18, meiotic error 47,XY,+18 
48 2 2 2 XX No T13, 18, 21 detected 46,XX 
49 - - - - No peaks 46,XX 
50 - - - XY Very weak peaks 47,XY+21 
51 - - - XY Very weak peaks 47,XY,+18 
52 2 3 2 XY Trisomy 18, meiotic error 47,XY,+18 
53 2 2 2 XX No T13, 18, 21 detected 47,XX,+mar 
54 2 2 2 XX No T13, 18, 21 detected 47,XX 
Table 4. Results of 50 samples from different tissues analyzes by Q-F PCR 
From the 50 cases, we could get partial results in 30. Although we had a very good 
technique for extracting DNA from paraffin (we’ve got enough DNA concentrations and 
relative good quality of DNA), this material showed to be inappropriate for molecular 
techniques, probably due to the formalin buffer used to embed the tissue at the time of 
collection. In all those cases we got no detectable peaks.  
In one case, the physician was quite sure about the clinical diagnosis of trisomy 13, and 
when the fetus died, his lung was collected for culture and karyotyping, and also umbilical 
cord for posterior DNA analysis. The lung culture failed, but we were able to apply QF-PCR 
in DNA extracted from UC and confirmed the clinical indication. In this case, three peaks 
were detected with markers D13S252, D13S305, D13S634 and D13S325. For marker D13S628 
we observed two peaks being one higher than the other indicating an extra allele.  
In two cases, trisomy 18 was detected, confirming the previous karyotyping. In one of the 
cases, three peaks were detected with marker D18S386 and D18S390, and two peaks, one 
being higher than the other, with markers D18S535 and D18S391. In the other case, three 
peaks were detected with marker D18S386, and two peaks detected, again one being higher 
than the other, with markers D18S391 and D18S978. 
From the floating amniocytes that did not adhere to the flask, and were collected at the first 
medium change (14 cases), we succeeded in extracting DNA and performed QF-PCR. This 
material would be normally discarded. From those, we were able to obtain eight molecular 
results from which two did not have a previous successful karyotype. 
The best results obtained for molecular analysis were from DNA extracted using a 
commercial kit as described before (Material and Methods). 
From 6 cases of aneuploidies that had previous karyotype, we were able to obtain two 
confirmations (cases number 47 and 52). On the other hand, for one case (case number 2) 
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For the molecular techniques, we first tested all the samples with the MLPA kit P095 and we 
observed that obtaining genetic profiles from samples containing minimal amounts of DNA 
can be difficult. Unfortunately, the quantity and quality of DNA was not adequate for this 
analysis and it was quite difficult to interpret the data obtained (the peak areas tend to be 
too variable when the DNA quality is not good enough). We then ran all samples again 
using QF-PCR. The XY test is very sensitive so that even when the quality of DNA was poor 
we could still determine the presence or absence of a Y chromosome. Thus, for some 
probands (09 cases), we could only give results for XY and not for autosomes. At times it 
was not possible to say whether the proband was 45,X or 46,XX since insufficient probes 










X / Y Interpretation/comments Traditional 
Karyotype 
01 2 2 2 XX No T13, 18, 21 detected  
02 2 2 3 XY Trisomy 13, meiotic error - 
03 2 2 2 XY No T13, 18, 21 detected  
04 2 2 2 XY No T13, 18, 21 detected  
05 - - - - Not enough DNA  
06 - - - XY Very weak peaks  
07 - - - XX No DNA left  
08 2 2 2 XX No T13, 18, 21 detected  
09 2 2 2 XY No T13, 18, 21 detected  
10 2 2 2 XX No T13, 18, 21 detected  
11 2 2 2 XY No T13, 18, 21 detected  
12 2 2 2 XY No T13, 18, 21 detected  
13 - - - XY Very weak peaks  
14 2 2 2 XX No T13, 18, 21 detected  
15 2 2 2 XY No T13, 18, 21 detected  
16 - - - XX Very weak peaks  
17 - - - XX Very weak peaks 46,XX 
18 2 2 2 XY No T13, 18, 21 detected  
19 2 2 2 XX No T13, 18, 21 detected  
20 - - - X/XX? Very weak peaks  
21 - - - XX Very weak peaks  
22 - - - XX Very weak peaks  
23 - - - - No peaks  
24 - - - XY? Very weak peaks  
25 - - - X/XX? Very weak peaks  
26 - - - - No peaks  
28 - - - - No peaks  
29 - - - - No peaks 46,XX 
30 - - - - No peaks 46,XY 
31 - - - - No peaks 47,XX+21 
32 - - - - No peaks  
33 - - - - No peaks  
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X / Y Interpretation/comments Traditional 
Karyotype 
37 - - - - No peaks  
38 - - - - No peaks 46,XX 
39 - - - - No peaks 45,X 
40 - - - - No peaks 46,XY 
41 - - - - No peaks  
42 - - - - No peaks  
43 - - - - No peaks  
44 - - - - No peaks  
45 - - - - No peaks  
46 - - - - No peaks  
47 2 3 2 XY Trisomy 18, meiotic error 47,XY,+18 
48 2 2 2 XX No T13, 18, 21 detected 46,XX 
49 - - - - No peaks 46,XX 
50 - - - XY Very weak peaks 47,XY+21 
51 - - - XY Very weak peaks 47,XY,+18 
52 2 3 2 XY Trisomy 18, meiotic error 47,XY,+18 
53 2 2 2 XX No T13, 18, 21 detected 47,XX,+mar 
54 2 2 2 XX No T13, 18, 21 detected 47,XX 
Table 4. Results of 50 samples from different tissues analyzes by Q-F PCR 
From the 50 cases, we could get partial results in 30. Although we had a very good 
technique for extracting DNA from paraffin (we’ve got enough DNA concentrations and 
relative good quality of DNA), this material showed to be inappropriate for molecular 
techniques, probably due to the formalin buffer used to embed the tissue at the time of 
collection. In all those cases we got no detectable peaks.  
In one case, the physician was quite sure about the clinical diagnosis of trisomy 13, and 
when the fetus died, his lung was collected for culture and karyotyping, and also umbilical 
cord for posterior DNA analysis. The lung culture failed, but we were able to apply QF-PCR 
in DNA extracted from UC and confirmed the clinical indication. In this case, three peaks 
were detected with markers D13S252, D13S305, D13S634 and D13S325. For marker D13S628 
we observed two peaks being one higher than the other indicating an extra allele.  
In two cases, trisomy 18 was detected, confirming the previous karyotyping. In one of the 
cases, three peaks were detected with marker D18S386 and D18S390, and two peaks, one 
being higher than the other, with markers D18S535 and D18S391. In the other case, three 
peaks were detected with marker D18S386, and two peaks detected, again one being higher 
than the other, with markers D18S391 and D18S978. 
From the floating amniocytes that did not adhere to the flask, and were collected at the first 
medium change (14 cases), we succeeded in extracting DNA and performed QF-PCR. This 
material would be normally discarded. From those, we were able to obtain eight molecular 
results from which two did not have a previous successful karyotype. 
The best results obtained for molecular analysis were from DNA extracted using a 
commercial kit as described before (Material and Methods). 
From 6 cases of aneuploidies that had previous karyotype, we were able to obtain two 
confirmations (cases number 47 and 52). On the other hand, for one case (case number 2) 
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which remained without karyotype, we obtained a positive result through QF-PCR. Case 
number 53 (table 4) could not be confirmed by molecular analysis because the origin of the 
extra chromosome marker was unknown and could not hybridize with the probes used. We 
had no discordant results between the molecular and traditional techniques for those cases 
were both analyses were performed. 
In Table 5, we describe the results from different sources of fetal material for karyotyping in 
115 multiple malformation fetuses. When, for some anatomical reason, AF CVS or UC could 
not be collected, the obstetrician strategy, sometimes for therapeutic reasons,  was the 
collection of alternative fetal material such as bladder drainage. Those biological materials 
could be also used for karyotying, and although there were few cases available, we had 
100% of culture success and karyotyping. 
 






AF 87 83 95.5 
UC 15 14 93.3 
Alternative fluidsa 13 13 100 
TOTAL 115 110 95.6 
aBladder  (6), cystic hygroma  (2), intraperitoneal  (2), displastic kidney  (1), cystic lung  (1), 
cerebrospinal (1) fluids. 
Table 5. Different materials from multiple malformations fetus and success rate of cell 
cultures 
4. Discussion  
Cytogenetic analysis is an important tool for detecting chromosome abnormalities, once this 
is the cause of most common genetic disease in man (Pena, 1998). It has been very useful for 
prenatal diagnosis, and also in clinical genetics. However the traditional technique has some 
limitations, and in order to overcome these problems some new molecular and rapid 
techniques have been developed, such as QF-PCR and MLPA. In our study, we tried to use 
all possible biological sources obtained form the fetuses to be able to reach a diagnosis for a 
multiple malformation that could evolve to death, or had already died without any 
laboratory findings. The main limitation we wanted to overcome was to avoid the situation 
of leaving a multiple malformation fetus without a final diagnosis or karyotype which is a 
vital information for genetic counseling and for the family. Thus we tried to apply molecular 
techniques in postmortem or paraffin-embedded fetal tissues, or even non adhered 
amniocytes that would be normally discarded after culture.  
Karyotyping unconventional fetal samples, when obtaining traditional biological material is 
difficult, is not a very common approach in most laboratories (Donnenfeld et al., 2001; Gole 
et al., 1997). Nevertheless, we used this alternative whenever necessary, and achieved 100% 
success rate on a limited sample of 13 cases (Kessler et al., 2008), being this rate much higher 
when compared to other studies (Teoh et al., 1996; Donnenfeld, 2001). 
There is an ongoing debate whether Rapid Aneuploidy Diagnosis (RAD) should be 
employed as an adjunct to karyotyping or whether it could be used as a stand-alone test in 
selected groups of women (Leung et al., 2003; Cirigliano et al., 2006). The controversy is due 
to residual probability of a chromosome abnormality (both balanced and unbalanced) when 
RAD demonstrates a normal result. Few studies have estimated the residual risk of a 
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clinically significant chromosome aberration for different indications when RAD results are 
normal. In a meta-analysis of 12 studies involving invasive tests, the risk of having a 
chromosome aberration that was not expected to be detected by RAD methods, was 
estimated to be 0.9% (Leung & Lao, 2005). In our results, from 6 aneuploidies already 
diagnosed by karyotyping, only two cases (33.3%) were detected by QF-PCR, probably 
because of poor quality of DNA (mainly in paraffin). On the other hand, a third case 
detected by QF-PCR, had failed for tissue culture at the time of karyotyping analysis, the 
result was obtained only using molecular approaches. Little is known about the patients’ 
preference regarding the type of analysis to be performed. However in Sweden a research 
was made including 6000 women and 70% chose QF-PCR analysis alone (Bui, 2007). In our 
opinion, the combination of both techniques is safer, in order to overcome the particular 
limitations of each one. .  
MLPA has the same inherent limitations as those of QF-PCR in that it will not detect most 
structural chromosome aberrations, or balanced rearrangements such as translocations and 
inversions. Moreover, maternal cell contamination and 69,XXX triploidy will not be 
diagnosed by MLPA (Bui, 2007). In our study, for example, when a marker chromosome 
was detected by the traditional karyotype, the molecular techniques were not able to detect 
it, because the origin of the marker was unknown, so no specific probe could be applied. 
Although we developed a good protocol for extracting DNA from paraffin block wax, this 
material showed to be inappropriate for the molecular techniques used, as demonstrated in 
other studies which also needed smaller fragments of DNA (Halvarsson et al. 2004). 
Another study in postmortem tissues embedded in paraffin succeeded to obtain longer 
amplification fragments of around 300 bp using a specific treatment called pre-PCR 
restoration (Bonin et al., 2003), thus achieving better results. 
Whenever AF was set up for culture, not all amniocytes adhered to the bottom of the flask. 
After few days, by the first medium change, we observed that there were still a considerable 
number of floating cells, which could be used to obtain a considerable amount of DNA. We 
proposed and developed a protocol to extract DNA from those cells in order to guarantee a 
result independently of the cell culture success, and also to abbreviate the result with 
molecular techniques. Although we did not succeed as expected, we could obtain results 
from two cases when cell culture had failed. We could probably improve the success rate of 
these analyses by extracting DNA with commercial kits rather than in-house techniques in 
order to obtain better quality DNA, which is essential for the molecular analysis used here. 
The need of faster testing methods which do not require cell culture has been recognized by 
the scientific community to improve pregnancy management and alleviate parental anxiety 
(Nicolini et al., 2004). 
The best results obtained were from the last 8 cases, in which the DNA was extracted using 
a commercial kit. This is very important information and corroborates the fact that high 
quality DNA is necessary, from which we can obtain results even with degraded DNA 
(Roeder et al., 2009). 
5. Conclusion 
In conclusion, for follow up diagnostic testing, karyotyping has proved to be the gold 
standard method. This technology has remained essentially unchanged over 30 years, as no 
new technology has proven to be superior in terms of being able to detect such a wide range 
of abnormalities with the necessary precision (Slater et al., 2009). Nevertheless, molecular 
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which remained without karyotype, we obtained a positive result through QF-PCR. Case 
number 53 (table 4) could not be confirmed by molecular analysis because the origin of the 
extra chromosome marker was unknown and could not hybridize with the probes used. We 
had no discordant results between the molecular and traditional techniques for those cases 
were both analyses were performed. 
In Table 5, we describe the results from different sources of fetal material for karyotyping in 
115 multiple malformation fetuses. When, for some anatomical reason, AF CVS or UC could 
not be collected, the obstetrician strategy, sometimes for therapeutic reasons,  was the 
collection of alternative fetal material such as bladder drainage. Those biological materials 
could be also used for karyotying, and although there were few cases available, we had 
100% of culture success and karyotyping. 
 






AF 87 83 95.5 
UC 15 14 93.3 
Alternative fluidsa 13 13 100 
TOTAL 115 110 95.6 
aBladder  (6), cystic hygroma  (2), intraperitoneal  (2), displastic kidney  (1), cystic lung  (1), 
cerebrospinal (1) fluids. 
Table 5. Different materials from multiple malformations fetus and success rate of cell 
cultures 
4. Discussion  
Cytogenetic analysis is an important tool for detecting chromosome abnormalities, once this 
is the cause of most common genetic disease in man (Pena, 1998). It has been very useful for 
prenatal diagnosis, and also in clinical genetics. However the traditional technique has some 
limitations, and in order to overcome these problems some new molecular and rapid 
techniques have been developed, such as QF-PCR and MLPA. In our study, we tried to use 
all possible biological sources obtained form the fetuses to be able to reach a diagnosis for a 
multiple malformation that could evolve to death, or had already died without any 
laboratory findings. The main limitation we wanted to overcome was to avoid the situation 
of leaving a multiple malformation fetus without a final diagnosis or karyotype which is a 
vital information for genetic counseling and for the family. Thus we tried to apply molecular 
techniques in postmortem or paraffin-embedded fetal tissues, or even non adhered 
amniocytes that would be normally discarded after culture.  
Karyotyping unconventional fetal samples, when obtaining traditional biological material is 
difficult, is not a very common approach in most laboratories (Donnenfeld et al., 2001; Gole 
et al., 1997). Nevertheless, we used this alternative whenever necessary, and achieved 100% 
success rate on a limited sample of 13 cases (Kessler et al., 2008), being this rate much higher 
when compared to other studies (Teoh et al., 1996; Donnenfeld, 2001). 
There is an ongoing debate whether Rapid Aneuploidy Diagnosis (RAD) should be 
employed as an adjunct to karyotyping or whether it could be used as a stand-alone test in 
selected groups of women (Leung et al., 2003; Cirigliano et al., 2006). The controversy is due 
to residual probability of a chromosome abnormality (both balanced and unbalanced) when 
RAD demonstrates a normal result. Few studies have estimated the residual risk of a 
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clinically significant chromosome aberration for different indications when RAD results are 
normal. In a meta-analysis of 12 studies involving invasive tests, the risk of having a 
chromosome aberration that was not expected to be detected by RAD methods, was 
estimated to be 0.9% (Leung & Lao, 2005). In our results, from 6 aneuploidies already 
diagnosed by karyotyping, only two cases (33.3%) were detected by QF-PCR, probably 
because of poor quality of DNA (mainly in paraffin). On the other hand, a third case 
detected by QF-PCR, had failed for tissue culture at the time of karyotyping analysis, the 
result was obtained only using molecular approaches. Little is known about the patients’ 
preference regarding the type of analysis to be performed. However in Sweden a research 
was made including 6000 women and 70% chose QF-PCR analysis alone (Bui, 2007). In our 
opinion, the combination of both techniques is safer, in order to overcome the particular 
limitations of each one. .  
MLPA has the same inherent limitations as those of QF-PCR in that it will not detect most 
structural chromosome aberrations, or balanced rearrangements such as translocations and 
inversions. Moreover, maternal cell contamination and 69,XXX triploidy will not be 
diagnosed by MLPA (Bui, 2007). In our study, for example, when a marker chromosome 
was detected by the traditional karyotype, the molecular techniques were not able to detect 
it, because the origin of the marker was unknown, so no specific probe could be applied. 
Although we developed a good protocol for extracting DNA from paraffin block wax, this 
material showed to be inappropriate for the molecular techniques used, as demonstrated in 
other studies which also needed smaller fragments of DNA (Halvarsson et al. 2004). 
Another study in postmortem tissues embedded in paraffin succeeded to obtain longer 
amplification fragments of around 300 bp using a specific treatment called pre-PCR 
restoration (Bonin et al., 2003), thus achieving better results. 
Whenever AF was set up for culture, not all amniocytes adhered to the bottom of the flask. 
After few days, by the first medium change, we observed that there were still a considerable 
number of floating cells, which could be used to obtain a considerable amount of DNA. We 
proposed and developed a protocol to extract DNA from those cells in order to guarantee a 
result independently of the cell culture success, and also to abbreviate the result with 
molecular techniques. Although we did not succeed as expected, we could obtain results 
from two cases when cell culture had failed. We could probably improve the success rate of 
these analyses by extracting DNA with commercial kits rather than in-house techniques in 
order to obtain better quality DNA, which is essential for the molecular analysis used here. 
The need of faster testing methods which do not require cell culture has been recognized by 
the scientific community to improve pregnancy management and alleviate parental anxiety 
(Nicolini et al., 2004). 
The best results obtained were from the last 8 cases, in which the DNA was extracted using 
a commercial kit. This is very important information and corroborates the fact that high 
quality DNA is necessary, from which we can obtain results even with degraded DNA 
(Roeder et al., 2009). 
5. Conclusion 
In conclusion, for follow up diagnostic testing, karyotyping has proved to be the gold 
standard method. This technology has remained essentially unchanged over 30 years, as no 
new technology has proven to be superior in terms of being able to detect such a wide range 
of abnormalities with the necessary precision (Slater et al., 2009). Nevertheless, molecular 
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testing, such as QF-PCR or MLPA, are becoming important alternatives in order to give a 
rapid result with low cost. Although these molecular techniques have some limitations, we 
did not find any discordant result, in comparison to traditional karyotype.  Nevertheless, the 
appropriate approach is always performing simultaneously both techniques. 
The importance of this study remains in the alternatives we proposed to give a final 
diagnosis to a multiple malformation fetus. We suggested some approaches to achieve a 
final laboratory result and deliver to the family the information they need to rebuild their 
lives, and make plans for their future, with the help of more rapid and efficient technology 
(RAD) and appropriate genetic counseling. 
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did not find any discordant result, in comparison to traditional karyotype.  Nevertheless, the 
appropriate approach is always performing simultaneously both techniques. 
The importance of this study remains in the alternatives we proposed to give a final 
diagnosis to a multiple malformation fetus. We suggested some approaches to achieve a 
final laboratory result and deliver to the family the information they need to rebuild their 
lives, and make plans for their future, with the help of more rapid and efficient technology 
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1. Introduction 
Infertility is a major health problem today, affecting about 15% of couples trying to have a 
child. Impaired fertility of the male factor is causative in 20% of infertile couples and 
contributory in up to another 30-40%. Infertility already affects about 5-7% of the general 
male population and may further increase in the future, considering the apparent trend of 
declining sperm count in industrialized countries. Despite enormous progress in the 
understanding of human reproductive physiology, the underlying cause of male infertility 
remains undefined in about 50% of cases, which are referred to as idiopathic infertility 
(Ferlin et al., 2006). Most of the idiopathic cases are likely to be of genetic origin because the 
number of genes involved in human spermatogenesis is probably over thousands. At 
present, only few of the genes implicated in the processes of testis determination, testis 
descent and spermatogenesis have routine clinical importance. These include the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, whose mutations cause cystic 
fibrosis and absence of vas deferens and the androgen receptor (AR) gene, whose mutations 
cause the androgen insensitivity syndrome and spermatogenic damage. 
1.1 Common genetic causes of male infertility 
Chromosomal anomalies and microdeletions of the azoospermia factor (AZF) regions of the 
Y chromosome are the only common known genetic causes of spermatogenic failure. The 
frequency of these two genetic anomalies increases with the severity of the spermatogenic 
defect, reaching to an overall 30% (15% karyotype abnormalities and 15% of AZF 
microdeletions) in azoospermic men. 
1.1.1 Sex chromosome aneuploidies 
Sex chromosome aneuploidies, such as 47,XXY (Klinefelter’s syndrome), 47,XYY and 46,XX 
males are the most common chromosome anomalies occurring at birth and in the population 
of infertile males (Hetch & Hetch, 1987; Gekas et al., 2001).  
Klinefelter’s syndrome (KS) is a form of primary testicular failure with testicular 
hypotrophy and elevated gonadotropin plasma levels, and it represents the most common 
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form of male hypogonadism. The prevalence of KS among infertile men is very high, up to 
5% in severe oligozoospermia and 10% in azoospermia (De Braekeleer & Dao, 1991). The 
syndrome usually causes the arrest of spermatogenesis at the primary spermatocyte stage, 
but occasionally later stages of sperm development are observed. There are two forms of 
Klinefelter syndrome: nonmosaic, 47,XXY; and mosaic, 47, XXY/ 46, XY. Although 
previously believed to be sterile, it has been estimated that 25% of nonmosaic Klinefelter 
syndrome patients have sperm in their ejaculate (Ferlin et al., 2007). Men with the mosaic 
form of the disease may have residual spermatogenesis in their seminiferous tubules (Foresta 
et al., 2005). Klinefelter syndrome patients may try to achieve pregnancy using ICSI, but they 
risk producing offspring with chromosomal abnormalities (Reubinoff et al., 1998). 
The karyotype 47,XYY is the second most frequent full aneuploidy of sex chromosomes. The 
spermatogenesis in XYY individuals range from severe oligozoospermia to 
normozoospermia (Skakkebaek et al., 1973; Sharara et al., 1999).  
46,XX chromosomal abnormality is observed mainly in azoospermic males, with frequency 
of 0.9% (Mau-Holzmann, 2005). The phenotype is similar to Klinefelter syndrome, but with 
normal height and unimpaired intelligence. The SRY gene is present in most of the cases 
(SRY+ XX males); in these cases males are invariably infertile, and azoospermia results from 
testicular atrophy. The other category are SRY− XXmales, which assumes a mutation in an 
autosomal or X-linked gene involved in the sex determining cascade which should 
substitute the SRY, permitting testicular determination in absence of SRY. 
1.1.2 Y chromosome microdeletions 
1.1.2.1 Deletions of AZFa, AZFb and AZFc regions 
Y chromosome microdeletions represent the etiological factor of 10-15% of idiopathic 
azoospermia and severe oligozoospermia (Foresta et al., 2000; Ma et al., 2000). In 1976, 
Tiepolo and Zuffardi provided the first evidence that the long arm of the Y chromosome is 
required for fertility in men, when they karyotyped 1170 men and found that six 
azoospermic men were missing most of the long arm of Y chromosome (Tiepolo & Zuffardi, 
1976). Subsequently, this cluster on Yq11 became known as the azoospermia factor or AZF. 
The use of polymerase chain reaction (PCR) of sequence tagged sites (STS) has made 
possible the detection of small, interstitial deletions invisible by karyotyping (Vollrath et al., 
1992). In 1996, the AZF region was subdivided into 25 deletion intervals (D1-D25) and the 
existence of three non-overlapping subregions, designated AZFa, AZFb and AZFc (Figure 
1A), was proposed (Vogt, 1996). Subsequent DNA sequencing approaches revealed eight 
large palindromic regions containing an array of different ampliconic sequences (Kuroda-
Kawaguchi et al., 2001) and demonstrated that these regions harbour a total of 12 different 
genes/gene families, most of which are exclusively expressed in testises (Kuroda-Kawaguchi 
et al., 2001; Tilford et al., 2001, Scaletsky et al., 2003). An overlap of 1.5Mb between distal AZFb 
and proximal AZFc was also demonstrated (Repping et al., 2002). Ampliconic sequences 
make up almost all of the AZFc sequence and 50% of the AZFb sequence (Figure 1B).  
The frequency of AZF deletions in infertile men ranges in worldwide surveys from 5 to 20% 
(Vogt, 1998; Krausz et al., 2003).  Y microdeletions are found almost exclusively in patients 
with azoospermia or severe oligozoospermia (Simoni et al., 1998). The prevalence of Y 
microdeletions among the infertile males from the Republic of Macedonia is 6.4%, among 
patients with azoospermia 16.7% and among those with severe oligozoospermia 2.8% 
(Plaseski et al., 2003). Deletions most frequently involve AZFc region, less frequently the 
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AZFb region, and only rarely the AZFa region. The most frequent deletions among 
Macedonian males are AZFc deletions, while AZFa deletions have not been detected 
(Plaseski et al., 2006; Plaseski et al., 2008). 
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Fig. 1. Schematic view of the AZF locus in Yq1. A) Deletion map of AZF locus: 25 intervals 
(D1-D25) and three AZF regions (AZFa, AZFb and AZFc). A/1) Complete AZFa deletion, 
caused by recombination of two homologous HERV 15Yq1/q2 blocks; B) Structural 
organization of the different amplicons in the AZFb and AZFc regions belonging to five 
palindromic structures (P1-P5); C) Partial and complete AZFc, AZFb and AZFb+c deletions 
caused by recombination between different amplicons. 
Distant homologous recombination between specific palindromic sequences is believed to 
be the mechanism for majority Yq deletions (Figure 1C) (Kamp et al., 2000; Repping et al., 
2002; Repping et al., 2003), although deletions based on mechanism of nonhomologous 
recombination were also identified (Costa et al., 2008). The AZFa deletions are located in 
proximal Yq and are caused by recombination that take place between retroviral 
homologous sequences. These deletions account for less then 1% of all microdeletions of the 
Y chromosome reported to be associated with spermatogenic failure. Clinically, AZFa 
deletions are associated with complete absence of germ cells in the testes (Vogt, 2005). 
Complete deletions of AZFb have a size of 6.23 Mb and extend within a 1.5 Mb of the 
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AZFb region, and only rarely the AZFa region. The most frequent deletions among 
Macedonian males are AZFc deletions, while AZFa deletions have not been detected 
(Plaseski et al., 2006; Plaseski et al., 2008). 
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proximal portion of AZFc. Deletions removing simultaneously part of the AZFb and AZFc 
regions result from homologous recombination, in which the proximal breakpoints are 
located in the P5 palindrome and the distal breakpoints mapped in either proximal P1 or 
distal P1 (Repping et al., 2002). Clinically, complete AZFb deletions are associated with 
meiotic arrest or Sertoly cell-only syndrome (Ferlin et al., 2003). 
The most common AZFc deletion (b2/b4 deletion) eliminates a 3.5 Mb segment that 
contains 21 genes and is present in about 1 in 4.000 men worldwide (Kuroda-Kawaguchi et al., 
2001). Deletions involving the AZFc region account for up to 90% of all Yq deletions with 
phenotypes varying from azoospermia to severe oligozoospermia (Reijo  et al., 1995, Simoni 
et al., 1997, Najmabadi et al., 1996) and occasionally to milder oligozoospermia (Oliva et al., 
1998). Although natural transmission of Y microdeletions has been reported, majority of the 
cases arise as a de novo event (Edwards & Bishop , 1997). 
1.1.2.2 Partial  AZFc deletions 
Partial deletions within the AZFc region (gr/gr and b2/b3) that remove smaller portions of 
the AZFc region (1.6 and 1.8 Mb) are much more common and are present at various 
frequencies in different Y haplogroups  (Repping et al., 2003; Vogt, 2005).  Partial and 
polymorphic AZF deletions have been also reported in the AZFa (Kamp  et al., 2000) and 
AZFb regions (Ferlin et al., 2003). 
While the association of the complete AZFc deletion with spermatogenic failure is well 
established, the role of partial AZFc deletions and duplications on spermatogenesis and 
male infertility is still controversial. With the exception of one study among Han-Chinese 
population (Wu et al., 2007), all other studies reported no association between the b2/b3 
deletion and impaired spermatogenesis. The results of the gr/gr deletion are more 
inconsistent; it is considered a new genetic risk factor by a number of research groups 
(Kuroda-Kawaguchi et al., 2001; de Llanos et al., 2005; Ferlin et al., 2005; Gianchini et al., 2005, 
Gianchini et al., 2008), but not by the others (Machev et al., 2004; Hucklenbroich  et al., 2005; 
Ravel et al., 2006; Carvalho et al., 2006; Lardone et al., 2007a; Lin et al., 2007). These 
contradictory results may in part be due to the methodological differences and differences in 
the controls (fertile controls, general population, or normozoospermic men).  
1.1.2.3 AZFc duplications 
In addition to deletions, different duplications at the AZFc region have been reported. 
Duplications can occur on a chromosome with partial AZFc deletion and generate a 
chromosome with four DAZ genes, but lacking some STS markers (Repping S et al., 2003; 
Repping S et al., 2004). Recently, AZFc partial duplication has been shown to be a risk factor 
for male infertility in Taiwan (Lin et al., 2007). A higher incidence of increased number of 
DAZ genes was demonstrated in azoospermic and oligozoospermic men in Slovenia (Writzl 
et al., 2005). Additional studies are needed to determine the role of AZFc partial deletions 
and duplications in spermatogenesis and male infertility.   
1.1.2.4 AZF candidate genes 
The AZF regions include genes that are expressed during spermatogenesis and encode 
proteins necessary for specific stages of spermatogenesis as well as for maintaining the general 
housekeeping functions of the cells involved (Lahn & Page, 1997).  The Dead box Y (DBY, 
recently renamed DDX3Y) encodes a putative RNA helicase. The ubiquitin-specific protease 
9Y gene (USP9Y, previously known as DFFRY) encodes a protease with activity specific to 
ubiquitin that is involved in the regulation of protein metabolism (protein turn-over). Both 
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genes are located at the AZFa region and have homologous genes on the X chromosome. The 
exact role of the candidate genes in the AZFa region are largely unknown, owing to the 
extreme rarity of naturally occurring, single-gene-specific mutations. Complete deletions of 
AZFa region is rare, but is well documented and always associated with Sertoli-cell-only 
syndrome and consequently azoospermia (Ferlin et al., 2007). The translation Initiation Factor 
1A Y isoform gene (EIF1AY) and the RNA binding motif (RBM) family are found on AZFb 
region. EIF1AY encodes an essential translation factor. The PTP-BL-related Y (PRY) family of 
genes is mapped to AZFb and AZFc regions and encodes proteins proposed to be involved in 
apoptosis. RBM and deleted-in-azoospermia (DAZ) genes encode RNA-binding proteins that 
are exclusively expressed in germ cells. In addition to DAZ, chromodomain Y genes (CDY1) 
are found on the AZFc region and encode a protein involved in DNA remodeling that can 
acetylate histone H4 in vitro. Among other Y chromosome genes, likely implicated in 
spermatogenesis but not related to microdeletions, TSPY is a candidate oncogene that, due to 
its limited expression pattern in germ cells, is thought to function as a proliferation factor 
during spermatogenesis. The quantities of AZF gene transcripts in testicular tissues of patients 
with different spermatogenic impairment have been recently examined and an important role 
of DDX3Y was suggested (Kleiman et al., 2007; Lardone et al., 2007).  
1.1.3 Androgen receptor CAG repeats  
Androgens are essential for male sexual development and for fertility. They act through the 
AR, which is a transcriptional factor that contains functional domains for DNA binding, 
ligand binding and transcriptional regulation. The 5' end of exon 1 of the AR gene includes a 
polymorphic CAG triplet repeat that codes for a polyglutamine tract. The number of CAG 
repeats in the normal population varies between 10 and 36. Expansion of the polyglutamine 
tract to >38 repeats in males leads to Kennedy disease [spinal bulbar muscular atrophy 
(SBMA)] (LaSpada et al., 1991). In addition to neurological symptoms, SBMA patients show 
signs of hypogonadism, such as gynecomastia, impotence, testicular atrophy and reduced 
fertility. 
In vitro studies have demonstrated a negative correlation between CAG repeat size and AR 
function (Chamberlain et al., 1994). The possible association of a long CAG repeat with male 
infertility in Asian populations was suggested because of a four-fold increase in the risk of 
impaired spermatogenesis in males who had >28 CAG repeats (Tut et al., 1997). Since then, 
the association of the long CAG repeat number in the AR gene and male infertility has been 
controversial.  
We have also studied the possible effect of long CAG repeat tracts in the AR on infertility 
among Macedonian men (Plaseski et al., 2007). Our results showed that the mean CAG length 
dos not differ significantly between males with azoospermia, mild oligozoospermia, severe 
oligozoospermia, normozoospermia, or known causes of infertility  and fertile controls. 
However, we found a significantly higher percentage of CAG repeats >26 (p = 0.022), >27 
(p = 0.018) and >28 (p = 0.009) in males with mild oligozoospermia. Thus, our initial results 
indicated a possible association between CAG repeat length and mild oligozoospermia.  
2. Screening for the presence of the most common genetic causes by 
quantitative fluorescent (QF)-PCR  
Screening for chromosomal abnormalities is usually done by cytogenetic analysis and for 
AZF deletions by PCR analysis of several sequence tagged sites (STSs) in the three AZF 
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proximal portion of AZFc. Deletions removing simultaneously part of the AZFb and AZFc 
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frequencies in different Y haplogroups  (Repping et al., 2003; Vogt, 2005).  Partial and 
polymorphic AZF deletions have been also reported in the AZFa (Kamp  et al., 2000) and 
AZFb regions (Ferlin et al., 2003). 
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genes are located at the AZFa region and have homologous genes on the X chromosome. The 
exact role of the candidate genes in the AZFa region are largely unknown, owing to the 
extreme rarity of naturally occurring, single-gene-specific mutations. Complete deletions of 
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apoptosis. RBM and deleted-in-azoospermia (DAZ) genes encode RNA-binding proteins that 
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acetylate histone H4 in vitro. Among other Y chromosome genes, likely implicated in 
spermatogenesis but not related to microdeletions, TSPY is a candidate oncogene that, due to 
its limited expression pattern in germ cells, is thought to function as a proliferation factor 
during spermatogenesis. The quantities of AZF gene transcripts in testicular tissues of patients 
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of DDX3Y was suggested (Kleiman et al., 2007; Lardone et al., 2007).  
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regions. Recently, we have described a multiplex QF-PCR method that allows simultaneous 
detection of the most common genetic causes of male infertility, i.e. sex chromosomal 
aneuploidies and AZFc and AZFb deletions, and some potential risk factors such as partial 
AZFc deletions/duplications and AR CAG repeats (Plaseski et al., 2008). This 11-plex QF-
PCR analysis was shown as a rapid, simple, reliable and inexpensive method that can be 
used as a first-step genetic analysis in infertile patients. Here, we present a modified system, 
where we have included additional markers in the AZFa and AZFb region, as well as a 
marker for determination of the X/ chromosome 3 ratio.   
2.1 QF-PCR method 
The quantitative fluorescent (QF) polymerase chain reaction (PCR) included 13 markers: 
amelogenin gene which is present on X and Y chromosomes and allows for the 
determination of the Y/X ratio (AMEL marker), TAF9B gene that is present on 
chromosomes X and 3 and permits the determination of x/chr 3 ratio, four polymorphic X-
specific short tandem repeat (STR) markers (XHPRT, DXS6803; DXS981 and exon 1 of the 
AR gene), three non-polymorphic Y-specific markers (SRY gene, sY86 in AZFa and sY134 in 
AZFb region), polymorphic Y-specific STR marker (DYS448), and co-amplification of 
DAZ/DAZL, MYPT2Y/MYPT2 and CDY2/CDY1 fragments that permit determination of 
the DAZ, MYPT2Y, CDY1 and CDY2 gene copy number. The details of the primers used in 
the 13-plex QF-PCR are given in Table 1, while the location of the markers on the Y 
chromosome is given in Figure 2. 
The AMEL marker exploits the 6bp deletion on the X chromosome sequence, enabling 
amplification of specific X-chromosome (106 bp) and Y-chromosome sequences (112 bp). 
The TAF9B marker co-amplifies a fragment of the TAF9B gene on X chromosome (144bp) 
and the one on chromosome 3 (140 bp). The DAZ gene copy number was quantified using 
primers that co-amplify a fragment of intron 10 from DAZ gene (208 bp) and from the 
homologous autosomal locus DAZL on chromosome 3 (211 bp or 251 bp). The two MYPT2Y 
copies in the AZFc region were co-amplified with the MYPT2 gene on chromosome 1, giving 
fragments of 181 bp and 176 bp respectively. The relative ratio of the two CDY1 genes in the 
AZFc region and two CDY2 genes in the AZFb region, which share 98% nucleotide identity 
was scored by two PCR sets which amplify a 6bp nucleotide difference in the 5’ region, 
producing fragments of 200 bp for CDY1 and 194 bp for CDY2.  
One primer in each set was labeled with 6-FAM or HEX fluorescent dye, which allowed the 
determination of the length of the different STR and STS alleles and for quantification of the 
relative Amel Y/Amel X, TAF9B-X/TAF9B-chr. 3, DAZ/DAZL, MYPT2Y/MYPT2 and 
CDY2/CDY1 ratios on ABIPrism 3130 Genetic Analyzer using a GeneMapper Software v.4.0 
(Applied Biosystems, Foster City, CA, USA).  
The PCR reaction mixture contained PCR buffer (Applied Biosystems), 50-100 ng genomic 
DNA, 200 M each of the four dNTP's (dATP, dCTP, dGTP and dTTP), 2-8 pmol each of the 
primers, and 1.5U TaqGold polymerase (Applied Biosystems) in a total volume of 15l. The 
PCR was performed under the following conditions: initial denaturation step at 950C for 5 
minutes, followed by 28 cycles of 1 minute denaturation at 950C, 1 minute annealing at 580C 
and 1.5 minutes elongation at 720C; and final elongation at 720C for 30 minutes.  
2.2 QF-PCR results 
The normal results of the 13 markers included in the QF-PCR analysis in males without sex 
chromosome aneuploidies and AZF rearrangements are shown in Table 2 and Figure 3.  The  
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* in app. 25% of individuals a 40bp insertion polymorphism in DAZL intron 10 is present 
(Machev  et al., 2004) 
Table 1. Details of the primers used in the QF-PCR for the detection of the most common 
causes of male infertility 
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Fig. 2. The location of Y chromosome markers included in the 13-plex QF-PCR system and 
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1 the ratio is slightly higher in  heterozygotes and homozygotes for DAZL polymorphism 
2 one allele in homozygotes and two alleles in heterozygotes for particular marker 
3 normal in SRY+ XX males; no fragment in SRY- XX males 
Table 2. Results of the 11-plex QF-PCR in normal males and males with sex chromosomal 
aneuploidies, AZF deletions, partial AZFc deletions and b2/b4 duplication 
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normal results in a male DNA samples are presented by a Amel Y/X ratio of 1, due to the 
presence of one X and one Y chromosome, DAZ/DAZL ratio of 2, due to the presence of 4 
DAZ genes in the AZFc region of Y chromosome and two DAZL genes, one on each 
chromosome 3. Around 30% of the samples showed the presence of a 40bp insertion 
polymorphism in the DAZL gene in a heterozygous or homozygous state. The DAZ/DAZL 
ratio was higher in the heterozygotes and homozygotes than in the individuals without this 
polymorphism due to the area of the 254bp peak being smaller than the 214bp peak. The 
normal MYPT2/MYPT2Y ratio is around 1 due to the presence of two copies of the gene in 
the AZFc region of the Y chromosome and one copy on each of the chromosomes 1, while 
the normal TAF9B-X/TAF9B-chr 3 ratio is 0,5 due to the presence of two copies of the gene 
on the chromosomes 3 and one copy on the chromosome X in males.  
 The four STR markers on chromosome X, as well as the one in the AZFb region on 
chromosome Y generate one PCR fragment due to the presence of one allele of each of the 
investigated markers. The non-plymorphic markers on the Y chromosome: SRY, sY134 (in 
the AZFb region) and sY86 (in the AZFa region) gave PCR fragments of 248 bp, 303 bp and 
317 bp in males without chromosome aneuploidies and/or AZF rearrangements. 
 
 
Fig. 3. Electrophoretogram of the 13-plex QF-PCR analysis in a blood sample of normal 
male. 
2.2.1 QF-PCR results in sex chromosome aneuploidies 
Among the studied males we detected four different chromosome aneuploidies: XXY or 
Klinefelter’s syndrome (n=12), XX  males (n=2), XYY males (n=2) and XY,XO mosaic male 
(n=1). All XXY and XX males, as well as one of the two XYY men were azoospermic, while 
the second XYY male and the XY,XO mosaic male presented with severe oligozoospermia. 
The electrophoreograms of the individuals with sex chromosome aneuploidies are shown in 
Figures 4-7 and the Y/X, DAZ/DAZL, MYPT2Y/MYPT2 and CDY2/CDY1 ratios are given 
in Table 2. All detected cases of chromosome aneuploidies were confirmed by cytogenetic 
analysis. 
Klinefelter’s syndrome (XXY) was detected by an abnormal Y/X ratio (~0.5), TAF9B-
X/TAF9B-chr 3 ratio of ~1 and presence of two alleles from some of the STR markers on the 
X chromosome in a ratio of approximately 1:1 (Figure 4).  
The two XX males were characterized by the absence of the Y fragment from the AMEL Y/X 
marker, DAZ, MYPT2Y, CDY1 and CDY2 fragments and TAF9B-X/TAF9B-chr 3 ratio of ~1 
(Figure 5). In both XX males the SRY fragment was present, sY134, sY86 and DYS 448 
fragments were absent and at least one of the four STR markers on the X chromosome 
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showed two alleles. Rarely, in XX males the SRY gene is not present in which case the PCR 
fragment from the SRY gene would be missing and 11-plex QF-PCR pattern would be same 








Fig. 5. Electrophoretogram of the 13-plex QF-PCR analysis in a men with XX male 
syndrome. 
The XYY individuals showed also a specific pattern, characterized by abnormal Y/X (~2), 
DAZ/DAZL (~4) and MYPT2Y/MYPT2 (~2) ratios, while the TAF9B-X/TAF9B-chr 3 and 
CDY2/CDY1 ratios were within the normal range (Figure 6).  
 
 
Fig. 6. Electrophoretogram of the 13-plex QF-PCR analysis in a men with XYY syndrome. 
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The 13-plex QF-PCR of  XY,XO mosaic male showed abnormal Y/X (0,35) and 
MYPT2Y/MYPT2 (0,25) and DAZ/DAZL (0,59) ratios, while the CDY2/CDY1 and TAF9B-
X/TAF9B-chr 3 ratios were normal (Figure 7). This result suggested that the Y chromosome 
is lost  in approximately half of the white blood cells in this patient. The result was 
confirmed on a DNA isolated from a fresh blood sample and by cytogenetic analysis as well. 
Analysis of DNA extracted from the buccal swab of this patient showed a normal result. 





Fig. 7. Electrophoretogram of the 13-plex QF-PCR analysis in a XY/X0 mosaic male. 
2.2.2 QF-PCR results in complete AZF deletions 
During our previous work we have detected eight different AZF deletions, including the 
two partial AZFc deletions, gr/gr and b2/b3 deletions (Plaseski et al., 2006, Plaseski et al., 
2008). Schematic presentation of the deletions is shown in Figure 2. 
The 13-plex QF-PCR patterns obtained in the patients with different AZF deletions are given 
in Table 2. We were able to distinguish all six types of AZF deletions that we detected 
previously amongst infertile patients (Plaseski et al., 2006). In the six patients with b2/b4 
deletions the DAZ fragment and the CDY1 fragments were missing, while the 
MYPT2Y/MYPT2 ratio was decreased suggesting the absence of one of the two MYPT2Y 
copies on the Y chromosome. All other fragments showed a normal pattern. 
The initial screening for AZF deletions following the guidelines for the detection of Y 
microdeletions showed presence of AZFc deletions in two other patients (Plaseski et al., 
2006). The analysis with additional STS markers showed that in these two patients the 5’ 
border of the deletion is identical and lies between sY 134 and sY 142 markers. The 3’ border 
differs and is identical to the 3’ border of the b2/b4 deletion in one of the two patients, while 
in the other it extends distal from the AZFc region (Figure 2). These two patients showed an 
identical pattern for all markers except for MYPT2Y/MYPT2 (Table 2). In one the MYPT2Y 
fragment was missing (Figure 8), while in the other it was present, but the ratio of 
MYPT2Y/MYPT2 was decreased to about half suggesting deletion of one MYPT2Y copy.  In 
both patients markers sY134 in the AZFb region and sY86 in AZFa region were present, 
while the DYS 448 marker was absent. 
During our routine screening for Y microdeletions we detected one patient with AZFb 
deletion. The additional Y STS markers showed that the 5’ border of this deletion is between 
sY 1228 and sY 1015, while the 3’ border extends in the 5’ part of the AZFc region between 
sY1291 and sY1191 (Figure 2). This deletion also gave a specific pattern with the 13-plex QF 
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PCR characterized by the absence of the DYS 448 and sY134 fragments and ratios of 
DAZ/DAZL and CDY2/CDY1 markers reduced to half (Table 2), suggesting that two of the 
four DAZ genes in the AZFc regions and one of the two CDY2 genes in the AZFb region 
were missing. 
 
Fig. 8. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFc-2 deletion. 
The patient with AZFb+c deletion also showed a specific pattern with the 13-plex QF-PCR, 
which was the same as AZFc-1 deletion in all but sY134 marker that was missing and Y/X 
AMEL marker which showed a reduced ratio of 0.23, due to the presence of XY/X0 mosaicism 
(Table 2 and Figure 9). The XY/XO mosaicism was confirmed by cytogenetic analysis. 
The QF-PCR result of the AZFa+b+c deletion showed absence of all markers in the AZF a, 
b and c regions (DAZ, MYPT2Y, CDY1, CDY2, sY134, sY86 and DYS448) (Figure 10). The 
patient with AZFa+b+c deletion also showed an abnormal Y/X ratio (0,42), suggesting 
that the Y chromosome was lost in half of the cells in this patient. 
 
 
Fig. 9. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFb+c deletion. 
 
Fig. 10. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFa+b+c 
deletion. 
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Fig. 7. Electrophoretogram of the 13-plex QF-PCR analysis in a XY/X0 mosaic male. 
2.2.2 QF-PCR results in complete AZF deletions 
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2008). Schematic presentation of the deletions is shown in Figure 2. 
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MYPT2Y/MYPT2 ratio was decreased suggesting the absence of one of the two MYPT2Y 
copies on the Y chromosome. All other fragments showed a normal pattern. 
The initial screening for AZF deletions following the guidelines for the detection of Y 
microdeletions showed presence of AZFc deletions in two other patients (Plaseski et al., 
2006). The analysis with additional STS markers showed that in these two patients the 5’ 
border of the deletion is identical and lies between sY 134 and sY 142 markers. The 3’ border 
differs and is identical to the 3’ border of the b2/b4 deletion in one of the two patients, while 
in the other it extends distal from the AZFc region (Figure 2). These two patients showed an 
identical pattern for all markers except for MYPT2Y/MYPT2 (Table 2). In one the MYPT2Y 
fragment was missing (Figure 8), while in the other it was present, but the ratio of 
MYPT2Y/MYPT2 was decreased to about half suggesting deletion of one MYPT2Y copy.  In 
both patients markers sY134 in the AZFb region and sY86 in AZFa region were present, 
while the DYS 448 marker was absent. 
During our routine screening for Y microdeletions we detected one patient with AZFb 
deletion. The additional Y STS markers showed that the 5’ border of this deletion is between 
sY 1228 and sY 1015, while the 3’ border extends in the 5’ part of the AZFc region between 
sY1291 and sY1191 (Figure 2). This deletion also gave a specific pattern with the 13-plex QF 
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PCR characterized by the absence of the DYS 448 and sY134 fragments and ratios of 
DAZ/DAZL and CDY2/CDY1 markers reduced to half (Table 2), suggesting that two of the 
four DAZ genes in the AZFc regions and one of the two CDY2 genes in the AZFb region 
were missing. 
 
Fig. 8. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFc-2 deletion. 
The patient with AZFb+c deletion also showed a specific pattern with the 13-plex QF-PCR, 
which was the same as AZFc-1 deletion in all but sY134 marker that was missing and Y/X 
AMEL marker which showed a reduced ratio of 0.23, due to the presence of XY/X0 mosaicism 
(Table 2 and Figure 9). The XY/XO mosaicism was confirmed by cytogenetic analysis. 
The QF-PCR result of the AZFa+b+c deletion showed absence of all markers in the AZF a, 
b and c regions (DAZ, MYPT2Y, CDY1, CDY2, sY134, sY86 and DYS448) (Figure 10). The 
patient with AZFa+b+c deletion also showed an abnormal Y/X ratio (0,42), suggesting 
that the Y chromosome was lost in half of the cells in this patient. 
 
 
Fig. 9. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFb+c deletion. 
 
Fig. 10. Electrophoretogram of the 13-plex QF-PCR analysis in a men with AZFa+b+c 
deletion. 
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2.2.3 QF-PCR results in partial AZFc deletions 
The 13-plex QF-PCR permitted detection of partial AZFc deletions and duplications (Table 
2). Both partial AZFc deletions (gr/gr and b2/b3) showed abnormal DAZ/DAZL (~1) and 
CDY2/CDY1 ratios (~2), but differ in the MYPT2Y/MYPT2 ratios which are within the 
normal range in b2/b3 deletion and reduced in gr/gr deletion (~0.5). The QF-PCR analysis 
in men with gr/gr deletion is shown in Figure 11. 
 
 
Fig. 11. Electrophoretogram of the 13-plex QF-PCR analysis in a men with gr/gr deletion. 
Three of the previously detected patients with gr/gr deletions, showed normal or increased 
DAZ/DAZL levels, normal, increased or decreased CDY2/CDY1 levels, while the 
MYPT2Y/MYPT2 ratio was reduced to half, similar to that in the other gr/gr deletions 
(Figure 12). This rearrangement has probably arisen from gr/gr deletion followed by 
duplication. All three males with both b2/b4 duplication and gr/gr deletion differ from 
normal individuals in the MYPT2Y/MYPT2 ratio which is reduced to half. 
 
 
Fig. 12. Electrophoretogram of the 13-plex QF-PCR analysis in a men with b2/b4 duplication 
and gr/gr deletion. 
2.2.4 QF-PCR results in AZFc duplications 
The 13-plex QF-PCR detected also the duplications mediated by the amplicons in the AZFc 
region. Samples with gr/gr or b2/b4 duplications were characterized by increased 
DAZ/DAZL (>3) and MYPT2Y/MYPT2 (>1.5) ratios and decreased CDY2/CDY1 ratios 
(<0.5) (Table 2). Samples with partial AZFc duplication on chromosomes with b2/b3 
inversion (b2/b3 duplications),  showed increased DAZ/DAZL (>3), normal 
MYPT2Y/MYPT2 and decreased CDY2/CDY1 ratios (<0.5) (Figure 13).  
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Fig. 12. Electrophoretogram of the 13-plex QF-PCR analysis in a men with b2/b3 
duplication. 
2.2.5 Detection of the number of AR CAG repeats 
An additional advantage of our QF-PCR system is that it can also assess the number of the 
AR CAG repeats, since one of the STR markers on the X chromosome in the 13-plex QF-PCR 
involves the CAG repeats in the exon 1 of the AR gene. The PCR amplification using 
oligonucleotide primers surrounding the CAG repeat region in the exon 1 of the AR gene 
generated fragments with a size ranging from 247 to 309 bp, corresponding to the 13 to 34 
CAG tandem repeats. The number of CAG repeats predicted by the GeneMapper software 
v.4.0. (Applied BioSystems) was previously compared with the actual CAG repeats 
determined by direct dideoxy terminator cycle sequencing using the BigDye Terminator 
Sequencing Kit v1.0 (Applied BioSystems) in several male DNA samples with 14, 19, 21, 25 
and 29 CAG repeats.  
3. Conclusion 
In conclusion, we have developed a rapid, simple, reliable and inexpensive multiplex QF-
PCR method, that can be used as a first-step genetic analysis in infertile/subfertile men to 
detect the most common genetic causes of male infertility (sex chromosomal aneuploidies 
and AZF deletions) and to study some potential risk factors (AZFc partial deletions and 
duplications and AR CAG repeats). 
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1. Introduction 
Epidermolysis bullosa (EB) is a very heterogeneous hereditary disease of the skin and 
mucous membranes, characterized by erosions and blistering after minor traumatization. 
Up to now at least 12 genes are known to underlie EB, which render structural and 
mechanical stability of the skin (Fine et al., 2008). The characteristic blister formation occurs 
on the level of the basement membrane zone and the basal keratinocytes, depending on the 
gene, which is mutated. In EB simplex (EBS) the split formation in the skin occurs due to 
cytolysis of the basal keratinocytes, in junctional EB (JEB) within the lamina lucida and in 
dystrophic EB (DEB) on the dermal aspect of the basement membrane zone. Due to the 
clinical and genetic heterogeneity of this disease the development of a gene therapy is 
challenging, since every type of EB has to be targeted separately. Furthermore, the different 
subtypes differ in their mode of inheritance. Especially for basal EB simplex, where 
mutations in the keratin 5 (K5), keratin 14 (K14) and plectin (PLEC) genes may cause the 
clinical phenotype, dominant mutations are frequent. But also in dystrophic EB, where 
mutations in the collagen VII gene (COL7A1) are causative for the disease, dominantly 
inherited subtypes are known. Another characteristic feature of the involved genes is that 
many of them are very large and exceed the packaging capacities of commonly used (viral) 
vectors (e.g. COL7A1: ~9,3kb, PLEC: ~14.8kb). Functionally, all genes involved in EB have 
structural significance. Whereas keratin 5 and keratin 14 are major components of the 
cytoskeleton in basal keratinocytes, plectin is a cytolinker protein, connecting the actin 
filament network with the microtubules, the intermediate filaments and the 
hemidesmosomes and desmosomes. Isoforms of plectin are expressed in many cell types 
and always have “networking” functions. This is the reason why epidermolysis bullosa 
triggered by mutations in this gene goes along with muscular dystrophy and pyloric atresia. 
12 plectin isoforms, differing in their 5’ transcript portion have been identified up to now, 
most of them differing in their first exon. However, the structure and mode of function is 
comparable between all isoforms (Rezniczek et al., 2003). Structurally, plectin consists of two 
globular domains, flanking a central rod domain. The 5’ globular domain is encoded by 
exons 1 to 30 and is over 4kb in length, whereas the rod is encoded by one single 3.38kb 
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exon. Plectin peptides form homodimers with a central coiled-coil of alpha helices and two 
globular domains. Within the globular domains the binding sites for its various binding 
partners are situated. Therefore, mutations in the rod cause mainly EBS with muscular 
dystrophy, whereas EBS with pylorus atresia is caused by mutations outside exon 31 
(Natsuga et al., 2010). In this chapter we describe a trans-splicing based gene therapeutic 
approach on the example of epidermolysis bullosa simplex, caused by mutations in the 
PLEC gene. Based on the first proof-of-principle publication from 2008 we developed a 
screening method to correct patient fibroblasts with a high efficiency and specificity, 
rendering this approach a potential candidate for future in vivo studies.  
2. Gene therapy in EB 
For many devastating diseases gene therapy is the only hope for a curative intervention. 
Many efforts have been made in a spectrum of gene therapeutic strategies, resulting in a 
small range of gene therapeutic approaches available in vitro, each having its advantages 
and limitations.  
A very straight-forward approach is gene supplementation therapy, in which a wildtype 
cDNA copy of a given mutated gene is brought into a cell to revert the phenotype. This gene 
complementation approach results in the rescue of the phenotype by providing the 
functional protein. Full-length cDNA therapy can be used for most recessively inherited 
diseases, where the transgene does not exceed the size of the packaging capacity of the 
vector of choice. In EB, cDNA therapy was already used for collagen 17 (COL17A1), laminin 
beta 3 (LAMB3) (Dellambra et al., 2000; Dellambra et al., 1998), integrin beta 4 (ITGB4) 
(Dellambra et al., 2001) and collagen 7 (COL7A1) (Siprashvili et al., 2010). In 2006, De Luca 
and his group applied ex vivo gene therapy for a patient suffering from recessive dystrophic 
EB for the first time (Mavilio et al., 2006). Patient’s epidermal stem cells were transduced 
with a LAMB3 expressing retrovirus. Expanded skin sheets were transplanted onto the 
anterior parts of the patient’s legs, showing complete epidermal regeneration after eight 
weeks. Molecular analysis confirmed the correct integration of the LAMB3 chain in the 
laminin-332 protein, rendering integrity to the transplanted skin section. 
Even though great achievements were made also for other genes, cDNA therapy has 
limitations. In the case of the LAMB3 approach described above, some case specific 
characteristics facilitated the success of this application. These were the autosomal recessive 
mode of inheritance, the limited size of the LAMB3 coding region, the residual 5% gene 
expression of the endogenous LAMB3 alleles (avoiding immune rejection) and the nature of 
LAMB3 in making part in a trimer, thereby avoiding an excess of the functional protein, as 
the amount of available laminin-332 is limited by laminin alpha 3 and laminin gamma 2. 
This last point is crucial as also overexpression of the transgene can have major impact on 
the therapeutic outcome. 
For other genes the starting situation is different. Mutated genes can be very large or 
dominantly inherited, or they need strict expression control due to their negative 
interference when overexpressed. Quite contrary, it was found that low levels of functional 
protein can be sufficient to render a normal phenotype. For this reason cDNA therapy is 
often complemented with knockdown approaches like RNA interference (RNAi) or 
antisense oligonucleotides (ASOs) to knock down the mutated gene and minimizing an 
excess of the transcript.  
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But not only complementary, but also standing alone such alternative strategies were 
developed, many of them acting on RNA level. Therapy on RNA level has the advantage 
that cell targeting does not have to be as strict, since the interfering process can only take 
place in cells actively expressing the targeted gene. This also regulates the amount of 
interference, thus avoiding the overexpression of the respective gene. A widely applied 
approach is the use of interfering RNAs (RNAi). There, specifically designed short-hairpin 
RNAs (shRNAs) or short interfering RNAs (siRNA) are introduced into cells of interest. 
After processing, specific 21bp RNA fragments are incorporated in an RNA induced 
silencing complex (RISC), specifically hybridizing to an allele harbouring a mutation. This 
leads to the cleavage of the target mRNA (Siomi and Siomi, 2009).  
For keratin 14, RNAi was used for characterization studies of EBS (Werner et al., 2004; 
Russell et al., 2009). However, the drawback of RNAi is that even though theoretically any 
gene and any mutation can be targeted, the risk of haploinsufficiency has to be considered. 
To meet this problem, rescue approaches are conducted by introducing the wildtype cDNA, 
leading to the limitations discussed above. 
Another approach on RNA level is the use of ribozymes. Ribozymes are RNA molecules, 
which can specifically cleave themselves, a DNA or RNA molecule at a specific site, 
mediating degradation or ligation of yonder. The mostly used ribozymes are hammerhead 
ribozymes and group-I-intron self-splicing ribozymes. Both have recognition sites 
specifically hybridizing to a target mRNA, mediating cleavage or splicing. Group-I-self 
splicing ribozymes can be altered to introduce a desired cDNA portion to be trans-spliced 
3’ of the endogenous target site. Besides the fact that recognition sites of ribozymes are 
rather short (~ 30nt for group-I-self splicing introns) and therefore increasing the 
probability of hybridizing unspecifically or off-target, only downstream gene portions can 
be replaced. For 5’ mRNA stretches this approach is not applicable. Regarding EB, 
McLean I and Terron A engineered three ribozymes mediating specific cleavage of EBS 
underlying keratin 14 (McLean & Terron, 2002). Cleavage of more than 90% of 
endogenous keratin 14 in cultured keratinocytes was achieved upon transfection. 
However, no differentiation between wildtype and mutated alleles was possible, resulting 
in a nearly complete loss of K14 mRNA, necessitating rescue by ribozyme resistant 
wildtype keratin 14. Given the limitations of the above mentioned approaches we assume 
that Spliceosome Mediated RNA Trans-splicing (SMaRT) is a promising tool for gene 
therapy.  
2.1 Spliceosome Mediated RNA Trans-Splicing 
Spliceosome Mediated RNA Trans-Splicing (SMaRT) is a gene therapeutic approach, taking 
advantage of the cell’s spliceosome to recombine two distinct pre-mRNAs to result in one 
mature mRNA. Pre-mRNA splicing is a naturally occurring process during mRNA 
maturation, which was first seen in trypanosomes, nematodes and recently also in humans 
(Murphy et al., 1986; Flouriot et al., 2002; Davis et al., 1995). During trans-splicing, the 
spliceosome ligates a 5’ exon from one pre-mRNA with a 3’ exon from another pre-mRNA, 
thereby producing an “alternative” mature mRNA, composed of exons derived from two 
different precursors. For SMaRT, this process is utilized to replace a disease causing gene 
portion by its wildtype copy. With this technology, any coding region of interest can be 
trans-spliced to any targeted, endogenous pre-mRNA (Puttaraju et al., 1999). Depending on 
the gene portion to be replaced, 5’ exon replacement, 3’ exon replacement and internal exon 
replacement (IER) are distinct (Figure 1).  
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However, no differentiation between wildtype and mutated alleles was possible, resulting 
in a nearly complete loss of K14 mRNA, necessitating rescue by ribozyme resistant 
wildtype keratin 14. Given the limitations of the above mentioned approaches we assume 
that Spliceosome Mediated RNA Trans-splicing (SMaRT) is a promising tool for gene 
therapy.  
2.1 Spliceosome Mediated RNA Trans-Splicing 
Spliceosome Mediated RNA Trans-Splicing (SMaRT) is a gene therapeutic approach, taking 
advantage of the cell’s spliceosome to recombine two distinct pre-mRNAs to result in one 
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the gene portion to be replaced, 5’ exon replacement, 3’ exon replacement and internal exon 
replacement (IER) are distinct (Figure 1).  
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Commonly, SMaRT is applied as a therapeutic tool, replacing gene portions harbouring a 
disease relevant mutation. Such settings were reported for epidermolysis bullosa (COL7A1, 
KRT14, PLEC) (Murauer et al., 2010; Wally et al., 2010; Wally et al., 2008), Duchenne 
muscular dystrophy (Lorain et al., 2010), cystic fibrosis (Liu et al., 2002; Song et al., 2009), 
frontotemporal dementia with parkinsonism (Rodriguez-Martin et al., 2009), severe 
combined immunodeficiency (Zayed et al., 2007), spinal muscular atrophy (Coady et al., 
2007), sickle cell anemia and ß-thalassemia (Kierlin-Duncan and Sullenger, 2007). First in 
vivo assays showed the functionality of SMaRT in a mouse model of spinal muscular 
atrophy (Coady et al., 2008; Coady and Lorson, 2010). However, SMaRT has also been 
shown to be functional for a number of other approaches like in vivo imaging (Walls et al., 
2008), antibody and therapeutic protein production (Wang et al., 2009; Iwasaki et al., 2009) 
and suicide therapy in squamous cell carcinoma (Gruber et al., 2011).  
 
 
Fig. 1. RNA trans-splicing can be performed to replace one or more (a) 5’, (b) 3’ or (c) 
internal exons.  
Technically, SMaRT is triggered by RNA-trans-splicing molecules (RTMs), which are 
specifically engineered for targeting a selected endogenous mRNA. Depending on the type of 
trans-splicing to be applied (5’, 3’ or IER), RTMs have to comprise certain features facilitating 
the trans-splicing process to take place. These are (a) The coding region to be replaced or 
integrated, (b) a hybridization/binding domain (BD), (c) a spacer region for sterical reasons 
and (d) splicing elements like a branch point (BP), polypyrimidine tract (PPT) and functional 
splice sites (SS). For 5’ trans-splicing the RTM comprises the 5’ (wildtype) coding sequence to 
be replaced, a spacer region and a binding domain. The binding domain hybridizes to the 
targeted intron, facilitating the generation of a mature mRNA mediated by the cell’s 
spliceosome, comprising the 5’ exons from the RTM and the 3’ exons from the endogenous 
target. For 3’ trans-splicing a PPT and a BP have to be included for spliceosome assembly (for 
5’ trans-splicing PPT and BP are provided by the endogenous target intron). Internal exon 
replacement is a combination of 5’ and 3’ trans-splicing (Figure 1). 
Recent studies have shown that the binding domain is crucial for the efficiency, 
functionality and specificity of the replacement process. The binding domain is cloned 
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reverse and complementary and usually targets the intron adjacent to the most central exon 
to be replaced. Recent studies showed that slight variations in the sequence can render an 
RTM from a highly functional to a non-functional or very weak RTM. The mechanisms to 
consider when rationally designing a binding domain are not yet clearly understood.  
3. SMaRT for EBS-MD 
Correction of PLEC by spliceosome mediated RNA trans-splicing was first demonstrated 
2008 (Wally et al., 2008). In brief, a rationally designed RTM was engineered, targeting 
intron 9 to replace the upstream coding sequence including exon 9 of the endogenous PLEC 
mRNA. EBS-MD patient fibroblasts, harbouring a 3bp insertion in exon 9 (1287ins3) (Bauer 
et al., 2001) were transduced with the RTM and trans-splicing was monitored on RNA level, 
protein level and by immunofluorescence microscopy. An increase of full-length plectin 
protein by 58,7% was detected in transfected fibroblasts, whereas untreated fibroblasts 
showed hardly any expression. Even though the whole amount of plectin was still less than 
in wildtype fibroblasts, characteristic cytoplasmatic plectin-specific staining was detected by 
immunofluorescence microscopy. On RNA level, semi-quantitative real-time PCR (SQRT-
PCR) revealed an increase of 83,42% of plectin mRNA expression. The rationally designed 
RTM used in this study was designed to cover the 3’ exon 9/intron 10 junction of the plectin 
pre-mRNA. Even though these results were promising, potential improvement by the 
variation of the binding domain was likely to be achieved. We therefore established a 
method to identify highly efficient binding domains for any gene of interest from a large 
pool of RTMs with randomly generated binding domains. From these libraries highly potent 
RTMs can be isolated and much information about the design of yonder can be obtained. 
4. Principles of a fluorescence based RTM screen 
The studies mentioned above showed that the binding domain is crucial for the efficiency 
and specificity of the trans-splicing process. Even minor variations in binding position, 
length and composition of the BDs result in significantly different efficiencies of the trans-
splicing process. Rational design and evaluation of RTM binding domains can be an 
arduous process as there are no convincing criteria for the design of the binding domain. To 
simplify the process of RTM design we have developed a screening system that can be used 
to select the most efficient RTMs from a library containing a diversity of RTMs with 
complementary binding domains (BDs) for a certain target region of a pre-mRNA of 
interest. Using this method we can test a high number of RTMs for the efficiency of 
randomly generated binding domains. Binding domains are obtained by sonication or 
restriction digest of the targeted exonic and/or intronic region of the gene of interest. The 
resulting fragments have a length between 50 and 400bp (depending on the target region of 
choice) and are cloned into a fluorescence based RTM backbone. This random cloning 
results in the inclusion of one or more binding domains in a sense or antisense orientation, 
thereby resulting in about 50% of RTMs with a binding domain in a correct orientation for 
target hybridization, which is complementary. The vector backbone consists of a 
fluorescence reporter gene (e.g. dsRed) as transfection control and a 5’ or 3’ portion of a 
second fluorescence reporter gene (e.g. acGFP) respectively, mimicking the target gene 
portion to be trans-spliced to, therefore being the trans-splicing reporter. The generated RTM 
libraries are co-transfected with a corresponding target vector, harbouring the targeted full-
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reverse and complementary and usually targets the intron adjacent to the most central exon 
to be replaced. Recent studies showed that slight variations in the sequence can render an 
RTM from a highly functional to a non-functional or very weak RTM. The mechanisms to 
consider when rationally designing a binding domain are not yet clearly understood.  
3. SMaRT for EBS-MD 
Correction of PLEC by spliceosome mediated RNA trans-splicing was first demonstrated 
2008 (Wally et al., 2008). In brief, a rationally designed RTM was engineered, targeting 
intron 9 to replace the upstream coding sequence including exon 9 of the endogenous PLEC 
mRNA. EBS-MD patient fibroblasts, harbouring a 3bp insertion in exon 9 (1287ins3) (Bauer 
et al., 2001) were transduced with the RTM and trans-splicing was monitored on RNA level, 
protein level and by immunofluorescence microscopy. An increase of full-length plectin 
protein by 58,7% was detected in transfected fibroblasts, whereas untreated fibroblasts 
showed hardly any expression. Even though the whole amount of plectin was still less than 
in wildtype fibroblasts, characteristic cytoplasmatic plectin-specific staining was detected by 
immunofluorescence microscopy. On RNA level, semi-quantitative real-time PCR (SQRT-
PCR) revealed an increase of 83,42% of plectin mRNA expression. The rationally designed 
RTM used in this study was designed to cover the 3’ exon 9/intron 10 junction of the plectin 
pre-mRNA. Even though these results were promising, potential improvement by the 
variation of the binding domain was likely to be achieved. We therefore established a 
method to identify highly efficient binding domains for any gene of interest from a large 
pool of RTMs with randomly generated binding domains. From these libraries highly potent 
RTMs can be isolated and much information about the design of yonder can be obtained. 
4. Principles of a fluorescence based RTM screen 
The studies mentioned above showed that the binding domain is crucial for the efficiency 
and specificity of the trans-splicing process. Even minor variations in binding position, 
length and composition of the BDs result in significantly different efficiencies of the trans-
splicing process. Rational design and evaluation of RTM binding domains can be an 
arduous process as there are no convincing criteria for the design of the binding domain. To 
simplify the process of RTM design we have developed a screening system that can be used 
to select the most efficient RTMs from a library containing a diversity of RTMs with 
complementary binding domains (BDs) for a certain target region of a pre-mRNA of 
interest. Using this method we can test a high number of RTMs for the efficiency of 
randomly generated binding domains. Binding domains are obtained by sonication or 
restriction digest of the targeted exonic and/or intronic region of the gene of interest. The 
resulting fragments have a length between 50 and 400bp (depending on the target region of 
choice) and are cloned into a fluorescence based RTM backbone. This random cloning 
results in the inclusion of one or more binding domains in a sense or antisense orientation, 
thereby resulting in about 50% of RTMs with a binding domain in a correct orientation for 
target hybridization, which is complementary. The vector backbone consists of a 
fluorescence reporter gene (e.g. dsRed) as transfection control and a 5’ or 3’ portion of a 
second fluorescence reporter gene (e.g. acGFP) respectively, mimicking the target gene 
portion to be trans-spliced to, therefore being the trans-splicing reporter. The generated RTM 
libraries are co-transfected with a corresponding target vector, harbouring the targeted full-
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length exonic and/or intronic region and the respective 5’ or 3’ reporter gene portion. 
Crucial is the inclusion of functional splice sites at the junctions of the split fluorescence 
reporter to facilitate trans-splicing. Functional trans-splicing upon co-transfection results in 
cells double positive for both reporter genes. The ratio between the transfection control 
reporter and the trans-splicing reporter gives information about the quality of the RTM. 
Cells transfected by highly functional RTMs show a proportional transfection control 
expression (dsRed) in relation to the trans-splicing reporter (acGFP), whereas RTMs with 
low trans-splicing efficiencies show a high amount of cells expressing exclusively the 
transfection control and less cells expressing the trans-splicing product (i.e. acGFP) as well. 
4.1 RTM library construction for plectin and screening for highly functional molecules 
For plectin we cloned two 5’ trans-splicing libraries. Trans-splicing of the RTM to the target 
results in the restoration of the open reading frame of acGFP, leading to the expression of 
the full-length protein in RTM and target co-transfected cells. Based on the previously 
described correction of PLEC by 5’ trans-splicing (Wally et al., 2008) we selected the target 
region exon/intron 9 (199bp in length) of PLEC, using the acGFP split reporter and dsRed as 
reporter for RTM transfection.  
 
 
Fig. 2. Schematic depiction of the fluorescence based RTM screening system for the plectin 
gene. 
To widen the spectrum of mutations included in the upstream coding region of PLEC, we 
constructed another library and its respective target molecule for exon/intron 30 (998bp in 
length) in parallel.  
The RTM backbone for the exon/intron 30 specific BD library includes the more intense 
tdTomato instead of dsRed as RTM transfection control. The RTM screening system requires 
cells expressing an RTM and a plectin specific target molecule. Interaction between the RTM 
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and target pre-mRNAs by RNA trans-splicing leads to the fusion of both split parts of 
acGFP, thus restoring the full-length coding sequence and expression of acGFP. The target 
molecule harbors the 3’ acGFP part flanked by a 3’ splice site (SS) and the genomic region of 
PLEC (exon/intron 9 or 30). The RTM contains the 5’ portion of acGFP linked in frame with 
the reporter gene tdTomato (for exon/intron 30) or dsRed (exon/intron 9) respectively. The 
5’ acGFP part is flanked by a functional 5’SS, a short spacer sequence and a binding domain 
randomly created by fragmenting the PLEC target region (Figure 2). 
 
 
Fig. 3. Composition of the binding domains of all RTMs tested for exon/intron 9 (A) and 
exon/intron 30 (B).  
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The 5’ trans-splicing arm of the RTM backbone, downstream of the 5’ portion of acGFP, 
contains a donor (5’) splice site, a short spacer region and a random binding domain created 
by fragmentation of the respective PLEC target region. A high diversity of RTMs with 
different binding properties to the targeted exon/intron regions was constructed either by 
sonication (exon/intron 30) or CviJI* digestion (exon/intron 9) of the PCR amplified target 
region. CviJI* produces blunt end DNA fragments, cleaving between a G and a C of the 
sequence 5’-PuGCPy-3’. The randomized CviJI* digested, as well as the blunt end repaired 
sonicated fragments were cloned into the RTM backbone. To show the robustness of the 
screening system, 5’ BD libraries consisting of about 102 to 104 individual clones were 
constructed and several randomly picked clones were sequenced to select those with the 
correct (complementary) orientation. 10 RTMs from the exon/intron 9 library (Figure 3A) 
and 22 RTMs from the exon/intron 30 library (Figure 3B) harboring one or more parallel 
and/or complementary binding domains were tested for their trans-splicing efficiency, 
quantifying GFP expression by semi-quantitative real time PCR (SQRT-PCR) on mRNA 
level (for exon/intron 30 specific RTMs) and by flow cytometry on protein level 
(exon/intron 9 and 30 specific RTMs).  
For all RTMs (1-10 for ex/in9 and 1-22 for ex/in 30) the binding domains were characterized 
and mapped (Figure 3). BDs in a complementary orientation (white bars) as well as BDs in a 
parallel orientation (black bars) were identified. Some RTMs had more than one BD 
included. BDs were named a to j and a to v respectively. Numbers next to the alphabetic 
characters indicate their order from 5’ to 3’. 
4.1.1 Screening for efficient 5’ RTMs targeting exon/intron 9 of the plectin gene 
Ten individual RTMs from a 5’ BD library were selected to show the potential and 
robustness of the RTM screening system. Eight RTMs contain complementary BDs to the 
target region exon/intron 9, inducing the trans-splicing reaction between target and RTM 
pre-mRNAs. RTMs 7 and 8 harbor a BD parallel to the target region and are therefore 
included as negative controls in the experiments. Co-transfection of target expression 
plasmids along with either one of the ten RTMs resulted in a diverse expression profile of 
dsRed and acGFP (Figure 4). Weak RTMs (1, 7-10) show only low expression levels of 
dsRED - acGFP protein in comparison to the highly efficient RTMs 2-6. RTMs 7 and 8, 
harboring parallel BDs, produce a background expression of acGFP in less than 1% of all 
analyzed cells. The most efficient RTMs 2-6 show functional acGFP expression in 44-67% of 
all treated cells with a geometric mean of acGFP expression ranging from 6 (RTM 3) to 8 
(RTM 6) (Figure 4B). These values reflect the average acGFP expression of all analyzed GFP 
positive cells. Geometric mean calculations after flow cytometric analysis were performed 
using the FlowJo software (Treestar). Flow cytometric analysis of RTM 6, 7 and 9 transfected 
HEK293AD cells show a significant difference in the amount of acGFP expression and 
fluorescence intensity (Figure 4A). RTM 6 contains a complementary BD, binding exon 9 
only, but close to the exon/intron junction, maybe influencing the 5’ splice site on the target 
molecule. This might be the reason why RTM 6 is significantly more efficient in comparison 
to RTM 7 or RTM 9, harboring a parallel (RTM 7) or a short antisense BD (RTM 9). No 
acGFP expression was detected in HEK293AD cells transfected with either target or RTM 
alone. As the binding position of RTMs 2-6 on the target molecule is similar, there was not 
much difference in reporter gene expression. Masking almost the whole exon 9 with 
complementary BDs seems to increase the trans-splicing efficiency significantly. RTMs 1, 9 
and 10 contain either short BDs specific for a short stretch of the target exon (RTM 10) or for 
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a short portion containing the 5’ exon/intron boundary (RTM 1 and 9). These RTMs induced 
acGFP expression in less than 14% of transfected cells. Additionally, the intensity of acGFP 
expression was much lower (Figure 4).  
 
 
Fig. 4. Exon/intron 9: Expression of the fluorescence reporter genes acGFP and dsRed and 
the percentage of acGFP positive cells.  
4.1.2 Screening for efficient 5’ RTMs targeting exon / intron 30 of the plectin gene 
The same experiments as described for exon/intron 9 were conducted for exon/intron 30. 
This intron was chosen to cover a maximum 5’ PLEC gene portion and thereby including 
more known mutations. Again, flow cytometric analysis was performed with HEK293AD 
cells co-transfected with RTM and target plasmids. For each RTM two independent co-
transfections were performed. Two days after co-transfection, the subset of acGFP 
expressing cells and the expression level of acGFP was quantified by flow cytometry. The 
number of acGFP positive cells and the relative amount of acGFP expressed reflect the 
functionality of RTMs and their respective binding domains. Between 5.103-2.104 
HEK293AD cells were analyzed for each transfection.  
After transfecting each of the 22 RTMs, harboring at least one complementary binding domain, 
together with the target molecule into HEK293AD cells, flow cytometry was performed. The 
geometric mean of acGFP expression ranged from 1.3 to 3.2 according to the RTM introduced 
into the target cells. The highly efficient RTMs 12, 13 and 17 showed acGFP expression in over 
20% of all transfected cells and had a calculated geometric mean of over 2.6. RTMs with a 
weak trans-splicing efficiency (e.g. RTMs 1, 4, 11) showed a high amount of cells expressing the 
RTM transfection control gene tdTomato only and less cells expressing acGFP as well (Figure 
5B). By setting the highly efficient RTMs 5, 12 and 17 in relation to the weak RTM 22, 
significant differences in their reporter gene expression were observed (Figure 5A). RTMs 5, 12 
and 17 produced significantly higher levels of acGFP. RTM 22 generated only a background 
expression of acGFP in about 1% of analyzed HEK293AD cells. 
Besides flow cytometry, all 22 RTMs with BDs ranging from 57 to 355 nucleotides, 
complementary to essentially all regions of the exon 30/intron 30 target (Figure 3B), were 
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a short portion containing the 5’ exon/intron boundary (RTM 1 and 9). These RTMs induced 
acGFP expression in less than 14% of transfected cells. Additionally, the intensity of acGFP 
expression was much lower (Figure 4).  
 
 
Fig. 4. Exon/intron 9: Expression of the fluorescence reporter genes acGFP and dsRed and 
the percentage of acGFP positive cells.  
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Besides flow cytometry, all 22 RTMs with BDs ranging from 57 to 355 nucleotides, 
complementary to essentially all regions of the exon 30/intron 30 target (Figure 3B), were 
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individually tested for trans-splicing induced restoration of acGFP expression by SQRT-
PCR. A PLEC specific 5’ trans-splicing RTM is able to recombine with a target pre-mRNA by 
a specific 5’ trans-splicing reaction. Thus the exon on the target molecule is replaced by the 
5’ part of acGFP, leading to the expression of the reporter molecule acGFP in RTM treated 
cells. Trans-splicing between the RTM and target molecule was detected by semi-
quantitative real-time PCR (SQRT-PCR). For that, an acGFP specific primer pair was used to 
quantify the amount of full-length acGFP transcripts present in HEK293AD cells co-
transfected with the target molecule plasmid harboring exon/intron 30 of PLEC along with 
either one of the 22 RTMs (Figure 6). This demonstrates that the acceptor (3’) and donor (5’) 
splice sites on the target molecule and the RTM were recognized by the endogenous splicing 
machinery and that both acGFP parts were connected by 5’ RNA trans-splicing, leading to 
full-length acGFP expression. By analyzing the amount of expressed acGFP transcripts in co-
transfected HEK293AD cells, the influence of different RTM binding domains on trans-
splicing efficiency can be shown on mRNA level. As a reference gene, GAPDH was used. 
For the evaluation of the results all RTMs were referred to the weakest RTM 11 (set to 1), 
producing a low level of acGFP. As shown in Figure 6, RTMs 5, 12 and 17, accomplishing 
the exon/intron boundary of the target molecule by their complementary BDs, showed a 
high trans-splicing efficiency. RTM 12 achieved an up to 90 fold expression of acGFP 
transcripts in comparison to RTM 11. Masking the 5’ splice site on the target molecule may 
direct the ratio of the splicing reactions from cis to trans, since the binding of splicing factors 







Fig. 5. Exon/intron 30: Expression of the fluorescence reporters acGFP : tdTomato was 
analyzed using flow cytometry (A) Four RTMs with different BDs show varying ratios of 
acGFP : tdTomato (B) The percentage of acGFP positive cells is summarized for all RTMs 
tested.   
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The data created by flow cytometric analysis (Figure 5) correlates with those obtained from 
semi-quantitative real-time PCR (SQRT-PCR). RTMs 5, 12 and 17, hybridizing to the 
exon/intron junction of the target molecule showed high trans-splicing efficiencies on 
mRNA (SQRT-PCR) and protein (flow cytometry) level, indicating the reliability of the RTM 
screening system. Since the highly efficient RTMs 5, 12 and 17 have similar complementary 
binding domains (exon/intron junction of the target molecule), this region seems to be the 
ideal binding position for efficient RNA trans-splicing in the case of the PLEC gene region 
exon/intron 30. The blockage of the exon/intron boundary of the target molecule, 







Fig. 6. Exon/intron 30: acGFP expression on mRNA level. 
4.2 Trans-splicing with endogenous PLEC transcripts 
One day after transfection of single RTMs into HEK293AD cells, endogenous trans-splicing 
was detected by RT-PCR. Specific trans-splicing between the RTM and the endogenous 
target pre-mRNA of PLEC resulted in the fusion of the 5’ portion of acGFP to exon 10 or 31 
of PLEC. The fusion mRNA was amplified by including an acGFP specific forward primer 
and an exon 10 or 31 specific reverse primer into the polymerase chain reaction. After gel 
electrophoresis the 5’acGFP-exon 10/31 PLEC fusion PCR product was visible on an agarose 
gel at a size of 413bp and 542bp respectively (Figure 7). The DNA band was gel purified and 
sequenced. All RTMs introduced into HEK293AD cells (RTMs specific for exon/intron 9: 1-
6, RTMs specific for exon/intron 30: 7, 12, 13), induced endogenous 5’ trans-splicing.  
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Fig. 7. Single transfection of selected RTMs (exon/intron 9 or 30 RTM screen) into 
HEK293AD cells resulted in the fusion of the 5’ portion of acGFP of the RTM to the 
respective endogenous target exon of PLEC (exon 10 or exon 31) on pre-mRNA level.  
5. Discussion 
During the last years it was shown that SMaRT is a functional tool for the correction of 
disease causing mutations of many genes on mRNA level. Several approaches in different 
settings (i.e. reporter gene based, endogenous trans-splicing, in vivo application) have 
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corroborated this assumption (Dallinger et al., 2003; Coady and Lorson, 2010; Wally et al., 
2010). Also the applicability of SMaRT beyond mRNA repair was shown, using it for in vivo 
imaging and antibody and protein production. For the latter, therapeutic protein encoding 
sequences were trans-spliced to the highly abundant albumin mRNA, resulting in the 
expression of the therapeutic molecule (Wang et al., 2009). For epidermolysis bullosa, 
SMaRT was applied for a number of underlying genes, including PLEC (Wally et al., 2008), 
COL7A1 (Murauer et al., 2010), K14 (Wally et al., 2010) and COL17A1 (our unpublished 
results). Whereas for PLEC and COL7A1 the binding domains of the RNA–trans-splicing 
molecules (RTMs) were designed empirically, based on preliminary data, the binding 
domains for K14 and COL17A1 resulted from the evaluation of a number of randomly 
cloned BDs. Using a fluorescence based screening system, we saw that binding domains are 
crucial for the efficiency and specificity of the trans-splicing process. In this reporter-based 
assay, BDs were tested independently from the influence of gene characteristics and 
variations in splicing domains. This facilitated a direct comparison of the BDs, revealing a 
high impact of (a) localization within the targeted exon/intron, (b) composition and (c) 
length. Comparing obtained data, hints on principles for BD design were extracted. These 
are: (a) highly functional BDs have a length between 90 and 170bp, (b) masking of the 
competitive exon/intron junction is mostly beneficial, (c) targeting of a large intron results 
in more potential and diverse trans-splicing results since more binding sites are available. 
Furthermore, these facts underlay a hierarchy, with length ranging before splice site 
masking. Best BDs identified in the exon/intron 30 screen had a length of around 140 - 
170bp AND masked the respective target splice site. An optimal target intron is not always 
available, restricting optimization in this aspect. However, screening for BDs also revealed 
exceptions from the rule. For example binding domains from RTMs 5 and 6 for exon/intron 
9 exclusively bind within the exon. Even though we know that also splicing domains and 
spacer sequences influence trans-splicing success, regarding the BDs, it is not yet clearly 
understood what further influences trans-splicing efficiency and specificity. The first 
published BD for PLEC (Wally et al., 2008) masked the target splice site to be used for trans-
splicing, resulting in reasonable trans-splicing rates. However, we still recommend using the 
fluorescence based screening system, as this is rather facile as soon as vector backbones are 
cloned. Backbones can be used for any gene of interest and any targeted intron. Within the 
K14 gene, the applicability of SMaRT for dominant diseases was shown. The concomitant 
knock-down of the mutated and the increase of the wildtype allele multiply the effect of 
correction. Even though endogenous efficiencies are not high level, trans-splicing rates can 
be enough to revert a disease phenotype. Werner et al. showed in an in vitro model that 
dominance is limited and depends on the ratio of wildtype versus mutated K14 molecules 
(Werner et al., 2004). Also, for dominant COL7A1 mutations, overexpression of the wildtype 
protein can rescue the RDEB phenotype (Fritsch et al., 2009). Finally, Cao et al. showed that 
dominance is dependent on a certain ratio of wildtype to mutant alleles; in their in vivo 
mouse model a neomycin-resistance gene inserted in intron 1 of K14 led to a 50% reduction 
of the mutated K14 expression, resulting in phenotypically normal pups which showed no 
blistering (Cao et al., 2001). In view of this ameliorative effect, therapeutic approaches able 
to reduce the expression of a mutant gene product by 50% could be sufficient. Functional 
assays with RTM treated patient cells showed a transition of migratory behaviour and 
invasiveness versus wildtype in respective tests. 
An improvement of the screen will be the sorting of analysed cells, resulting in a faster and 
more restricted identification of highly functional RTMs. Isolation of cells showing a certain 
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COL7A1 (Murauer et al., 2010), K14 (Wally et al., 2010) and COL17A1 (our unpublished 
results). Whereas for PLEC and COL7A1 the binding domains of the RNA–trans-splicing 
molecules (RTMs) were designed empirically, based on preliminary data, the binding 
domains for K14 and COL17A1 resulted from the evaluation of a number of randomly 
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ratio of the two fluorescence reporters expressed will increase the number of potential 
binding domains characterized. Single cell expansion and plasmid extraction will provide 
highly potential BDs to integrate into an endogenous setting of spliceosome mediated RNA 
trans-splicing.  
The development of an RTM selection system has a high impact on trans-splicing efficiency 
and specificity. Further improvements can be made regarding codon usage, nuclear 
retention signals, promoter selection and mode of delivery. Inclusion of nuclear retention 
signals might have great influence on the trans-splicing efficiency, but also regarding 
minimization of side effects and background expression of unspliced RTMs. Codon 
optimization and the use of weaker promoters and enhancers can be used to increase the 
safety of retrovirally introduced RTMs (Baum and Schambach, 2011; Fath et al., 2011).  
Currently, a limiting fact is the lack of mouse models meeting the exigencies of a SMaRT 
approach. Many mouse models are generated by the inclusion of intron-free genes, making 
them unfeasible trans-splicing experiments. However, mouse models are becoming easier 
available and creatable. This will pave the way to in vivo studies as the basis for clinical 
trials. 
6. Prospects and visions 
Bringing spliceosome mediated RNA trans-splicing toward clinics is the aim of presumably 
all conducted studies for mRNA correction. This technology also gives hope to patients 
suffering from EB subtypes which cannot be treated by commonly used approaches like full-
length cDNA based therapy. Patients regarding this have alterations in very large genes like 
PLEC, COL7A1 and COL17A1, and also those harbouring mutations in dominantly inherited 
genes, like K14 and K5. The next step will be to show in vivo, that trans-splicing can convert a 
disease phenotype to wildtype. The generation of viable, intron-posessing mouse models is 
a task that is being gone about currently. Looking further, ex vivo gene therapy is the 
currently most favoured approach for epidermolysis bullosa patients. Transplantation of 
skin sheets derived from autologous epidermal stem cells that were transduced with a 
respective corrective molecule is the current state of the art. This approach was successfully 
conducted for full-length cDNA therapy in junctional epidermolysis bullosa in 2006 
(Mavilio et al., 2006). There, a 50cm2 area was replaced on the patient legs. Even five years 
after transplantation the transplanted areas have not shown any blisters at all and are 
indistinguishable from healthy skin (De Luca, personal communication).  
However, systemic application of SMaRT is the technology to go for, which is not 
available yet. Delivery of (any) gene therapeutic advice is a problem common to all 
approaches. Increasing the safety of lenti- and retroviral vectors is being pushed forward 
with good results. Also the use of transposons like sleeping beauty (Hackett et al., 2010) 
and piggyBack (Yusa et al., 2011) are promising tools. Finally, targeting is another 
challenge to be overcome. However, in this case SMaRT has the advantage of being 
functional only in cells expressing the target gene, therefore minimizing off-target effects 
in other cell types.  
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1. Introduction  
Effective diagnostic and therapeutic intervention of genetic diseases have been particularly 
pending on technological development. It was not until the last two decades of the past 
century that molecular biology and recombinant DNA have provided diagnostic and 
therapeutic tools for these diseases. Since then, our understanding of the biological processes 
underscoring genetic conditions and the development of technologies enabling their study and 
treatment have vastly grown, providing scientists and clinicians with means to continue 
advancing in these directions. Recently, another technology has strongly impacted the fields of 
molecular biology, medicine, diagnostic and therapeutic development: nanotechnology. 
More precisely, nanotechnology focuses on the study and manipulation of matter and 
processes at the nanometer (10-9 m) scale, encompassing the atomic, molecular, and 
macromolecular scales. In this chapter, we use the term nanotechnology from a more broad 
perspective, referring to devices fabricated at the sub-micrometer scale, a size compatible 
with that of large biological macromolecular complexes and cellular organelles, which are 
often referred to as nano- as well, due to the nanoscale of their architectural and/or 
functional components. The application of nanotechnology principles and tools to the field 
of medicine, known as nanomedicine, is also a relatively young field that has vastly 
expanded within the last couple of decades to render new diagnostic and treatment 
approaches. However, delivery of active agents assisted by these technologies is still a 
relatively unexplored strategy in the case of genetic diseases. 
This chapter discusses some of the technological advances regarding the application of 
nanomedicine to the treatment of genetic conditions. Some basic foundation on the design 
and features of these technologies are provided, including targeting, transport, and delivery 
capabilities of drug delivery systems. Applications in the context of genetic diseases are also 
discussed, including treatment of phenotypic symptoms and complications associated to 
these conditions, and correction therapies, such as treatment with small molecules, non-viral 
gene therapies, cell therapies, and enzyme replacement therapies.  
2. Types and properties of drug delivery tools used in nanomedicine 
An area of research where nanotechnology and nanomedicine applications have been 
particularly prolific pertains to delivery of diagnostic and therapeutic agents. Drug delivery 
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carriers are macromolecular assemblies that can incorporate imaging and therapeutic 
compounds of distinct nature, such as small chemicals, fluorophores and biosensors, 
peptides and proteins, and oligonucleotides and genes. They can be designed to improve 
the solubility of these cargo molecules and their bioavailability, and also to control their 
circulation, biodistribution in the body, and release rate, altogether enhancing their efficacy 
(Langer, 1998, Duncan, 2003, Panyam & Labhasetwar, 2003, Moghimi, et al., 2005).  
2.1 Nanocarrier design  
A broad spectrum of materials (biological, synthetic and semi-synthetic) assembled in a variety 
of conformational arrays (from linear structures to branched and dendritic counterparts, 
micelles, hollow capsules, porous or solid particles, etc.) have been designed to help in 
diagnostic and therapeutic interventions (Langer, 1998, Discher & Eisenberg, 2002). Examples 
of these include carbon nanostructures, quantum dots, metal particles, liposomes, and 
formulations based on natural and/or synthetic polymers (Figure 1). The composition and 
architecture of these systems play an important role in determining their translational 
capabilities, including their ability to carry cargoes of different chemistries and their loading 
capacity, stability, biodegradability and overall biocompatibility, and various functional 
aspects (Moghimi, et al., 2001, El-Sayed, et al., 2005, Stayton, et al., 2005, Torchilin, 2006).  
 
 
Fig. 1. Composition and architecture of carriers and other assemblies (not drawn to scale) 
utilized in nanomedicine for diagnosis, imaging, and drug delivery. Yellow, purple, and 
blue colors correspond to formulations discussed in sections 2.1.1, 2.1.2, and 2.1.3. 
2.1.1 Lipid vesicles 
Lipid-based micelles (encapsulating vesicles formed by a single phospholipid layer, ranging 
from ~5 to 100 nm in diameter) and mostly liposomes (vesicles delimited by a phospholipid 
bilayer, with sizes from 50 nm to several micrometers) have been extensively studied for 
more than half a century in the context of transport of diagnostic and therapeutic agents 
(Musacchio & Torchilin, 2011). These vesicles can be constructed with natural lipids, mainly 
derivatives of phosphatidyletanolamine, phosphatidylcholine, phosphatidylserine, and 
phosphatidylglycerol, to mimic cellular membranes. Because phospholipids can 
spontaneously form lipid bilayer-contained capsules in aqueous solution, hydrophilic 
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molecules can be loaded within the inner volume of the vesicle or attached on the liposome 
surface, while hydrophobic cargo can be embedded within the bilayer. Targeting moieties 
with affinity to markers in the body, imaging molecules, and/or polymer coats (discussed 
below) can be incorporated on the surface in order to enhance their circulation, provide 
selective targeting, and improve transport (Minko, et al., 2006, Musacchio & Torchilin, 2011).  
Yet, liposomes can only bear a relatively low degree of said modifications, rendering them 
relatively unstable and susceptible for rapid clearance, mainly due to deposition of plasma 
immunoglobulins and proteins on their surface, favoring uptake by macrophages of the 
reticuloendothelial system (Moghimi & Szebeni, 2003). New approaches are combining 
polymers with liposomal formulations to improve these aspects (Musacchio & Torchilin, 2011).  
2.1.2 Polymer nanocarriers 
Polymers are macromolecules that result from covalent linkage of smaller structural units or 
repeats referred to as monomers, and can be designed from fully synthetic to biological 
blocks (Moghimi, et al., 2001). Some examples of synthetic polymers employed in drug 
delivery include chemically inert and non-toxic materials such as poly(methyl 
methacrylate), poly(acrylic acid), polyacrylamide, poly(vinyl alcohol), and poly(ethylene 
glycol), among many others. Biological polymers include (but are not restricted to) natural 
gums, polysaccharide-, and polypeptide-based formulations (e.g., chitosan, sodium alginate, 
gelatin, albumin, etc.). Also commonly used due to their biocompatibility and ability to be 
degraded in the body are polyanhydrides, polyorthoesters, polycaprolactone, polylactides, 
polyglycolides, and poly(lactide-co-glycolides). These carriers encompass linear polymers, 
branched polymers and tree-like hyperbranched dendrimers, self-assembled polymersomes 
(the polymer counterpart of liposomes), and more stable particles, with overall sizes ranging 
from a few nanometers to several micrometers (Torchilin, 2006). They can endure a degree 
of modification higher than that of lipososomes, rendering multifunctional formulations that 
can carry therapeutics, targeting moieties, and imaging agents (Duncan, 2003). 
Among them, the polyether poly(ethylene glycol), a polymer of ethylene oxide also known 
as PEG (Figure 2B in section 2.2.1), is one of the polymers most broadly used in 
nanomedicine due to its high hydrophilicity and, hence, its ability to solubilize hydrophobic 
drugs, minimize interaction with the immune system, and prolong the circulation of 
compounds (Moghimi, et al., 2001, Panyam & Labhasetwar, 2003). PEG can be directly 
linked to the therapeutic cargo of interest (oligonucleotides or DNA, proteins, small 
molecules, etc), or it can be coupled to or grafted onto other carriers (Moghimi, et al., 2003).  
Poly(lactide-co-glycolide), known as PLGA, is an FDA-approved material that is also 
commonly used for drug delivery due to its biocompatibility: PLGA is hydrolyzed into 
lactic and glycolic acids with minimal toxicity (Mundargi, et al., 2008) and the rate of 
degradation can be adjusted by modification of the particle size and the lactide-to-glycolide 
ratio for controlled release of the cargo (Panyam & Labhasetwar, 2003). In addition, endo-
lysosomal escape of PLGA carriers can be regulated to some extent by modifying these 
design parameters (Panyam, et al., 2002), which is useful for gaining access to other cell 
compartments. This is also a property of cationic polymers, such as poly-L-lysine and 
poly(ethylenimine) (PEI), whose amine groups become protonated at endosomal pH, 
resulting in osmotic swelling that bursts the endosome (Sonawane, et al., 2003). Although 
these polymers are useful for transfection in cell cultures, due to toxicity, other experimental 
formulations more amenable for in vivo applications are being explored. This is the case for 
pH-sensitive poly(acrylic acid) derivative carriers that act as proton sponges within 
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carriers are macromolecular assemblies that can incorporate imaging and therapeutic 
compounds of distinct nature, such as small chemicals, fluorophores and biosensors, 
peptides and proteins, and oligonucleotides and genes. They can be designed to improve 
the solubility of these cargo molecules and their bioavailability, and also to control their 
circulation, biodistribution in the body, and release rate, altogether enhancing their efficacy 
(Langer, 1998, Duncan, 2003, Panyam & Labhasetwar, 2003, Moghimi, et al., 2005).  
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of conformational arrays (from linear structures to branched and dendritic counterparts, 
micelles, hollow capsules, porous or solid particles, etc.) have been designed to help in 
diagnostic and therapeutic interventions (Langer, 1998, Discher & Eisenberg, 2002). Examples 
of these include carbon nanostructures, quantum dots, metal particles, liposomes, and 
formulations based on natural and/or synthetic polymers (Figure 1). The composition and 
architecture of these systems play an important role in determining their translational 
capabilities, including their ability to carry cargoes of different chemistries and their loading 
capacity, stability, biodegradability and overall biocompatibility, and various functional 
aspects (Moghimi, et al., 2001, El-Sayed, et al., 2005, Stayton, et al., 2005, Torchilin, 2006).  
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molecules can be loaded within the inner volume of the vesicle or attached on the liposome 
surface, while hydrophobic cargo can be embedded within the bilayer. Targeting moieties 
with affinity to markers in the body, imaging molecules, and/or polymer coats (discussed 
below) can be incorporated on the surface in order to enhance their circulation, provide 
selective targeting, and improve transport (Minko, et al., 2006, Musacchio & Torchilin, 2011).  
Yet, liposomes can only bear a relatively low degree of said modifications, rendering them 
relatively unstable and susceptible for rapid clearance, mainly due to deposition of plasma 
immunoglobulins and proteins on their surface, favoring uptake by macrophages of the 
reticuloendothelial system (Moghimi & Szebeni, 2003). New approaches are combining 
polymers with liposomal formulations to improve these aspects (Musacchio & Torchilin, 2011).  
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delivery include chemically inert and non-toxic materials such as poly(methyl 
methacrylate), poly(acrylic acid), polyacrylamide, poly(vinyl alcohol), and poly(ethylene 
glycol), among many others. Biological polymers include (but are not restricted to) natural 
gums, polysaccharide-, and polypeptide-based formulations (e.g., chitosan, sodium alginate, 
gelatin, albumin, etc.). Also commonly used due to their biocompatibility and ability to be 
degraded in the body are polyanhydrides, polyorthoesters, polycaprolactone, polylactides, 
polyglycolides, and poly(lactide-co-glycolides). These carriers encompass linear polymers, 
branched polymers and tree-like hyperbranched dendrimers, self-assembled polymersomes 
(the polymer counterpart of liposomes), and more stable particles, with overall sizes ranging 
from a few nanometers to several micrometers (Torchilin, 2006). They can endure a degree 
of modification higher than that of lipososomes, rendering multifunctional formulations that 
can carry therapeutics, targeting moieties, and imaging agents (Duncan, 2003). 
Among them, the polyether poly(ethylene glycol), a polymer of ethylene oxide also known 
as PEG (Figure 2B in section 2.2.1), is one of the polymers most broadly used in 
nanomedicine due to its high hydrophilicity and, hence, its ability to solubilize hydrophobic 
drugs, minimize interaction with the immune system, and prolong the circulation of 
compounds (Moghimi, et al., 2001, Panyam & Labhasetwar, 2003). PEG can be directly 
linked to the therapeutic cargo of interest (oligonucleotides or DNA, proteins, small 
molecules, etc), or it can be coupled to or grafted onto other carriers (Moghimi, et al., 2003).  
Poly(lactide-co-glycolide), known as PLGA, is an FDA-approved material that is also 
commonly used for drug delivery due to its biocompatibility: PLGA is hydrolyzed into 
lactic and glycolic acids with minimal toxicity (Mundargi, et al., 2008) and the rate of 
degradation can be adjusted by modification of the particle size and the lactide-to-glycolide 
ratio for controlled release of the cargo (Panyam & Labhasetwar, 2003). In addition, endo-
lysosomal escape of PLGA carriers can be regulated to some extent by modifying these 
design parameters (Panyam, et al., 2002), which is useful for gaining access to other cell 
compartments. This is also a property of cationic polymers, such as poly-L-lysine and 
poly(ethylenimine) (PEI), whose amine groups become protonated at endosomal pH, 
resulting in osmotic swelling that bursts the endosome (Sonawane, et al., 2003). Although 
these polymers are useful for transfection in cell cultures, due to toxicity, other experimental 
formulations more amenable for in vivo applications are being explored. This is the case for 
pH-sensitive poly(acrylic acid) derivative carriers that act as proton sponges within 
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lysosomes, and temperature-responsive polyelectrolyte hydrogels whose hydration rate 
varies with temperature, leading to changes in the carrier volume within the endo-
lysosomal compartment (Yessine & Leroux, 2004, El-Sayed, et al., 2005, Choi, et al., 2006).  
Also natural polymers, such as chitosan, are often exploited for their pH sensitivity and 
bioadhesive properties. Chitosan is cationic under neutral or basic conditions, favoring 
adhesion to negatively-charged membranes of cells, and is depolymerized under acidic 
conditions, resulting in pH controlled drug release (Agnihotri, et al., 2004). Since chitosan is 
mucoadhesive and favors permeabilization through the gastrointestinal epithelial layer, this 
polymer is particularly useful to deliver agents by the oral route (Agnihotri, et al., 2004). 
Polymer dendrimers are also suitable for transport across the intestine due to their small 
size and ability to enhance permeability of the epithelial layer (Kitchens, et al., 2005).  
2.1.3 Carbon nanostructures, metal particles and quantum dots 
In addition to liposomes and (synthetic or natural) polymer carriers, carbon nanostructures, 
quantum dots, and metal particles are becoming more commonly used in nanomedicine. 
These materials are often employed in the design of biosensors for diagnostic applications, 
and also some derivatives have been studied in the context of drug delivery.  
Carbon nanostructures (~1-3 nm diameter, (Chen, et al., 2003)), such as single- or multi-
walled carbon nanotubes, carbon nanospheres, extended carbon nanocube networks, etc., 
possess interesting physical properties suitable for applications in nanotechnology, 
electronics, and optics. They are highly stable and versatile in terms of their structural 
conformation, charge, strength, flexibility, etc. (Cheung, et al., 2010). This material can 
also be functionalized with drugs and/or biomolecules for diagnostic and therapeutic 
purposes.  
Quantum dots (QDs) are semiconductors fabricated from a combination of metals and 
non-metals (Choi & Frangioni, 2010). These nanoparticles (~2-10 nm diameter) have 
unique photophysical properties, e.g., upon excitation they emit fluorescence that is 
brighter and more stable than that of traditional fluorophores, and their size can be varied 
to achieve excitation and emission at different wavelengths. They can be detected with 
high sensitivity, which along with their stability, provides an ideal ground for the design 
of ex vivo screening technologies, such as the case of effective diagnosis of genetic diseases 
(Bailey, et al., 2009).  
Metal nanoparticles are also used in biosensors due to their charge, high sensitivity, and 
output stability. Gold is often used for imaging and biosensing due to its biocompatibility 
and unique optical sensitivity (Cai, et al., 2008). Phosphor particles contain rare earth metals 
and have similar characteristics as QDs, being highly photostable and rendering virtually no 
autofluorescence, yet their larger size limits their applications (Corstjens, et al., 2005).  
While the formulations described above are mostly employed for ex vivo diagnostic 
applications due to toxicity, iron oxide nanoparticles, preferentially 10-100 nm in size 
(Shubayev, et al., 2009), which can be additionally coupled to polymers, are being explored 
for imaging and drug delivery. These carriers can be functionalized with various cargoes 
and have been shown to be relatively suitable for transport of therapeutics (Shubayev, et al., 
2009). They present low toxicity, being biocompatible for in vivo applications. Iron oxide 
and, particularly, superparamagnetic iron oxide (SPIO) nanoparticles exhibit magnetic 
properties, which is used for MRI imaging (Kamaly & Miller, 2010) and also provides an 
opportunity to control particle transport by external magnets (Nacev, et al., 2010). 
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2.2 Pharmacokinetics, targeting, and sub-cellular transport of nanocarriers 
Development of effective diagnostic techniques and therapeutic delivery methods carry a 
number of important challenges, many of which may be overcome with the input of 
nanomedicine approaches. The size scale of nanomedicines and the degree of manipulation 
to which they can be subjected, make these endeavors seemingly tangible. Drug delivery 
carriers can be functionalized to improve control of their circulation and biodistribution in 
the body at the tissue, cellular, and sub-cellular level. This can be achieved by incorporating 
immune-evading moieties and/or affinity molecules that favor adhesion to either general or 
specific biological markers, depending on the degree of selectivity required. In addition, 
when carriers are targeted to cellular receptors involved in endocytic transport or coupled to 
cell penetrating peptides, or if they are designed to modify the permeability of cellular 
barriers, they also provide delivery to a variety of intracellular compartments, such as the 
lysosome, cytosol, nuclei, etc., and can furthermore be transported at some extent across 
cellular layers, a requirement for a number of clinical goals (Langer, 1998, Moghimi, et al., 
2001, Panyam & Labhasetwar, 2003, Sahay, et al., 2010, Sawant & Torchilin, 2010). 
2.2.1 Circulation and clearance 
When administered in vivo, therapeutic agents are often recognized as foreign substances 
and, consequently, are rapidly cleared from the body (Moghimi, et al., 2001, Yoo, et al., 
2010). This is a general obstacle of classical means of drug delivery that also applies to 
chemicals used as palliative treatment of symptoms associated to genetic diseases, and 
more specific small molecules used to regulate affected metabolic pathways, inhibitors 
and activators of the affected molecules, chaperones to improve folding and stability, and 
recombinant proteins and enzymes used for replacement therapies. Clearance of foreign 
compounds in the body occurs mainly by the reticuloendothelial system and other 
elements of the immune system, as well as by renal filtration (Moghimi & Szebeni, 2003). 
Resident macrophages in the alveoli remove substances administered into the lungs 
through the respiratory tract, Kupffer’s cells in the liver sinusoids remove materials that 
enter the portal circulation through the gastrointestinal epithelium, materials 
administered in the systemic circulation are cleared mainly by the spleen and liver, and 
the lymph nodes remove substances that arrive to the tissue parenchyma by draining 
them through the lymphatics.  
For most applications, including those designed for treatment of genetic conditions, e.g., 
mostly applicable to small molecule therapies and enzyme replacement therapies, rapid 
clearance is detrimental as it minimizes the chances of the delivered agent to reach its 
targets in the body and accumulate there at amounts amenable to render significant efficacy. 
Avoiding recognition by said clearance systems, e.g., by designing immune evasive 
strategies leading to lengthening of the life-span of the cargo, can improve the efficiency.  
One strategy to control this parameter consists of coupling to poly(ethylene glycol) or PEG, 
known as PEGylation or stealth technology. PEG helps form a hydrophilic brush around 
cargoes and/or their carriers, minimizing interactions with plasma opsonins, the 
complement, professional phagocytes, and lymphocytes which provide specific immunity 
(Moghimi & Szebeni, 2003) (Figure 2A and 2B). As a consequence, certain physiochemical 
properties of the cargo (such as hydrophobicity) are altered, allowing the platform to gain 
solubility and to remain elusive from immune detection. This prolongs the circulation in the 
bloodstream from a few hours to days, which favors lengthened medicinal effects and less 
frequent administrations (Moghimi & Szebeni, 2003, Musacchio & Torchilin, 2011). 
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2010). This is a general obstacle of classical means of drug delivery that also applies to 
chemicals used as palliative treatment of symptoms associated to genetic diseases, and 
more specific small molecules used to regulate affected metabolic pathways, inhibitors 
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through the respiratory tract, Kupffer’s cells in the liver sinusoids remove materials that 
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them through the lymphatics.  
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clearance is detrimental as it minimizes the chances of the delivered agent to reach its 
targets in the body and accumulate there at amounts amenable to render significant efficacy. 
Avoiding recognition by said clearance systems, e.g., by designing immune evasive 
strategies leading to lengthening of the life-span of the cargo, can improve the efficiency.  
One strategy to control this parameter consists of coupling to poly(ethylene glycol) or PEG, 
known as PEGylation or stealth technology. PEG helps form a hydrophilic brush around 
cargoes and/or their carriers, minimizing interactions with plasma opsonins, the 
complement, professional phagocytes, and lymphocytes which provide specific immunity 
(Moghimi & Szebeni, 2003) (Figure 2A and 2B). As a consequence, certain physiochemical 
properties of the cargo (such as hydrophobicity) are altered, allowing the platform to gain 
solubility and to remain elusive from immune detection. This prolongs the circulation in the 
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Fig. 2. Strategies to minimize rapid clearance of nanocarriers. (A) Poly(ethylene glycol) or 
PEG minimizes interaction with plasma proteins and binding to macrophages. (B) CD47 
binding to the surface of immune cells inhibits engulfment and phagocytosis.  
Other strategy to minimize drug removal takes advantage of the natural mechanism by 
which red blood cells in the body avoid clearance by elements of the innate immune system. 
This is the case for CD47 (Figure 2C), a transmembrane protein that acts like a marker of the 
“self” by binding to its cognate receptor expressed on leukocytes, inhibitory receptor signal 
regulatory protein alpha (SIRPα). CD47 binding to SIRP inhibits phagocytosis, in part  via 
regulation of the cytoskeleton and inhibition of engulfing structures. Incorporation of CD47 
on drug carrier surfaces reduces attachment to neutrophils and macrophages, therefore 
prolonging circulation and inhibiting inflammation (Stachelek, et al., 2011). 
In addition to controlling the solubility level, half-life in circulation, and immune system 
recognition, nanocarriers can also improve control of the drug efficacy upon release in the 
case of therapeutic interventions where administration is local. Localized implantation of 
bioactive agents embedded within porous matrices and/or hydrogels capable of responding 
to microenvironment properties can provide controlled release and effects (Tokarev & 
Minko, 2010). Encapsulation within these formulations can also provide sustained release 
over prolonged periods of time, as oppose to bulk delivery of a naked therapeutic (Tokarev 
& Minko, 2010), which can apply to the release of encapsulated drugs and also bioactive 
substances produced by cells encapsulated within these matrices (discussed in section 3.4).  
2.2.2 Targeting  
As described above, nanomedicines can improve the bioavailability and pharmacokinetics 
of diagnostic and therapeutic agents, also protecting them from rapid degradation. In order 
to maximize their efficacy, carriers can also be designed to help maximize bioadhesion to 
areas in the body where their action is required, a strategy known as targeting (Figure 3).  
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Fig. 3. Passive (A) and active (B) targeting of drug carriers helps localize their cargo within 
the body, either via non-specific interactions with the target cells (i) or more specific 
recognition of particular surface markers (ii). 
In some cases, general enhanced delivery throughout the body, rather than specific delivery 
to particular organs, is preferred. This is the case for genetic conditions that affect multi-
organ systems due to ubiquitous distribution of the molecular markers or functions affected, 
such as in many monogenic disorders with both peripheral and central nervous system 
components. Since most therapeutics do not present intrinsic affinity to cells in the body, 
coupling them to carriers with affinity properties provides advantages. Hydrophilic and 
slightly positively-charged polymers provide affinity to the negatively-charged plasma 
membrane of cells (Panyam & Labhasetwar, 2003, El-Sayed, et al., 2005). Also, these systems 
can be coupled to affinity moieties that enhance bioadhesion. This is the case for 
promiscuous affinity peptides such as Tat, antennapedia, and other sequences that gain 
access to the plasma membrane of cells due to their positively-charged nature (Suk, et al., 
2006, Sawant & Torchilin, 2010) (Figure 3Bi), similarly to polymer carriers described above.  
In other cases, more specific localization of drug cargoes and imaging agents is necessary for 
optimal effects, such as the case of diseases with more prominent symptoms in particular 
organs or cell types (Langer, 1998, Torchilin, 2006, Pardridge, 2010). Moreover, such specific 
targeting may also reduce potential side effects of the therapeutic in non-intended targets. 
For instance, carriers injected in the circulation are passively targeted to organs irrigated by 
the vascular bed immediately downstream the area of administration (first pass 
phenomenon), such as the case of pulmonary accumulation of carriers administered 
intravenously. Also, nanocarriers can gain preferential access to organs irrigated by 
discontinuous blood vessels (Figure 3A), which do not pose a barrier from free diffusion of 
substances between the circulation and tissue, such as in the liver, an organ considered a 
main therapeutic target for many monogenic diseases that affect metabolic pathways.  
However, delivery of therapeutics to most other sites in the body requires more complex 
and precise strategies of active targeting. This can be achieved by coupling to affinity 
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organ systems due to ubiquitous distribution of the molecular markers or functions affected, 
such as in many monogenic disorders with both peripheral and central nervous system 
components. Since most therapeutics do not present intrinsic affinity to cells in the body, 
coupling them to carriers with affinity properties provides advantages. Hydrophilic and 
slightly positively-charged polymers provide affinity to the negatively-charged plasma 
membrane of cells (Panyam & Labhasetwar, 2003, El-Sayed, et al., 2005). Also, these systems 
can be coupled to affinity moieties that enhance bioadhesion. This is the case for 
promiscuous affinity peptides such as Tat, antennapedia, and other sequences that gain 
access to the plasma membrane of cells due to their positively-charged nature (Suk, et al., 
2006, Sawant & Torchilin, 2010) (Figure 3Bi), similarly to polymer carriers described above.  
In other cases, more specific localization of drug cargoes and imaging agents is necessary for 
optimal effects, such as the case of diseases with more prominent symptoms in particular 
organs or cell types (Langer, 1998, Torchilin, 2006, Pardridge, 2010). Moreover, such specific 
targeting may also reduce potential side effects of the therapeutic in non-intended targets. 
For instance, carriers injected in the circulation are passively targeted to organs irrigated by 
the vascular bed immediately downstream the area of administration (first pass 
phenomenon), such as the case of pulmonary accumulation of carriers administered 
intravenously. Also, nanocarriers can gain preferential access to organs irrigated by 
discontinuous blood vessels (Figure 3A), which do not pose a barrier from free diffusion of 
substances between the circulation and tissue, such as in the liver, an organ considered a 
main therapeutic target for many monogenic diseases that affect metabolic pathways.  
However, delivery of therapeutics to most other sites in the body requires more complex 
and precise strategies of active targeting. This can be achieved by coupling to affinity 
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moieties that recognize specific markers expressed by the cells which require intervention 
(Figure 3Bii), including natural ligands of such markers, proteins and peptides, antibodies 
and their fragments, sugars, and aptamers. Also, targeting to markers that are expressed 
under certain pathological processes (as opposed to control physiological conditions) helps 
favoring delivery to disease sites (Muro & Muzykantov, 2005, Bareford & Swaan, 2007). 
Whether it is due to targeting via positively-charged moieties or by specific affinity means, 
targeted delivery of drug carriers offers advantages over direct targeting of therapeutics. 
Apart from the described advantages posed by increased solubility, circulation time, and 
release control, carriers bearing multiple copies of an affinity moiety display greater affinity 
due to this multivalency, compared to drugs that are directly coupled to one copy of the 
same affinity molecule (Muro, et al., 2006a). As described below, multivalency of targeted 
carriers also provides tight binding to cell surface receptors, which can favor uptake within 
the cell, a necessary requirement for many diagnostic and therapeutic applications.  
2.2.3 Sub-cellular transport 
For most applications the molecular targets for intervention are intracellular (Langer, 1998, 
Torchilin, 2006). Therefore, targeting to selected cells and tissues is not sufficient to attain 
significant effects, the delivered cargoes must also gain access to intracellular compartments 
where their molecular targets are located. Interventions related to RNA interference or 
delivery of antisense oligonucleotides require transport of these cargoes to the cytosol of the 
cell, where the target is accessible. This is also the case for delivery of some chaperones, 
inhibitors or activators, enzymes and other proteins located in the cytosol or sub-cellular 
organelles such as the mitochondria, peroxisomes, etc., which can be re-directed to these 
compartments by signal peptides if delivered previously to the cytosol. Gene therapies also 
require delivery to the cytosol, with subsequent transport to the cell nucleus. In all these 
cases, cytosolic delivery can be granted mainly by two routes: direct transport of the cargoes 
and/or their carriers from the extracellular space to the cytosol of cells, or engulfment by the 
plasma membrane and uptake into vesicular compartments (Muro & Muzykantov, 2005, 
Suk, et al., 2006, Bareford & Swaan, 2007, Sahay, et al., 2010).  
Several strategies have been designed to directly overcome the plasmalemma, gaining 
access to the cytosol. These include physical means such as electroporation and ultrasound, 
where a local electric or ultrasound pulse is exerted in the immediate post-administration 
period, causing transient enhancement of the plasmalemma permeability (Trollet, et al., 
2008), and biolistic particle delivery systems, where penetration into cells is gained by 
means of tungsten or gold particles that are propelled by a “gene gun” across the plasma 
membrane (O'Brien, et al., 2001). Other methods providing a similar outcome relate to 
polycationic lipids used to assist cell transfection, which can bind negatively charged 
proteoglycans at the cell surface and favor cytosolic delivery by porating the plasmalemma 
(Dincer, et al., 2005, Zuhorn, et al., 2005). Positively-charged cell penetrating peptides (such 
as RGD and Tat peptides) also bind to the cell surface due to electrostatic interactions and 
can facilitate cytosolic delivery of cargoes (Magzoub, et al., 2005, Suk, et al., 2006).  
As opposed to gaining access to the cell interior by direct penetration into the cytosol, 
uptake within endocytic vesicles and subsequent selective permeabilization of these 
compartments for cytosolic release is another major area of research regarding the design of 
precise nanomedicines (Figure 4A). For instance, drug carriers can be targeted to cell surface 
receptors involved in endocytosis (Muro & Muzykantov, 2005, Bareford & Swaan, 2007, 
Pardridge, 2010, Sahay, et al., 2010). This term refers to a group of processes by which cells 
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engulf extracellular material with their plasma membrane, followed by pinching off the 
resulting vesicles into the cytosol. Uptake by endocytosis is regulated by numerous 
pathways (clathrin- and caveolar-mediated mechanisms, macropinocytosis, phagocytosis, 
and other non-classical mechanisms), and most commonly results in transport of the 
internalized materials to endosomes and lysosomes (Bareford & Swaan, 2007, Sahay, et al., 
2010). This strategy is ideal in the case of delivery of therapeutic agents whose action is 
required at said sub-cellular compartments, such as in the case of carrier-assisted delivery of 
enzyme replacement for lysosomal storage disorders (Figure 4A right) (Garnacho, et al., 
2008, Muro, et al., 2008, Muro, 2010, Hsu, et al., 2011).  For those cases where delivery to the 
cytosol and access to other sub-cellular compartments is required (Figure 4A left), carriers 
can be coupled to fusogenic peptides derived from bacterial toxins (e.g., hemaglutinnin and 
GALA peptides), which can induce poration of the endosomal membrane in response to 
gradual pH lowering in these compartments (Kakudo, et al., 2004). Carriers themselves can 
also be designed to overcome endosomal membranes, such as in the case of pH-sensitive 
poly(acid) carriers and temperature-responsive poly(electrolyte) hydrogels (Yessine & 
Leroux, 2004, Stayton, et al., 2005, Choi, et al., 2006, Oishi, et al., 2006).  
 
 
Fig. 4. Sub-cellular delivery of nanocarriers. (A) Endocytosis of carriers can lead to transport 
to endosomes and lysosomes, where acidic pH and hydrolases can degrade the carrier 
components and release the therapeutic cargo. Alternatively, pH-sensitive carriers can 
destabilize the endosome, releasing the cargo to the cytosol. (B) Transport across cellular 
layers can take place either via paracellular transport between adjacent cells or via 
transcytosis across the cell body (by vesicular mediated endocytosis and exocytosis). 
Finally, effective accumulation within particular tissues requires penetration across cellular 
barriers. This is most evident in the example of diagnostic and therapeutic agents aimed to 
exert their activities in the central nervous systems (Pardridge, 2010), and those which need 
to be transported across the gastrointestinal epithelial layer upon oral administration 
(Kitchens, et al., 2005, Serra, et al., 2009, Park, et al., 2011). In addition, except for a few cases 
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moieties that recognize specific markers expressed by the cells which require intervention 
(Figure 3Bii), including natural ligands of such markers, proteins and peptides, antibodies 
and their fragments, sugars, and aptamers. Also, targeting to markers that are expressed 
under certain pathological processes (as opposed to control physiological conditions) helps 
favoring delivery to disease sites (Muro & Muzykantov, 2005, Bareford & Swaan, 2007). 
Whether it is due to targeting via positively-charged moieties or by specific affinity means, 
targeted delivery of drug carriers offers advantages over direct targeting of therapeutics. 
Apart from the described advantages posed by increased solubility, circulation time, and 
release control, carriers bearing multiple copies of an affinity moiety display greater affinity 
due to this multivalency, compared to drugs that are directly coupled to one copy of the 
same affinity molecule (Muro, et al., 2006a). As described below, multivalency of targeted 
carriers also provides tight binding to cell surface receptors, which can favor uptake within 
the cell, a necessary requirement for many diagnostic and therapeutic applications.  
2.2.3 Sub-cellular transport 
For most applications the molecular targets for intervention are intracellular (Langer, 1998, 
Torchilin, 2006). Therefore, targeting to selected cells and tissues is not sufficient to attain 
significant effects, the delivered cargoes must also gain access to intracellular compartments 
where their molecular targets are located. Interventions related to RNA interference or 
delivery of antisense oligonucleotides require transport of these cargoes to the cytosol of the 
cell, where the target is accessible. This is also the case for delivery of some chaperones, 
inhibitors or activators, enzymes and other proteins located in the cytosol or sub-cellular 
organelles such as the mitochondria, peroxisomes, etc., which can be re-directed to these 
compartments by signal peptides if delivered previously to the cytosol. Gene therapies also 
require delivery to the cytosol, with subsequent transport to the cell nucleus. In all these 
cases, cytosolic delivery can be granted mainly by two routes: direct transport of the cargoes 
and/or their carriers from the extracellular space to the cytosol of cells, or engulfment by the 
plasma membrane and uptake into vesicular compartments (Muro & Muzykantov, 2005, 
Suk, et al., 2006, Bareford & Swaan, 2007, Sahay, et al., 2010).  
Several strategies have been designed to directly overcome the plasmalemma, gaining 
access to the cytosol. These include physical means such as electroporation and ultrasound, 
where a local electric or ultrasound pulse is exerted in the immediate post-administration 
period, causing transient enhancement of the plasmalemma permeability (Trollet, et al., 
2008), and biolistic particle delivery systems, where penetration into cells is gained by 
means of tungsten or gold particles that are propelled by a “gene gun” across the plasma 
membrane (O'Brien, et al., 2001). Other methods providing a similar outcome relate to 
polycationic lipids used to assist cell transfection, which can bind negatively charged 
proteoglycans at the cell surface and favor cytosolic delivery by porating the plasmalemma 
(Dincer, et al., 2005, Zuhorn, et al., 2005). Positively-charged cell penetrating peptides (such 
as RGD and Tat peptides) also bind to the cell surface due to electrostatic interactions and 
can facilitate cytosolic delivery of cargoes (Magzoub, et al., 2005, Suk, et al., 2006).  
As opposed to gaining access to the cell interior by direct penetration into the cytosol, 
uptake within endocytic vesicles and subsequent selective permeabilization of these 
compartments for cytosolic release is another major area of research regarding the design of 
precise nanomedicines (Figure 4A). For instance, drug carriers can be targeted to cell surface 
receptors involved in endocytosis (Muro & Muzykantov, 2005, Bareford & Swaan, 2007, 
Pardridge, 2010, Sahay, et al., 2010). This term refers to a group of processes by which cells 
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engulf extracellular material with their plasma membrane, followed by pinching off the 
resulting vesicles into the cytosol. Uptake by endocytosis is regulated by numerous 
pathways (clathrin- and caveolar-mediated mechanisms, macropinocytosis, phagocytosis, 
and other non-classical mechanisms), and most commonly results in transport of the 
internalized materials to endosomes and lysosomes (Bareford & Swaan, 2007, Sahay, et al., 
2010). This strategy is ideal in the case of delivery of therapeutic agents whose action is 
required at said sub-cellular compartments, such as in the case of carrier-assisted delivery of 
enzyme replacement for lysosomal storage disorders (Figure 4A right) (Garnacho, et al., 
2008, Muro, et al., 2008, Muro, 2010, Hsu, et al., 2011).  For those cases where delivery to the 
cytosol and access to other sub-cellular compartments is required (Figure 4A left), carriers 
can be coupled to fusogenic peptides derived from bacterial toxins (e.g., hemaglutinnin and 
GALA peptides), which can induce poration of the endosomal membrane in response to 
gradual pH lowering in these compartments (Kakudo, et al., 2004). Carriers themselves can 
also be designed to overcome endosomal membranes, such as in the case of pH-sensitive 
poly(acid) carriers and temperature-responsive poly(electrolyte) hydrogels (Yessine & 
Leroux, 2004, Stayton, et al., 2005, Choi, et al., 2006, Oishi, et al., 2006).  
 
 
Fig. 4. Sub-cellular delivery of nanocarriers. (A) Endocytosis of carriers can lead to transport 
to endosomes and lysosomes, where acidic pH and hydrolases can degrade the carrier 
components and release the therapeutic cargo. Alternatively, pH-sensitive carriers can 
destabilize the endosome, releasing the cargo to the cytosol. (B) Transport across cellular 
layers can take place either via paracellular transport between adjacent cells or via 
transcytosis across the cell body (by vesicular mediated endocytosis and exocytosis). 
Finally, effective accumulation within particular tissues requires penetration across cellular 
barriers. This is most evident in the example of diagnostic and therapeutic agents aimed to 
exert their activities in the central nervous systems (Pardridge, 2010), and those which need 
to be transported across the gastrointestinal epithelial layer upon oral administration 
(Kitchens, et al., 2005, Serra, et al., 2009, Park, et al., 2011). In addition, except for a few cases 
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of vascular beds characterized by discontinuous endothelium where free diffusion is 
granted, transport of substances from the bloodstream into the irrigated tissues is regulated 
by the layer of endothelial cells that separate the microvascular wall from the tissue 
parenchyma and this poses an obstacle to penetration (Pardridge, 2010). Transport of 
hydrophilic and/or relatively large substances (molecular chaperones, proteins and 
enzymes, polysaccharides, and oligo- and poly-nucleotides) across endothelial or epithelial 
barriers is restricted to the transcellular or paracellular routes (Figure 4B). The transcellular 
route involves internalization of materials on the apical membrane via endocytosis, traffic of 
endocytic vesicles across the cell body, and exocytosis at the basolateral membrane 
(transcytosis; Figure 4B left), which occurs mainly via clathrin- and caveolar-mediated 
pathways (Muro, et al., 2004, Bareford & Swaan, 2007). Due to its safety, this route is 
preferred for transport into the central nervous system, which can be achieved to some 
extent by targeting receptors such as the folate, insulin, low density lipoprotein, and 
transferrin receptors (Hilgenbrink & Low, 2005, Pardridge, 2010, Musacchio & Torchilin, 
2011). The paracellular pathway (Figure 4B right) involves transport between adjacent cells 
via regulation of the junctions that interlock them (Dejana, 2004). This may lead to more 
uncontrolled, passive transport compared to the transcellular route, hence it is less desired 
in gaining access into the brain, whereas it seems relatively safe for transport across the 
gastrointestinal epithelium in oral applications (Kitchens, et al., 2005, Park, et al., 2011). 
3. Nanomedicine applications for treatment of genetic diseases  
Several properties of nanomedicine designs, mainly pertaining their biocompatible size and 
high degree of manipulation that allow adaptation to different biomedical applications, have 
caused this field to be considered a new technological revolution. Nanotechnology has opened 
new possibilities for ex vivo detection methods (e.g., applicable to mutation screening) as well 
as biomarkers of disease, with several technologies being also applicable for in vivo imaging 
(Cai, et al., 2003, Corstjens, et al., 2005, Bailey, et al., 2009, Cheung, et al., 2010, Choi & 
Frangioni, 2010). These strategies are considerably more sensitive than traditional methods, 
permitting detection in smaller samples and/or providing more accurate measurements and 
tracings of the parameters of interest. From the therapeutic perspective, nanomedicine 
strategies hold considerable promise to improve control parameters such as the solubility, 
stability, clearance, biodistribution, sub-cellular transport, controlled release of therapeutic 
cargoes of diverse nature, improving their efficacy and minimizing potential side effects 
(Langer, 1998, Moghimi, et al., 2001, Stayton, et al., 2005, Torchilin, 2006).  
For the most part, these technologies are still at the experimental stage, particularly those 
that require in vivo administration as opposed to those designed for ex vivo diagnosis and 
detection. However, research has shown a great potential of these platforms for clinical 
translation in the near future, with some examples being already available in the market, 
mostly in the case of cancer therapeutics. Although relatively unexplored in the case of 
genetic deficiencies, the use of nanomedicine principles and strategies for diagnosis and 
treatment of these conditions is a rapidly growing field with highly promising perspectives. 
3.1 Small molecule therapy 
Small molecule therapy typically encompasses chemicals used either for palliative care of 
symptoms or more specifically designed to cope with a particular landmark that regulates 
disease progression. In many cases, their small size and chemical properties are relatively 
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permissive of diffusion through the body and cells, with relatively good efficacy. However, 
in other cases they suffer from the obstacles discussed in section 2.2 above, including rapid 
clearance, inactivation, and sub-optimal access through biological barriers.  
For instance, when delivered intravenously rapid loss of therapeutic activity may arise from 
the direct interaction with blood components and elements of the reticuloendothelial or 
immune systems. This can be prevented by encapsulating small molecule therapeutics 
within carriers designed to minimize interaction with said clearance or inactivating systems, 
prolong their circulation, enhance their accumulation in certain areas of the body, and 
control their release over long periods of time. Some examples of such applications in the 
realm of intravenous administration of small molecule therapies for genetic conditions have 
been reported, such as the case of treatment of hemophilia with coagulation factors 
encapsulated in biocompatible liposomes, which prolongs the therapeutic window (Yatuv, 
et al., 2010), or enhanced efficacy of liposomal formulations of antibiotics to treat lung 
infections in cystic fibrosis (CF) (Mugabe, et al., 2005, Rukholm, et al., 2006). In other cases, 
interaction with blood components is desired, yet formulation as a nanocarrier still provides 
therapeutic advantages, such as the case of hexadentate-terminated hydroxypyridinone-
based dendrimers, an iron chelating formulation that has been shown to effectively 
sequester excess iron in haemochromatosis and the thalassaemias (Zhou, et al., 2006).  
Regarding penetration in the body, nanomedicine formulations can also help by providing 
means to modulate viscosity of physiological barriers, such as the sputum in the lungs in the 
case of inhaled drugs, or enhance the permeability of cellular barriers, such as that 
encountered by oral drugs in the gastrointestinal epithelium or small molecules that can not 
cross from the bloodstream into the brain. For instance, the thick lung sputum encountered 
in CF patients is a major obstacle for effective penetration of classical inhaled therapeutics, 
hindering access to the underlining epithelial layer. Encapsulation of antibiotics within 
liposomes modified with amiloride hydrochloride has been shown to force water retention 
and reduce viscosity of the sputum, resulting in enhanced release and effects (Chougule, et 
al., 2006). Liposomes modified with the bioadhesive metal, gallium, improved delivery of 
antibiotics in the CF airways, permitting reduction of the administered dose by an order of 
magnitude compared to the naked antibiotic (Halwani, et al., 2008). Biodegradable 
PEGylated PLGA nanoparticles have also been shown to effectively cross the sputum, which 
has been used to enhance delivery of proteosome inhibitors in CF (Vij, et al., 2010).  
With regard to delivery of small molecules by the oral route (preferred to minimize cost and 
improve patient compliance), encapsulation in enteric-coated capsules is typically required. 
Classically, bulk capsules protect therapeutics from exposure to the acidic environment in 
the stomach. Coupling to nanocarriers has shown advantages in this arena, particularly 
regarding intestinal absorption. This has been shown in the case of oral delivery of anti-
diabetic agents by solid lipid particles, which effectively decreased glucose in circulation 
(Nnamani, et al., 2010) or the case of PLGA nanocarriers encapsulating curcumin for CF, 
which surpassed the effects of its non-encapsulated counterpart (Cartiera, et al., 2010). 
Similar results were rendered using chitosan nanocarriers designed for pH-sensitive release 
and enhanced mucoadhesive potential, resulting in improved absorption of anti-diabetic 
drugs (Wong, 2010). A combination of classical oral delivery formulations and 
nanotechnologies, e.g., chitosan nanocarriers encased within enteric-coated capsules for 
insulin delivery, has shown enhanced results, reflecting the potential of nanomedicine to 
impact oral delivery of active therapeutics (Cui, et al., 2009, Sonaje, et al., 2010).  
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of vascular beds characterized by discontinuous endothelium where free diffusion is 
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permissive of diffusion through the body and cells, with relatively good efficacy. However, 
in other cases they suffer from the obstacles discussed in section 2.2 above, including rapid 
clearance, inactivation, and sub-optimal access through biological barriers.  
For instance, when delivered intravenously rapid loss of therapeutic activity may arise from 
the direct interaction with blood components and elements of the reticuloendothelial or 
immune systems. This can be prevented by encapsulating small molecule therapeutics 
within carriers designed to minimize interaction with said clearance or inactivating systems, 
prolong their circulation, enhance their accumulation in certain areas of the body, and 
control their release over long periods of time. Some examples of such applications in the 
realm of intravenous administration of small molecule therapies for genetic conditions have 
been reported, such as the case of treatment of hemophilia with coagulation factors 
encapsulated in biocompatible liposomes, which prolongs the therapeutic window (Yatuv, 
et al., 2010), or enhanced efficacy of liposomal formulations of antibiotics to treat lung 
infections in cystic fibrosis (CF) (Mugabe, et al., 2005, Rukholm, et al., 2006). In other cases, 
interaction with blood components is desired, yet formulation as a nanocarrier still provides 
therapeutic advantages, such as the case of hexadentate-terminated hydroxypyridinone-
based dendrimers, an iron chelating formulation that has been shown to effectively 
sequester excess iron in haemochromatosis and the thalassaemias (Zhou, et al., 2006).  
Regarding penetration in the body, nanomedicine formulations can also help by providing 
means to modulate viscosity of physiological barriers, such as the sputum in the lungs in the 
case of inhaled drugs, or enhance the permeability of cellular barriers, such as that 
encountered by oral drugs in the gastrointestinal epithelium or small molecules that can not 
cross from the bloodstream into the brain. For instance, the thick lung sputum encountered 
in CF patients is a major obstacle for effective penetration of classical inhaled therapeutics, 
hindering access to the underlining epithelial layer. Encapsulation of antibiotics within 
liposomes modified with amiloride hydrochloride has been shown to force water retention 
and reduce viscosity of the sputum, resulting in enhanced release and effects (Chougule, et 
al., 2006). Liposomes modified with the bioadhesive metal, gallium, improved delivery of 
antibiotics in the CF airways, permitting reduction of the administered dose by an order of 
magnitude compared to the naked antibiotic (Halwani, et al., 2008). Biodegradable 
PEGylated PLGA nanoparticles have also been shown to effectively cross the sputum, which 
has been used to enhance delivery of proteosome inhibitors in CF (Vij, et al., 2010).  
With regard to delivery of small molecules by the oral route (preferred to minimize cost and 
improve patient compliance), encapsulation in enteric-coated capsules is typically required. 
Classically, bulk capsules protect therapeutics from exposure to the acidic environment in 
the stomach. Coupling to nanocarriers has shown advantages in this arena, particularly 
regarding intestinal absorption. This has been shown in the case of oral delivery of anti-
diabetic agents by solid lipid particles, which effectively decreased glucose in circulation 
(Nnamani, et al., 2010) or the case of PLGA nanocarriers encapsulating curcumin for CF, 
which surpassed the effects of its non-encapsulated counterpart (Cartiera, et al., 2010). 
Similar results were rendered using chitosan nanocarriers designed for pH-sensitive release 
and enhanced mucoadhesive potential, resulting in improved absorption of anti-diabetic 
drugs (Wong, 2010). A combination of classical oral delivery formulations and 
nanotechnologies, e.g., chitosan nanocarriers encased within enteric-coated capsules for 
insulin delivery, has shown enhanced results, reflecting the potential of nanomedicine to 
impact oral delivery of active therapeutics (Cui, et al., 2009, Sonaje, et al., 2010).  
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Another important cellular barrier encountered by some small molecule therapies is that of 
the blood-brain interface, which forces more invasive means of local delivery, including 
direct injection or implantation of the naked therapeutic agent or different scaffolds 
containing said therapeutic into the brain, e.g., by intracerebral or intraventricular, 
administration (Menei, et al., 2000, Nakaji-Hirabayashi, et al., 2009, Emerich, et al., 2010). In 
this regard, prolonged circulation and stability rendered by nanocarriers can enhance the 
chances of drug diffusion into the brain parenchyma. As discussed in section 2.2.3, carriers 
targeted to particular transporters of the blood-brain barrier can also improve entry into the 
central nervous system. Examples illustrating this are those that capitalize on targeting the 
transferrin receptor, which provides transendothelial transport by a clathirn-mediated 
mechanism. This has been explored for delivery of nerve growth factor for Huntingon’s 
disease (Kordower, et al., 1994). Nanocarriers have also been used as vehicles to assist in 
transporting chelating agents into the brain for iron capture and removal in Alzheimer’s 
disease, also with potential in Huntington’s and Parkinson’s diseases (Liu, et al., 2009).  
Similar nanomedicine strategies can improve delivery of other small molecule therapies for 
genetic diseases, including hormones to control regulatory pathways, antibiotics, growth 
factors, cofactors, inhibitors or activators that act upstream or downstream of affected 
pathways, chaperones that favor proper protein folding, and other chemicals.  
3.2 Enzyme therapy 
The term enzyme therapy describes the administration of exogenous enzymes to replace 
their defective endogenous counterparts (enzyme replacement therapy or ERT) and can also 
be extended beyond the treatment of genetic diseases with impaired enzyme production, for 
instance in cases where administration of additional enzymes that are not encountered 
endogenously in the human body can help alleviate phenotypic symptoms. Classical 
examples of the first approach have been applied to the treatment of lysosomal storage 
disorders (LSDs), mostly caused by genetic defects affecting enzymes involved in lysosomal 
degradation of varied substrates (Burrow, et al., 2007), neuropathic phenylketonuria (PKU) 
as a consequence of a defect in phenylalanine hydroxylase (PAH) (Kim, et al., 2004, Harding 
& Blau, 2010), or prolidase deficiency affecting collagen metabolism (Colonna, et al., 2008b), 
among many others. The second approach is illustrated in examples pertaining, for instance, 
administration of alginate lyase to degrade components of infectious biofilms in CF 
(Lamppa, et al., 2011) or delivery of uricase for gout treatment (Sherman, et al., 2008). 
However, effective delivery of enzymes often suffers from the impediments stated above for 
small molecule therapies, with the added disadvantages that arise from using proteins as 
therapeutic agents: susceptibility to proteases, high potential for immunogenicity, and even 
more reduced penetration within tissues and cells in the body. Hence, these therapeutic 
strategies represent good targets for improvement by nanomedicine approaches. 
For instance, several lysosomal ERTs are clinically available, providing a marked 
phenotypic improvement. However, in many cases, production of antibodies against the 
administered recombinant enzymes hinders the efficacy of this treatment over time, which 
represents a major obstacle for treatment of these chronic conditions (Ponder, 2008, 
Linthorst, et al., 2004). This could be ameliorated by encapsulating or coupling said enzymes 
within immuno-evasive carriers or polymers, such as those described in section 2.2.1. Some 
preliminary attempts in this direction include the case of delivery of PEG-modified 
dextranase, which achieved prolonged activity by bypassing immunorecognition in a mouse 
model of LSD mimicked by lysosomal accumulation of dextran (Mumtaz & Bachhawat, 
1994). Similar strategies of PEGylation have been useful for delivery of uricase for gout 
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treatment in hyperuricemia (Sherman, et al., 2008), non-mammalian phenylalanine 
ammonia lyase for treatment of PKU (Ikeda, et al., 2005), or alginate lyase delivery targeted 
to CF infections (Lamppa, et al., 2011).  
In addition to protecting from inactivation and immunogenic responses, by masking the 
enzymes from the immune and clearance systems, it is expected that these strategies 
involving incorporation of PEG in the formulation will also provide prolonged circulation, 
hence enhancing the chances to reach tissues and cell targets in the body, a capacity 
otherwise considerably restricted for large molecules such as these enzymes. Encapsulation 
within or coupling to liposomes and polymer carriers, as well as the incorporation of active 
targeting moieties, may help these aspects. Some examples of these applications were 
explored in the late 70’s, such as in the case of enhanced delivery of glucocerebrosidase 
deficient in Gaucher disease upon encapsulation within liposomes (Dale, et al., 1979), or 
liposomes coupled to aggregated immunoglobulins or apolipoproteins for enhanced 
enzyme targeting to polymorphonucleocytes for treatment of Batten disease (Weissmann, et 
al., 1975, Steger & Desnick, 1977). Yet, not many subsequent works have risen from these 
seminal studies, adapting the rapid evolving arena of nanomedicine to formulations for 
treatment of genetic conditions, and both fields have developed independently. A recent 
attempt to bridge this gap studied enhancement of delivery of acid sphingomyelinase or -
galactosidase (deficient in types A-B Niemann-Pick disease or Fabry disease, respectively) to 
peripheral organs and the brain, which was achieved by coupling said enzymes to polymer 
nanocarriers targeted to intercellular adhesion molecule-1 (ICAM-1), a molecule present in 
multiple tissues and cell types in the body, whose expression is highly upregulated in many 
pathological conditions (Garnacho, et al., 2008, Muro, 2010, Hsu, et al., 2011).  
This type of strategy can not only assists with targeting of enzymes through the body, but it 
can also provide access to intracellular compartments where their action is required, 
improving efficacy. This can be achieved by either exploiting targeting to receptors involved 
in endocytic transport and/or carriers capable of transporting materials across the plasma 
membrane or the membranous envelop of intracellular compartments (described in section 
2.2.3). This is the case for prolidase delivery by chitosan nanoparticles, which enhance 
absorptive endocytosis of the enzyme into cells, with subsequent pH-triggered release to the 
cytosol (Colonna, et al., 2008a), or enhanced delivery of acid sphingomyelinase or -
galactosidase to lysosomal compartments by ICAM-1-targeted nanocarriers (Muro, et al., 
2006b, Garnacho, et al., 2008, Hsu, et al., 2011). In the latter example, ICAM-1 targeting 
provides a means for switching the entry pathway of lysosomal enzymes within cells from 
clathrin-mediated endocytosis, typically induced by binding of mannose or mannose-6-
phosphate residues present on the naked lysosomal enzymes to the corresponding cell 
receptors, to cell adhesion molecule (CAM)-mediated endocytosis induced by ICAM-1 
targeting. This provides an advantage for those cases when the pathology itself tends to 
alter the expression or function of cell receptors, such as the case of the mannose-6-
phosphate receptor in some LSDs (Dhami & Schuchman, 2004, Cardone, et al., 2008). Finally, 
transport across cellular barriers, greatly impaired for many enzyme therapies, could be 
improved by formulating said enzymes as their nanocarrier counterparts, as those described 
in section 2.2.3, enabling these treatment strategies to reach the central nervous system or to 
be converted into oral delivery modalities. 
3.3 Gene therapy 
In a broad definition, gene therapy encompasses the modulation of the expression of genes 
affected in genetic conditions, which can be achieved at the level of providing codifying 
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represents a major obstacle for treatment of these chronic conditions (Ponder, 2008, 
Linthorst, et al., 2004). This could be ameliorated by encapsulating or coupling said enzymes 
within immuno-evasive carriers or polymers, such as those described in section 2.2.1. Some 
preliminary attempts in this direction include the case of delivery of PEG-modified 
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multiple tissues and cell types in the body, whose expression is highly upregulated in many 
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provides a means for switching the entry pathway of lysosomal enzymes within cells from 
clathrin-mediated endocytosis, typically induced by binding of mannose or mannose-6-
phosphate residues present on the naked lysosomal enzymes to the corresponding cell 
receptors, to cell adhesion molecule (CAM)-mediated endocytosis induced by ICAM-1 
targeting. This provides an advantage for those cases when the pathology itself tends to 
alter the expression or function of cell receptors, such as the case of the mannose-6-
phosphate receptor in some LSDs (Dhami & Schuchman, 2004, Cardone, et al., 2008). Finally, 
transport across cellular barriers, greatly impaired for many enzyme therapies, could be 
improved by formulating said enzymes as their nanocarrier counterparts, as those described 
in section 2.2.3, enabling these treatment strategies to reach the central nervous system or to 
be converted into oral delivery modalities. 
3.3 Gene therapy 
In a broad definition, gene therapy encompasses the modulation of the expression of genes 
affected in genetic conditions, which can be achieved at the level of providing codifying 
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gene sequences that can enable the transcription and translation of functional proteins 
otherwise affected by these defects, or other regulatory sequences that can up-regulate or 
down-regulate said expression at any stage during transcription or translation. This is 
inclusive of, but not limited to, delivery of cDNA to replace the codifying sequence of the 
affected gene, or delivery of oligonucleotides for correction of mRNA transcripts by mRNA 
insertion/deletion, small interference RNA (siRNA) for silencing, etc.  
This strategy capitalizes on viral vectors, given that many viruses can actively bind to cell 
surface receptors, enter cells by endocytosis, and gain access to the cytosol and the 
nucleus, in certain cases, by escaping the endo-lysosomal vesicles in which they are 
contained (Campbell & Hope, 2005). These viruses have evolved mechanisms capable of 
“sensing” the lowering pH within endosomes and lysosomes, e.g., by protonation of 
amphiphilic molecules, which can then destabilize and porate the endo-lysosomal 
membrane (Campbell & Hope, 2005). Delivery of said nucleic acid-based therapeutics has 
been shown to be markedly effective when using viral vectors, which is attributable to 
their innate ability to effectively deliver double-stranded or single-stranded DNA or RNA 
molecules within cells.  
Most strategies attempted include somatic gene transfer in animal models using adenovirus, 
adeno-associated virus, herpesvirus and, more recently, retrovirus and lentivirus vectors 
capable of integrating the exogenous gene sequences into the host genome for prolonged 
expression (Wilson, 2004, Sands & Davidson, 2006). Other strategies consist of transforming 
cells ex vivo by viral vectors to express functional proteins, with subsequent local 
implantation of the transformed cells in the body (Ohashi, et al., 2000, Karolewski & Wolfe, 
2006). However, while these strategies are highly promising, their current translational 
application is still limited due to cargo size limitations and mainly safety concerns that 
involve immunogenicity and potential for random insertions in the host genome. 
In this regard, nanomedicine offers an opportunity to develop complementary approaches 
to traditional gene therapy. For instance, PEGylation strategies can improve the masking 
from the immune system, such as the case of PEGylated DNA/nanoparticles shown to 
provide effective intraocular transfection for retinitis pigmentosa while avoiding immune 
recognition (Cai, et al., 2008), or PEGylation of adenoviruses to confer protection against 
neutralizing antibodies (O'Riordan, et al., 1999), which may enable subsequent 
administrations. Similarly, encapsulation of the viral vectors themselves within polymer 
materials can also minimize immunogenicity, illustrated by successful gene transduction 
using adenoviruses encapsulated into PLGA microspheres (Turner, et al., 2007).  
Encapsulation or complexation of nucleic acid material within liposomes or polymer carriers 
(lipoplexes or polyplexes) is also being optimized in order to avoid utilization of protein-
rich viral capsids (arguably highly immunogenic) and viral genetic elements. Properties 
such as immune evasion, improved penetration through viscous fluids, targeting to 
particular cellular markers, and membrane permeabilization (those of the plasmalemma or 
intracellular compartments), discussed in section 2.2, are being built in these systems, to 
enable them to achieve delivery of nucleic acid materials. For instance, addition of albumin 
to polyplexes improves penetration through the sputum and provides transfection in CF (Di 
Gioia, et al., 2008). Bioadhesive and pH-responsive properties of chitosan nanoparticles, 
along with its lack of toxicity, can also benefit delivery of gene therapies (Agnihotri, et al., 
2004), including oral gene delivery applications such that of coagulation factor VIII in a 
hemophilia mouse model (Dhadwar, et al., 2010) or glucagon-liked peptide 1 (GLP-1) to 
reduce blood glucose in diabetes (Jean, et al., 2011).  
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As discussed for other therapeutic applications, these nanomedicine strategies can be 
targeted to particular receptors encountered in cells where transfection is needed. As an 
example, this has been shown in the case of lipoplexes encoding for low-density lipoprotein 
receptor (LDLR) and targeted to the tranferrin receptor to provide expression of LDLR for 
treatment of familial hypercholesterolemia (Shichiri, et al., 2003). The same targeting 
strategy has been used for expression of glial-derived neurotrophic growth factor (GDNF) to 
reduce neurotoxicity in Parkinson’s disease (Zhang, et al., 2006).  
Coupling to cell penetrating peptides and/or carrier scaffolds amenable for escaping from 
endocytic compartments (discussed in section 2.2.3), reminiscent of viral escape from these 
vesicles, improves the efficacy of transfection. Examples illustrating these strategies are 
those of facilitated transfection by PEGylated PEI encasing oligonucleotides for Duschenne 
muscular dystrophy, hemophilia, and CF (Lee, et al., 2004, Carrabino, et al., 2005, Dif, et al., 
2006, Sirsi, et al., 2008), lipoplexes coupled to arginine-glycine-aspartic acid (RGD) peptides 
that can bind to integrins (Scott, et al., 2001), or direct coupling of DNA to cell penetrating 
peptides, such as in the case of gene therapy for Fabry disease (Lavigne, et al., 2008).  
3.4 Cell therapy 
Cell therapy has been largely utilized as a therapeutic generating system, where cells from 
healthy subjects or cells from the patient properly modified are implanted in the body to 
provide sustained production of a molecule of interest that is innately defective in the 
diseased patient. Hence, the cell itself can be considered the vehicle of delivery and 
sustained effects can be achieved. This is beneficial in the case of certain proteins, hormones, 
and small molecules (such as neurotrophic factors) that display short circulatory longevity 
and are easily subjected to proteases, shortening their therapeutic effects.  
By directly producing these molecules at the required site, cell therapy provides a means to 
bypass secondary strategies to stabilize said molecules or the necessity for enabling crossing 
of physiological barriers. This is the case for implantation of alginate microparticles carrying 
recombinant fibroblasts for sustained systemic release of -glucuronidase for 
mucopolysaccharidosis VII (Ross, et al., 2000a). Local implantation of the encapsulated cells 
into the brain lateral ventricles circumvents the blood-brain barrier and results in 
considerable delivery of the secreted enzyme (Ross, et al., 2000b).  Similarly, implantation of 
encapsulated, genetically modified fibroblasts capable of producing ciliary neurotrophic 
factor (CNTF), a neuroprotective agent, in the brain or within vitreous humor of the eye 
have been explored in the context of treatment for Huntington’s disease and retinitis 
pigmentosa (Emerich, et al., 1996, Tao, et al., 2002, Bloch, et al., 2004). 
In most of these applications, encapsulation of cells to be implanted within polymer 
matrices is advantageous, if not required, in order to create a protective physical barrier to 
the immune system while permitting sustained release of the therapeutic by the implanted 
cells. Such scaffolds can avoid unwanted cell escape and neoplastic growth, yet allow 
oxygen and nutrients to access the matrix to maintain cell viability, while permitting 
therapeutics to be secreted to the surrounding environment. In this regard, nanotechnology 
has permitted nano-scale manipulation of these materials to achieve controlled diffusion, 
limiting immune response while supporting sustained release of the therapeutic molecules. 
An example of this strategy capitalizes on the use of alginate poly(L-lysine) hydrogels, an 
immune elusive and non-toxic polymer, (Koch, et al., 2003) with a nanoporous architecture, 
suitable to allow minimal yet sufficient nutrient exchange (Desai, et al., 2004).  
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otherwise affected by these defects, or other regulatory sequences that can up-regulate or 
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amphiphilic molecules, which can then destabilize and porate the endo-lysosomal 
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molecules within cells.  
Most strategies attempted include somatic gene transfer in animal models using adenovirus, 
adeno-associated virus, herpesvirus and, more recently, retrovirus and lentivirus vectors 
capable of integrating the exogenous gene sequences into the host genome for prolonged 
expression (Wilson, 2004, Sands & Davidson, 2006). Other strategies consist of transforming 
cells ex vivo by viral vectors to express functional proteins, with subsequent local 
implantation of the transformed cells in the body (Ohashi, et al., 2000, Karolewski & Wolfe, 
2006). However, while these strategies are highly promising, their current translational 
application is still limited due to cargo size limitations and mainly safety concerns that 
involve immunogenicity and potential for random insertions in the host genome. 
In this regard, nanomedicine offers an opportunity to develop complementary approaches 
to traditional gene therapy. For instance, PEGylation strategies can improve the masking 
from the immune system, such as the case of PEGylated DNA/nanoparticles shown to 
provide effective intraocular transfection for retinitis pigmentosa while avoiding immune 
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rich viral capsids (arguably highly immunogenic) and viral genetic elements. Properties 
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Gioia, et al., 2008). Bioadhesive and pH-responsive properties of chitosan nanoparticles, 
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encapsulated, genetically modified fibroblasts capable of producing ciliary neurotrophic 
factor (CNTF), a neuroprotective agent, in the brain or within vitreous humor of the eye 
have been explored in the context of treatment for Huntington’s disease and retinitis 
pigmentosa (Emerich, et al., 1996, Tao, et al., 2002, Bloch, et al., 2004). 
In most of these applications, encapsulation of cells to be implanted within polymer 
matrices is advantageous, if not required, in order to create a protective physical barrier to 
the immune system while permitting sustained release of the therapeutic by the implanted 
cells. Such scaffolds can avoid unwanted cell escape and neoplastic growth, yet allow 
oxygen and nutrients to access the matrix to maintain cell viability, while permitting 
therapeutics to be secreted to the surrounding environment. In this regard, nanotechnology 
has permitted nano-scale manipulation of these materials to achieve controlled diffusion, 
limiting immune response while supporting sustained release of the therapeutic molecules. 
An example of this strategy capitalizes on the use of alginate poly(L-lysine) hydrogels, an 
immune elusive and non-toxic polymer, (Koch, et al., 2003) with a nanoporous architecture, 
suitable to allow minimal yet sufficient nutrient exchange (Desai, et al., 2004).  
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Reduced access to elements of the immune system may also provide an avenue for use of 
allografts or xenografts, as in the case of long term implantation into rats of bovine islet cells 
encapsulated within alginate poly(L-lysine) microcapsules (Lanza, et al., 1999). Similarly, 
this property can be exploited to achieve more sustained therapeutic effects, such as those 
obtained in the case of genetically modified endothelial cells in treatment of hemophilia A, 
effective for ~150 days (Lin, et al., 2002), modified myoblasts to secrete erythropoietin, hence 
reducing the need of constant blood transfusions and hormone injections for treatment of 
the thalassemias (Dalle, et al., 1999), or encapsulated fibroblasts that release GDNF for 
Parkinson’s disease, which was effective for up to 2 years (Zurn, et al., 2001).  
4. Conclusion 
During the last 2-3 decades, the development of nanotechnologies for medical applications 
has provided important new avenues to improve diagnosis and treatment of human 
maladies. Said nanomedicines display a considerable degree of control of parameters such 
as increased solubility of various cargoes, evasion from the immune system, controlled 
circulation, improved stability, enhanced biodistribution in the body, modulatable transport 
into and/or across cells, and controlled release at the final destination. These approaches 
can be applied to the development of sensors and imaging agents with improved detection 
and diagnostic sensitivity, and also delivery of therapeutic strategies pertaining to small 
molecule, enzyme, gene, and cell therapies. Several nanoconstructs with varied chemical 
nature, architectural design, and functional properties have been successfully translated into 
the clinics, mainly for applications other than treatment of genetic conditions. Although, 
their application in this field has been only modestly explored, these systems rather 
represent general platforms, offering a unique opportunity to develop alternative and 
complementary therapeutic interventions applicable to the treatment of genetic diseases.  
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Reduced access to elements of the immune system may also provide an avenue for use of 
allografts or xenografts, as in the case of long term implantation into rats of bovine islet cells 
encapsulated within alginate poly(L-lysine) microcapsules (Lanza, et al., 1999). Similarly, 
this property can be exploited to achieve more sustained therapeutic effects, such as those 
obtained in the case of genetically modified endothelial cells in treatment of hemophilia A, 
effective for ~150 days (Lin, et al., 2002), modified myoblasts to secrete erythropoietin, hence 
reducing the need of constant blood transfusions and hormone injections for treatment of 
the thalassemias (Dalle, et al., 1999), or encapsulated fibroblasts that release GDNF for 
Parkinson’s disease, which was effective for up to 2 years (Zurn, et al., 2001).  
4. Conclusion 
During the last 2-3 decades, the development of nanotechnologies for medical applications 
has provided important new avenues to improve diagnosis and treatment of human 
maladies. Said nanomedicines display a considerable degree of control of parameters such 
as increased solubility of various cargoes, evasion from the immune system, controlled 
circulation, improved stability, enhanced biodistribution in the body, modulatable transport 
into and/or across cells, and controlled release at the final destination. These approaches 
can be applied to the development of sensors and imaging agents with improved detection 
and diagnostic sensitivity, and also delivery of therapeutic strategies pertaining to small 
molecule, enzyme, gene, and cell therapies. Several nanoconstructs with varied chemical 
nature, architectural design, and functional properties have been successfully translated into 
the clinics, mainly for applications other than treatment of genetic conditions. Although, 
their application in this field has been only modestly explored, these systems rather 
represent general platforms, offering a unique opportunity to develop alternative and 
complementary therapeutic interventions applicable to the treatment of genetic diseases.  
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1. Introduction 
Genetic diseases, especially autosomal recessive diseases, are rare in the general population. 
However, they become unusually frequent in certain communities worldwide as a result of 
genetic isolation due to social, geographic or religious factors. When a new mutation is 
inserted in such a population it spreads rapidly, leading to an increased prevalence of 
carriers and a large number of affected homozygous individuals. There are high frequencies 
of genetic diseases and congenital disorders among Arab populations (Tadmouri et al., 2009; 
Teebi & S.A. Teebi 2005).  The high rates of genetic diseases and congenital disorders in the 
Arab populations  can be attributed to several factors including: a) The high rate of 
traditional consanguineous marriages, which increases the frequency of autosomal recessive 
diseases; b) a relatively high birth rate of infants with chromosomal disorders related to 
advanced maternal age such as Down Syndrome and other trisomies; c)  a relatively high 
birth rate of infants with malformations due to new dominant mutations related to 
advanced paternal age; d) large family sizes, which may increase the number of affected 
children in families with autosomal recessive conditions; and e) the lack of public health 
measures directed at the prevention of congenital and genetically determined disorders, and 
the shortage  of genetic services and inadequate health care prior to and during pregnancy 
(Al-Gazali et al., 2006; Teebi, 2010, as cited in Teebi, 1010). Thus, in Arab populations, 
several recessive diseases like Cystic Fibrosis, Phenylketonuria, Beta Thalassemia and 
Wilson disease are very frequent.  However, due to the tribal society style life among Arab 
and consecutive genetic founder effects, the distribution of autosomal recessive disorders 
among the Arab populations is not uniformly distributed, but shows large geographic 
differences (Teebi & S.A. Teebi 2005; Zolotogora  2002). 
Consanguinity has been recognized as the main social factor related to a high prevalence of 
genetic and congenital disorders in Arab communities' worldwide (Bener et al., 2007; Bittles 
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& Hamamy 2010, as cited in Teebi, 2010; Jaber et al., 1992; Sharkia et al., 2010; Zlotogora, 
1997). Consanguineous marriage refers to a union contracted between biologically related 
individuals. In clinical genetics, this includes relationships of second cousins or closer 
(Bittles & Hamamy 2010, as cited in Teebi, 2010).  The phenomenon of consanguineous 
marriages has been common in different societies worldwide, especially in the Arab rural 
populations due to socio-cultural factors like maintenance of family structure, and 
properties or ease of marital arrangements (Alper et al., 2004; Qidwai et al., 2003; Varela et 
al., 2003). The prevalence of consanguineous marriages in the Arab world is considered to 
be much higher (35% - 55%) as compared to Western countries (~1%)  (Bittles, 2001; Jaber et 
al. 1998). Recently, different studies of various Arab societies have shown that the 
consanguinity rates decrease with time (Hamamy et al., 2005; Khlat, 1988; Sharkia et al., 
2008). Consanguinity rates in various societies were found to be dependent on multiple 
factors e.g. religion, educational level, local traditions socio-economic status and 
demography (Fuster & Colantonio, 2004; Jaber et al., 1996,). The Arab population of Israel 
reaches about 1.5 million people consisting of about 84 % Muslims, 8 % Christians and 8% 
Druze (Central Bureau of Statistics, 2010). The Arab community in Israel is characterized by 
some unique features: most of the population lives in villages or towns which were founded 
by small numbers of originators and the majority of families have a large number of 
children. It was also believed that the favorite marriage is the consanguineous one (Jaber et 
al., 2000). It was found that the frequency of consanguineous marriages in the Arab society 
in Israel is about 44% (half of which are first cousin marriages) and its incidence is highest in 
rural areas (Jaber et al., 1994). Consanguinity was recently found to have decreased (Sharkia 
et al., 2008), in selected Arab communities in Israel but its rate is still high as compared to 
western communities. 
The relationship between consanguineous marriages, inherited genetic diseases and 
congenital malformation has been studied for many decades. During the 1950s in Japan, a 
high frequency of infant mortality was associated with consanguinity (Schull, 1958). A study 
that focused on the consanguinity effects on common adult diseases among the Qatari 
population revealed a strong correlation between high rates of common adult diseases and 
consanguineous marriages (Bener et al., 2007). In another study which explored the genetic 
aspect of beta-Thalassemia among 130 inflicted families from the West Bank and Gaza, 
77.3% of the tested couples were found to carry the same mutation. Actually, 77.9% of these 
couples were from consanguineous marriages (Ayesh et al., 2005). Furthermore, the high 
rate of infant mortality among the Palestinian population was related to consanguineous 
marriages (Pedersen, 2002). It was found that consanguineous marriages were a major cause 
of congenital malformation among the Arab communities in Israel (Jaber et al., 1992). 
Various forms of congenital malformation of the central nervous system, speech and 
infertility were found at a higher frequency in those individuals whose parents are family-
related, than those with unrelated parents (Bromiker et al., 2004; Zlotogora, 1997). A high 
proportion of infant mortality due to congenital malformation in the Arab community in 
Israel is mainly caused by the high frequency of consanguineous marriages (Zlotogora et al., 
2003). A report published by Abu-Rabia & Maroun (2005) showed that consanguinity 
negatively affects children's reading abilities. Recently, it was found that the prevalence of 
neurological hereditary diseases and mental retardation was associated with consanguinity 
in selected samples of Arab communities in Israel (Sharkia et al., 2010). From the geneticist’s 
point of view, consanguineous marriage alleviates genetic diagnostics. One main 
scientifically useful feature of consanguinity is that it facilitates homozygosity mapping of 
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disease related genes. The present study was undertaken to determine the prevalence of 
various genetic and congenital disorders and their association with parental consanguinity 
in a selected sample of the Israeli Arab community. Investigation of hereditary disorders is 
vital for improving health care. This can be achieved by identifying and diagnosing their 
molecular genetic basis, with a view to developing preventative intervention measures 
aimed at reducing the occurrence of these inherited genetic disorders. 
2. Subjects and methods 
2.1 Study population and sample 
This research is based on data from the socio-economic survey (SES) conducted by the 
Galilee Society (GS) and Al Ahali Center in the year 2007. This survey included a sample of 
3,173 households. This sample was a stratified multi-stage random sample which was 
designed in three stages: selection of enumeration areas in one stratification level, selection 
of thirty responsive households in the chosen enumeration area and selection of two 
persons, male and female, from persons aged 10 years and above from each household that 
was chosen in the second stage.  The total rate of completed questionnaires in this survey 
was 81.9% of the households in the field. 
This sample was divided into four levels of stratification: Region (North, Center, Haifa and 
South), Community Classification (urban communities "A" with a population over 15,000 
and urban communities "B" with a population between 5,000 and 15,000, rural communities 
with a population less than 5,000), Locality Type (unrecognized and recognized by the 
Israeli authorities), and Locality Characteristics (mixed: Arabs and others, unmixed: Arabs 
only). 
The following criteria were used in calculating the sample size: Use of the unemployment 
indicator (rate of unemployment) as a principal indicator in defining the margin of error 
which was estimated according to previous data at around 12%, Period of confidence is 95%, 
The ultimate margin of error for the principal indicator (rate of unemployment) is 3% on the 
stratification level. 
Therefore the size of the stratification level is: 
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D is the effect of sample design of multi-stage stratified samples and is estimated at 1.2. 
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3,173 households. This sample was a stratified multi-stage random sample which was 
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persons, male and female, from persons aged 10 years and above from each household that 
was chosen in the second stage.  The total rate of completed questionnaires in this survey 
was 81.9% of the households in the field. 
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N= 564*18 =10152 
It is important to note that the required number of persons applies to persons in the labor 
force because the principal feature that was studied (unemployment) is only related to 
persons in the labor force. Since the sample selection was households, and not persons, 
therefore we had to choose a number of households which included approximately 10,152 
persons in the labor force. According to previous data, the number of persons in the labor 
force is on average 3.2 persons per household, thus the sample size becomes 3,173 
households. Since 30 responsive households were selected from each enumeration area, the 
required number of enumeration areas was 107.1 and was adjusted to 109 areas, i.e. 3,173 
households in order to correlate the enumeration areas with the different levels of 
stratification. 
The target population consisted of all Israeli Arab households that reside inside the green 
line, and focused on individuals aged 15 years and above during 2007. The study group 
comprised the full pediatric population (0-18 year old), that was affected with one or more 
types of disorders caused by congenital, illness or during birth cause.  The sample excluded 
children with disorders caused by accidents or environmental factors. The total number of 
the study group was 565 affected children. 
2.2 Survey questionnaire and data collection 
For the current study we used two parts from the general questionnaire that contained:  
a. Identification information for the household and the relationship of the household to its 
head, gender, age, religion and place. 
b. Personal status information: included marital status, whether husband and wife are 
related, and the degree of consanguinity, and the number of births for married women. 
c. Health status information: included incidence of chronic diseases, disabilities, kinds of 
disabilities, and causes of disabilities, availability of supplementary health insurance, 
and places of treatment. 
The response compliance rate was 81.0% of the total households who were visited in the 
enumeration areas where refusals were recorded. 
Questionnaires were completed through face to face interviews. The fieldwork team was 
recruited from a group of field experienced surveyors. A training course was conducted for 
these surveyors by the supervisors and the project administrators. The total rate of 
completed questionnaires in this survey was 82% of the households in the field, which was a 
total of 107 areas out of 109.  
2.3 Consanguinity 
Information on consanguinity between the parents was obtained through the interviews. 
Relationships were grouped into two major categories: consanguineous and non-
consanguineous marriages, defined as follows: 
Consanguineous marriage: This group included two main levels of relationships:   
a. First cousins and closer. These include double-first cousins (in which all grandparents 
are shared) and first cousins in which the couple are parallel or cross cousins of either 
paternal or maternal descent;  
b. Distant relative marriages, in which the members of the couple were relatives but not 
with first-degree relations, for example they were first cousin once removed, second 
cousin, second cousin once removed. 
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Non-consanguineous marriage: The couple is not related. 
2.4 Data analysis  
The SPSS program was used for data management and descriptive statistical analysis. The 
statistical significance of associations between consanguinity and various types of disorders 
was examined by means of the 2 test. 
3. Results 
Of 3,173 total marriages (households), 1267 (39.9%) were consanguineous and 1906 (60.01%) 
were non-consanguineous.  The various subtypes of consanguinity was observed; 19.7% 
(N=623) were first-cousin marriage type and a similar incidence was found for distant 
relative marriage type (N=644, 20.3%). Of the 6,017 total children (siblings) from all the 
family samples, 565 children were found to have one or more kinds of various types of 
disorders, comprising an overall prevalence of 93.9 per 1000 children sampled. 
The total numbers of affected children of varying degrees separated into those from 
consanguineous and from non-consanguineous marriages are presented in Table 1. More 
than half of affected children (56%) were found to be products of parental consanguinity; 
68.4% of this prevalence was offspring of first cousins or closer, and 31.6% were offspring of 
distant relatives.  About 44% of the affected children were born to unrelated couples. There 
was a significant difference in the prevalence between the offspring of consanguineous 
versus non-consanguineous mating for various types of examined disorders. All reported 
disorders were more frequent in   consanguineous marriages, except for the respiratory 
disorders which were more frequent in   non-consanguineous marriages, indicating that 
there is a significant association between consanguinity and types of disorders, and that 

















Total FC                 DR 
Respiratory 130 56  (21.5) 32 (57.1)       24 (42.9) 74 (78.5) 16.6 0.003 
Mental 53 28 (52.8) 19 (67.8)         9 (32.2) 25 (47.2) 14.03 0.002 
Physical 160 90 (56.3) 68 (75.5)       22 (24.5) 70 (43.7) 13.25 0.001 
Visual 100 66  (66) 47 (71.2)       19 (28.8) 34 (34) 15.2 0.0013 




45 25 (55.5) 14 (56)          11 (44) 20 (45.5) 18.41 0.000 
Total N=565 316 (56%) 216 (68.4)   100 (31.6) 249 (44%) 17.98 0.000 
 
Table 1. Distribution of disorder types among Offspring from Consanguineous and Non-
consanguineous Marriages 
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Table 2 records the numbers and prevalence of disorder types among all the siblings aged 0 
to 18 in the presented families. The data shows that approximately 31% (565 cases) of the 
siblings from all 356 families had one or more kinds of diseases with a prevalence range of 
22% to 40%. This indicates that there is an associated familial background.  Selected 
characteristics of affected children with disorders types are presented in Table 3.  The 
prevalence of disorders' types was higher in boys (60%) than in girls (40%), this difference 
was significant. The detailed age distribution recorded in the table shows that the most 
(70%) of affected children were in the 10 to 18-year age group. 
 




All siblings aged between 
0 and18 years in the 
families 
Number and 
percentage of affected 
children (%) 
Respiratory 70 420 130 (30) 
Mental 33 132 53 (40) 
Physical 89 445 160 (35.9) 
Visual 92 460 100 (21.7) 




31 155 45 (29) 
Total 356 1817 565 (31.9) 





Affected children with disorders' types 




























































Gender  P<0.05 sig=0.01 
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Table 3. Age and Gender of affected Children with disorders' types 
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Table 4 compares the prevalence of disorders' types among the offspring from three 
category causes of disorders: illness, congenital and during birth.  Most (97%) of the 
disorders causes among affected children were illness and congenital. The illness cause was 
recorded in 300 cases (53.2%) and in 251 cases (44.4%) there was a congenital cause. Only 14 
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Table 4. Frequency of disorders' types by cause of disorders 
4. Discussion 
The highest prevalence of congenital malformations and genetic diseases  was reported in 
the Eastern Mediterranean region, with >65 affected children per 1,000 live births as 
opposed to 52/1,000 live births in Europe, North America and Australia (Alwan & Modell, 
2003).  In the selected sample for the present study we found that various types of disorders 
affected, on average, 93.9 per 1000 children.  This finding indicates that morbidity in the 
studied population is considerably more prevalent than in Eastern Mediterranean regions as 
well as in western societies.  
The phenomenon of consanguineous marriages has been common in the Arab world for 
many decades and its prevalence is considered to be much higher (35% - 55%) as  compared 
to that (~1%) of Western countries (Bittles, 2001; Jaber et al., 1998; Tadmouri et al., 2009). 
Nevertheless, despite the previously reported decrease in the rate of consanguineous 
marriages within selected regions of Israeli Arab communities (Sharkia et al., 2008), the 
consanguinity rate is still high in this community as the current study indicates. Our study, 
which is based on data obtained from all regions of the Israeli Arab community, showed 
that the incidence of consanguinity is relatively high with a rate of about 40%. 
Approximately 50% of all these consanguineous marriages are of the first-cousin and closer 
marriage type. These findings can be explained by the preference of consanguineous 
marriages in Arab populations that are related to socio-cultural factors. It has been reported 
that consanguineous marriages have a negative effect on reproductive health factors in 
general. Consanguinity is still the most common risk factor for a high frequency of 
autosomal recessive diseases and congenital malformations within Arab communities in 
Israel (Sharkia et al., 2010; Zoltogora et al., 2003). In addition, several studies among Arab 
societies show that there is a higher occurrence of consanguineous marriages among parents 
of offspring with congenital malformations than in the general population (Bener et al., 
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marriages within selected regions of Israeli Arab communities (Sharkia et al., 2008), the 
consanguinity rate is still high in this community as the current study indicates. Our study, 
which is based on data obtained from all regions of the Israeli Arab community, showed 
that the incidence of consanguinity is relatively high with a rate of about 40%. 
Approximately 50% of all these consanguineous marriages are of the first-cousin and closer 
marriage type. These findings can be explained by the preference of consanguineous 
marriages in Arab populations that are related to socio-cultural factors. It has been reported 
that consanguineous marriages have a negative effect on reproductive health factors in 
general. Consanguinity is still the most common risk factor for a high frequency of 
autosomal recessive diseases and congenital malformations within Arab communities in 
Israel (Sharkia et al., 2010; Zoltogora et al., 2003). In addition, several studies among Arab 
societies show that there is a higher occurrence of consanguineous marriages among parents 
of offspring with congenital malformations than in the general population (Bener et al., 
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2007; Tadmoure et al., 2009; Teebi, 2010, as cited in Teebi, 2010).  A strong association 
between most of the examined disorders and consanguinity was demonstrated in the 
present study; approximately 56% of the children with one or more disorders were the 
offspring of consanguineous marriages, and in approximately 68% of these marriages the 
parents were first cousins or closer. This association between consanguinity and disorder 
rate as well as the familial effect of most disorders' types that were obtained by the current 
results indicate that genetic factors are involved with the underlying cause. In addition, we 
found that the frequency of the disorders' types were higher among males (60%) than 
females (40%) in our studied sample, possibly `reflecting the elevated levels of X-
chromosome homozygosity inheritance.  The relationship between consanguinity and 
genetic disorders is attributed to the fact that a high prevalence of consanguinity increases 
homozygosity and reduces the genetic variation which may protect against the expression 
of recessive genes that can lead to genetic disorders in a group. When a new mutation is 
inserted in such a population, it will rapidly spread, leading to an increased prevalence of 
carriers, and a high number of affected homozygous individuals. An analysis of data in the 
Catalogue for Transmission Genetics in Arabs (CTGA) carried out by  Tadmouri et al., 
(2009), indicates that the overwhelming proportion of the disorders follow a recessive mode 
of inheritance of about 63% as compared to the smaller proportion of dominantly inherited 
traits (27%).  A detailed analysis study of the molecular basis of autosomal recessive 
diseases among Palestinian Arabs in Israel found that most of the responsible mutations 
among the affected patients were homozygosity (Zlotogora, 2002). We believe that the 
genetic conditions of the disorders in the present studied sample probably relates to 
homozygosity autosomal recessive diseases. 
The largest age distribution (70%) of affected children was in the 10 to 18-year range, in 
contrast to the 16% of affected children who were in the less than 5 year age group. 
Furthermore, most (97.6 %) of the disorders causes among the affected children were by 
illness and congenital, while only (2.4%) were caused by "during birth". These results 
demonstrated that implementing various health interventions and genetic counseling 
services in order to improve public health issues in the Israeli Arab community will have a 
positive effect, even if only partial. Therefore, such programs are needed, particularly, for 
identifying and diagnosing the molecular genetic basis of the most common disorders so 
that a preventive program can be launched, with the aim of minimizing the occurrence of 
different spectrum disorders in future generations. 
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1. Introduction 
Islam has approximately 1.5 billion followers worldwide, the majority of whom live in 
Arabic/Islamic states with an appreciable number live in non-Islamic states.1,2 In both 
environments the Muslims maintain a “Code of life”, where they adhere to the instructions 
of Islam and respect its guidance in all aspects of their daily life. In this respect, Islam 
responds to person's need through the “Code of Conduct” drawn from Al-Sharea'h, the 
Islamic law.3,4,5,6,7,8 . The Teaching of Islamic Law include all that is required to appropriately 
serve the needs of the individual, the family and the community at large 3     
To respond to various issues learned from Human Genome and associated studies, varieties 
of scientific activities, including conferences, symposia and workshops were held during the 
last 15 years in a number of Islamic countries to discuss the new issues arising from the 
scientific and technical developments and their applications in genetical practices. These 
include an international conference on Islamic medicine held, to discuss ethics of medicine 
in the light of Islamic views and a seminar on "Genetics, Genetic Engineering, the Human 
Genes, and Genetic Treatment - An Islamic Perspective".9 Thereafter, World Health 
Organization (W.H.O) organized two relevant meetings. A meeting to discuss “Ethical 
aspects of scientific application in Genetics”, followed by another meeting to discuss the 
“Ethical issues in application to genetics in developing countries”, which include a large 
number of Islamic countries.10,11 A complementary workshop entitled: “The 1st Regional 
workshop on Ethical issues in Genetic counseling” was held, thereafter.12 The last three 
events benefited from the previously held conferences and from related  “Fiqh” Council 
Fatwas, the guidelines of the Learned. Of significance also, is the United Nations 
Educational, Scientific and Cultural Organization (UNESCO) general guidelines on 
Bioethics and Human rights.13  
2. Genetic investigations and community ethical beliefs 
As Science has global identity, research was advanced by collaborative efforts between 
scientists from various countries. However, the genetic research outcome encroaches into 
the individuals and the family beliefs in all communities. Nevertheless, the basic ethical 
aspects remain universal, though with specific unique features that are relevant to the 
concerned community, its societal beliefs, customs and prevailing traditions.  
In general, Medical Ethics combines a set of societal values and beliefs that are relevant to 
diagnosing illnesses, preventing and controlling diseases and provision of care for patients. 
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The health care teams are required to conduct research and acquire further knowledge and 
technology to help improving medical care. The balance between the medical services and 
research aimed to enrich knowledge, is necessary, but has to meet a battery of ethical 
elements, including:6,14 -18  
 Autonomy 
 Beneficence 
 Non-maleficence  
 Justice 
 Confidentiality 
 Medical professionalism        
In Islam, the Holy Book of Moslems (The Qur’an) and the Prophet's instructions (The 
Hadeeth), Peace Be Upon Him (PBUH), the Consensus (Al Ijmaa') of the Learned (Al-Ulama) 
and Analogy (Al Qiyas) on the newly found matters of life,  are the sources of religious 
practices and govern all aspects of life through Al-Sharea'h.19-24 Consideration is also given to 
“Maslaha” (public interest) and urf (the local customary precedent).21 These Islamic teachings 
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The Arabian Peninsula is the cradle of Arabs and Islam, with the two Holy Mosques of 
Moslems in the cities of "Makkah Al Mokarramah" and "Al-Madinah Al-Monawarrah"  in 
Saudi Arabia. Makkah Al-Mokarramah houses "The Islamic Jurisprudence (Figh) Council of 
Islamic World League of the Organization of Islamic Countries", with members representing 
Islamic States. In this article, this source of guidance, in addition to relevant verses of Qura' 
n and the Hadeeths are followed. 
Cultural awareness and contextual knowledge are necessary prerequisites for health care in 
culturally sensitive communities with strong societal values and beliefs, as is the case in 
Islamic communities. An appreciation of the societal values and beliefs must be reflected in 
all aspects of life as well as in individual and family interactions. In Islamic countries, as 
well as among Islamic communities in non-Islamic countries, Islam continues to influence 
the societal conduct of life and customs of an estimated one fifth of the inhabitants of the 
globe 19 (Figure 2) 
 











Fig. 2. Arabic/Islamic Communities – Pattern of life 
In Islamic Teachings, preservation of the five necessities, “Magasid Al-Sharea'h” represents 
the respect for human being and human life20. The five necessities are: 
1. Maintenance of religion (A-ddeen) ; including the five Pillars of Islam . 
2. Maintenance of self (Al-nafs) ; including Human Dignity Prohibition of abortion and 
fetus rights to survive  Prohibition of Killing  and suicidal . 
3. Maintenance of brain – intellect (Al-aql) ; including education freedom of intellect and 
research . 
4. Preservation of Progeny (Al-nasl) ; including encourage of marriage  and prohibition of 
adultery . 
5. Preservation of wealth and honor (A-tharwal wa , Al-erdh) ; including freedom of 
commerce and offering of Alms "A-Zakat   " to the needy .  
In addition, varieties of costumes and traditions that, over the years, became part of the 
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3. Genetic screening and counseling as means of prevention of genetics 
diseases 
The genetic disorders can give rise to chronic diseases that currently have no or limited 
definite cure. Preventive measures of genetic diseases,  particularly at an earlier stage, 
proved to be of practical value. The main pillars of prevention are genetic screening and 
supportive counseling. Genetic screening or testing can be carried out at different stages, as 
follows25 - 27: 
 Age of puberty  
 School age 
 Post-natal screening 
 Screening during pregnancy 
 Pre - implantation Genetic Screening - before implementation and after in vitro 
fertilization (IVF). 
Genetic counseling is considered an important complementary approach to the screening 
procedure. As a service, it is offered to the members of the high risk groups, i.e. carriers of 
recessive genetic disease or those with an affected member of the family. 25 - 36 
As a profession, the genetic counseling demands certain ethical frameworks that are 
required by the very nature of the function of the counselor. Being considerate and 
compassionate should complement the counsellor and colour the communication with the 
client. The counseling process should be nondirective, where the decision-making should lie 
in the hands of the person concerned, but to be based on full understanding of the genetic 
situation and the pros and cons of the outcome of the probable condition. The principles and 
components of the "Informed Consent" that are generally acceptable in western countries are 
also applicable to Muslim community 28 – 44 .  However, Muslims, in general, will often want 
to consult with family members and religious scholars, particularly in aspects of religious 
and social relevance. 
4. "Islamic Teachings" on prevention of genetic disorders 
Ethics in medical practices, within the framework of Islamic teaching, emphasizes the 
importance of educating the people and raising their awareness of the pattern of inheritance, 
its implications and the available means of prevention and care. On prevention side, pre-
marital screening seems to be the preferable means of choice and appropriate counseling 
that takes into account the religious beliefs and prevailing traditions can be effective. These 
practices are carried out in a number of Islamic Countries and considered the method of 
choice in prevention of Single Gene Disorders. Similarly, neo-natal testing, avoiding of 
terratogenes and provision of folate and iodine in the diet is encouraged as supportive 
measures. On the care side, drug treatment, supportive care, Stem cell and gene therapy are 
welcomed. 
Islam pays special attention to the reproduction of mankind and the maintenance of human 
race on earth. One of the necessaties in the Magasid Al Sharea'h is that progeny is to be 
protected throughout life, namely pre-marital, pre-conception, pre-natal, natal and post-
natal stages. At pre-marital stage, selection of the parent (man/women) includes that the 
parent should be healthy, and perform a good deeds. At pre-conception stage, Islam 
prohibits any attempt to tamper with the productive process. At natal stage, Islam prohibits 
abortion after the fourth months of pregnancy, i.e. after the Spirit is blown into the foetus. 
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Thereafter, the parents should appropriately care for the newborn including advocacy for 
breastfeeding until two years of age. The parents looking after the children should include 
observing their rights of having a decent, peaceful and worthy life.  
5. Directions regarding abortion of the genetically affected foetus 
"The Fatwa" number 4 of "The Islamic Jurisprudence Council of Islamic World league of the 
Organization of Islamic Countries", at its 12th session,47 allows for the option of abortion 
under certain specific conditions. The fatwa determined that the abortion may take place 
only if a committee of specialized, competent physicians has decided the foetus is grossly 
malformed, and that its life would be a calamity for both the family and itself. The 
malformation must be untreatable, unmanageable and very serious, and the abortion may 
only be carried out prior to the 120th day of conception (computed from the date of 
fertilization, not the last menstrual cycle). Beyond 120 days, i.e. after the sprit blown into the 
fetus, abortion only is allowed if there is a danger threatening the mothers' health. 
6. The “Sharea'h” views toward human genetic research outcome and use 
In Islamic communities, genomics research and the applications of its outcome into medical 
practices, are conducted within the context of culture and religion framework. In this 
respect, 'The Islamic jurisprudence Councils in Islamic Countries' paralleled the scientific 
advancements in looking into the usefulness of the genetic research outcome to human kind. 
"The Islamic Jurisprudence (Figh) Council of the Islamic World League of the Organization 
of Islamic Countries" in Makkah Al-Mukarama and The High Council of Al-Ulama"  of 
Saudi Arabia, as well as similar bodies in other Islamic Countries, as the need rises, discuss 
and pass guidelines and "Fatwas" of the Learned, an authoritative ruling, on subjects of 
general concern to Islamic communities. The decision making leading to the Fatwas and the 
guidelines, are based on information provided by professionals and experts in the relevant 
field under discussion.  
7. Guidelines on the use of genetic information and technologies in the 
management of genetic diseases 
"The Islamic Jurisprudence Council of the Islamic World League of the Organization of 
Islamic Countries", in its 15th session gave the following guidance on the use of the genetic 
information and research technology 45:  
1. allow the use of genetic engineering for disease prevention, treatment, or amelioration 
on the condition that do not cause further damage; 
2. forbid the use of engineering in evil and criminal use or what is forbidden religiously; 
3. forbid using genetic engineering and its tool to change human personality and 
responsibility, or interfering with genes to improve the human race; 
4. forbid any research or therapy of human genes except in extreme need, after critical 
evaluation of its benefits and dangers and after an official consent of the concerned, 
respecting the extreme confidentiality of the information and human rights and dignity 
as dictated by Islamic Sharea'h; 
5. allow the use of bio-engineering in the field of agriculture and animals, on the condition 
that precautions are taken not to inflict harm (even in the long term) on humans, 
animals or vegetation; 
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6. call on biotechnology companies and food and medical factories to reveal the structure 
of these bioengineered products so they can be dealt with and used with caution in light 
of potential harm or if any are forbidden religiously; 
7. recommend all doctors, factory and laboratory owners to fear Allah (GOD) and to 
watch out for Allah to avoid inflicting harm to humans, society or the environment 
8. DNA fingerprinting and its use 
On DNA fingerprinting, "The Islamic Jurisprudence Council of Islamic World league of the 
Organization of Islamic Countries", in its 16th session, issued the following guidance:46 
1. It is religiously allowed to use DNA fingerprinting in forensic interrogations to prove 
crime which has no definite penalty in Islamic law (Share'ah) (Avoid punishment if 
there is any doubt, as doubt should always be used for the sake of the accused), this will 
lead to justice and to safety of the community, as the criminal will be punished and the 
innocent will be freed from guilt, which is one of the most important goals of Share'ah. 
2. DNA fingerprinting may be used in lineage (genealogy) only with great caution and 
confidentiality as the Share'ah rules take precedence over DNA fingerprinting. 
3. It is forbidden to use DNA fingerprinting in paternity (lineage) disputes, which should 
not precede the oath of condemnation (the sworn allegation of adultery committed by 
one’s spouse). 
4. It is forbidden to use DNA fingerprinting to confirm or refute legally proven lineage; 
the state should forbid this and inflict punishment, in order to protect people’s honor 
and to preserve their lineage.   
5. It is allowed to use DNA fingerprinting in proving lineage on the following 
conditions; 
- in case of a dispute about unknown lineage, as mentioned by the Islamic scholars 
because the evidence is either absent or equivocal, and to overcome (inundate) the 
vagueness (suspicion). 
- in case of a dispute over babies in hospitals and nurseries or test tube babies; 
- in case of children lost because of war, accidents or natural disasters, where there 
family could not be found; 
- to identify babies or prisoners of war. 
6. The human genome of an individual, nation or race should not be sold for any reason; 
neither should it be given because of the harm it can cause. The counsel recommends 
that: 
i. the state to forbid DNA fingerprinting testing except on judge’s orders and 
performed in the state laboratories; the private sector should be forbidden from 
doing such tests because of the great danger and harm. 
ii. each state should have a committee on DNA fingerprinting tests which should 
include legal scholars, physicians and administrators to supervise and approve the 
result of such tests. 
iii. there should be a precise mechanism to prevent deceit, cheating, contamination or 
human error in such laboratories, so the results are compatible with reality. The 
accuracy of these laboratories needs to be confirmed. 
iv. the number of genes used for a test should be sufficient, in the opinion of 
specialists, to overcome any doubts about the accuracy of the results.  
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9. Cloning and stem cell research 
"The Islamic Jurisprudence Council of Islamic World League of the Organization of Islamic 
Countries", in its 10th session,48 explored all the research papers and recommendations of the 
9th Medical and Fiqh Seminar held by the Islamic Medical Organization during 14-17 June 
1987 and agreed on the Decree no. 2/100D 10, which states that: 
1. Human Cloning is forbidden in these two (or any other) methods that lead to human 
reproduction. 
2. If the first legal rule is overstepped, the consequences should follow the legal rulings. 
3. It is forbidden in all cases to introduce a third party into marriage, i.e an egg donor, a 
surrogate womb, a sperm donor, or a cloned cell. 
4. It is permissible to use genetic engineering and cloning in the fields of germs, 
microorganisms, plants, and animals following legitimate rules which lead to benefits 
and prevent harm. 
5. All Muslim countries are called upon to formulate the necessary legislation to prevent 
foreign research institutes, organizations and experts from directly or indirectly using 
Muslim countries for experimentations on human cloning or promoting it. 
6. The Islamic Organization for Medical Sciences and other similar bodies are called upon 
to monitor all scientific developments in the field of cloning and define its terminology 
and organize seminars and meetings, as required, to determine and articulate the 
Islamic rulings and principles pertaining thereto. 
7. Specialized committees should be set up to look into the ethics of biological research 
and adopt protocols for study and research in Muslim countries. 
8. Biological and bioengineering research institutions ( other than cloning research) should 
be supported and established, according to the Islamic rulings, so that Muslim world 
will not be dependent  on others in this field. 
"The communication media are called upon to deal with recent scientific advances from an 
Islamic perspective in a faithful way and avoid employing their services against Islam, 
aiming to educate the public to be confident before any decision. According to God saying 
(When there comes to them some matter touching (Public) safety or fear, they divulge it. If 
they had only referred it to the Messenger, or to those charged with authority among them, 
the proper investigations would have tested it from them (direct). Were it not for the Grace 
and Mercy of Allah unto you, all but a few of you would have fallen into the clutches of 
Satan (The Holy Qura'n, Sorat Al Nesae, Ayat 83)".  
After listening to the research papers and the opinion of the Council members and the 
experts with relevant knowledge, the Council made the following decree: 
FIRST: It is permissible to obtain stem cells, to be grown and used for therapy or for 
permissible scientific research, if its course is legitimate, as for example: 
1. adults if they give permission, without inflicting harm on them. 
2. children provided that their guardians allow it, for a legal benefit and  without 
inflicting harm on the children. 
3. the placenta or umbilical cord, with the permission of parents. 
4. a fetus is spontaneously aborted or when aborted for a therapeutic reason permitted by 
Shareah, with parents’ permission. (Be reminded of decree No. 7 of the counsel in its 
12th session about abortion). 
5. left over zygotes remaining from in vitro fertilization, if donated by the parents, when it 
is ascertained that they will not be used in an illegal pregnancy. 
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6. call on biotechnology companies and food and medical factories to reveal the structure 
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confidentiality as the Share'ah rules take precedence over DNA fingerprinting. 
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not precede the oath of condemnation (the sworn allegation of adultery committed by 
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- in case of a dispute about unknown lineage, as mentioned by the Islamic scholars 
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family could not be found; 
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neither should it be given because of the harm it can cause. The counsel recommends 
that: 
i. the state to forbid DNA fingerprinting testing except on judge’s orders and 
performed in the state laboratories; the private sector should be forbidden from 
doing such tests because of the great danger and harm. 
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include legal scholars, physicians and administrators to supervise and approve the 
result of such tests. 
iii. there should be a precise mechanism to prevent deceit, cheating, contamination or 
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iv. the number of genes used for a test should be sufficient, in the opinion of 
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SECOND: It is forbidden to use stem cells, if their source is illegal. As for example: 
1. intentionally aborted fetuses (that is, abortion without a legal medical reason). 
2. intentional fertilization between a donated ovum and sperm. 
3. therapeutic human cloning". 
10. Conclusions 
Islamic teachings in all aspects of life are drown  from the Holy Book of all Muslims (The 
Qura'n), the Prophet (PBUH) speech (The Hadeeths), then  Consensus (Al ijma) and Analogy 
(Al Qiyas), resulting in "Islamic Jurisprudence". Where appropriate, consideration is also 
given to public interest " Maslaha" through the decision of the Learned, i.e. the "Fatwa", and 
local customary precedent, i.e. "The urf " 49. 
Bio- and medical ethics are extension of Sharea'h, where decision-making observe Magasid 
Al-Isalm, that emphasizes the need for preservation of the components of human being and 
the patterns of human life. In these principles, Islam shares many foundational values with 
the other Abrahamic" religions, Judaism and Christianity, where similar teachings are given 
50-54 .  Of relevance are these religions  teachings regarding the restriction on abortion and the 
wrights of the foetus. Like other religions, Islam has diverse sects and, therefore, diversity of 
views in bioethical matters does exist. However, there is little that is controversial, 
concerning pre-natal diagnosis and abortion of the malformed or genetically disordered 
foetus. The Islamic Teachings in medical practices, particularly those related to genetic 
services as outlined in this article, are not meant to be exclusive, where there may be 
different opinions based on other "Fatwas", or sources related to other Islamic sects. It is 
hoped that the insights gained from this presentation will aid clinicians and other health 
care workers providing genetics services to better serve their Moslem patients, their families 
and the whole community and deliver care that pays due respect to their beliefs, customs 
and prevailing traditions.    
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views in bioethical matters does exist. However, there is little that is controversial, 
concerning pre-natal diagnosis and abortion of the malformed or genetically disordered 
foetus. The Islamic Teachings in medical practices, particularly those related to genetic 
services as outlined in this article, are not meant to be exclusive, where there may be 
different opinions based on other "Fatwas", or sources related to other Islamic sects. It is 
hoped that the insights gained from this presentation will aid clinicians and other health 
care workers providing genetics services to better serve their Moslem patients, their families 
and the whole community and deliver care that pays due respect to their beliefs, customs 
and prevailing traditions.    
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